Application Procedure & Selected Cv

Supplementary Document 3 LIVE Invited Scholars: application procedure & selected c.v.

PREAMBLE

This file is the supplementary document 3 (SupDoc3) for the project of the Erasmus Mundus Joint Master Degree “Leading International Vaccinology Education” (LIVE+). LIVE+ is submitted to the Erasmus Mundus call of Feb 15th, 2018.

This document contains: - The procedure to apply for “Invited Scholar” position in the EMJMD LIVE, also published online on the LIVE website - The c.v. of 25 selected invited scholars, including the 8 invited scholars registered in the EACEA Mobility Tools for the intake 1 of the EMJMD LIVE - The c.v. of the 2 external experts for the External Quality Assurance Committee (E-QAC): Czerkinsky Cecil & Plotkin Stanley A

Note: Next page, the Table of Contents is interactive and hyperlinks refer to the paragraph

Table of contents: click to navigate The procedure to apply for “Invited Scholar” position in the EMJMD LIVE ...... 3 HEI network: 22 institutions involved in the LIVE programme ...... 4 LIVE 2016-18: List of 8 EACEA-invited Scholars / intake 1 ...... 5 Curriculum vitae of 25 LIVE Scholars ...... 5 Aramburu Beltrán Jose ...... 6 Arcangeli Annarosa ...... 11 Ashhab Yaqoub ...... 21 Bigas Anna ...... 28 Bonanni Paolo ...... 41 Catálfamo Marta ...... 43 C.C. Leite Luciana ...... 53 Czerkinsky Cecil ...... 56 De Clerck Norbert ...... 58 Dieye Tandakha Ndiaye ...... 59 Espinosa Blay Lluis ...... 70 Finn Adam ...... 73 Jonjic Stipan ...... 75 Kieber-Emmons Thomas ...... 90 Kollmann Tobias ...... 101 Marchant Arnaud...... 114 Martinez-Picado Javier ...... 116 Moulin Anne-Marie ...... 117 Papaevangelou Vana ...... 120 Pashov Anastas ...... 121 Plotkin Stanley A...... 125 Scheifele David ...... 131 Seib Kate ...... 153 Tsai Theodore Fang ...... 155 Van Der Pol Leo ...... 163

The procedure to apply for “Invited Scholar” position in the EMJMD LIVE Also available on the LIVE website in the menu “About Us > Scholars, Lecturers, QAC members” Future Scholars: From 1 week to 3 months Are you an expert on vaccinology or regulations applied to vaccinology? Whatever your view on the subject, from scientific or industrial fields (immunology, infectiology, epidemiology, industrial process or quality) to humanities and laws (public health, health policy, regulations), you will:  make an impact by joining the LIVE consortium faculty and get the unique opportunity to meet our students,  meet the vaccinology leaders of tomorrow, and  share knowledge and good practices with the largest vaccinology science community. The consortium offers each year guest lecturer’s funding opportunity with competitive remuneration. Travel and accommodation costs of the visiting scholar are funded by the LIVE consortium. The LIVE course offers 3 to 8 positions / year for a maximum duration of three months to leading academics and practitioners preferentially, but not exclusively, from outside the European Union to contribute to the teaching programme. The scholar will be integrated in the department organising the LIVE Master at the hosting university.

Scholars can be asked:  to lecture students on a topic for a time slot to be agreed upon and corresponding to the scholar's field of expertise and availability  to assist in the preparation, development and/or implementation of a practical seminar or case study or MOOC development organised with the LIVE students and other national students from the national Master involved in the LIVE Master at the hosting university  to explore potential collaboration between the LIVE consortium and the home institution of the scholar. The lecturers / scholars can apply to the LIVE consortium on their own initiative or can be invited by the LIVE consortium to do so. The application (see details in the next §) should:  mention the academic year the scholar applies for  include a motivation pointing out the potential contribution to research and education in scientific or humanities or industrial process related to Immunology, infectiology or vaccinology  produce an extensive CV, stating publication records, research activities, etc. Duration of the visit: 1 week to 3 months The selection is organized and proceeded by the LIVE consortium on the basis of:  elective criteria, i.e. academic performance and credentials of the candidates  potential contribution to research and education within the LIVE framework  origin of the home institution of the scholar, according to this order of preference: third-country, developed country from outside EU, country from inside European Union  potential partnerships with the home institution of the scholar.

Future Scholars: application rules 1. Selection criteria Applicants must either: - hold a PhD (or be near completion of one) OR a substantial track-record in the industry - AND be able to demonstrate their ability to teach at a high level. We equally welcome professors from higher education institutions as well as practitioners from the private sector. Academic / professional profile is the main criteria that will be used to assess applications.

2. To apply, please send us at [email protected] the following documents in “.pdf” format: - A CV, including o full contact information; o a short professional profile; o current employment status; o academic and professional background (positions and projects); o teaching track-record and professional references. - A short (no more than 600 words) cover letter laying out what added-value your course proposal could bring to the programme, and notably with respect to student-centred teaching/lecturing, research activities and academic/professional networking; - A course proposal, including: o Master programme name; o course title; o learning outcomes (prerequisites, learning objectives and how these objectives fits into the sequence of the LIVE programme); o short course syllabus (course duration, themes covered by the courses, course sequence, cases-studies, learning materials, modes of learning, suggested readings…); o desired teaching campus (Spain, Belgium, France) and suggested teaching dates. We will consider online course proposals as well. - Your LinkedIn page if you have one in the cover email. - Application are to be sent with the subject line: “LIVE_Guest_Lecturer_Application_SURNAME_NAME.pdf”. - No handwritten application will be considered.

3. Agenda A selection committee is convened each year in March. Applicants will be informed on selection results at the end of March by email. Please note that the Academic and Management Board may suggest modification of course contents should your proposal be accepted. The consortium is an equal opportunity employer. Minority individuals, persons with disabilities, and woman are encouraged to apply. The consortium offer support to women who face difficult circumstances or barriers to their full participation in the programme.

HEI network: 22 institutions involved in the LIVE programme INSTITUTION (founded year) 2014 Shanghai Category *contact person, LIVE organising partners Country website General rank Role in LIVE Selected scholars, QAC member LIFE/MED rank Université Libre de Bruxelles (1834) PIC associate HEI 101-150 BELGIUM www.ulb.ac.be *Arnaud Marchant Invited scholars 101-150 University of Antwerp (2003) PIC associate HEI 301-400 BELGIUM www.uantwerpen.be *Peter Delputte Local coordinator 151-200 University of Sofia (1913) - BULGARIA Invited scholars www.sofia.edu/ *Anastas D. Pashov - University of British Columbia (1908) 37 CANADA Invited scholars www.ubc.ca/ *Tobias R. Kollmann, David Scheiffele 33 Fudan University Medical School (1905) CHINA Invited scholars www.fudan.edu.cn/ 151-200- *Bin wan University of Rijeka (1973) - CROATIA Invited scholars www.uniri.hr *Stipan Jonjic - Ecole Normale Supérieur de Lyon (1987) 201-300 FRANCE PIC associate HEI www.ens-lyon.eu *Contact: François-Loïc Cosset - Université Claude Bernard Lyon 1 (1809) PIC associate HEI 201-300 FRANCE www.univ-lyon1.fr/ *Christine Delprat LIVE coordinator 151-200

INSTITUTION (founded year) 2014 Shanghai Category *contact person, LIVE organising partners Country website General rank Role in LIVE Selected scholars, QAC member LIFE/MED rank Université Jean Monnet de Saint-Etienne (1969) PIC associate HEI - FRANCE www.univ-st-etienne.fr/ *Stéphane Paul Local coordinator - University of Paris 7 Diderot (1805) 101-150 FRANCE Invited scholars www.univ-paris-diderot.fr/ *Anne-Marie Moulin 101-150 University of Athens (1837) - GREECE Invited scholars www.uoa.gr/ *Vana Papaevangelou - University of Florence (1321) 201-300 ITALY PIC associate HEI www.unifi.it/ *Annarosa Arcangeli 151-200 Palestine Polytechnic University, Hebron (1978) - PALESTINE Invited scholars www.ppu.edu/ *Yaqoub Ashhab - Université Cheikh Anta Diop, Dakar (1957) PIC associate HEI - SENEGAL www.ucad.sn/ *Tandakha Ndiaye Dieye Invited scholars - Universitat Autònoma de Barcelona (1968) PIC associate HEI 201-300 SPAIN www.uab.es *Paz Martinez Local coordinator 151-200 Universitat de Barcelona (1450) PIC associate HEI 151-200 SPAIN www.ub.edu *Thomas Stratmann Local coordinator 51-75 Universitat Pompeu Fabra, Barcelona (1990) 301-400 SPAIN Invited scholars www.upf.edu *Jose Aramburu - University of Bristol (1876) 63 UK Invited scholars www.bristol.ac.uk *Adam Finn 51-75 Johns Hopkins University, Baltimore (1876) E-QAC member 17 USA www.jhu.edu *Stanley Plotkin Professor Adjunct Invited scholars 4 University of Arkansas Medical Sciences, PIC associate HEI 401-500 Little Rock (1927) USA www.uams.edu/ Invited scholars 151-200 *Thomas Kieber-Emmons University of Pennsylvania (1740) E-QAC member USA www.upenn.edu/ 19 *Stanley Plotkin Emeritus Professor of Paediatrics Invited scholars universidad de Oriente (1947): CUBA Support http://www.uo.edu.cu/ - Suyén Rodriguez Pérez

LIVE 2016-18: List of 8 EACEA-invited Scholars / intake 1

Family name Given name Semester Teaching unit title Arcangeli Annarosa 3 Immunology and Cancer Ashhab Yaqoub 1 Antigen recognition C.C. Leite Luciana 3 Project Management Catálfamo Marta 1 Immune response to pathogens De Clercq Norbert 2 Vaccine manufacturing, quality, regulatory approval Kollmann Tobias 2 Immune system of newborns, pregnant women and elderly Seib Kate 3 Clinical vaccine development Van der Pol Leo 3 Vaccine specific applications

Curriculum vitae of 25 LIVE Scholars

ABBREVIATED CV

Aramburu Beltrán Jose ABBREVIATED SKETCH

Name and Surname José Francisco Aramburu Beltrán Researcher ID G-8991-2014 Researcher ID Orcid number 0000-0001-9279-9523

CURRENT POSITION Centre Universitat Pompeu Fabra Departmet Department of Experimental and Health Sciences Addresss Carrer Dr Aiguader, 88, 08003 Barcelona, Spain Phone 933160809 e-mail [email protected] Position Profesor agregado (Senior lecturer) Academic Vice-director, Department of Experimental and Health Sciences appointment UNESCO codes 2407, 2412, 2415 Keywords Immune cells, T lymphocytes, gene expression, stress responses

A.2. Formación académica (título, institución, fecha) Degree University Year BSc Biology Autónoma de 1986 Madrid PhD Biology Autónoma de 1992 Madrid

GENERAL INDICATORS

- Research tracks (6-year tracks): 4 - Last research track awarded: 2012 - PhD thesis directed in last 10 years: 4 - Total citations: 3236 (Web of Science TR); 4006 (Google Scholar) - Publications in 1st quartile (Q1): 37 - H index: 25 (Web of Science TR); 27 (Google Scholar) - Others: Total number of articles: 43 Original articles: 35 (33 in Q1) Review articles: 8 (6 in Q1) Book chapters: 3 Grants: PI in 4 grants from Spanish Goverment and 3 from Foundations since 2003.

BRIEF OUTLINE OF RESEARCH TRAJECTORY

Synopsis. PhD in the Immunology group of Hospital de la Princesa, Madrid (1992, group led by Dr Miguel LópezBotet) and 7 years of postdoctoral (2 at Thomas Jefferson University in Philadelphia, group led by Dr Bice Perussia, and 5 at Harvard Medical School, group led Dr Anjana Rao). Joined Universitat Pompeu Fabra (UPF) in 2000. 43 articles published (39 Q1), 3236 citations, 4 grants as PI from Spanish Plan Nacional since 2003, and 3 from Foundations. 4 PhD theses directed, 3 ongoing. Recent publications (since 2010) in Science Signaling, Nucleic Acid Research, PNAS USA, J Experimental Medicine, J Immunology.

ABBREVIATED CV

Current research. Stress responses allow cells to survive microenvironment disturbances until homeostasis is reestablished. However, stress is not an occasional threat, but in variable forms is intrinsic to life and integrated in the flow of information that cells exchange with their environment. This connection is still poorly understood, but is particularly relevant in the immune system, composed by mobile cells that function in a variety of anatomical niches where they can be exposed to diverse stress sources, but have to maintain adequate responsiveness to relevant signals from tissues and threats such as pathogens. Our current work focuses on understanding how immune cells interpret specific stress signals in different growth and differentiation contexts to modify their functional capabilities in an organism.

Teaching and management. Besides my research activity, I am intensively involved in teaching and academic management at UPF. In addition to direct teaching in different subjects, I have coordinated the research course program for students of the degree in Biology (2003 to 2012), the degree project program in the recently created 4-year degree in Human Biology (2011 to present), and directed (2006 to 2013) the Master in Biomedical Research, created in the European higher education (Bologna) framework. Since 2013 I serve as vice-director of our department.

SCIENTIFIC ACTIVITY

Selected Publications (10 of 53 indexed in SCI)

Tellechea M, Buxadé M, Tejedor S, Aramburu J, López-Rodríguez C. NFAT5-Regulated Macrophage Polarization Supports the Proinflammatory Function of Macrophages and T Lymphocytes.J Immunol. 2018 Jan 1;200(1):305-315.

Alberdi M, Iglesias M, Tejedor S, Merino R, López-Rodríguez C, Aramburu J. Context-dependent regulation of Th17-associated genes and IFNγ expression by the transcription factor NFAT5. Immunol Cell Biol. 2017 Jan;95(1):56-67.

Martínez C, Aramburu J, Rubio L, Galipienso L. Complete Genome Sequence of a Tomato Isolate of Parietaria Mottle Virus from Italy. Genome Announc. 2015 Dec 17;3(6).

Debreczeni DE, López C, Aramburu J, Darós JA, Soler S, Galipienso L, Falk BW, Rubio L. Complete sequence of three different biotypes of tomato spotted wilt virus (wild type, tomato Sw-5 resistance- breaking and pepper Tsw resistance-breaking) from Spain. Arch Virol. 2015 Aug;160(8):2117-23

López-Rodríguez C, Aramburu J, Berga-Bolaños R. Transcription factors and target genes of pre-TCR signaling. Cell Mol Life Sci. 2015 Jun;72(12):2305-21.

Aramburu J, Ortells MC, Tejedor S, Buxadé M, López-Rodríguez C. 2014. Transcriptional Regulation of the Stress Response by mTOR. Science Signaling, 7: re2 (review) (IF: 7.65; Citations 2)

Berga-Bolaños R, Alberdi M, Buxadé M, Aramburu J, López-Rodríguez C. 2013. NFAT5 induction by the pre-Tcell receptor serves as a selective survival signal in T-lymphocyte development. Proc Natl Acad Sci U S A. 110: 16091-16096 (IF: 10.5; Citations 3)

Ortells MC, Morancho B, Drews-Elger K, Viollet B, Laderoute KR, López-Rodríguez C, Aramburu J. 2012. Transcriptional regulation of gene expression during osmotic stress responses by the mammalian target of rapamycin (mTOR). Nucleic Acids Res. 40: 4368-4384 (IF: 8.02; citations 9)

ABBREVIATED CV

Buxadé M, Lunazzi G, Minguillón J, Iborra S, del Val M, Aramburu J, López-Rodríguez C. 2012. Gene expression induced by Toll-like receptors in macrophages requires the transcription factor NFAT5. J Exp Med. 209: 379-393 (IF: 14.78; citations 35)

Berga-Bolaños R, Drews-Elger K, Aramburu J, López-Rodríguez C. 2010. NFAT5 regulates T lymphocyte homeostasis and CD24-dependent T cell expansion under pathologic hypernatremia. J Immunol, 185:6624- 6635. (IF: 5.65; citations 19)

Drews-Elger K, Ortells MC, Rao A, López-Rodríguez C, Aramburu J. 2009. The Transcription Factor NFAT5 Is Required for Cyclin Expression and Cell Cycle Progression in Cells Exposed to Hypertonic Stress. PLoS ONE, 4: e5245. (IF: 4.35; citations: 19)

Minguillón J, Morancho B, Kim S-J, López-Botet M, Aramburu J. 2005. Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-β1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-β1. J Leukocyte. Biol. 77: 748-758. (IF: 4.13; citations: 18)

López-Rodríguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A. 2001. Bridging the NFAT and NFkappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress. Immunity, 15:47-58. (IF: 18.31; citations: 153)

Aramburu J., Yaffe, M.B., López-Rodríguez, C., Cantley, L. C., Hogan, P.G., and Rao, A. 1999. Affinity- driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science, 285: 2129-2133. (IF: 30.03; citations: 461)

Aramburu, J., Azzoni L., Rao A., and Perussia B. 1995. Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc in human natural killer cells: regulation upon CD16 ligand binding. J Exp Med. 182:801-810. (IF: 14.48; citations: 99)

Projects (4 out of 7 as PI and 2 as collaborator)

Project title: Cell therapy approaches in transplantation by promoting anti-inflammatory and tolerogenic innate immunity: roles of calcineurin and NFAT5. Funding agency: Fundació La Marató TV3 (264/C/2012) Duration: March 2013 - March 2016 Investigators: José Aramburu (project coordinator, Universitat Pompeu Fabra, UPF), Cristina López Rodríguez (Universitat Pompeu Fabra, UPF), Susana de la Luna (Center for Genomic Regulation, CRG), Sara Martínez (National Center for Cardiovascular Research, CNIC) and Juan Miguel Redondo (National Center for Cardiovascular Research, CNIC).

Project title: Role of the transcription factor NFAT5 in T cell differentiation in response to stress and growth signals. Funding agency: Ministerio de Ciencia e Innovación (SAF2011-24268) Duration: January 2012 - December 2014 Principal investigator: José Aramburu

Project title: Regulation of cell growth by the transcription factor NFAT5. Funding agency: Ministerio de Ciencia e Innovación (BFU2008-01070). Duration: January 2010 - December 2011 8

ABBREVIATED CV

Principal investigator: José Aramburu

Project title: Characterization of the molecular basis of the regulation of NFAT5, a transcription factor of the Rel family. Funding agency: Ministerio de Educación y Ciencia (BFU2005-02247/BMC). Duration: January 2006 - December 2008 Principal investigator: José Aramburu

PhD Thesis Director

4 PhD theses directed. Currently directing 3 PhD theses

Honours and other professional activities

Dates: Description: 2013 Advanced Researcher accreditation by the Agency for the Quality of the University System of Catalonia (AQU). 2011 Accreditation of four research terms (6-year terms) by AQU. 2009 Accreditation of two teaching terms (5-year terms) by AQU. 2006 Award of the Social Council, Universitat Pompeu Fabra, for teaching merits. 2004 Researcher accreditation by AQU. 2003 Generalitat de Catalunya Distinction for the Promotion of University Research. 1996-1999 Postdoctoral Fellowship of the Arthritis Foundation, USA. 1995-1996 Postdoctoral Fellowship of the Lady Tata Foundation, UK. 1992-1994 Postdoctoral Fellowship, Ministry of Science and Education, Spain. 1988-1991 Predoctoral FPU Fellowship, Ministry of Science and Education, Spain.

Participation in research networks with external evaluation 2005-present: Consolidated Research Group (Grups de Recerca Consolidats de la Generalitat de Catalunya) SGR2005, 2009 SGR 601, 2014 SGR 1153 “Communication in the Immune System”. 2009-2013: Adscription to the HERACLES network (ISCIII-RETIC RD06/0009-FEDER), of the Ministry of Science and Innovation and Institute of Health Carlos III. Editorial activity Ad hoc reviewer of the following journals: Journal of Cell Biology, Science Signaling, Cancer Cell, Journal of Immunology, Blood, EMBO Molecular Medicine, Nucleic Acid Research, Mol Cell Biol, Biochemical Pharmacology, BBA-Gene Regulatory Mechanisms, Cell Cycle, PLoS ONE, Journal of Molecular Medicine, European Journal of Biochemistry, FEBS Letters, Experimental Cell Research.

Evaluation agencies. 2010-present: Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 2001- present: Agencia Nacional de Evaluación y Prospectiva de España (ANEP). 2008: Evaluator ad hoc of the National Research Agency (ANR) of the CNRS, France.

Academic appointments and teaching 2013-present: Vice-director, Department of Experimental and Health Sciences, Universitat Pompeu Fabra.

ABBREVIATED CV

2006-2013: Academic coordinator of the university master in Biomedical Research of Department of Experimental and Health Sciences, Universitat Pompeu Fabra. I was in charge of preparing the master accreditation by the Ministerio de Educación in 2010, and am currently co-supervising the comprehensive 2015 degree accreditation renewal (BSc in biology and associated Masters) by the Ministerio de Educación (ANECA) and Catalonian Agency for University Quality (AQU). 2002-2012: Coordinator of the biomedical research professional track in the BSc of Biology, Universitat Pompeu Fabra. These professional tracks received the Jaume Vicens Vives award of the Generalitat de Catalunya for teaching innovation in 2005. In 2006 I received the Social Council of Universitat Pompeu Fabra award for teaching merits. 2000-current: coordination and or teaching duties in 5 undergraduate (degree in Biology) subjects and 4 master subjects (Master in Biomedical Research).

Arcangeli Annarosa

Sept 20, 2017 The tumor microenvironment: cells and mechanisms underlying immunosurveillance in oncology. The cells of the immune system within a cancer tissue: morphological and functional aspects Morning lectures (3 hours) + practical histopathology course (afternoon, 3 hours)

Sept 21, 2017 Ion channels: novel actors in the immune system. Biochemical and functional aspects of ion channels. The signaling role of ion channels in the immune system. How to target ion channels: drugs vs antibodies? Morning lectures (3 hours) + practical course on bioinformatics to acquire skills for designing specific antigenic peptides and for analyzing antibody structral characteristics (afternoon, 3 hours) “Mab design for cancer immunotherapy” with the participation of Claudia DURANDI, PhD, post at A. Arcangeli Lab.

Sept 22 (morning) Business plan: development of monoclonal antibodies and engineered antibodies (scFv, diabodies, bispecific antibodies, nanobodies) towards a specific cancer-related ion channel.

CURRICULUM VITAE ANNAROSA ARCANGELI, M.D., Ph.D.

Personal Data: Date and place of birth: 20/7/1956, Pistoia, Italy Address: Viale Giovanni Milton 59, 50129, Firenze, Italy Marital status: married; two children. Education:

1975-1981- University of Florence, School of Medicine, M.D. (magna cum laude) 1981-1984- University of Florence, School of Medicine, Specialisation in Clinical and Laboratory Haematology (magna cum laude). 1986-1990- University of Florence, PhD in Experimental Pathology, 1990

Academic and Professional Appointments: 1983-1984: Fellowship of the Italian League against tumours 1984-1986: Fellowship of the Italian Association for Cancer Research 1990-1994: Fellowship of the Italian Association Against Leukaemia 1994-1998: Researcher in General Pathology, University of Florence 1998- 2012: Associate Professor of General Pathology, University of Florence 2002-2004. Member of the Committee on Equal Opportunities of the University of Florence 2005-2007: President Associazione Italiana contro le Leucemie (AIL)- Pistoia 2006-present: Scientific Director of LIGeMA (a joined laboratory of the University of Florence for the production of transgenic mice and preclinical in vivo tests) 2010-2013: Elected Member of the Board of the Associazione di Biologia Cellulare e del Differenziamento (ABCD) 2012-present: Full professor of General Pathology, University of Florence, School of Medicine. 2012-present: Co-founder and scientific director of the spin-off of the University of Florence Dival-Toscana Srl. 2013-present: Scientific Director of DIVAL-RISE laboratory (a joined laboratory of the University of Florence for the accomplishment of pre-clinical and molecular biology tests) 2014-present: Member of the Directory Committee of the Center for Valorization of the Research and Management of the Incubator (CSAVRI) of the University of Florence. 2016: designed member of the Tuscan Committee for Health Education 2016-present: designed member of the Board of Administration of the Fondazione Cassa di Risparmio di Pistoia e Pescia. 2017: co-founder and scientific director of the spin-off of the University of Florence MCK Therapeutics.

Visiting Scientist: 1982:Laboratory of Dr. G.Clarke, Imperial Cancer Research Fund, London, UK 1986-87:Laboratory of Electrophysiology (chairmam Dr.E.Wanke), University of Milano, Italy. 1994 :Laboratory of Embryology (chair Dr Catherine Ziller), Istitut d'Embryologie Cellulaire et Moleculaire (chair Prof.N.M.Le Douarin), Paris, France. 1997:"ICRF Cell Interaction Laboratory" (Dr.E, Gherardi), Medical Research Council, Cambridge, UK (as fellowship of the Italian Foundation for Cancer Research). 2002- “MRC- Growth Factors Group (Dr. E.Gherardi) Medical Research Council, Cambridge, UK (as fellowship of the Italian Foundation for Cancer Research). 2003: Dr. Sam Aparicio: Deparment of Oncology. University of Cambridge. 2007: Dr. E. Gherardi, Growth factors Group, MRC-LMB, Cambridge 2015: Dr. M. Stelzle, NMI, University of Tubingen, Reutlingen, Germany.

Scientific Society Memberships: SIP (Società Italiana di Patologia) ABCD (Associazione di Biologia Cellulare e Differenziamento) ASH (American Society of Hemathology) 12

EACR (European Association for Cancer Research)

TEACHING

Prof. A. Arcangeli is Full Professor of General Pathology at the University of Florence. Since 1998 she teaches: (1) General Pathology at the School of Medicine, Master Degree in Medicine; (2) General Pathology, Oncology, Immunology and Immunological Techniques, Immunology and Immunopathology at the Faculty of Sciences (SMFN), Master Degree in Biology and Master Degree in Molecular Biotechnology; (3) General Pathology at the School of Specialization in Pediatrics, School of Specialization in Neurology of the School of Medicine; (3) General Pathology at the Second level Master in Obstetrics of the School of Medicine. Since 2006, Prof. A. Arcangeli is the organizer of the annual Erasmus Course in Oncology, in collaboration with the University Paris 7. During her teaching activity Prof. Arcangeli has been supervisor of more than 400 graduate students.

Prof. Arcangeli has been teacher at the PhD School of Experimental and Clinical Oncology at the University of Florence, at the PhD School of Engineering and Informatics (curriculum: Non linear dynamics and Complex Systems) of the University of Florence, and since 2015, at the Tuscan PhD School in Genetics, Oncology and Clinical Medicine. During her teaching activity Prof. Arcangeli has been supervisor of more than 40 PhD students. Prof. Arcangeli has been supervisor of PhD students at the Universitè de Lion, University of Glauchester and of three Marie Curie PhD students.

RESEARCH ACTIVITY:

Research Interest:

Since more than thirty years Prof. Arcangeli has been involved in oncological studies. Her M.D. thesis (1981) contributed to define the cytokinetic charateristics of leukemia cell cycle and growth. After her specialization in Hemathology, she started studies to define the biophysical aspects of leukemias.

1) The paper “A novel inward rectifiying K+current with a cell cycle-dependence governs the resting potential of neuroblastoma cells”. J Physiol., 489, 455-471, 1995 was the first showing the role of a K+ channel in tumor cell cycle regulation. Afterwards, the PI defined the role of hERG1 channel in cancer establishment and progression, integrating biophysical, biomolecular and genetic approaches. Ten years later (“Expression and role of hERG channels in cancer cells. Novartis Foundation symposium 2005; 266:225-32; discussion 232-4) she presented to cardiologists, pharmacologists and regulatory authorities, at the Novartis headquarters, the wide expression of hERG1 in tumor cells and the possibility of considering hERG1 an oncological target (see also the recent paper Arcangeli A, Becchetti A. Novel perspectives in cancer therapy: Targeting ion channels. Drug Resist Updat. 2015 Jul 6. pii: S1368-7646(15)00034-5. doi: 10.1016/j.drup.2015.06.002).

2) The manuscript Arcangeli, A. et al., HERG- and IRK-like inward rectifier currents are sequentially expressed during neuronal development of neural crest cells and their derivatives. Eur J Neurosci 9: 2596-2604, 1997 was the first showing the presence of a hERG1 –like current in neurons developing from neural crest cells in quail embryos. This discovery was followed by several papers in high impact journals aimed at deciphering the expression and role of hERG1 currents in the regulation of cell excitability in selected populations of the CNS and PNS. All the studies regarding this topic have been recently reviewed in a chapter of the book Ion Channel Drug Discovery, from the series RSC Drug Discovery (Mitcheson J. and Arcangeli A. The Therapeutic Potential of hERG1 Channels for Treating Cancer and Cardiac Arrhythmias. 2014).

3) The manuscript “Complex functional interaction between integrin receptors and ion channels By: Arcangeli A, Becchetti A. Trends Cell Biol. 2006; 16:631-39”. This review followed, after fifteen years, the first demonstration of a functional and 13

physical association between different ion channels and integrins in cancer cells (Arcangeli, A. et al., Integrin-mediated neurite outgrowth in Neuroblastoma cells depends on the activation of potassium channels. J Cell Biol 122: 1131-1143, 1993). In fact, from 1991 several papers have been published by the Prof. Arcangeli to better define the molecular characteristics of this association. Overall, the concept that integrin-mediated adhesion activates different ion channels can be reconducted mainly to the scientific work of Prof. Arcangeli. These findings are reaching the translability thanks to the development of single chain diabodies, targeting the molecular complex constituted by hERG1 and 1 integrin (Italian patent Nr. FI2014A000189 (08.08.2015)”Anti-hERG1 molecules”).

4) The manuscript “Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells By: Crociani O, et al. J. Biol. Chem. 2003; 278:2947-55”. This pioneer paper identified a tumor specific isoform of hERG1 channels, hERG1B. This manuscript has attracted pharmaceutical companies (BlackSwanPharma at first, and more recently Ono Pharmaceuticals) to accept and adopt the new concept that hERG1B could be considered a pharmaceutical target instead of an anti-target as the cardiac full length hERG1A isoform. The main clinical translations of this paper are: (1) the recently published paper Pillozzi S et al. “Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups” Leukemia 2014 Jan 16. doi: 10.1038/leu.2014.26) showing that hERG1B is the only hERG1 isoform in pediatric leukemias, and contributes to identify a subset of patients with worse prognosis; (2) the paper published on Molecular Pharmacology (Gasparoli L, D'Amico M, et al. The New Pyrimido-indole Compound CD-160130 Preferentially Inhibits the KV11.1B Isoform and Produces Antileukemic Effects Without Cardio-toxicity. Mol Pharmacol. 2015 Feb;87(2):183-96. doi: 10.1124/mol.114.094920. Publication List:

Peer reviewed publications (2017-2010/1981)

1. Beer M, Kuppalu N, Stefanini M, Becker H, Schulz I, Manoli S, Schuette J, Schmees C, Casazza A, Stelzle M, Arcangeli A. A novel microfluidic 3D platform for culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures and in vivo xenografts. Scientific Reports 7(1):1325. doi: 10.1038/s41598- 017-01256-8, 2017.

2. Becchetti A, Crescioli S, Zanieri F, Petroni G, Mercatelli R, Coppola S, Gasparoli L, D'Amico M, Pillozzi S, Crociani O, Stefanini M, Fiore A, Carraresi L, Morello V, Manoli S, Brizzi MF, Ricci D, Rinaldi M, Masi A, Schmidt T, Quercioli F, Defilippi P, Arcangeli A. The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Science Signaling.;10(473). pii: eaaf3236. doi: 10.1126/scisignal.aaf3236. PMID: 28377405, 2017.

3. Cirri D, Pillozzi S, Gabbiani C, Tricomi J, Bartoli G, Stefanini M, Michelucci E, Arcangeli A, Messori L, Marzo T. PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. Dalton Trans.;46(10):3311-3317. doi: 10.1039/c6dt03867k.PMID: 28229139, 2017. 4. Arcangeli A and Becchetti A. hERG Channels: From Antitargets to Novel Targets for Cancer Therapy. Clin Cancer Res. 23(1):3-5. doi: 10.1158/1078-0432.CCR-16-2322. Epub 2016 Nov 30. PMID: 27903676, 2017.

5. Muratori L*, Petroni G*, Antonuzzo L, Boni L, Iorio J, Lastraioli E, Bartoli G, Messerini L, Di Costanzo F, Arcangeli A. hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther. 14;9:6325-6332. PMID: 277899, 2016.

6. Noci I, Sorbi F, Mannini L, Projetto E, Pillozzi S, Ghizzoni V, Lottini T, Moncini D, Baroni G, Mungai F, Arcangeli A, Fambrini M. LH/hCG-Receptor Expression May Have a Negative Prognostic Value in Low-Risk Endometrial Cancer. Front Oncol.;6:190. doi: 10.3389/fonc.2016.00190, 2016.

7. Lastraioli E, Lottini T, Iorio J, Freschi G, Fazi M, Duranti C, Carraresi L, Messerini L, Taddei A, Ringressi MN, Salemme M, Villanacci V, Vindigni C, Tomezzoli A, La Mendola R, Bencivenga M, Compagnoni B, Chiudinelli M, Saragoni L, Manzi I, De Manzoni G, Bechi P, Boni L, Arcangeli A. hERG1 behaves as a biomarker of progression to adenocarcinoma in Barrett’s esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget. ;7(37):59535-59547. doi: 10.18632/oncotarget.11149. PMID: 27517748, 2016.

8. Pillozzi S, Masselli M, Gasparoli L, D'Amico M, Polletta L, Veltroni M, Favre C, Basso G, Becchetti A, Arcangeli A. Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels. Blood Cancer J., 6:e423. doi: 10.1038/bcj.2016.32, 2016.

9. Marzo T, Bartoli G, Gabbiani C, Pescitelli G, Severi M, Pillozzi S, Michelucci E, Fiorini B, Arcangeli A, Quiroga AG, Messori L. Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles. Biometals ;29(3):535-42. doi: 10.1007/s10534-016-9934-4, 2016.

10. Battistin F, Scaletti F, Balducci G, Pillozzi S, Arcangeli A, Messori L, Alessio E. Water-soluble Ru(II)- and Ru(III)- halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. J Inorg Biochem. 160:180-8. doi: 10.1016/j.jinorgbio.2016.02.009, 2016.

11. Brunetti J, Pillozzi S, Falciani C, Depau L, Tenori E, Scali S, Lozzi L, Pini A, Arcangeli A, Menichetti S, Bracci L. Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. Sci Rep.;5:17736. doi: 10.1038/srep17736, 2015.

12. Marzo T, Pillozzi S, Hrabina O, Kasparkova J, Brabec V, Arcangeli A, Bartoli G, Severi M, Lunghi A, Totti F, Gabbiani C, Quiroga AG, Messori L. cis-Pt I2(NH3)2: a reappraisal. Dalton Trans. 7;44(33):14896-905. doi: 10.1039/c5dt01196e, 2015.

13. Lastraioli E, Lottini T, Bencini L, Bernini M, Arcangeli A. hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers. Biomed Res Int. 2015:896432. doi: 10.1155/2015/896432. 2015.

14. Arcangeli A, Becchetti A. Novel perspectives in cancer therapy: Targeting ion channels. Drug Resist Updat. 21-22: 11-9, pii: S1368-7646(15)00034-5. doi: 10.1016/j.drup.2015.06.002, 2015.

15. Massai L, Fernández-Gallardo J, Guerri A, Arcangeli A, Pillozzi S, Contel M, Messori L. Design, synthesis and characterisation of new chimeric ruthenium(ii)-gold(i) complexes as improved cytotoxic agents. Dalton Trans. 28;44(24):11067-76. doi: 10.1039/c5dt01614b, 2015.

16. Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D'Amico M, Masselli M, Iorio J, Callea M, Borzomati D, Nappo G, Bartolozzi F, Santini D, Bencini L, Farsi M, Boni L, Di Costanzo F, Schwab A, Onetti Muda A, Coppola R, Arcangeli A. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer. 112(6):1076-87. doi: 10.1038/bjc.2015.28, 2015.

17. Bandinelli F, Milia AF, Manetti M, Lastraioli E, D' Amico M, Tonelli P, Fazi M, Arcangeli A, Matucci-Cerinic M, Ibba-Manneschi L. Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn's disease: two overlapping diseases? Clin Exp Rheumatol. ;33(2):195-200. PMID: 25664492, 2015.

18. Gasparoli L, D'Amico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A, Mitcheson JS, Basso G, Becchetti A, Arcangeli A. The New Pyrimido-indole Compound CD-160130 Preferentially Inhibits the KV11.1B Isoform and Produces Antileukemic Effects Without Cardio-toxicity. Mol Pharmacol. 87(2):183-96. doi: 10.1124/mol.114.094920, 2015.

19. Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. Biochim Biophys Acta. pii: S0005-2736(14)00452-0. doi: 10.1016/j.bbamem.2014.12.016, 2014.

20. Chiu M, Tardito S, Pillozzi S, Arcangeli A, Armento A, Uggeri J, Missale G, Bianchi MG, Barilli A, Dall'Asta V, Campanini N, Silini EM, Fuchs J, Armeanu-Ebinger S, Bussolati O. Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. Br J Cancer. 9;111(6):1159-67. doi: 10.1038/bjc.2014.425, 2014.

21. Pillozzi S, Gasparoli L, Stefanini M, Ristori M, D'Amico M, Alessio E, Scaletti F, Becchetti A, Arcangeli A* and Messori L*. NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. Dalton Trans. 28;43(32):12150-5. doi: 10.1039/c4dt01356e, 2014.

22. Falsini S, Ristori S, Ciani L, Di Cola E, Supuran CT, Arcangeli A, In M. Time resolved SAXS to study the complexation of siRNA with cationic micelles of divalent surfactants. Soft Matter. 7;10(13):2226-33. doi: 10.1039/c3sm52429a, 2014.

23. Lastraioli E, Boni L, Romoli MR, Crescioli S, Taddei A, Beghelli S, Tomezzoli A, Vindigni C, Saragoni L, Messerini L, Bernini M, Bencini L, Giommoni E, Freschi G, Di Costanzo F, Scarpa A, Morgagni P, Farsi M, Roviello F, De Manzoni G, Bechi P, Arcangeli A; Gruppo Italiano di Ricerca Cancro Gastrico (GIRCG). VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort. Eur J Surg Oncol. Apr 12. pii: S0748-7983(14)00395-3. doi: 10.1016/j.ejso.2014.03.028, 2014.

24. Arcangeli A, Crociani O, Bencini L. Interaction of tumour cells with their microenvironment: ion channels and cell adhesion molecules. A focus on pancreatic cancer. Philos Trans R Soc Lond B Biol Sci. 369:20130101, 2014.

25. Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, D’Amico M, Stefanini M, Crescioli S, Taddei A, Bencini L, Bernini M, Farsi M, Beghelli S, Scarpa A, Messerini L, Tomezzoli A, Vindigni C, Morgagni P, Saragoni L, Giommoni E, Gasperoni S, Di Costanzo F, Roviello F, De Manzoni G, Bechi P, Arcangeli A. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathologial correlations and therapeutical implications. Clin Cancer Res 20: 1502-1516, 2014.

26. Pillozzi S, Accordi B, Rebora P, Serafin V, Valsecchi MG, Basso G, Arcangeli A. Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. Leukemia 2: 1-4, 2014.

27. Bernini A, De Angelis LH, Morandi E, Spiga O, Santucci A, Assfalg M, Molinari H, Pillozzi S, Arcangeli A, Niccolai N. Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies. Biochim Biophys Acta 1844: 561-566, 2014.

28. Sette A, Spadavecchia J, Landoulsi J, Casale S, Haye B, Crociani O, Arcangeli A. Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO(2) nanoparticles for targeting pancreatic ductal adenocarcinoma cells. J Nanopart Res 15:2111-2118, 2013.

29. Pillozzi S, Fortunato A, De Lorenzo E, Borrani E, Giachi M, Scarselli G, Arcangeli A*, Noci I*. Over-Expression of the LH Receptor Increases Distant Metastases in an Endometrial Cancer Mouse Model. Front Oncol 3: 285-296, 2013.

30. Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A, Fortunato A, D'Amico M, Masselli M, De Lorenzo E, Gasparoli L, Chiu M, Bussolati O, Becchetti A, Arcangeli A. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep. 3:3308-3329, 2013. 31. Becchetti A, Munaron L, Arcangeli A. The role of ion channels and transporters in cell proliferation and cancer. Front Physiol. 4: 312, 2013.

32. Fortunato A, Gasparoli L, Falsini S, Boni L, and Arcangeli A. An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer. Diagn Mol Pathol 22: 215-221, 2013.

33. Falsini S, Ciani L, Ristori S, Fortunato A, Arcangeli A. Advances in Lipid-Based Platforms for RNAi Therapeutics. J Med Chem. 57: 1138-1146, 2013.

34. Fiore A, Carraresi L, Morabito A, Polvani S, Fortunato A, Lastraioli E, Femia AP, De Lorenzo E, Caderni G, Arcangeli A. Characterization of hERG1 channel role in mouse colorectal carcinogenesis. Cancer Med 2: 583-594, 2013.

35. Arcangeli A, Romoli MR, Boni L, Gerlini G, Tofani L, Urso C, Borgognoni L. High hERG1 expression in advanced melanoma. Melanoma Res. 23: 185-90, 2013.

36. Munaron L, Arcangeli A. Ion fluxes and Cancer. Recent Pat Anticancer Drug Discov 8:1-3, 2013.

37. D'Amico M, Gasparoli L, Arcangeli A. Potassium channels: novel emerging biomarkers and targets for therapy in cancer. Recent Pat Anticancer Drug Discov 8: 53-65, 2013.

38. Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol 2012:868645, 2012.

39. Masselli M, Laise P, Tonini G, Fanelli D, Pillozzi S, Cetica V, Da Ros M, Sardi I, Buccoliero AM, Aricò M, Genitori L, Becchetti A, Arcangeli A. Deregulation of ion channel and transporter encoding genes in pediatric gliomas. Front Ped Oncol 2: 53-65, 2012. 17

40. Mori M, De Lorenzo E, Torre E, Fragai M, Nativi C, Luchinat C, Arcangeli A. A Highly Soluble Matrix Metalloproteinase-9 Inhibitor for Potential Treatment of Dry Eye Syndrome. Basic Clin Pharmacol Toxicol 111: 289-295, 2012

41. Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, Messerini L, Gasperoni S, Moretti R, Di Costanzo F, Boni L, Arcangeli A. hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Transl Oncol 5: 105-12, 2012.

42. Laise P., Fanelli D., Lió P. and Arcangeli A. Modeling TGF-β signaling pathway in epithelial-mesenchymal transition. AIP Advances 2: 011201-11, 2012.

43. Arcangeli A., Pillozzi S. and Becchetti A. Targeting Ion Channels in Leukemias: a New Challenge for Treatment. Curr Med Chem 19: 683-689, 2012.

44. Bogani P., Spiriti M.M., Lazzarano S., Arcangeli A., Buiatti M. and Minunni M. Transgene traceability in transgenic mice: a bioanalytical approach for potential gene-doping analysis. Bioanalysis, 3: 2523-2531, 2011.

45. Laise P., Fanelli D. and Arcangeli A. A dynamical model of apoptosis and its role in tumor progression. Communications in Nonlinear Science and Numerical Simulation 17: 1795-1806, 2012.

46. Arcangeli A. Ion channels and transporters in cancer. 3. Ion channels in the tumor cell-microenvironment cross talk. Am J Physiol Cell Physiol. 30: C762-771, 2011.

47. Arcangeli A, Yuan JX. American Journal of Physiology-Cell Physiology theme: ion channels and transporters in cancer. Am J Physiol Cell Physiol. 301: C253-254. 2011.

48. Laise P, Di Patti F, Fanelli D, Masselli M, Arcangeli A. Deterministic and stochastic aspects of VEGF-A production and the cooperative behavior of tumoral cell colony. J Theor Biol. 272: 55-63, 2011.

49. Pillozzi S, Masselli M, DeLorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D’Amico M, Basso G, Becchetti A, Campana D and Arcangeli A. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117: 902-914, 2011.

50. Fortunato P, Pillozzi S, Tamburini A, Pollazzi L, Franchi A, La Torre A, Arcangeli A. Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer 10: 504-510, 2010.

51. Arcangeli A, Toma L, Contiero L, Crociani O, Legnani L, Lunghi C, Nesti E, Moneti G, Richichi B, Nativi C. Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells. Bioconjug Chem 21: 1432-1438, 2010.

52. Redaelli E, Restano Cassulini R, Fuentes Silva D, Clement H, Schiavon E, Zamudio FZ, Odell G, Arcangeli A, Clare JJ, Alagon A, Rodriguez de la Vega RC, Possani LD, Wanke E. Target promiscuity and heterogeneous effects of tarantula venom peptides affecting Na+ and K+ ion channels. J Biol Chem. 285: 4130-4142, 2010 18

2. Books and invited chapters

1) Olivotto, M., Arcangeli, A., Dello Sbarba, P., Meccanismi di innesco del ciclo mitotico e differenziamento in cellule normali e neoplastiche. In: "La cellula neoplastica", G.Prodi, L.Alberghina, M.I.Colnaghi, P.M.Comoglio, F.Squartini, P.Calissano, S.Pontremoli e G.Rotilio Eds. (CEA, Milano), pp.81-88, 1986

2) Arcangeli, A., Del Bene, M.R., Olivotto, M. and Wanke, E., Ion channels in cancer cells.In " Membrane Technology", Vol.64, pp.65-79, Raven Press, New York, 1989.

3) Arcangeli, A. Ruolo dei flussi ionici e del potenziale di membrana nella biologia delle cellule di Eritroleucemia di Friend. Tesi di Dottorato in Patologia Sperimentale, 1990.

4) Arcangeli A. Expression and role of hERG channels in cancer cells. The hERG cardiac potassium channel: structure, function, and long QT syndrome. Wiley, Chichester. “Novartis Foundation Symposium”. 266: 225-234, 2005.

5) Arcangeli A. and Becchetti A. “Ion channels and cell cycle” in “Cell cycle and the central nervous system” d. D. Janigro. Humana Press Inc., New Jersey Totowa, 2005.

6) Becchetti A., Pillozzi S., Morini R., Nesti E. and Arcangeli A. “New insights into the regulation of ion channels by integrins”. Int. Rev. Cell Mol. Biol., vol. 279: 135-190. K.Jeon, Ed., Elsevier, 2010.

7) Becchetti A, Arcangeli A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 674:107-23, 2010.

8) Pillozzi S, Arcangeli A.Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol. 674:55-67, 2010.

9) Masi A, Cicchi R, Carloni A, Pavone FS, Arcangeli A. Optical methods in the study of protein-protein interactions. Adv Exp Med Biol. 674:33-42 2010.

10) Arcangeli A, Becchetti A. Integrin structure and functional relation with ion channels.Adv Exp Med Biol. 674:1-7, 2010.

11) Becchetti A, Arcangeli A. Integrins and ion channels: molecular complexes and signaling. Adv Exp Med Biol.674:v-vii, 2010.

12) Arcangeli A, Noci I, Fortunato A, Scarselli GF. The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease.Obstet Gynecol Int. pii: 486164. Epub 2010 Jul 15, 2010.

13) Arcangeli A. and Becchetti A. “New trends in cancer therapy: targeting ion channels and transporters.” Pharmaceuticals, 3: 1202-1224, 2010.

14) Arcangeli A., Pillozzi S., Becchetti A. Ion Channels: Novel Functional Hubs in Leukemia. In: Cancer Treatment/Book 1, InTech Open Access Publisher, 2011.

15) Mitcheson J. and Arcangeli A. The Therapeutic Potential of hERG1 K1 Channels for Treating Cancer and Cardiac Arrhythmias. In: Ion Channel Drug Discovery, 2014.

Books: 19

1. Integrins and Ion Channels. Andrea Beccjetti and Annarosa Arcangeli Eds. , Springer, 2010

Grants:

Present:

- AIRC (Associazione Italiana per la Ricerca sul cancro) 2014 (2015-2017): grant N°15627; € 250.000

- Associazione Genitori Noi per Voi € 150.000;

- ECRF 2015-2017: € 50.000

-Tuscan Region (FAS; Omiterc): € 430.000

Past (2001-2015): AIRC (Italian Association for Cancer Research) 2007-2010; grant N°10275 € 180.000

-Associazione Noi per Voi Onlus 2007-2010, € 300.000. ECRF 2010,€ 40.000; AIRC (Italian Association for Cancer Research) grant N° 06-0491, 2004-2007; € 120.000; AICR (Association for International Cancer Research) 2005-2009; £ 123.000; ITT 2006, € 60.000; ECRF -MIUR-PRIN 2005 € 78.000; MIUR-PRIN 2003, € 78.000; MIUR-PRIN 2001, € 90.000; ECRF 2008, € 50.000; ECRF 2005, € 78.000; ITT (Tuscany Institute for Cancer Research) 2007-2011; €193.000; MIUR-PRIN 2008; € 34000; ECRF 2011, € 50.000; AIRC (Italian Association for Cancer Research) 2010-2013; € 90.000 per year; Tuscan Region (POR CReO FESR 2007 - 2013 ATTIVITA' 1.1. C); 2010-2013; € 497.800; Associazione Noi per Voi Onlus; 2010-2013; € 300.000; FP7-People-2011-ITN, project N°289648 IonTraC—Ion Transport Proteins in Control of Cancer Cell Behaviour. € 254.454; ITT (Tuscany Institute for Cancer Research); 2009-2012; shared with AOUC; €101.000; ITT (Tuscany Institute for Cancer Research); 2010-2012; shared with Dept. Chemistry UNIFI, € 50.000.Tuscan Region (POR CReO FESR 2007 - 2013 ATTIVITA' 1.1. C); 2012-2015; € 432.000.

Patents and Spin-offs: - FI2006A000008: “Ibridoma capace di produrre un anticorpo monoclonale anti-HERG1, anticorpo monoclonale così prodotto, metodo per la determinazione dei livelli di proteina HERG1, e kit per tale determinazione“ * This patent was awarded with the Vespucci Award in 2008. - European Patent n. EP2498773 “New compositions for the treatment of chemoresistant and/or potentially chemoresistant leukaemias”. This patent translates to the clinical setting the findings published in Pillozzi et al., Blood, 2007 and Pillozzi et al., Blood, 2011. The patent has defined for the first time a treatment schedule for chemoresistant leukemias, including hERG1 targeting drugs. Patent license has been submitted for extension to U.S.A. - European Patent n. 12756392.2 - "HERG1 and GLUT-1 in colorectal cancer"- This patent translates to the clinical setting the findings published in Lastraioli et al., Canc. Res., 2004, Lastraioli et al., Transl. Oncol., 2012. The patent defines the procedures for exploiting hERG1 and Glut1 expression to stratify stage II colorectal cancer patients with worse prognosis, and hence more adapt for adjuvant chemotherapy. Patent license has been submitted for extension to U.S.A. The patent has been recently (end 2015) licensed to DIVAL. - 7) Italian patent Nr. FI2014A000189 (08.08.2015)”Anti-hERG1 molecules”. This patent covers the development of a single chain variable fragment (scFV) from the manoclonal anti-hERG1 antibody, and its

sequence. Moreover any further engineered antibodies (e.g. bifunctional diabodies) or nanoparticles functionalized with the scFV are covered by the patent. Patent license has been extended as PCT and the patent has been recently (end 2015) licensed to DIVAL. Co-founder of the spin-off of the University of Florence DIVAL Toscana Srl. (2012) and of the spin-off of the University of Florence MCK Therapeutics Srl. (2017).

Ashhab Yaqoub Curriculum vitae

Name: Yaqoub Ashhab Date of birth: 1 Jul.1967 Place of birth: Hebron, Palestine Nationality: Palestinian /Spanish Marital status: Married Address: Biotechnology Research Center, Palestine Polytechnic University, Hebron, Palestine. Tel: +972-2-2235505 ext. 140 E-mail: [email protected]

Academic and Professional Experience

2008 - Associated Professor and Director Biotechnology Research Center, Palestine Polytechnic University.

2009 -2011 Dean of Graduate Studies and Scientific Research Palestine Polytechnic University, Hebron, Palestine.

2005 -2008 Assistant Professor Palestine Polytechnic University, Hebron, Palestine.

2002 -2004 Research Associate Hadassah Medical Center, Hebrew University, Jerusalem.

Fellowships

May 2013–Sep 2013 Visiting Researcher Research Center of Novartis Vaccines & Diagnostics - Siena, Italy

1998 -2002 Postdoctoral Fellow Hadassah Medical Center, Hebrew University, Jerusalem

Education

1998 Ph.D. Molecular Immunology Universitat Autònoma de Barcelona, Spain. (high honor) Advisor: Prof. Ricardo Pujol-Borrell

1995 M.Sc. Molecular Immunology Universitat Autònoma de Barcelona, Spain. (high honor) Advisor: Prof. Ricardo Pujol-Borrell

1991 B.Sc. Biology Middle East Technical University- Ankara, (GPA 3.74/4.0 Class Rank: First) Turkey.

Honors and Awards

2010 Board of Trustee Shield of Recognition Distinguished applied research project

2002 Lady Davis fellowship Distinguished post-doctoral fellow

1991 Rector Prize Prof. Ömer Saatçioğlu. Middle East Technical University

1991 Turkish Minster of Higher Education Prize Prof. Avni Akyol

Scientific and Professional Societies Memberships Founder and board member: the Palestinian Forum for Medical Research (PFMR). www.pfmr.ps. Associate editor: Network Modeling Analysis in Health Informatics and Bioinformatics Review editor: Frontiers in Non-Coding RNA journal Technical committee member: The International Arab Journal of Information Technology Member: The International Society of Computational Biology "ISCB" 2004-2006 Member: The international Human Genome Organization "HUGO" 2004-2005. Member: The British Biochemical Society 1998-99. Ad-hoc reviewer: International Journal of Data Mining and Bioinformatics, journal of Amino Acids, and Infection, Genetics and Evolution.

Teaching Activities Graduate courses

1. Immunoinformatics (2006-) A module of Immunogenetics course of the Immunology Master Program, which is offered jointly by Universitat Autònoma de Barcelona (UAB) and Universitat de Barcelona (UB).

2. Bioinformatics (2008-) An obligatory 3 credit hours course of the Biotechnology Master Program that is offered jointly by Palestine Polytechnic and University Bethlehem University.

3. Introduction to Bioinformatics and Sequence Analysis (2008-2012) 22

This is an intensive practical course to graduate students from different Turkish universities that is organized by Marmara National Research Center, Istanbul.

Undergraduate courses: Immunology

Student Supervision • 5 M. Sc. Students, Biotechnology Master Program that is offered jointly by Palestine Polytechnic and University Bethlehem University. • 4 M. Sc. Students, Informatics Master Program, Palestine Polytechnic and University.

Curriculum Development Project name: Development of M. Sc. program in biotechnology 2007. (Offered jointly by Palestine Polytechnic and University Bethlehem University) (Role: project coordinator)

Project name: Improving Biotechnology Curricula Content and Relevance to Sustainable Development in Palestine. This project was presented to TEMPUS program, EC. It was a joint project with three Palestinian universities and 3 European universities.(Role: Proposal writing and project coordinator)

Spoken Languages • Arabic (native language) • English (very good) • Spanish (good) • Hebrew (good) • Turkish (fair)

Publications

Papers published in peer-reviewed Journals

1. Tamimi A, Ashhab Y, Tamimi H. Accelerating Information Retrieval from Profile Hidden Markov Model Databases. PLoS One. 2016 Nov 22;11(11):e0166358. 2. Issa MN, Ashhab Y. Identification of Brucella melitensis Rev.1 vaccine-strain genetic markers: Towards understanding the molecular mechanism behind virulence attenuation. Vaccine. 2016 Sep 22;34(41):4884-4891. 3. Mohammad Qabajah, Elena Awwad, and Yaqoub Ashhab. Molecular characterization of Escherichia coli from dead broiler chickens with signs of colibacillosis and ready-to-market chicken meat in the West-Bank. Br Poult Sci. 2014 Sep 3:1-10 4. B. Nesta, M. Valeri, A. Spagnuolo, R. Rosini, M. Mora, P. Donato, C.J. Alteri, M. Del-Vecchio, S. Buccato, A. Pezzicoli, I. Bertoldi, L. Buzzigoli. G. Tuscano, M. Falduto, V. Rippa, Y. Ashhab, G. Bensi, M.R.Fontana, K. L. Seib, H. L.T. Mobley, M. Pizza, M. Soriani, and L. Serino. "SslE elicits functional antibodies that impair in vitro

mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains". PLOS Pathogens 2014 May 8;10(5):e1004124. 5. Ayyash M., Tamimi H., Ashhab Y. Developing a Powerful In Silico Tool for the Discovery of Novel Caspase-3 Substrates: A Preliminary Screening of the Human Proteome. BMC Bioinformatics 2012, 13:14. 1. Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D. Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 2009 Apr;15(3):20613 2. Nachmias B, Mizrahi S, Elmalech M, Lazar I, Ashhab Y, Gazit R, Markel G, Ben-Yehuda D, Mandelboim O. Manipulation of NK cytotoxicity by the IAP family member Livin. Eur J Immunol. 2007, 37(12):3467-76. 3. Nachmias B, Lazar I, Elmalech M, Abed-El-Rahaman I, Asshab Y, Mandelboim O, Perlman R, Ben-Yehuda D. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin. Apoptosis. 2007, 12(7):1129-42. 4. Ferrer-Francesch X, Caro P, Alcalde L, Armengol MP, Ashhab Y, Lucas-Martin A, Martinez-Caceres EM, Juan M, Pujol- Borrell R. One-tube-PCR technique for CCL2, CCL3, CCL4 and CCL5 applied to fine needle aspiration biopsies shows different profiles in autoimmune and non-autoimmune thyroid disorders. J Endocrinol Invest. 2006, 29(4):342-349. 5. Colobran R, Adreani P, Ashhab Y, Llano A, Este J, Dominguez O, Pujol-Borrell R, Juan M. "Multiple products derived from two CCl4 loci: high incidence of a new polymorphism in HIV+ patients". Journal of Immunology. 2005, 174:5655-5664. 6. Lossos A, Ashhab Y, Sverdlin E, Amir G, Ben-Yehuda D, Siegal T. "Late-delayed cerebral involvement in systemic non- Hodgkin's lymphoma: a second primary tumor or a tardy recurrence?". Cancer. 2004, 101(8):1843- 9. 7. Nachmias B, Ashhab Y, and Ben-Yehuda D. “The Anti Apoptosis Protein Family (IAPs)- An Emerging Therapeutic Target in Cancer”. Seminars in Cancer Biology. 2004, 14: 231-243. 8. Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, Peretz T, Mandelboim O, and Ben-Yehuda D. “Caspase-Mediated Cleavage Converts Livin from an Anti-apoptotic to a Pro-apoptotic Factor: Implications for Drug- resistant Melanoma”. Cancer Research. 2003, 63(19):6340-9. 9. Shteper PJ, Zacharia E, Ashhab Y, Peretz T, Vlodavsky I, and Ben-Yehuda D. “Role of promoter methylation in regulation of the mammalian heparanase gene”. Oncogene 2003, 22(49):7737-49. 10. Domínguez O, Sabater L, Ashhab Y, Belloso E, and Pujol-Borrell R. “AU-Differential Display (AU-DD), Reproducibility of a Differential mRNA Display Targeted to AU Motifs”. Methods Mol Biol. 2003; 226:225 36. 11. Sabater L, Ashhab Y, Caro P, Kolkowski EC, Pujol-Borrell R, Dominguez O. “Identification of a KRABcontaining zinc finger protein, ZNF304, by AU-motif-directed display method and initial characterization in lymphocyte activation”. Biochem Biophys Res Commun. 2002; 293(3):1066-72. 12. Ashhab Y, Alian A, Polliack A, Panet A, Yehuda DB.Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 2001 Apr 20; 495(1-2):56-60. 13. Ashhab Y, Dominguez O, Sospedra M, Roura-Mir C, Lucas-Martin A, Pujol-Borrell R. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. J Clin Endocrinol Metab 1999;84(8):2873-82. 14. Dominguez O, Ashhab Y, Sabater L, Belloso E, Caro P, Pujol-Borrell R. Cloning of ARE-containing genes by AU-motif- directed display. Genomics 1998 Dec 1;54(2):278-86. 15. Sospedra M., Tolosa E, Armengol P, Ashhab Y, Urlinger S, Lucas-Martin A, Foz-Sala M, Jaraquemada D, and Pujol- Borrell R, “Hyperexpression of transporter in antigen processing-1 (TAP-1) in thyroid glands affected by autoimmunity: a contributory factor to the breach of tolerance to thyroid antigen?” Clin Exp Immunol 1997; 109: 98-106. 24

Book Chapters

1. Ashhab Y. Bioinformatics and Genomics Sciences in the Middle East; Opportunities and Challenges. New life Sciences; Future Prospects. Biovision 2010. Bibliotheca Alexandrina. 2. Sasson S, Ashhab Y, Melloul D, Cerasi E. “Autoregulation of glucose transporter: effects of glucose on glucose transporter expression and cellular location in muscle” New Concepts in the Pathogenesis of NIDDM, p113-127, C.G. Ostenson et al., Plenum Press, New York , 1993.

Conference Proceedings 1. Sharabati A and Ashhab Y. Novel genetic marker for the identification of Salmonella gallinarum 9R vaccine. DAAD Biotechnology Day, Bethlehem University. Dec 1, 2014. 2. Sheibat F., Ashhab Y. and Shahin H. Identification of Achromatopsia Genetic Determinants in Affected Palestinian Families. 4th Biomedical Research Symposium. An-Najah National University. April 26, 2014. 3. Noh-Issa M. and Ashhab Y. Developing a New PCR Approach to Distinguish Between Rev1 Vaccine Strain And Field Strain of Brucella melitensis. The 2nd Palestinian Biomedical Research Symposium, Bethlehem University, Palestine. May, 2012. 4. Qabajah M. and Ashhab Y. Avian Pathogenic E. coli (APEC): A Potential Source of Public Health Problems in Palestine. The 1st Palestinian Biomedical Research Symposium, Palestine Polytechnic University, Palestine. May 2011. 5. Tamimi B., Tamimi H., and Ashhab Y. BACTOSOM; A novel tool for Comparative Bacterial Proteomics. The 1st Palestinian Biomedical Research Symposium, Palestine Polytechnic University, Palestine. May 2011. 6. Y. Ashhab Searching for Potential Anti-Cancer Drug Targets Using In Silico Fishing Approaches. BioVisionAlexandria. Bibliotheca Alexandrina, Alexandria, Egypt 11- 15 April 2010 7. Ayyash M. and Ashhab Y. Developing a Powerful Bioinformatics Tool for Prediction of Caspase 3 Substrate: Preliminary Analysis of the Human Proteome International Biotechnology Symposium 2008, Sfax, Tunisia, 4- 8, 2008. 8. Colobran R., Patricia Adreani, Ashhab Y., Pujol-Borrell R., Juan M. Multiple Transcripts Expression from a Second (SCYA4L1) CCL4 Locus. 12th International Congress of Immunology, July 18-23, 2004. Montreal, Canada. 9. Ashhab Y., Identification and Characterization of New IAP Gene by Mining the Human Genome Databases. The 3rd Arab Conference in Medical & Biological Sciences, 20-22nd April 2004, Zarqa Private University, Jordan. 10. Nachmias B., Ashhab Y., Bucholtz V., Ben-Yehuda D. Caspase-mediated cleavage paradoxically converts livin from an anti-apoptotic to a pro-apoptotic factor: implications for CLL, AML and drug resistant melanoma. 8th Congress of the European Hematology Association. 13-15 June, 2003. Lyon. France. 11. Nachmias B., Ashhab Y., Bucholtz V., and Ben-Yehuda D., Caspase-mediated cleavage paradoxically converts livin from an antiapoptotic to a pro-apoptotic factor: implications for drug resistant melanoma. 4th International Conference on Basic Biology and Clinical Impact of Immunosenescence. May 21-26, 2003. Orthodox Academy of Crete, Kolymbari, Crete, Greece. 12. Ashhab Y, Alian A, Polliack A, Zelig O, Panet A, Ben Yehuda D. Livin, a new inhibitor of apoptosis protein, is expressed at high levels in some chronic lymphatic leukemia (CLL) patients, and may contribute to the

apoptotic defect in low grade hematological malignancies. The 43-th Annual meeting of the American Society of Hematology, Orlando, USA, 4-9 December 2001. 13. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. The 6th Congress of the European Hematology Association, Frankfurt, Germany, June 21-24 2001. 14. Ben-Yehuda D, Lossos A, Ludlovsky I, Ashhab Y, Amir G, Polliack A, Siegal T. Late CNS relapse of non- Hodgkin’s lymphoma: residual primary disease or a second novel lymphoma?. The 41-th Annual meeting of the American Society of Hematology, New Orleans , USA, 4-9 December 1999. 15. P. Adreani Rizo, I. Gómez Melé, R. Colobrán Oriol, Ashhab Y. F. Pelusa, R. Pujol Borrell, M. Juan i Otero. Cuantificación de los dos loci de la quimiocina MIP-1β por medio de la generación de un estándar interno. XXVII meeting of the Spanish Society of Immunology. Madrid, 19-22, June 2001 16. R. Colobran, P. Adreani, I. Gómez, Y. Ashhab, P. Caro, O. Domínguez, R. Pujol Borrell, M. Juan. aproximación para el estudio funcional de las variantes iso y alotípicas codificadas por los loci de MIP-1β. XXVII meeting of the Spanish Society of Immunology. Madrid, 19-22, June 2001 17. Ashhab Y, Dominguez O, Sospedra M, Roura-Mir C, Lucas-Martin A, Pujol-Borrell R. A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands. The second joint meeting of the International Cytokine Society and the International Society for Interferon and Cytokine Research, Jerusalem, 25-30 October 1998. 18. Ashhab Y, Dominguez O, Caro P, Pujol-Borrell R. Detection of a novel internally truncated MIP-1b cDNA that is associated to a splice junction mutation at intron2/exon3 in one of the two loci of MIP-1b gene. The second joint meeting of the International Cytokine Society and the International Society for Interferon and CytokineResearch, Jerusalem, 25-30 October 1998.

Invited lectures

1. Searching For Potential Anti-Cancer Drug Targets Using In Silico Fishing Approaches. BioVision Alexandria 2010, 11-15 April 2010. 2. Using Bioinformatics to Study Gene Duplications and its Impact on Molecular Evolution of Innate Immune System Darwin’s Living Legacy: An International Conference on Evolution and Society, Organized by British Council, Bibliotheca Alexandrina, Egypt, 14th-6th November 2009. 3. TwinGene; a bioinformatics approach to identify recent gene duplication. Centre National de Génotypage. 7 December, 2007, Paris, France. 4. “Bioinformatics: Rediscovering Biological Sciences In Silico” Keynote Speaker in the 2nd Palestinian International Conference on Computer and Information Technology, September 1-3, 2007, Palestine. 5. "Recent gene duplication; mining EST database for new functional genes". As an invited speaker to the International Centre for Genetic Engineering and Biotechnology (ICGEB), 4 April 2006, Trieste, Italy. 6. "Recent Duplication in genes of the immune system; exploring new functions". As an invited speaker to the Academy of Medical Sciences of Catalonia and Balears, 20 June 2005, Barcelona, Spain. 7. "Nuevos enfoques genómicos del estudio del polimorfismo" in Spanish. During the Immunobiology of Organ Transplantation workshop- modulo VI that was organized by the Spanish National Organization of Transplantation, th 16-17 June 2005, Barcelona, Spain.

8. “Bioinformatics: A new approach for Biology Investigations”. During the 3rd Arab Conference in Medical & Biological Sciences, 20-22nd April 2004, Zarqa Private University, Jordan. 9. "A novel regulation mechanism of Livin in Tumour cells". As an invited speaker to the Servei Català de la Salut, Laboratory of Immunology for Research and Applications to Diagnosis (LIRAD), 30 January 2004, Barcelona, Spain. 10. "Chromosomal translocations in haematological malignancies". During the 1st Scientific Day that was organized by the Palestinian Society for Medical Technology, 3erd September 1999, which was held at Hebron University. 11. "Clinical Applications of PCR". During the 2end Palestinian Conference of Medical Technology, 4th September 1998, Birzeit University, Ramallah, Palestine.

Patents

1. Livin-derived peptides, compositions and uses thereof. Accession number at (http://www.ebi.ac.uk) is WO2004106371

Bigas Anna ANNA BIGAS, PhD

Personal Address: Villarroel 75, 4-1, Barcelona (SPAIN) Office address: Parc de Recerca Biomèdica Barcelona, Dr. Aiguader 88, Barcelona, SPAIN Office telephone: 0034 933 160 440 E-mail: [email protected]

EDUCATION

Degree Institution Year(s) Ph.D. in Biology University of Barcelona. 1993 (Biochemistry and Physiology) Supervisor: Juan García Lopez, MD, PhD

Bachelor in Science University of Barcelona 1983-1988

PROFESSIONAL ACADEMIC POSITIONS

Dates Position Department & Institution (from-until) 2009-now Coordinator Stem Cells and Cancer Program in Cancer Research, Research Group. Senior Group Leader Institute Hospital del Mar (IMIM), Spain.

2000-2008 Researcher (Senior Group leader) Department of Molecular Oncology, IDIBELL, Barcelona, Spain 1997-2000 Researcher (Junior Group leader) Department of Cell Therapy, Institut Recerca Oncol gica, Barcelona, Spain 1993-1997 Research Fellow Fred Hutchinson Cancer Research Center, Seattle, USA Mentor: Irwing D.Bernstein and Laurie A Milner 1989-1992 Ph. D. student Fundació Investigació Sant Pau (FISP). University of Barcelona

LANGUAGES Spanish (native), Catalan (native) and English (fluent)

HIGHLIGHTED ACHIEVEMENTS

-Awards from 2005-2013: Fundació Marató TV3, AECC, AICR. -Member of the National Cancer Network since 2008, Member of ISEH (International Society of Experimental Hematology) since 2010, Member of the Spanish Society of Cell Biology (2013). -Coordinator of the Stem Cells and Cancer Group comprising two research teams (Bigas and Espinosa labs) with postdocs, technicians and PhD students (average 15 people) -Invited Speaker to several international seminars/workshops including EHA 2008, Notch meeting (2007,2008, 2009, 2010, 2011, 2013), EMBO workshops (Notch 2006, GATA meeting 2008, 2010), ESF workshops (2006, 2007, 2008), SEBBM (2011), ASH (2011), Gordon Conference (2012), Molecular Hematopoiesis UK (2012), Biomed Stem Cell conference (2012), BSDB/BSCB Spring joing meeting (2013), Notch meeting (2013), Gordon Conference (2014) -Supervisor of 8 doctoral theses from 2000-2014. -Supervisor of 15 Master students from 2005-2014. -Supervisor of 10 undergraduate student projects. -Coordinator of the Oncogenes and signalling pathways group of the National Network for Cancer Research (RETIC, 2008-2012). - Meeting organizer: Eurostells Stem Cell Niches (2008), Notch meeting (2009), Notch and Stem cell meeting (2010). -Ad hoc Reviewer for Nature, Science, Nat. Cell Biol, J. Clin. Invest., Blood, MCB, Stem Cells, Leukemia, Experimental Cell Research, Development, FEBS Letters, Plos One, EMBO J. -Ad Hoc Reviewer for Spanish Science Ministry, Norwegian Research Council, ERC, MRC (UK), ANR (France), Israeli Minitry of Science and others. -Nominated member of the Spanish Evaluation Agency for Scientific Research (ANEP) from 2012. -Elected EMBO member 2014

LIST OF PUBLICATIONS

Colomer C, Margalef P, Gonzalez J, Vert A, Bigas A, Espinosa L. IKKα is required in the intestinal epithelial cells for tumour stemness. Br J Cancer. 2018 Feb 13.

Robles-Valero J, Lorenzo-Martín LF, Menacho-Márquez M, Fernández-Pisonero I, Abad A, Camós M, Toribio ML, Espinosa L, Bigas A, Bustelo XR. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2017 Nov 13;32(5):608-623.e9.

Giorgetti A, Castaño J, Bueno C, Díaz de la Guardia R, Delgado M, Bigas A, Espinosa L, Menendez P. Proinflammatory signals are insufficient to drive definitive hematopoietic specification of human HSCs in vitro. Exp Hematol. 2017 Jan;45:85-93.e2

Aguilera C, Fernández-Majada V, Inglés-Esteve J, Rodilla V, Bigas A, Espinosa L. Efficient nuclear export of p65-IκBα complexes requires 14-3-3 proteins. J Cell Sci. 2016 Jun 15;129(12):2472.

Sanjuan-Pla A, Romero-Moya D, Prieto C, Bueno C, Bigas A, Menendez P. Intra-Bone Marrow Transplantation Confers Superior Multilineage Engraftment of Murine Aorta-Gonad Mesonephros Cells Over Intravenous Transplantation. Stem Cells Dev. 2016 Feb 1;25(3):259-65.

Gama-Norton L, Ferrando E, Ruiz-Herguido C, Liu Z, Guiu J, Islam AB, Lee SU, Yan M, Guidos CJ, López-Bigas N, Maeda T, Espinosa L, Kopan R, Bigas A. Notch signal strength controls cell fate in the haemogenic endothelium. Nat Commun. 2015 Oct 14;6:8510.

Margalef P, Colomer C, Villanueva A, Montagut C, Iglesias M, Bellosillo B, Salazar R, Martínez-Iniesta M, Bigas A, Espinosa L BRAF-induced tumorigenesis is IKKα-dependent but NF-κB-independent. Sci Signal. 2015 Apr 21;8(373):ra38.

Gallardo F, Padrón A, Garcia-Carbonell R, Rius C, González-Perez A, Arumí-Uria M, Iglesias M, Nonell L, Bellosillo B, Segura S, Pujol RM, Lopez-Bigas N, Bertran J, Bigas A, Espinosa L. Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance. Oncotarget. 2015 Apr 20;6(11):9284-94.

Notch 1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium. Jang IH, Lu YF, Zhao L, Wenzel PL, Kume T, Datta SM, Arora N, Guiu J, Lagha M, Kim PG, Do EK, Kim JH, Schlaeger TM, Zon LI, Bigas A, Burns CE, Daley GQ.Blood. 2015 Jan 13. pii: blood-2014-04-568170

Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch .López-Arribillaga E, Rodilla V, Pellegrinet L, Guiu J, Iglesias M, Roman AC, Gutarra S, González S, Muñoz-Cánoves P, Fernández-Salguero P, Radtke F, Bigas A, Espinosa L.Development. 2015 Jan 1;142(1):41-50.

Identification of Cdca7 as a novel Notch transcriptional target involved in Hematopoietic Stem Cells emergente. Jordi Guiu, Dylan J.M. Bergen, Emma De Pater, Abul B.M.M.K. Islam, Verónica Ayllón, Leonor Gama-Norton, Cristina Ruiz-Herguido, Jessica González, Nuria López-Bigas, Pablo Menendez, Elaine Dzierzak, LLuis Espinosa, Anna Bigas. J Exp Med. 2014 Nov 17;211(12):2411-23

Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression. Alaña L, Sesé M, Cánovas V, Punyal Y, Fernández Y, Abasolo I, de Torres I, Ruiz C, Espinosa L, Bigas A, Y Cajal SR, Fernández PL, Serras F, Corominas M, Thomson TM, Paciucci R. Mol Cancer. 2014 Mar 31;13:74. doi: 10.1186/1476-4598-13-74.

The Notch1 transcriptional activation domain is required for development and reveals a novel role for Notch1 signaling in fetal hematopoietic stem cells. Dawson M. Gerhardt, Kostandin V. Pajcini, Teresa D’altri, LiLi Tu, Rajan Jain, Lanwei Xu, Michael Chen, Stacey Rentschler, Olga Shestova, Gerald B. Wertheim, John Tobias, Michael Kluk, Antony W. Wood, Jon C. Aster, Phyllis A. Gimotty, Jonathan A. Epstein, Nancy Speck, Anna Bigas, Warren S. Pear. Genes and Development 2014;28(6):576-93.

Deficiency in p53 is required for doxorubicin induced transcripcional activation of NFkB target genes in human breast cancer. Dalmases A, González I, Menendez S, Arpi O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F. Oncotarget 2013 (Epub)

Mucus Enhances Gut Homeostasis and Oral Tolerance by delivering Immunoregulatory signals 30

Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, He B, Cassis L, Bigas A, Cols M, Comerma L, Huang B, Blander JM, Xiong H, Mayer L, Berin C, Augenlicht LH, Velcich A, Cerutti A. Science, 2013 Oct 25;342(6157):447-53.

Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells Marta Forn, Mar Muñoz, Daniele Tauriello, Anna Merlos-Suarez, Verónica Rodilla, Anna Bigas, Eduard Batlle, Mireia Jorda, Miguel A. Peinado. Molecular Oncology, 2013 Dec;7(6):1129- 41

Rachael Nimmo, Aldo Ciau-Uitz, Cristina Ruiz-Herguido, Shamit Soneji, Anna Bigas, Roger Patient and Tariq Enver. miR-142-3p controls specification of the hemangioblastic precursors of the blood stem cell lineage. Dev Cell. 2013 Aug 12;26(3):237-49.

María Carmen Mulero; Dolors Ferres Marco; Abul Islam; Pol Margalef; Matteo Pecoraro; Agustí Toll; Nils Drechsel;Cristina Charneco; Shelly Davis; Nicolas Bellora; Fernando Gallardo; Erika López Arribillaga; Elena Asensio;Verónica Rodilla; Jessica González; Mar Iglesias; Vincent Shih; Mar M. Albà; Luciano Di Croce; Alexander Hoffmann; Shigeki Miyamoto; Jordi Villà Freixa; Nuria López Bigas; William M. Keyes; María Dominguez; Anna Bigas*; LLuis Espinosa* (*equal contribution). Chromatinbound IkBa regulates a subset of Polycomb-target genes in differentiation and cancer. Cancer Cell. 2013 Aug 12;24(2):151-66.

-Jordi Farrés, Juan Martín-Caballero, Carlos Martínez, Juan J. Lozano, Laura Llacuna, Coral Ampurdanés, Cristina Ruiz-Herguido, Françoise Dantzer, Valérie Schreiber, Andreas Villunger, Anna Bigas, José Yélamos PARP-2 is required to maintain hematopoietic homeostasis following sublethal γ-irradiation treatment. Blood. 2013 Jul 4;122(1):44-54.

- Jordi Guiu, Ritsuko Shimizu, Teresa D’Altri, Stuart T. Fraser, Jun Hatakeyama, Emery H. Bresnick, Ryoichiro Kageyama, Elaine Dzierzak, Masayuki Yamamoto, Lluis Espinosa and Anna Bigas (*equal contribution). Hes repressors are essential regulators of Hematopoietic Stem Cell Development downstream of Notch signaling. J. Exp. Med. 2013 Jan 14;210(1):71-84

- Margalef P, Fernández-Majada V, Villanueva A, Garcia-Carbonell R, Iglesias M, López L, Martínez- Iniesta M, Villà-Freixa J, Mulero MC, Andreu M, Torres F, Mayo MW, Bigas A, Espinosa L(*equal contribution).. A novel truncated form of IKKα is responsible for specific nuclear IKK activity in Colorectal Cancer. Cell Reports, 2 (4), 840-854, 2012.

-Ruiz-Herguido C, Guiu J, D’Altri T, Inglés-Esteve J, Dzierzak E, Espinosa L, Bigas A (*equal contribution). Hematopoietic Stem Cell development requires transient Wnt/bcatenin activity. J. Exp. Med 2012 Jul 30;209(8):1457-68

-Inglés-Esteve J, Morales M, Dalmases A, Garcia-Carbonell R, Jené-Sanz A, LópezBigas N, Iglesias M, Ruiz-Herguido C, Rovira A, Rojo F, Albanell J, Gomis RR, Bigas A*, Espinosa L* (*equal contribution). Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer. PlosOne. 2012; 7(5): e38347.

-Neves J, Bigas A, Giraldez F. The dual regulation of Atoh1 by Sox2: a mechanism for neural commitmentand deferred differentiation. Plos One, 2012;7(1): e30871.

-Pippa R, Espinosa L, Gundem G, García-Escudero R, Dominguez A, Orlando S, Gallastegui E, Saiz C, Besson A, Pujol MJ, López-Bigas N, Paramio JM, Bigas A, Bachs O. p27(Kip1) represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene. 2012 Sep 20;31(38):4207-20.

-D’Altri T, Gonzalez J., Aifantis I., Espinosa Ll* and Bigas A.* (*equal contribution). Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia. Cell Cycle Apr 1;10(7):1031-6, 2011

- Espinosa L, Cathelin S, D’Altri T, Trimarchi T, Guiu J, Rodilla V, Inglés-Esteve J, Nomdedeu J, Bellosillo B, Besses C, Rajewsky K, Aifantis I* and Bigas A* (*equal contribution). The Notch/Hes1 pathway sustains NFkB activation through CYLD repression in T cell leukemia. Cancer Cell. Sep 14;18 (3):268-81, 2010.

- Oliver Ehm, Christian Goritz, Marcela Covic, Iris Schaffner, Tobias J. Schwarz, Esra Karaca, Bettina Kempkes, Elisabeth Kremmer, Frank W. Pfrieger, Lluis Espinosa, Anna Bigas, Claudio Giachino, Verdon Taylor, Jonas Frisen, D. Chichung Lie. RBPJkDependent Signaling Is Essential for Long-Term Maintenance of Neural Stem Cells in the Adult Hippocampus J. Neuroscience, 30 (41):13794 –13807, 2010

- Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernandez-Majada V, Grilli A, Lopez-Bigas N, Bellora N, Albà MM, Duñach M, Sanjuan X, Gonzalez S, Capella G, Gridley T, Bigas A* and Espinosa Ll*. (*equal contribution). Notch is an essential mediator downstream of b-catenin in colorectal cancer. Proc. Natl. Acad. Sci. USA, 2009 Apr 14;106(15):6315-20.

-Robert-Moreno A, Guiu J, Ruiz-Herguido C, López ME, Inglés-Esteve J, Riera L, Tipping A, Enver T, Dzierzak E, Gridley T, Espinosa E* and Bigas A.* (*equal contribution). Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1. EMBO J, 1- 10, 2008.

- Hidefumi Fukushima, Akihiro Nakao, Fujio Okamoto, Masashi Shin, Hiroshi Kajiya, Seiji Sakano, Anna Bigas, Eijiro Jimi and Koji Okabe. The association of Notch2 and NF-kB accelerates RANKL-induced osteoclastogenesis by suppression of RBPJk/CBF1 binding to NFATc1 promoter. Mol. Cell Biol. 2008 , 28(20):6402-12

- Robert-Moreno A, Espinosa L, Sanchez MJ, de la Pompa JL, Bigas A. The Notch Pathway Positively Regulates Programmed Cell Death during Erythroid Differentiation. Leukemia (2007) 21, 1496–1503

- Fernandez-Majada V, Pujadas J, Vilardell F, Capellà G, Mayo MW, Bigas A*, Espinosa L* (*equal contribution). Aberrant cytoplasmic localization of N-CoR in Colorectal Tumors. Cell Cycle, 6-14, 1748-1752, 2007.

Fernández-Majada, V., Aguilera, C., Villanueva, A., Vilardell, F., Robert-Moreno, A., Real, F.X., Capella, G., Mayo, M.W., Espinosa, L.*, Bigas, A.* (*equal contribution). Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc. Natl. Acad. Sci. USA, 104, 276-281 (2007)

Aguilera, C., Fernández-Majada, V., Inglés-Esteve, J., Bigas, A., Espinosa, L.l. Efficient nuclear export of p65-IkappaBalpha complexes requires 14-3-3 proteins. J Cell Sci 119, 36953704 (2006).

Robert-Moreno, A., Espinosa, L., de la Pompa J.L., Bigas A. RBPJk-dependent Notch function regulates GATA-2 and is essential for the formation of intraembryonic hematopoietic cells. Development 132, 1117- 26 (2005).

Aguilera C, Hoya-Arias R, Haegeman G, Espinosa L*, Bigas A* (*equal contribution). Recruitment of IkBalpha to the hes1 promoter is associated with transcriptional repression. Proc. Natl. Acad. Sci. USA, 101, 47, pp 16537-16542, 2004.

- Espinosa L, Inglés-Esteve J, Robert A, Bigas A. IkBalpha and p65 regulate thecytoplasmic shuttling of Nuclear Corepressors: crosstalk between Notch and NFkB pathways. Mol. Biol. Cell. 14, 491-502, 2003

- Espinosa Ll, Inglés-Esteve J, Aguilera C, Bigas A. Phosphorylation by Glycogen Synthase kinase-3b downregulates Notch activity: a link for Notch and Wnt pathways. J. Biol. Chem., 278,34 pp32227-32235, 2003.

- Inglés-Esteve J, Espinosa Ll, Milner LA, Caelles C, Bigas A. Phosphorylation of Ser2078 modulates the Notch2 function in 32D cell differentiation. J. Biol. Chem., 276(48):44873-44880. 2001.

- Espinosa Ll, Santos S, Inglés-Esteve J, Muñoz-Canoves P, Bigas A. p65-NFkB synergizes with Notch to activate transcription by triggering degradation of the Nuclear Receptor Corepressor N-CoR. J. Cell Sci., 115(pt 6): 1295-1303 2002

-Delgado D, Chernukhin IV, Bigas A, Klenova EM, León J. Differential expression and phosphorylation of CTCF, a c-myc transcriptional regulator, during differentiation of human myeloid cells. FEBS letter 444, 1, 5-10, 1999.

-Bigas A, Black M, Martin DIK, Milner LA. Notch1 and Notch 2 inhibit myeloid differentiation in response to different cytokines. Molecular and Cellular Biology, 18, 4, 2324-2333, 1998

-Milner LA, Bigas A, Kopan R, Brashem-Stein C, Black M, Bernstein ID, Martin DIK. Inhibition of Granulocytic Differentiation by mNotch1. Proc. Natl. Acad. Sci. 93, 13014-13019, 1996.

-Bigas A, Martin DIK, Berstein ID. Generation of hematopoietic colony-forming cells from embryonic stem cells: synergy between a soluble factor from NIH3T3 cells an hematopoietic growth factors. Blood, 85 (11):3127-3133, 1995 .

-Bigas A, Berenson RJ, Kalamasz D, Bensinger WI, Ramon I, Tugues D, Amill B, Pardo N, Grañena A, Garcia J. Positive Stem cell selection : preliminary "in vitro" and clinical studies. Transplantology, 3 (2): 44-50, 1992.

-Sureda A, Valls A, Kadar E, Algara M., Ingles-Esteve J, Bigas A, Jaume M, Lacruz M, Tobajas LM, Rutllant M, García J. A single dose of granulocyte colony-stimulating factor modifies radiation-induced death in B6D2F1.Experimental Hematology 21: 1605-1607, 1993.

REVIEW ARTICLES Novel functions of chromatin-bound IκBα in oncogenic transformation.Espinosa L, Bigas A, Mulero MC. Br J Cancer. 2014 Oct 28;111(9):1688-92. doi: 10.1038/bjc.2014.84. Epub 2014 Sep 18. Review.

Non-conventional functions for NF-κB members: the dark side of NF-κB.Espinosa L, Margalef P, Bigas A. Oncogene. 2014 Jun 30

-Mulero MC, Bigas A, Espinosa L. IkBa beyond the NFkB dogma. Oncotarget 2013, 1550-1

-Anna Bigas, Jordi Guiu and Leonor Gama-Norton. Notch and Wnt in the emergente of hematopoietic stem cells. Blood Cells, Molecules and Diseases, 2013.

-Bigas A, Espinosa L. Hematopoietic Stem Cells: To be or Notch to be. Blood 5;119(14):3226-35. 2012

-Bigas A, Espinosa L, D’Altri T. Notch in Hematopoietic Stem Cells. Current Topics in Microbiology and Immunol 2012.

Bigas, A., Robert-Moreno, A. and Espinosa L.l. The Notch pathway in the developing hematopoietic system. Int J. Dev Biol. 4 (6-7), 1175-88 (2010).

Milner LA, Bigas A. Notch in Hematopoiesis: Cell fate Decisions and Self-renewal of progenitors. Ikeda Y, Hata J, Koyasu S, Kawakami Y, Hattori Y Eds. In Cell Therapy, pp 107-121, 2000.

Milner LA, Bigas A. Notch as a mediator of cell fate determination in Hematopoiesis: evidence and speculation. Blood 93, 8, 2431-2448, 1999

-Garcia J, Ingles-Esteve J, Bigas A. Los progenitores hemopoyéticos pluripotenciales. Bio-reguladores 1, 27-38, 1993 (Spanish).

COMPETITIVE FUNDING (2005-2015)

REGULATION OF HEMATOPOIETIC STEM CELLS IN THE EMBRYO Funding Agency: European Science Foundation/MEC. EUROSTELLS PROGRAM Colaborating Entities:Elaine Dzierzak (Rotterdam) (Coordinator) and Tariq Enver (Oxford) Duration, from: 2006 to: 2009 Amount: 174.000 Principal Investigator: Anna Bigas Total number of participating investigators: 3

CONSOLIDATED RESEARCH GROUPS: LOCAL/CATALAN GOVERMENT DURSI (Generalitat de Catalunya) (2005SGR00977). 2007-2010.

ROLE OF NOTCH Y WNT IN THE SELF-RENEWAL OF NORMAL AND LEUKEMIC STEM CELLS Funding Agency: SAF2007-60080 Duration, from: 2008 to: 2010 Amount: 257,000 Euros Principal Investigator: Anna Bigas Total number of participating investigators: 4

STUDY OF THE NUCLEAR IKK FUNCTIONS ASSOCIATED TO TUMORIGENESIS Funding Agency: MARATO TV3 (051730) Colaborating Entities: University of Virginia (M. Mayo) Duration, from: 2006 to: 2009 Amount: 125,000 Euros/lab Principal Investigator/Coordinator: Lluís Espinosa Total number of participating investigators: 5

RED TEMÁTICA DE INVESTIGACIÓN DE CÁNCER (SPANISH CANCER NETWORK) Funding Agency: Fondo de Investigación Sanitaria, ISCIII (RD06/0020/0098) SPANISH MINISTRY OF SCIENCE From: 2009 to: 2011 Amount: 85,864 Euros Principal Investigator: Anna Bigas Total number of participating investigators: 10

RED TEMÁTICA DE INVESTIGACIÓN DE CÁNCER Fondo de Investigación Sanitaria, ISCIII (RD12/0036/0054) Principal Investigator: Oriol Bachs Valldeneu From 2013 to: 2017 Amount: 59,512 Euros /year Total number of participating investigators: 15

CONTRIBUCIÓN DE LA VIA DE NOTCH A LA TUMORIGENESIS Y MANTINIMIENTO DE LAS CÉLULAS MADRE TUMORALES. Funding Agency: SPANISH MINISTRY OF SCIENCE (ACI2009-0918) Duration, from: 2009 to: 2012 Amount: 100.000 Euros Principal Investigator/Coordinator: LLuis Espinosa Blay (Co-IP: Sudhir Krishna, Bangalore, India) Total number of participating investigators in Espinosa’s Group:3 (Anna Bigas is one participant.

STEM CELLS AND CANCER 35

Funding Agency: SGR 23. LOCAL/CATALAN GOVERMENT From: 2009 to: 2013 Amount: 41,600 € Principal Investigator/Coordinator: Anna Bigas. Total number of participating investigators: 12

DETERMINACION DEL DESTINO HEMATOPOYETICO EN EL EMBRION DE RATON: ESTUDIO PARA GENERAR CELULAS MADRE NORMALES Y LEUCEMICAS Funding Agency: SPANISH MINISTRY OF SCIENCE (SAF2010-15450) Duration, from: 2011 to: 2013 Amount: 257.000 Euros Principal Investigator: Anna Bigas

MOLECULAR MECHANISMS INVOLVED IN THE DEVELOPMENT OF INFANT LEUKEMIAS Funding Agency: AECC (Asociación Española contra el Cancer) From: 2012 to: 2015 Amount: 150,000 € Principal Investigator/Coordinator: Anna Bigas. Total number of participating investigators: 6

NOTCH1 AND β-CATENIN CROSSTALK IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Funding Agency: AICR (13-0064) From: 2013 to: 2016 Amount: 240,000 € Principal Investigator: Anna Bigas Total number of participating investigators: 5

NUCLEAR ACTIVE IKKa AS BIOMARKER AND NEW TARGET FOR COLORECTAL CANCER Funding Agency: Fundació Marató TV3 From: 2014 to: 2017 Amount: 200,000 € Principal Investigator: LLuís Espinosa Total number of participating investigators: 7

IDENTIFYING SIGNALS INVOLVED IN THE ACQUISITION OF NORMAL AND LEUKEMIC STEMNESS CHARACTERISTICS Funding Agency: Spanish Minitry of Science (SAF2013) From: 2014 to: 2017 Amount: 370,000 € Principal Investigator: Anna Bigas. Total number of participating investigators: 6

SUPERVISION OF DOCTORAL THESIS

Title: Role of IkappaB in transcriptional repression Name: Cristina Aguilera Xiol University: University of Barcelona/Biomedicine Program Faculty: Biology Date: 2006 36

Qualification: EXCELLENT CUM LAUDE (Extraordinary Award)

Title: Functional role of RBPjk and Notch in embryonic Hematopoiesis Name: Alex Robert Moreno University: University of Barcelona Faculty: Biology/Biomedicine Program Date: 2007 Qualification: EXCELLENT CUM LAUDE

Title: Role of transcriptional corepressors in tumoral transformation Name: Vanessa Fernández-Majada University: University of Barcelona Faculty: Biology/Biomedicine Program Date: 2009 Qualification: EXCELLENT CUM LAUDE

Title: Wnt and Notch: Joining efforts to maintain intestinal homeostasis Name: Verónica Rodilla University: University of Barcelona Faculty: Biology/Biomedicina Program Date: 2010 Qualification: EXCELLENT CUM LAUDE

Title: Role of Wnt in embryonic Hematopoiesis Name: Cristina Ruiz Herguido University: University of Barcelona Faculty: Biology/Genetics Program Date: 2011 Qualification: EXCELLENT CUM LAUDE

Title: Notch activation and downstream targets in embryonic Hematopoiesis Name: Jordi Guiu University: University Pompeu Fabra, UPF Faculty: Experimental Sciences Date: 2012 Qualification: EXCELLENT CUM LAUDE (Extraordinary award)

Title: Understanding the molecular mechanisms involved in Notch1 induced leukemia. Name: Teresa D’Altri University: University Pompeu Fabra, UPF Faculty: Experimental Sciences Date: 2013 Qualification: EXCELLENT CUM LAUDE

Title: Identification and characterization of an oncogenic form of IKKα in colorectal cancer. Name: Pol Margalef University: University Pompeu Fabra, UPF Faculty: Experimental Sciences

Date: 17th February 2014 Qualification: EXCELLENT CUM LAUDE

SUPERVISION OF MASTER STUDENTS

2014 Meritxell Miquel, UB Ariadna Boloix, UB Ricard Garcia Carbonell, UPF Cristina Rius, UPF 2013 Vera Horvath, U. Vienna 2011 Dylan Bergen, U. Utrech Erika López-Arribillaga 2010 Jorik Verbiest, U. Gent

TEACHING ACTIVITY

Name of subject/course: Molecular Pathology of Systems Qualification: Master Biomedicina Start date: 22/11/2012 (yearly until 2013) Institution: Universidad Pompeu Fabra

Name of subject/course: Activación y Transducción de señales (Signal Transduction) Qualification: Master en Inmunologia Start date: 01/11/2005 (yearly until 2013) Institution: Universitat de Barcelona Type of institution: University

Name of subject/course: Células madre y Cancer: avances y retos (Stem Cells and Cancer) Qualification: summer course Start date: 13/07/2011 End date: 15/07/2011 Institution: Universidad Internacional de Andalucía

Name of subject/course: Cáncer y Modelos animales: avances y retos (Cancer and animal models) Qualification: summer course Start date: 15/07/2009 End date: 17/07/2009 Institution: Universidad Internacional de Andalucía

Name of subject/course: Biologia Celular y Molecular de la Sangre (Molecular and Cellular Biology of the Blood) Qualification: Master en Medicina Transfusional Start date: 13/12/2004 End date: 17/12/2004 Institution: Centre de transfusió i Banc de Teixits and Universitat Autonoma Barcelona

INVITATED SPEAKER (2009-2014) (most important conferences and seminars)

2009 -"Signaling Mechanisms in Embryogenesis and Organogenesis" University of Freiburg, the Freiburg University Hospital, and the Max-Planck-Institute. Freiburg, Germany. - Banco de células madre embrionarias. Fundación progreso y Salud, Granada. -Congreso Nacional de SETS (Sociedad Española de Transfusión Sanguínea yTerápia Celular), Tarragona. -Curso de modelos animales en Cancer. Universidad Internacional de Andalucia. Málaga - Notch meeting. Athens, Greece (Co-organizer) -Stem cells in Development and Disease, Amsterdam, Netherlands -Asociación Española de Hematología y Hemoterapia (AEHH)

2010 -Notch and Stem Cells Meeting 2010 (co-organizer) Athens, Greece -Notch and Hematopoiesis. Notch-IT meeting, Edinburgh, UK -5th international GATA factor symposium (GATA-V) Sendai, Japan,

2011 -34th meeting of the Spanish Society for Biochemistry and Molecular Biology, Barcelona -Notch signalling in Normal and leukemic Hematopoiesis.Symposium on New Frontiers on Hematological Malignancies, Pamplona, Spain -Notch in Normal Hematopoietic Stem Cells. 53rd American Society of Hematology (ASH), San Diego, USA

2012 -Epigenetics in Lymphocyte Biology and Disease (September) Barcelona, Spain -Gordon Conference on Notch signalling (August) Bates Collage, Maine, USA -Molecular Hematopoiesis 15, October, London, UK,

2013 -Erasmus University, Rotterdam, Netherlands. -BSDB/CB (British Society for Developmental Biology/British Society for Cellular Biology) joint spring meeting. University of Warwick, Coventry, UK -The Notch meeting, Athens, Greece -Club Hematopoïèse et Oncogenèse (CHO). Giens, France. The Hemato-Vascular system: Development and disease. Baeza, Spain.

2014 - International Course on Biology and treatment of Hematological malignancies (February 2014) 7TH International Conference on WT1 in Human Neoplasia (Barcelona, 2014) -Developmental Haematopoiesis symposium, Hopital Saint Louis, Paris 2014 -Gordon Conference on Notch signalling (July, Bates College, USA) -EMBO workshop on Cancer Stem Cells 20 years later,Catanzaro, Italy)

2015 -International Society for Experimental Hematology (ISEH), Kyoto, Next Oct 2015 -Notch meeting, Athens, next Oct 2015

Bonanni Paolo Paolo Bonanni graduated in Medicine and Surgery (MD) in 1985 and got two specializations in Hygiene and Preventive Medicine at the University of Genoa, Italy. From 1992 to 2000 he was Associate Professor, and since 2000 he is Full Professor of Hygiene in the Faculty of Medicine, University of Florence, Italy. His scientific activity has covered the epidemiology and prevention of infectious diseases, particularly viral hepatitis, diphtheria, tetanus, pertussis, influenza, measles, rubella, varicella, and, most recently, bacterial invasive diseases and HPV, including clinical trials and economic evaluation of vaccination strategies. He has been a member of the National Vaccination Commission of the Italian Ministry of Health, and he acts as an expert consultant for the European Centre for Disease Prevention and Control (ECDC) based in Stockholm. He is also a member of ETAGE (European Technical Advisory Group of Experts), WHO Euro, Copenhagen. He is standing adviser of the Viral Hepatitis Prevention Board (VHPB), an international independent committee of experts in viral hepatitis prevention. Paolo Bonanni is the author or co‐author of more than 200 scientific papers published in international and national journals. He received several grants from the Italian Ministry of University on projects regarding vaccine preventable infections and was responsible of a research unit in 4 EU‐funded projects named ANTRES (antibiotic resistance in Latin America), EURO‐ HEPNET (feasibility of a EU network for surveillance of vaccine preventable hepatitis), VACSATC (vaccine safety, attitudes and training) and EURO-HEP SCREEN (screening practices, counselling, referral and treatment for hepatitis B and C in migrants in Europe). Paolo Bonanni is the Director of the University of Florence Post‐Graduate Course on 'Vaccines and Vaccination Strategies', established in 2001, 13 editions of which have been followed by over 600 Italian MDs (mostly public health doctors and paediatricians) coming from all over the country. Contact details: Professor Paolo Bonanni, MD Hygiene and Epidemiology University of Florence Department of Health Sciences Viale G.B. Morgagni 48 50134 Florence, Italy Phone +39‐055‐4598511 /4598504/4598508 Fax +39‐055‐4598935 E‐mail: [email protected]

Selected publications Levi M, Bonanni P, Biffino M, Conversano M, Corongiu M, Morato P, Maio T. Influenza vaccination 2014-2015: Results of a survey conducted among general practitioners in Italy. Hum Vaccin Immunother. 2018 Feb 16:0.

Bini C, Grazzini M, Chellini M, Mucci N, Arcangeli G, Tiscione E, Bonanni P. Is hepatitis B vaccination performed at infant and adolescent age able to provide long-term immunological memory? An observational study on healthcare students and workers in Florence, Italy. Hum Vaccin Immunother. 2018 Feb 1;14(2):450-455

Lorini C, Santomauro F, Donzellini M, Capecchi L, Bechini A, Boccalini S, Bonanni P, Bonaccorsi G. Health literacy and vaccination: A systematic review. Hum Vaccin Immunother. 2018 Feb 1;14(2):478-488.

Bonanni P, Chiamenti G, Conforti G, Maio T, Odone A, Russo R, Scotti S, Signorelli C, Villani A; The 2016 Lifetime Immunization Schedule, approved by the Italian scientific societies: A new paradigm to promote vaccination at all ages. Scientific Board of “Lifetime Immunization Schedule”. Hum Vaccin Immunother. 2017 Nov 2;13(11):2531-2537.

Bonanni P, Bonaccorsi G, Lorini C, Santomauro F, Tiscione E, Boccalini S, Bechini A. Focusing on the implementation of 21st century vaccines for adults. Vaccine. 2017 Aug 11.

Bonanni P, Zanella B, Santomauro F, Lorini C, Bechini A, Boccalini S. Safety and perception: What are the greatest enemies of HPV vaccination programmes? Vaccine. 2017 Jun 10. pii: S0264-410X(17)30730-2

Bonanni P, Grazzini M, Niccolai G, Paolini D, Varone O, Bartoloni A, Bartalesi F, Santini MG, Baretti S, Bonito C, Zini P, Mechi MT, Niccolini F, Magistri L, Pulci MB, Boccalini S, Bechini A. Recommended vaccinations for asplenic and hyposplenic adult patients. Hum Vaccin Immunother. 2017 Feb;13(2):359-368.

Catálfamo Marta CURRICULUM VITAE

NAME: Marta Catalfamo, Ph.D.

OFFICE ADDRESS: CMRS/Laboratory of Immunoregulation. National Institute of Allergy and Infectious Diseases National Institutes of Health Bldg10 Room 11B01 9000 Rockville Pike Bethesda, MD 20892-1360 EMAIL: [email protected]

PHONE: (301) 496-5309

IMMIGRANT STATUS: US citizen

BRIEF CHRONOLOGY OF EMPLOYMENT:

(2013-present) Associate Scientist. Clinical and Molecular Retrovirology Section. Laboratory of Immunoregulation. NIAID. NIH

(2007-2013) Staff Scientist. Clinical and Molecular Retrovirology Section. Laboratory of Immunoregulation. NIAID. NIH

(2005-2007) Scientist. Clinical and Molecular Retrovirology Section. Laboratory of Immunoregulation, NIAID. NIH

(2005-2007) Scientist Officer. HIV Initiative: SEREFO Project, Bamako, Mali. Collaborative Clinical Research Branch. NIAID. NIH

(May 2005- International Science Officer for Latin America and the Dec 2005) Caribbean. Office of Global Affairs. NIAID/NIH

(2004 – 2005) Research Fellow. Lymphocyte Cytotoxicity Section. Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

(1999 – 2004) Visiting Fellow. Lymphocyte Cytotoxicity Section. Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

(1998 – 1999) Lecturer/ Instructor. Cellular Biology Department, Aut noma, University of Barcelona, Barcelona, Spain

(1992 -1997) Pre-doctoral Fellow, Immunology Unit, Hospital Universitari Germans Trias i Pujol. Universitat Aut noma de Barcelona. Badalona, Spain

(1987-1991) Research Assistant, Laboratory of Immunology, Hospital de la Santa Creu i San Pau, Barcelona, Spain

EDUCATION:

1998 Ph.D. (Doctor in Biological Sciences), Aut noma University of Barcelona, Barcelona, Spain.

1986 Biochemistry (6-years degree in Biochemistry). National University of Tucuman, Argentina.

HONORS AND AWARDS:

2013 Associate Scientist, CMRS/Laboratory of Immunoregulation. NIAID, NIH

2013 Bench-to-Bed-Side Award. Office of AIDS Research. NIAID. NIH

2011 International Society for Interferon and Cytokine Research. “Milstein Travel Award”

2011 Special Achievement Award. CMRS/Laboratory of Immunoregulation NIAID, NIH

2007 Office of AIDS Research Funding Award. NIAID

2006 Special Achievement Award. Collaborative Clinical Research Branch. Division of Clinical Research. NIAID, NIH

2002 FARE Award, NIH,

1999-2004 FOGARTY Intramural Program. NIH

1997 Magna Cum Laude, Aut noma University of Barcelona, Spain

1991 Young Investigator Award 'Mutual Medica', Medical Sciences Academy, Barcelona, Spain.

1987-1990 Research Award. Empresa Curi Hnos. Rep. Argentina

SOCIETY MEMBERSHIPS

2013-2016 Member of the American Association of Immunologists Minority Affairs Committee (AAI-MAC).

2011-present Chair Steering Committee, Cytokine Interest Group (CIG), NIH-FDA

2011-present Full Member. AAI. American Association of Immunology. 2011-present Membership Committee. ISICR. International Society for Interferon and Cytokine Research.

2009-2011 Member Elected. Steering Committee. Immunology Interest Group (IIG) NIH

2009-2011 Vice-Chair. Cytokine Interest Group Steering Committee (CIG) NIH

1999-present Immunology Interest Group (IIG)

2007-present Cytokine Interest Group (CIG)

1995-1998 Catalan Society of Immunology

1993-1998 Spanish Society of Immunology

SCIENTIFIC ACTIVITIES

2014 “Lipids Mediators and the regulation of Inflammation and Disease” organized by Marta Catalfamo and Katrin Mayer-Barber

2013 "Receptors and Cytokines in Innate Immunity" Organized by Zhu Jinfang, Eric Long, Daniel McVicar, Giorgio Trinchieri, Alan Sher, Rachel Caspi and Marta Catalfamo.

2012 Minisymposium “Dendritic Cells in Health and Disease-A Tribute to Ralph Steinman Symposium” Organized by Robert Seder (VRC), Kristin Tarbell (NIDDK), Romina Goldszmid (NCI), Alan Sher (NIAID) and Marta Catalfamo (NIAID).

2011-present Associate Editor International Society for Interferon and Cytokine Research (ISICR) Newsletter.

2009-2011 Organization of the Wednesday afternoon IIG seminar lectures and administrative duties.

2011 Organization of the IIG retreat 2011. Organization of scientific sessions and scientific program

2011 Minisymposium “Recent Advances in Interferon Biology” Organized by Raymond Donnelly (FDA), Howard Young (NCI) and Marta Catalfamo (NIAID)

2011 Cytokine Interest Group. Coordination of 3 annual scientific Minis-symposiums in the field of the cytokine biology sponsored by the Cytokine Interest Group at NIH. 2011

Organization of the 2011 Annual Award for the Best Publications in Cytokine Research sponsored by the Cytokine Interest Group at NIH. Fundraising for the CIG.

2010 Minisymposium “T cell differentiation: Stability and Plasticity” Organized by Dr. William Paul (NIAID), John O’Shea (NIAMS) and Marta Catalfamo (NIAID)

2010 Organization IIG retreat 2010. Organization of scientific sessions, program and administrative duties.

NIH-SCIENTIFIC REVIEW GROUP

R03/R21 applications submitted in response to the NCI Omnibus announcements Special Emphasis Panel/Scientific Review Group 2013/05 ZCA1 RPRB-B (M1) 1 meeting, scheduled for 03/15/2013-03/15/2013.

AD-HOC REVIEWER

Journal of Immunology, Blood, Immunology, The Journal of Infectious Diseases, International Immunology, Immunology and Cell Biology, Viral Immunology, Critical Care Medicine and Vaccine, PLOS One, Journal of Leukocyte Biology, AIDS Research and Human Retroviruses, Jornal of Virology, Clinical and Experimental Immunology.

IAS 2014 Scientific Programme Committee: 7th IAS Conference on HIV Pathogenesis 2013

Abstract Reviewer IAS 2013 Scientific Programme Committee: 7th IAS Conference on HIV Pathogenesis 2013

Abstract Reviewer

MTA

EMD-SERONO. US. Development of Immunotherapies for HIV infection.

INVITED LECTURES

2013 Humanitas Clinical and Research Center. Milan, Italy. March 6th. “HIV immunopathogenesis: the interplay between T cell homeostasis and Type-I IFN”

2013 Immunology Department. Autonomous University of Barcelona. Bellaterra. Spain. March 2th. “Thrombin mediates rapid kinesis in human resting CD8 T cells from healthy controls and HIV infected individuals through specific activation of thrombin receptor (PAR-1).

2012 BIOcluster Visitors Program. Autonomous University of Barcelona. Bellaterra. Spain. March 6th. “CD4 and CD8 T cell homeostasis during HIV infection: the interaction between IL-7 and Type-I IFN.

2011 International Cytokine Meeting. Florence. Italy. “Thrombin mediates chemokinesis in human resting CD8 T cells through specific interaction with thrombin receptor (PAR-1)”

2011 Minisymposium “Recent Advances in Interferon Biology”. Lipsett. NIH. “In vivo IL-7 exposure of CD4 T cells during HIV induced lymphopenia leads to an enhanced Type–I IFN response”

2011 Institute of Human Immunology. Baltimore, MD. USA. April. “T cell homeostasis in HIV infection”

2011 Biotechnology and Biomedicine Institute. Autonomous University of Barcelona. Bellaterra. Spain. March 7th. “HIV induced inflammation decreases CD127 expression on memory CD8 T cells by altering balance between Eomesodermin and T-bet”

2011 Catalan Society of Immunology. March 3rd. Barcelona. Spain. “T cell homeostasis in HIV infection” The interplay between IL-7 and Type-IFN.

2009 Interferon Interest Group and Center for Human Immunology. NIH. December 22nd. “HIV associated immune activation differentially affects CD4 and CD8 T cells: Role of Type I IFN”

2009 Experimental Immunology Branch. NCI, NHI. April 2nd. “Exploring mechanisms of Immune activation in HIV infection”

2007 Universitat Pompeu Fabra. Immunology Unit. Barcelona. Spain. March 30th. “Role of the granule exocytosis in T regulatory function”

2007 Universitaet Hamburg Zentrum für Molekulare Neurobiologie Institut Martin. Hamburg. Germany. March 24th. “Role of the granule exocytosis in T cell function”

2005 Annual Meeting of the Catalan Society of Immunology November 24-25. “Proyecto SEREFO Iniciativa del NIAID/NIH para el estudio VIH/TB en Mali”

2004 III Workshop. Procesamiento and presentation de Antigeno. Centro San Juan de la Cruz Segovia. Spain. March 29-31. “Role of the granule exocytosis in RANTES secretion by human CD8 T cells”

2002 Medical Sciences Academy, Barcelona, Spain. July 23rd. “The role of granule exocytosis for chemokine secretion by human CD4 and CD8 T cells”

TEACHING EXPERIENCE:

2013 Invited lecturer. Sponsored by the Ministry of Education of Spain. Joint Master in Immunology by the University of Barcelona and Autonomous University of Barcelona. February 28-March 8th

2012 Invited Lecturer. Graduate School Course: Interdisciplinary Global Infectious Diseases: HIV Pathogenesis. Department of Microbiology and Immunology. Georgetown University. Washington DC. Nov 19.

2012 Invited lecturer. Sponsored by the Ministry of Education of Spain. Joint Master in Immunology by the University of Barcelona and Autonomous University of Barcelona. February 26-March 8th

2011 Invited Lecturer. Graduate School Course: Interdisciplinary Global Infectious Diseases: HIV Pathogenesis and Tuberculosis. Department of Microbiology and Immunology. Georgetown University. Washington DC. Nov 18 and Nov 28.

2011 Invited lecturer. Sponsored by the Ministry of Education of Spain. Joint Master in Immunology by the University of Barcelona and Autonomous University of Barcelona. February 28-March 11th

2009 Host-pathogen interaction of the MTB infection in the context co-infection with HIV. SEREFO program. Mali

2004 Lecture for Postdocs: “CD8 T cell effector Function”. Experimental Immunology Branch. National Cancer Institute. NIH

2003 Lecture for Postdocs: “CD8 T cell effector Function”. Experimental Immunology Branch. National Cancer Institute. NIH

MENTORING AND SUPERVISION ACTIVITIES:

SEREFO. Bamako-Mali 2005-2008 I had been actively involved in organization and research activities of the collaborative NIAID-Research Program SEREFO in Mali. Mentoring activities of the 9 Junior Scientists.

Laboratory of Immunoregulation. NIAID

2010-Present. 1 Post-doctoral Fellow 2013-Present. 1 Post-doctoral Fellow 2010-Present. 1 Biologist 2012-Present. 2 IRTAProgram students

FUNDING

2013-2015 270,000. Bench to Bed Side Award. Principal Investigator: Marta Catalfamo. Title: “PAR1 signaling in T cells and its role in HIV infection”. Office of AIDS Research. NIAID. NIH

2009-2010 $70,000. Office of AIDS Research Award. Principal Investigator: Marta Catalfamo. Title: “Molecular pathways of immune activation in HIV infection. NIH Office of AIDS Research”

FELLOWSHIPS:

1999-2004 FOGARTY Intramural Program.

BIBLIOGRAPHY

1. M. J. Amengual, M. Catalfamo, A. Pujol, C. Juarez, C. Gelpí, J. L. Rodriguez. Autoantibodies in Chronic Delta Virus Infection Recognize a Common Protein of 46 kD in Both Rat Forestmach Basal Cell Layer and Strellate Thymic Epithelial Cells. Clin.Exp.Immunol. 1989, 78:80.

2. E. Tolosa, C. Roura-Mir, M. Catalfamo, M. Martí, A. Lucas-Martín, A. Sanmartí, I. Salinas, G. Obiols, M. Foz Sala, and R. Pujol-Borrell. Expression of Intercellular Adhesion Molecule-1 in Thyroid Follicular Cells in Autoimmune, Non autoimmune and Neoplastic Diseases of the Thyroid Gland: Discordance with HLA. J. Autoimmunity. 1992, 5: 94.

3. F. Vargas, E. Tolosa, M. Sospedra, M. Catalfamo, A. Lucas-Martín, G. Obiols and R. PujolBorrell. Characterization of neural cell adhesion molecule (NCAM) expression in thyroid follicular cells: induction by cytokines and over-expression in autoimmune glands. Clin. Exp. Immunol. 1994, 98: 478.

4. M. Catalfamo, C. Roura-Mir, M. Sospedra, P. Aparicio, S.Costagliola, M. Ludgate, R. PujolBorrell and D. Jaraquemada. Self-reactive cytotoxic gd T lymphocytes in Graves' disease recognize thyroid epithelial cells. J. Immunol. 1996, 156: 804.

5. C. Roura-Mir, M. Catalfamo, L. Alcalde, M. Sospedra, R. Pujol-Borrell and D. Jaraquemada. Single- cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto's and Graves' disease. Eur J Immunol. 1997, 27:3290-302.

6. M. J. Castro, P. Morales, M. Catalfamo, D. Jaraquemada, V. Fernández-Soria, B. Súarez, P. Varela, M. Pérez-Blas, M. Alvarez, N. Díaz-Campos and A. Arnaiz-Villena. Lack of HLA-G soluble isoforms in Graves-Basedow thyrocytes and complete cDNA sequence of the HLAG*01012 allele. Eur. J. Immunogenetics. 1998, 25:311-5.

7. G. Díaz, M. Catalfamo, M. T. Coiras, A. M. Alvarez, D. Jaraquemada, M. Sánchez-Pérez and J. Arroyo. HLA-DPB residue 69 plays a crucial role in allorecognition. Tissue Antigens. 1998, 52:27-36.

8. M. Catalfamo, L. Serradell, C. Roura-Mir, E. Kolkowski, M. Sospedra, M. Vives-Pi, F. Vargas-Nieto, R. Pujol-Borrell, and D. Jaraquemada. HLA-DM and Invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules. M. Int. Immunol. 1999, 11:269-77.

9. Serradell L, Muntasell A, Catalfamo M, Marti M, Costa M, de Preval C, Jaraquemada D. HLADM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells. Tissue Antigens. 1999, 447-58.

10. Liu K, Catalfamo M, Li Y, Henkart PA, Weng NP. IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells. Proc Natl Acad Sci U SA. 2002. 99(9):6192-7.

11. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med. 2002. 196(4):493-503.

12.Weng NP, Liu K, Catalfamo M, Li Y, Henkart PA. IL-15 is a growth factor and an activator of CD8 memory T cells. Ann N Y Acad Sci. 2002. 975:46-56.

13. Marta Catalfamo and Pierre A. Henkart. Perforin and the Granule Exocytosis Cytotoxicity Pathway. Curr. Op.Immunol. 2003. 15(5):522-7.

14. Katano H, MA, Patera AC, Catalfamo M, Jaffe ES, Kimura H, Dale JK, Straus SE, and Cohen JI. Chronic Active Epstein-Barr Virus Infection Associated with Mutations in Perforin that Impair Its Maturation. Blood. 2003. 103: 1244-52.

15. Marta Catalfamo, Tatiana Karpova, James McNally, Sylvain V. Coste, Stephen J. Lockett, Eric Bos, Peter J. Peters, and Pierre A. Henkart. CD8+ store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity. 2004. 20:210-230).

16. Pierre Henkart and Marta Catalfamo. T cell subsets. Adv. Immunology. 2004. (83:215-234)

17. D.C. Slavin-Chiorini, M. Catalfamo, J. Schlom and H. Sabzevari. Amplification of the lytic potential of effector/memory CD8 T cells by vector-mediated overexpression of CD54 (ICAM-1) on targets and its consequence in vaccine therapy. Cancer gene therapy. 2004 (10:665-680).

18. Carme Roura-Mir, Marta Catalfamo, Tan-Yun Cheng, Ellen Marqusee, Gurdyal S. Besra, Dolores Jaraquemada, D. Branch Moody. CD1a and CD1c participate in intrathyroidal activation of T cells during Grave’s Disease and Hashimoto’s thyroiditis. J. Immunol. 2005 (6:3776-3780))

19. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. NK Cells Mediate Immunomodulatory Effects of IL-2Rα-Targeted Therapy in Multiple Sclerosis. Proc Natl Acad Sci. 2006 11: 5941-6.

20. Fann M, Godlove JM, Catalfamo M, Wood Iii WH, Chrest FJ, Chun N, Granger L, Wersto R, Madara K, Becker K, Henkart PA, Weng NP.. Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8+ T cell response. Blood. 2006 108:3363.

21. Sven Mostböck, Marta Catalfamo, Yutaka Tagaya, Jeffrey Schlom, Helen Sabzevari. Acquisition of Antigen Presentasomes (APS), an MHC/costimulatory complex, is a check-point of memory T cell homeostasis. Blood 2007. 109:2488.

22. M. Catalfamo, X. Tai, Tatiana Karpova, and P. Henkart. TcR-induced regulated secretion leads to surface expression of CTLA-4 in CD4+CD25+ T cells. Immunology. 2008. 70-9

23. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane HC. HIV infection leads to increased immune activation by 2 distinct pathwaysthat differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A. 2008. 19851-6

24. Michele Di Mascio, Chang H. Paik, Jorge A. Carrasquillo, Jin-Soo Maeng, Beom-su Jang, In Soo Shin, Sharat Srinivasula, Russ Byrum, Achilles Neria, William Kopp, Marta Catalfamo, Yoshiaki Nishimura, Keith Reimann, Malcolm Martin and H. Clifford Lane. Non-Invasive In Vivo Imaging of CD4 Cells in SHIV Infected Non-human Primates. Blood. 2009. 114:328-37

25. Park JH, Adoro S, Guinter T, Erman B, Alag AS, Catalfamo M, Kimura MY, Cui Y, Lucas PJ, Gress RE, Kubo M, Hennighausen L, Feigenbaum L, Singer A. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat Immunol. 2010, 3:257-64.

26. Marta Catalfamo, Christopher Wilhelm, Lueng Tcheung, Michael Proschan, Travis Friesen, Jung- Hyun Park, Joseph Adelsberger, Michael Baseler, Frank Maldarelli, Richard Davey, Gregg Roby, Catherine Rehm, and Clifford Lane. CD4 and CD8 T cell immune activation during chronic HIV infection: Roles of Homeostasis, HIV, Type-I IFN and IL-7. J. Immunol. 2011,186:2106-16

27. Imaging of lytic granule exocytosis in CD8(+) cytotoxic T lymphocytes reveals a modified form of full fusion. Martina JA, Wu XS, Catalfamo M, Sakamoto T, Yi C, Hammer JA 3rd. Cell. Immunol. 2011. 271(2):267-79

28. Catalfamo M, Le Saout C, Lane HC. The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine Growth Factor Rev. 2012. 23(4-5):207-14.

29. Amanda Hurley, Tatiana Karpova, Erin Nikel, Hiromi Himamichi, Beverly Packard, Higgins Jeanette, Clifford Lane and Marta Catalfamo. Thrombin mediates rapid kinesis in human resting CD8 T cells from healthy controls and HIV infected individuals through specific activation of thrombin receptor (PAR-1) Journal of Infectious Disease. 2013. 15;207(4):638-50

30. Rebecca B. Hasley, Changwan Hong, Wenqing Li, Travis Friesen, Yoriko Nakamura, Grace Y. Kim, Jung-Hyun Park, Julie A. Hixon, Scott Durum, Zonghui Hu, Michael C. Sneller, Raphael Oguariri, Tomozumi Imamichi, H. Clifford Lane and Marta Catalfamo. HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. AIDS. 2013. 27(12): 1867-77

31. Cecile Le Saout, Rebecca B. Hasley, Hiromi Imamichi, Lueng Tcheung, Megan Luckey, Mindy Smith, Zonghui Hu, Adam W. Rupert, Michael C. Sneller, H. Clifford Lane and Marta Catalfamo. Chronic exposure to Type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis. PLOS Pathogens. 2014. 10(3): e1003976.

32. Changwan Hong, Megan A Luckey, Grace Y Kim, Hilary R Keller, Ruth Etzensperger, Xuguang Tai, Lionel Feigenbaum, Marta Catalfamo, Scott T R Walsh and Jung-Hyun Park. Activated T cells secrete an alternatively spliced form of the common g-chain cytokine receptor that impairs cytokine signaling and exacerbates inflammatory disease. Immunity. 2014. 40(6):910-23.

33. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, Yuan X, Zhang G, Cai Y, Babu S, Catalfamo M, Salazar AM, Via LE, Barry CE 3rd, Sher A. Nature. 2014. 511:99-103.

34. Immunology careers at the NIH, FDA and CDC: different paths that focus on advancing public health. Catalfamo M, Mawle A, Verthelyi D. Nat Immunol. 2015. 16:129-32.

35. Activated platelet-T-cell conjugates in peripheral blood of patients with HIV infection: coupling coagulation/inflammation and T cells. Green SA, Smith M, Hasley RB, Stephany D, Harned A, Nagashima K, Abdullah S, Pittaluga S, Imamichi T, Qin J, Rupert A, Ober A, Lane HC, Catalfamo M. AIDS. 2015 Jul 17;29(11):1297-308

36. Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). Gill AL, Green SA, Abdullah S, Le Saout C, Pittaluga S, Chen H, Turnier R, Lifson J, Godin S, Qin J, Sneller MC, Cuillerot JM, Sabzevari H, Lane HC, Catalfamo M. AIDS. 2016 Oct 23;30(16):2487-2493.

37. IL-7-dependent STAT1 activation limits homeostatic CD4+ T cell expansion. Le Saout C, Luckey MA, Villarino AV, Smith M, Hasley RB, Myers TG, Imamichi H, Park JH, O'Shea JJ, Lane HC, Catalfamo M. JCI Insight. 2017 Nov 16;2(22). pii: 96228.

C.C. Leite Luciana

Luciana C C Leite PhD

Introduction

Dr. Leite is an expert in Molecular Biotechnology applied to the Development of Vaccines, especially in recombinant BCG and development of pneumococcal and schistosoma vaccines, having participated in many of the Brazilian genomic projects with over 90 papers and several patents. She has been Vice-President of Fundação Butantan and member of the Developing Countries Vaccine Manufacturers Network. She is currently on the National Committee for Regulation of Genetically Modified Organisms.

Current Institution

Instituto Butantan | butanan

Centro de Biotecnologia

São Paulo

Current position

Director of Center of Biotechnology

Skills and Expertise

Vaccine DevelopmentVaccinologyAdjuvants

Research Experience Mar 1987

Director of Center of Biotechnology Instituto Butantan · Centro de Biotecnologia São Paulo, Brazil Description Dr. Leite is an expert in molecular biotechnology applied to the development of vaccines, especially in the recombinant BCG field and the development of recombinant pneumococcal and schistosoma vaccines.

Education Feb 1983 - Apr 1988

University of São Paulo Biochemistry Mar 1978 - Nov 1982

University of Campinas Chemistry

Last 5-year publication: A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis. Goulart C, Rodriguez D, Kanno AI, Converso TR, Lu YJ, Malley R, Leite LCC. Clin Vaccine Immunol. 2017 Oct 5;24(10). pii: e00133-17.

Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis. Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP, Gonçalves EDC, D'Império-Lima MR, Hirata MH, Silva CL, Winter N, Gicquel B, Mills KHG, Pizza M, Rappuoli R, Leite LCC. Sci Rep. 2017 May 18;7(1):2109.

Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime- boost strategy. Goulart C, Rodriguez D, Kanno AI, Lu YJ, Malley R, Leite LC. Vaccine. 2017 Mar 23;35(13):1683-1691.

IL-17A and complement contribute to killing of pneumococci following immunization with a pneumococcal whole cell vaccine. Campos IB, Herd M, Moffitt KL, Lu YJ, Darrieux M, Malley R, Leite LC, Gonçalves VM. Vaccine. 2017 Mar 1;35(9):1306-1315.

Advocacy, partnership and political commitment for TB vaccine research. Olesen OF, Chan S, Chappell J, Guo Y, Leite LC. Tuberculosis (Edinb). 2016 Aug;99 Suppl 1:S26-9.

New Recombinant Mycobacterium bovis BCG Expression Vectors: Improving Genetic Control over Mycobacterial Promoters. Kanno AI, Goulart C, Rofatto HK, Oliveira SC, Leite LC, McFadden J. Appl Environ Microbiol. 2016 Apr 4;82(8):2240-6.

Vaccines of the Future: The Role of Inflammation and Adjuvanticity. Yun CH, Leite LC, Tagliabue A, Boraschi D. J Immunol Res. 2015;2015:789595.

Development of a whole cell pneumococcal vaccine: BPL inactivation, cGMP production, and stability. Gonçalves VM, Dias WO, Campos IB, Liberman C, Sbrogio-Almeida ME, Silva EP, Cardoso CP Jr, Alderson M, Robertson G, Maisonneuve JF, Tate A, Anderson P, Malley R, Fratelli F, Leite LC. Vaccine. 2014 Feb 19;32(9):1113-20.

On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni. Farias LP, Krautz-Peterson G, Tararam CA, Araujo-Montoya BO, Fraga TR, Rofatto HK, Silva FP Jr, Isaac L, Da'dara AA, Wilson RA, Shoemaker CB, Leite LC. PLoS Negl Trop Dis. 2013 Oct 24;7(10):e2482.

Conjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune response. Perciani CT, Barazzone GC, Goulart C, Carvalho E, Cabrera-Crespo J, Gonçalves VM, Leite LC, Tanizaki MM. Clin Vaccine Immunol. 2013 Jun;20(6):858-66

Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives. Goulart C, da Silva TR, Rodriguez D, Politano WR, Leite LC, Darrieux M. PLoS One. 2013;8(3):e59605.

Schistosoma mansoni venom allergen like proteins present differential allergic responses in a murine model of airway inflammation. Farias LP, Rodrigues D, Cunna V, Rofatto HK, Faquim-Mauro EL, Leite LC. PLoS Negl Trop Dis. 2012;6(2):e1510.

Czerkinsky Cecil Cecil Czerkinsky, DMD, PhD, Dr Med Sci, graduated from Nice and Lyon Medical and Dental Schools (France) in 1978 and 1980 and from Göteborg Medical Faculty (Dr Med Sci) in 1987. After postdoctoral stays in London (UK) and Birmingham (USA), Czerkinsky established a laboratory of Mucosal Immunology at Göteborg University, which he led from 1989 to 1998. In 1998, Dr Czerkinsky was appointed Research Director at INSERM (French National Institute of Health and Medical Research) in Nice, France and spearheaded a research unit dedicated to Vaccination and Mucosal Immunity. In 2005, he was appointed Deputy Director General of the International Vaccine Institute in Seoul, South Korea, where he served as head of the R&D program. Under his leadership, the IVI R&D program grew from a staff of 18 to 62 and its international extramural funding increased by nearly 800% between 2005 and 2012. The IVI R&D program entailed basic exploratory research in antigen discovery, pathogen discovery, adjuvant discovery, formulation science, clinical (immune monitoring and diagnostics) and experimental (neonatal and mucosal) immunology, molecular epidemiology, and vaccine manufacturing process and technology transfer activities. Programmatic activities included regulatory issues, policy research and establishment of strategic partnerships with academia, industry and national as well as public health agencies. During his mandate at the IVI, Dr Czerkinsky held secondary professorship appointments at Seoul National University (School of Biological Sciences) and at Korea University (Clinical Professor of Immunology). Dr Czerkinsky has served as adviser for several supranational (WHO) and national (Sweden, France, Korea) health or biomedical research agencies as well as foundations (Gates Foundation (USA), ANRS (France), ESAC (EU), and pharmaceutical corporations. He has published over 170 articles in the areas of experimental and clinical immunology with a focus in vaccinology and particularly on enteric vaccines and immune modulators (adjuvants, therapeutics). He is inventor or co-inventor of several patents covering products and methods in these areas. Cecil Czerkinsky currently serves as Research Director at the Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), a joint CNRS-INSERM-University research center located in Sophia-Antipolis (France), and is consultant/adviser for various organizations, including pharmaceutical corporations, biotechnology firms, non-profit research organizations and development aid agencies.

Selected publications:

Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice. Rho S, Kim H, Shim SH, Lee SY, Kim MJ, Yang BG, Jang MH, Han BW, Song MK, Czerkinsky C, Kim JO. Immunol Lett. 2017 Oct;190:247- 256.

Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea. Sinha A, Dey A, Saletti G, Samanta P, Chakraborty PS, Bhattacharya MK, Ghosh S, Ramamurthy T, Kim JO, Yang JS, Kim DW, Czerkinsky C, Nandy RK. Clin Vaccine Immunol. 2016 Jul 5;23(7):610-7.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus. Dey A, Molodecky NA, Verma H, Sharma P, Yang JS, Saletti G, Ahmad M, Bahl SK, Wierzba TF, Nandy RK, Deshpande JM, Sutter RW, Czerkinsky C. PLoS One. 2016 Jan 5;11(1):e0146010.

Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection. Kim JO, Rho S, Kim SH, Kim H, Song HJ, Kim EJ, Kim RY, Kim EH, Sinha A, Dey A, Yang JS, Song MK, Nandy RK, Czerkinsky C, Kim DW. Clin Vaccine Immunol. 2015 Apr;22(4):381-8.

Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Saletti G, Çuburu N, Yang JS, Dey A, Czerkinsky C. Nat Protoc. 2013 Jun;8(6):1073-87.

Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim DW, Chang J, Czerkinsky C, Song MK. Virol J. 2012 Sep 21;9:215.

Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, Egorov A, Muster T, Seong B, Kweon MN, Song M, Czerkinsky C, Nguyen HH. PLoS One. 2012;7(6):e39921.

B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitis. Sun JB, Czerkinsky C, Holmgren J. J Immunol. 2012 Feb 15;188(4):1686-97

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK. PLoS One. 2011;6(11):e27953.

Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. Vaccine. 2011 Oct 26;29(46):8205-14.

Evidence for several waves of global transmission in the seventh cholera pandemic. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, Croucher NJ, Choi SY, Harris SR, Lebens M, Niyogi SK, Kim EJ, Ramamurthy T, Chun J, Wood JL, Clemens JD, Czerkinsky C, Nair GB, Holmgren J, Parkhill J, Dougan G. Nature. 2011 Aug 24;477(7365):462-5.

Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Raghavan S, Ostberg AK, Flach CF, Ekman A, Blomquist M, Czerkinsky C, Holmgren J. Infect Immun. 2010 Oct;78(10):4251- 60.

Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, Vimeux L, Marañon C, Czerkinsky C, Hosmalin A, Anjuère F. Vaccine. 2010 Aug 2;28(34):5582-90.

De Clerck Norbert

Norbert De Clercq Director, Regulatory Policy & Intelligence Senior Expert at GSK Vaccines GlaxoSmithKline Vaccines

Katholieke Universiteit Leuven Leuven, Flandre, Belgique - 20 years’ experience in the vaccines industry at global level - Unique mix of science and business acumen - Good analytic skills and sharp strategic thinker and deliverer - Demonstrated ability to succesfully operate in complex and highly matrixed organisations - Good interpersonal skills, connecting with people, teams, senior management and experts - Proven writing & communication skills - Experienced in leadership with in-line management, cross functional and task force management

- Deep and broad knowledge of vaccines industry, across different functions (commercial, RA, Medical, manufacturing, clinical, BD) - Polio, hepatitis and pertussis expert

- Positive optimist - Creative and resourceful solution seeker - Enterprise thinker and team player striving to make a team succeed on its mission - Driver to break silo’s - Ability to identify customer needs and exceptional customer focus - Ability to deliver out of comfort zone and on time - Ability to focus on bigger picture but still capture relevant details - Quickly adapt to new and changing tasks, content and environments

Dieye Tandakha Ndiaye

BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

NAME POSITION TITLE DIEYE, Tandakha Ndiaye Professor in Immunology, -Université Cheikh Anta Diop, Dakar (UCAD) eRA COMMONS USER NAME (credential, e.g., agency login) -Center of Blood Transfusion Dakar (CNTS) DIEYE, Tandakha Ndiaye -Immunology unit of Bacteriology&Virology lab, Le Dantec

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training. )

INSTITUTION AND LOCATION DEGREE FIELD OF STUDY YEARS (if applicable) Immunodeficiency unit (UTI) , Erasme Hospital, Free University of Brussels, (ULB), Belgium 1996 – 2001

Immunology International Institute of Cellular and Molecular Pathology PhD (ICP),Experimental Medicine Unit (MEXP), Catholic University of Immunology Louvain (UCL), Brussels Master of 1993 -1995 Science

National Center of Blood Transfusion and Immunology Unit, LBV, Le Dantec University Hospital, Dakar Resident medical 1988 -1992 Biology studentship

1988 -1992 Doctoral study in Pharmacy

Cheikh.Anta Diop. University, Dakar, Senegal Pharmacy

PROFESSIONAL ACTIVITIES:

1999-2014 Head of laboratories (National Center of Blood Transfusion (CNTS) Dakar, Senegal

2001-2014 Head of Immunology Unit, (Bateriology/virology Laboratory-CHU A Le Dantec), Dakar, Senegal : Souleymane Mboup’s lab) -HIV/AIDS project (Discordant couples)-Tropical Medicine Institute, Anvers, Belgium and WHAPHIR - Development of a TB vaccine in Africa – AFTBVAC, EU project - Cellular and Molecular immunology in Serodiscordant couples in HIV-infected patients in collaboration with Tropical Medicine Institute, Anvers, Belgium - AAVP/WHO collaborating centre programme on HIV/AIDS vaccine - Innate and Cellular Immunology of Schistosomiasis infection (EU project) - MVA 85A Phase I vaccine on HIV infected subjects (EuropAID project) - MVA 85A Phase IIb vaccine on HIV infected subjects (EDCTP project) - ICEMR (NIH-Malaria) project, 2010 to 2016 2003-2013 Coordinator of the National Blood Transfusion Security Program(National AIDS Program Committee)

CONSULTANT:

o WHO consultant (Seychelles, 04 – 26 Février 2004) o WHO facilitator (Vaccinology course) 2007, 2011 and 2012, 2013 o GSK facilitator (Vaccinology course) 2010 o WHO African Regional Measles and Rubella Technical Advisory Group member 2013 o Member of Senegalese National Immunization Technical Advisory ou comité consultative pour la vaccination au Sénégal (NITAG or CCVS) 2013

COMPLEMENTARY TRAINING: 1988 – 1989 • Pharmaceutical industry training : WestAfrican Society of Pharmaceutical Industry (SIPOA) - AVENTIS (control laboratory, tablet manufacture unit,..…), Dakar, Senegal 1995 – 2000 • Virology : AIDS reference laboratory (LRS), ErasmeUniversityHospital, ULB, Brussels (C. Liesnard, MD) 1998 –2000 • Pasteur Institute Dakar (PAD), Immunogenetic Unit (Pr A. Dieye, PharmD, PhD) 1998 –2000 • Bacteriology-Virology laboratory, A. Le Dantec University hospital, Dakar (Professor S. Mboup, PharmD, PhD) 2004 • Training for « Management », by SANTEXEL Dakar, 14 to 15 january 2004

• Fulbright scholar, Viral& Ricketsial Disease laboratory (VRDL, California Dept of Public 2011 Health (CDPH), February 15th to November 15th , 2011 RESEARCH ACTIVITIES : HIV/AIDS

2011-2015 Innate immunity (NK cells) and Discordants couples in HIV 2005-2016 Cellular immune responses in HIV discordants couples (in collaboration with DIGIS /AIDS program-Institute of Tropical Medicine, Antwerpen, Belgium) Affordable flow cytometry (AFC) for CD4 count : 2002-2012 Evaluation of new flow cytomètres (cyflow counter) Validation of Point of Care Flow Cytometers (PIMA; MiniPoc,…) o Point of care technology for CD4 testing 60

*PIMA * Cyflow counter MiniPoc

o Cellular and molecular immunology in HIV infection and in Acquired immunodeficiency 1995-2001 syndrom (AIDS) : * Proliferation and apoptosis of Kaposi cells among HIV-1-infected individuals * Spontaneous apoptosis and highly Active Anti-Retroviral Therapy (HAART) * Effects of immunization with recall antigens among human immunodeficiency virus type 1 (HIV-1) individuals (Belgium) * Effects of immunization with recall antigens among human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)-infected senegalese individuals

TB studies : o Evaluation of a new TB Diagnosis test for acute TB on HIV infected subjects (Quantiferon and HBHA) o Evaluation of a new TB Diagnosis test for acute TB on HIV infected subjects (AlaDH 2009-2016 (Secreted L-alanine dehydrogenase de M. tuberculosis) o Hémodialysis patient & kidney transplant patient and latent TB detection using Quantiferon o DCTP-TB trial vaccine Phase IIb in HIV infected volunteers o Development of a TB vaccine in Africa–AFTBVAC (in collaboration with Oxford- UK, European Union (EU), IRD-France) 2010-2015 Eliprev project : ELISPOT utility for TB chimioprophylaxie anti-TB in HIV patients (Secure the Futur-BMS) 2003-2008 EuropAID-TB vaccine Phase I project (vaccination in HIV infected patients) EDCTP/MVA85A/AERAS-485 2007-2009 Schistosomiasis studies (SchistoINIR-EU Project): Innate immunity and immunoregulation of Schistosomiasis infection Malaria project : ICEMR, NIH project

Cell mediated immunity against AMA1 and MSP1 antigens 2007-2016 Antibody responses against AMA1 and MSP1 antigens Hemoglobin typing in malaria infected subjects 2010-2017 Malaria vaccine project Vac 047 :EDCTP-Oxford, UK, Senior investigator Immunochemical and mucosal immunology, Institute of Cellular and Molecular Pathology (ICP), Catholic University of Louvain, Brussels Hematology and immunology of Sickle Cell Anemia 2011-2015 National Center for Blood Transfusion & Pediatric University Hospital Albert Royer (Dakar (Prof L. Diakhate, MD and Prof M. Fall, MD

Teaching sessions:

1988 – 1992 - Practical works in hematology and immunology, National Blood Transfusion and Faculty of Medicine C.A. Diop University, Dakar 1999 – 2014 - Lecturer of Immunology, Faculty of Medicine C.A.Diop, Dakar University - Lecturer of Immunology, Faculty of Medicine Gaston Berger, UFR santé, University, St Louis - Lecturer of Immunology, Faculty of Medicine, UFR Santé, Ziguinchor University 61

- Lecturer of Immunology, Faculty of Medicine, Thiès University - Facilitator in international vacinology; Immunology and virology courses and workshops

MEMBER OF SCIENTIFIC SOCIETY:

1998 - Senegalese Society of Immunology (SSI) 1998 - Medical Society of West Africa 1999 - National AIDS Research Network, Senegal (RESER-SIDA) 1999 - African AIDS Research Network (RESER-SIDA) 2003 - International AIDS Society (IAS) 2003 - Thyroid Study Group (GET) 2005 - AAVP (African Aids vaccine Programme} 2009 - NESI (Network for Education and Support of Immunization) 2009 - ASID (African Society of Immunodeficiencies) 2010 - Belgium Transplantation Society(BTS) 2011 - African Society of Laboratory Medicine (ASML) 2013 - European Society of immunodeficiencies (EFI) 2013 - Regional Measles Technical Advisory Group (TAG); WHO AFRO 2013 - National Immunization Technical Advisory group (NITAG) for Senegal

SCIENTIFIC MEETINGS AND COURSES:

1996 First European Conference on Experimental AIDS Research (ECEAR), Cannes, March 1013,1996. Meeting of the Groupe de contact FNRS « Vaccins humains », Liege, December 12, 1996. 1998 Think Thank of Harvard AIDS Institute: « HIV vaccine for developing countries : Vaccination against the leading infectious Killers of children », Dakar, December 6-9, 1998. 2000 Fifth European Conference on Experimental AIDS Research (ECEAR), Madrid, June 16-19, 2000. 2001 Malaria research in Africa: Epidemiology, Vaccinology, Drug resistance and interaction with HIV (Harvard Malaria Initiative), Dakar, Senegal, May 28-June 1st, 2001 2001 6th International Course for Clinical Immunology of Infectious disease & Introduction to Molecular Biology (ICCI), Ismailia, Egypt, October 1st to november 3rd , 2001. 2002 Training WHO workshop on ” Application of the IFN gamma ELISPOT assay to monitor cellular immune responses in HIV vaccine-related research in Africa” , National Institute of Communicable Diseases (NCID), Johannesburg, September 16 – 21 th, 2002. 2003 Harvard AIDS Institute’s Vaccine Think Thank, « HIV vaccine for developping countries: prospects for an HIV vaccine for West Africa.Abuja, Nigeria, February 19 – 21st, 2003 Oxford Tropical Network Meeting. St – Hilda’s College, Oxford, 31st March to 2 nd April Second International AIDS Society Meeting on HIV treatment and pathogenesis.Palais des Congrès, Paris, France, July, 13 – 16 th, 2003. International Conference of AIDS and Sexual Transmission Disease in Africa AIDS (ICASA), Naïrobie, Kenya, September, 22 – 27 th , 2003. WHOintercountry workshop on CD4 T-cell enumeration technologies, Dakar, Senegal, 20 – 25 october, 2003 (facilitator)

Workshop on laboratory Quality assurance, National Center of Blood Transfusion, Dakar,

Senegal, 13 – 23 april, 2004 (facilitator) 2004 1st International Course for Immuno-haematology of french African Countries,Tunis, Tunisia, 10 – 13th May, 2004. 2004 Good Clinical Practicies (GCP) workshop-Westat, Comprehensive International Programme Research in AIDS (CIPRA), Dakar, Senegal , 1st– 4th November, 2004 2005 International Workshop for French Country on" HIV Viral load determination techniques

", Dakar, Senegal, du 18 – 22April , 2005 (Facilitator). Atelier sur les Gestion des données" CIPRA", Dakar, Sénégal, du 9 – 12Mai, 2005 . 2005 Six Advanced Vaccinology Course, Fondation Mérieux, Les Pensières, Vervier du Lac, 23 May – 3 june, 2005. • Ethics, Law, Human Rights and HIV Vaccine Development: 3 rd Capacity Bulding Workshop for African Resource Persons (REC/IRB Members) involved in Ethical Review, AAVP, Dakar, Senegal, 25 – 27 th August, 2005. • VI International Flow Cytometry School " Antigen specific Flow-Cytometry",Berlin, September 27 – October 1st , 2005. • 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA),Abuja, 4 – 9 December 2005.

2006 1erCours Francophone de rétrovirologie Biologie. Dakar, 23 Janvier au 17 Février 2006. • Journées Médicales de Dakar, 6 au 9 Février, 2006 2007 4 ème conférence Francophone sur le SIDA, 27-31 Mars 2007, Paris • 2 éme Cours Francophone de rétrovirologie Biologie. Dakar, 1er au 27 Mars 2007 External Validation of CD4 and Viral Load Technologies. Forum for HIV collaborative research. Paris june 29, 2007 • Elispot AAVP-OMS Workshop Dakar; 29 October – 2 November 2007 • 4th AAVP forum, Abuja, 28- 30th November 2007

2008 3éme Cours Francophone de rétrovirologie Biologie. Dakar, 3 Mars au 1er Avril 2008 • AAVP-OMS Workshop in Sequencing and molecular characterisation of HIV strains : HIV vaccine Application and ARV resistance. Dakar, 07-18 April, 2008 • 2ème Cours Régional de Vaccinologie.Ouidah, 06-11 Octobre 2008 • ITM international Colloquium ’Primary health Care in times of globalisation’& 3rd Join partner meeting, Antwerp, November 26-28th , 2008 • 15 ème International Conference of AIDS and Sexual Transmission Disease in Africa (ICASA), Dakar, Senegal, September, 03 – 07 th , 2008

2009 XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires.Dakar, 23 - 26 Février 2009 4ème Cours Francophone de rétrovirologie Biologie.Dakar, 26 Octobre au 23 Novembre 2009. EuropAID vaccine meeting, Oxford University, 11-12 August, 2009 2ième Ecole Africaine sur les Déficits Immunitaires Primitifs (DIP), Dakar, 17-18 Décembre 2009.

2010 Vaccinology Course, Rixenxart, Belgium, January, 10-15, 2010. Workshop on « Connecting Genotype to phenotype in Malaria; Dakar, January 18 – 22, 2010 2ieme Cours Régional de Vaccinologie de l’OMS des pays africains francophones. Benin,23-28 August 2010 KIDNEY TRANSPLANT MEETING, Dakar, march 4th & 5th 2010 2nd TB vaccine global forum. Tallinn, Estonia ;21-24 september 2010 ICEMR start up meeting, Rockville, MD, 27th- 29th October 2010 Artemisinin Resistance Meeting (NIH), Washington DC, 1st-2ndNovember 2010 5ème Cours Francophone de rétrovirologie Biologie.Dakar, Octobre au Novembre 2010. First regional ICEMR meeting. Dakar, 26 January to 1 February 2011 Virology class spring summer, st Richmond, California Department of Public Health June 6 to July 1 2011 2011 • 6ème Cours Francophone de rétrovirologie Biologie.Dakar, Octobre au Novembre 2011.

• 16 International Conference of AIDS and Sexual Transmission Disease in Africa (ICASA), Addis Ababa, Ethiopia, Dec, 04 – 09 , 2011 • 1st Francophone ASLM ,African Association of Laboratoth ry MedicineManuscript Writing, Saly, Senegal, January-16-27 , 2012 • 2nd ASID Congress, and 5th African School of PIDs, March 0811th,Hammamet,Tunisia,2012 • ATELIER-ELISPOT : Application au vaccine anti-palustre, Dakar, 16-20 juillet 2012 • 7ème Cours Francophone de rétrovirologie Biologie.Dakar, Octobre au Novembre 2012. 2012 • ITM colloquium”Pathogen Survival Strategies”, Antwerp,3 to 5 December 2012 • Malaria Vectored vaccine consortium (MVVC, Annual meetingDakar, Novotel, 14-15th January, 2013 • 2nd African Congress for Blood Transfusion, ABBOTT, Lusaka, 15th-18th April, 2013 • 10th NESI (Network for Education and Support in Immunization) symposium, Antwerp, 22th-23rd, April, 2013 • ASID Conference, Ithemba, Sun City, South Africa,5th-9th June, 2013 • ICAS AIDS conference, Cap Town, South Africa,7th-11thDecember 2013 • Regional Measles Technical Advisory Group (TAG); WHO/AFRO (Brazzaville, Congo) from 08 to 09 July, 2013. • Meeting of the African regional measles & rubella technical advisory group. Dakar, Senegal. 12 – 13 december 2013 2014 • NESI (Network for Education and Support in Immunization) symposium, LONDON,Lshtm 24 -25 , April, 2014 • TB021/C‐030 MVA85A Consortium Meeting – CHU Le Dantec, Dakar, Senegal 19-20 August 2014 • 2nd VaxInEU symposium, Lyon, October 2014 • ITM Colloquium & join Partners meeting, Antwerp, 24th -28th November 2014 2015 • African Voice And Leadership Meeting To Accelerate The Evaluation Of Potential Treatments And Vaccines For Ebola In West Africa King Fahd Palace,Dakar, Senegal, January 19-20, 2015 • 6th A-project & Biol project : Atelier sur les immunodéficiences primitives ; Le Dantec Hospital, Dakar, Senegal, January 25-26,February 2015

ORAL COMMUNICATIONS 1. Farber C.M., Barath A.A., Dieye T., Van Vooren J.P., Delforge M.L., Liesnard C. Tetanus toxin immunization-induce apoptosis in HIV carriers. Abstract, First European on Experimental AIDS Research, Cannes, March 10-13, 1996. 2. Farber C.M., Barath A.A., Dieye T., Van Vooren J.P. Antigen-specific apoptosis after tetanus toxoid booster in healthy HIV-1 carriers. Abstract, Meeting of the Groupe de contact FNRS « Vaccins humains », Liege, December 12, 1996. 3. Dieye T.N., Ndiaye O., Ndiaye AB., Thiam D., Seck-Fall K., Diop S., Diop BM., Fall M., Diakhate L. Complément et immunoglobulines sériques chez des drépanocytaires homozygotes SS et hétérozygotes AS au Sénégal. Abstract, 1 ère Journée scientifique de la Société Sénégalaise d’Immunologie (SSI), Dakar 26 Juin, 1999 4. Helen Fletcher1, Ansar Pathan1, Sheila Keating1, Tamara Berthoud1, Clare Sander1, Hannah Ibanga2, Patrick Owiafe2, Roger Brookes2, Philip Hill2, Farba Karam3, Tandakha Dieye3, Souleymane Mboup3, Fatou Mbow4, Christian Lienhardt4, Helen McShane1, Adrian Hill1. Oxford Tropical Network Meeting. Kilifi, Kenyan, October 2004. 5. Karam F., Dieye T.N., Abdoulaye O., Ndao C.T., Senghor C.S., Niang A., Ondoa P., Mbow F., Soumare M., Gaye-Diallo A., Sow P.S., Hane A., Lienhardt C., Kestens L., Mboup S. Impact of T cell and activated CD38 on IFN- ELISpot assay among TB, HIV and TB household contact. Abuja, 14th International Conference on HIV/AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005. Abst N°156 page 58-59. 6. Ondoa P., Dieye T., Vereeckeen C., Camara M., Diallo A., Fransen K., Litzroth A., Mboup S., Kestens L. 64

Evaluation of heat denatured HIV-1 p24 antigenemia and level of CD8+ CD38+ T cell as surrogate markers of HIV-1 RNA viral load in HIV-1 infected patients from Dakar, Senegal. Abuja, 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005. Abst N° 158 page 59. 7. Diaw PA, Barbesti S, Tagliabue E, Dieye T, Diallo AA, Mboup S. Comparison of a novel portable flow Cytometer for CD4 T cells counts A40 based on thermoresistant reagents againts FACSCOUNT system in Dakar. Abuja, 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005. Abst N° 224 page 84. 8. Camara M, Jennes W, Dieye T, Tavernier A, Diallo A, Karam F, Diaw PA, , Kestens L, Mboup S. Crossreactivity of Gag-specific T cell responses in HIV-1- and HIV-2-infected subjects in Dakar, Senegal. Abuja, 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005.Abst N°191 page 71. 9. Diop S, Ndiaye M, Seck M, Dieye TN, Touré AO, Thiam D, Diakhaté L. Quelle stratégie de prévention du paludisme post-transfusionnel en Afrique au Sud du Sahara. XVI Journées Médicales , Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 06-09 Février 2006; Abst N° 126, page 85. 10. . Dieye TN, Karam F, Ndao CT, Senghor CS, Fletcher H, Diack C, Mbow F, Ngom-Gueye NF, Sow PS, Hanne Mboup S, Lienhardt C. Détection de l’infection tuberculose latente à Mycobactérium tuberculosis par Esat6/CFP10 ELISPOT IFN- dépendant de la progression du VIH/SIDA 4 ème Conférence Francophone VIH/SIDA, 2007, Médecine Sciences, Vol 23, Abst : 84/23A, pp 87. 11. Camara M, Dieye TN, Jennes W, Diallo AA, Mboup S, Kestens L.Etude des réactions croisées des croisées des réponses celluliares T spécifiques contre les peptides des gènes Gag du VIH chez des patients VIH-1 et VIH-2 à Dakar, Sénégal, Médecine Sciences, 2007, Vol 23, Abst 57/13A, pp 82. 12. Camara M, Jennes W, Dieye Ndiaye T, Seydi M, Diallo AA, Fall M, Diaw PA, Sow PS, Mboup S, Kestens L. Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIV-discordant couples is associate with low immune activation status. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 28 page 41. 13. Kyongo J, Vanhommerig E, Camara M, Dieye TN, Seydi M, Sow PS, Mboup S, Franzen K, Heyndrickx L, Kestens L, Jennes W. Confirmation of HIV-1 intracouple by gp 41 sequence analysis. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 57 page 49. 14. Dieng AB, Ndao CT, Karam F, Niang A, Dieye T, Lienhardt C, Hane A, Sow PS, Mboup S. Study to validate the diagnostic of tuberculosis infection by IFN ELISPOT in HIV infected patients. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 314 page 89. 15. Sall A, Toure A, Dieye T, Diop M, Seck M, Diop S, Thiam D, Diakhate L. Residual risk of transmission of HIV, HVB and HCV by blood transfusion between 2003 and 2005 at the National Blood Transfusion Center in Senegal. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 691 page 159. 16. Touré/Fall A.O., Soumboudou M., Sall A., Wagué/Guèye M., Diop S., Seck M.,Ndiaye/Dieye T., Thiam D. Le medulogramme : interet dans le diagnostic des hemopathies malignes.XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009, Abst C10, page 11. 17. Ndiaye Fatou Samba Diago ; Dieye T N; Fall S ; Pouye A; Moreira-Diop T. Apport de l’immunophenotypage dans le diagnostic des hemopathies malignes lymphoides.XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009, Abst C11, page 12. 18. Diagne Ibrahima, Dème-Ly I., Dièye T.N., Sylla A., Signaté-Sy H., Diagne-Guèye N.R., Camara B., Fall A.L., Sow H.D. HLA-E et susceptibilite aux infections bacteriennes severes chez les enfants et adolescents drepanocytaires homzygotes senegalais. XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009, Abst C12, page 13. 19. Seck Moussa, Diop S., Diongue M., Diallo A., Dièye T., Touré A.O., Thiam D., Diakhaté L.les polyglobulies a dakar : etude de 15 cas.XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009, Abst C14, page 15. 20. Touré/Fall A O, Wagué/Gueye M., Sall A., Soumboudou M. Seck M., Dieye T., Diop S., Thiam D.Apport de la cytoponction dans le diagnostic d’une adenopathie chronique au CHU A LeDANTEC. XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009Abst C138, page 16. XVIIème Journées Médicales, Pharmaceutiques, Odontologiques

et Vétérinaires. Dakar, 23 -26 Février 2009, Abst C14, page 165. 21. Dieye T.N., Mbaye F, Sadio-Yade A, Diop S, Seck M, Senghor AB, Sall-Diallo A, Loum T, Toure-Fall AO, Thiam D, Diakhate L. Evaluation d’un nouveau test de diagnostic de la syphylis par technique de gel filtration PaGI. XVIIème Journées Médicales, Pharmaceutiques, Odontologiques et Vétérinaires. Dakar, 23 - 26 Février 2009, Abst C30, page 36. 22. A Sall, M Seck, AO Touré,Dieye T, S Diop, D Thiam. Detection de la mutation de JACK2 V617F dans les Syndrome Myeloprolifératifs “Philadelphie Negatifs” Etude préliminaire à propos de 10 cas suivis à Dakar (Senegal). Abst C19, page 41.Dakar Mai 2010 23. A Sall, FS Ndiaye, AO Touré, M Seck, M Gadji,Dieye T, S Diop, D Thiam. Etude de la réponse moléculaire par la recherche du transcript de fusion BCR-ABL chez des patients suivis pour LMC à l’hôpital A Le Dantec de Dakar Senegal. Etude preliminaire de 21 casAbst C20, page 42. Dakar Mai 2010 24. AO Touré, Diabong R, Sall A, Ndiaye/Sene FS, Moreira C, Seck M, Diop S,Ndiaye/Dieye T, Thiam D. Adénogramme et Lymphome : Bilan de 5 ans d’activités au laboratoire d’hématologie de l’hôpital A Le Dantec. Abst C21, page 43 Dakar, Mai 2010 25. NO Touré,TN Dieye, Y Dia Kane, A Diatta, HD Konté, EM Ndiaye, K Thiam, MF Cisse, FBR Mbaye, AA Hane. Depistage des contacts de patients tuberculeux (TPM+): IDRT VS ELISPOT. Abst C41, page 63.Dakar Mai 2010 26. Santos Ndeye Salimata Sall , Camara M,Dieye T, Niang A, Daneau G, Wade D, Badiane Seye JK, Diallo AA, Fall M, Diaw PA, Kestens L, MBoup S. Etude de la regulation de l’activation du systéme immunitaire chez des patients ayant une tuberculose active co infectés ou non par le VIH 16 ième ICASA, Abst WEAA0601Addis AbabaDecembre 2011 27. Diaw Papa Alassane, Daneau G, Coly Abdoul A, Ndiaye Birahim P, Wade Djibril, Camara Makhtar, MBoup Souleymane,Dieye Tandakha Multi sites evaluation of the point of care PIMA instrument for CD4+T cell enumeration Using intravenous and capillary Blood. 16 ième ICASA, Abst WEAA0601, page 238-239, Addis AbabaDecembre 2011 28. Sarr Salematou, Camara Makhtar, Chentouffi A, Tran Michael, Dasgupta Gargi, Fall Marema, Daneau Geraldine, Diaw Papa A, Jennes W, Kestens L, MBoup Souleymane, BenMohamed L Bachir,Dieye Tandakha Ndiaye. Determination de la réponse cellulaire anti-HSV 2 par la method ELISPOT – IFN- chez des sujets co-infectés par le VIH.16 ième ICASA, Abst WEAA0604, page 369-370, Addis Ababa Decembre 2011 29. Mbow M., Meurs L., de Jong S.E., Wammers L., Labuda L., Wade D., Smith H.H., Polman K., Mboup S., Dieye T.N., and Yazdanbakhsh M. Changes in immunological profiles as a function of urbanization and life style. First International Conference of The African Society of Laboratory Medicine - Cape Town, South Africa, 1st – 7th December 2012. 30. Wade Djibril, Diaw Papa Alassane, Daneau Geraldine, CamaraMakhtar, DieyeTandakhaNdiaye, Mboup Souleymane and Kestens Luc. Point-of-Care Pima CD4 and CyFlow Counter using the CD4 easy count kit-dry systems are suitable for CD4 T-cell enumeration in remote areas.First International Conference of The African Society of Laboratory Medicine - Cape Town, South Africa, 1st – 7th December 2012. 31. Santos N.S.S.ӿ, Mbow M.ӿ, Camara M., Niang A., Daneau G., Wade D., Diallo A.A., Ba A., Toupane M., Diakhaté M., Lèye N., Diaw P.A., Mboup S., Kestens L., Dieye T.N. TB impacts T cell activation markers but not regulatory T cells during HIV-1 infection.First International Conference of The African Society of Laboratory Medicine - Cape Town, South Africa, 1st – 7th December 2012.

32. Dieye TN. Malaria Vaccines, 10th NESI (Network for Education and Support in Immunization) symposium, Antwerp, 22th-23rd, April, 2013 33. Abdou Padane, M. Camara, M. Seydi, W. Jennes, A.A. Diallo, M. Fall, P.A. Diaw, P.S. Sow, S. Mboup, L. Kestens. TNDieye...“Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIVdiscordant couples is associated with higher frequency of CD8+ T cells expressing CD107a and b molecules”. 4th Symposium of Infectious Diseases in Africaand the 5th African Flow Cytometry Workshop, Cape Town, 30 August – 6 September 2013., 34. Josephine Khady Badiane, Geraldine Daneau ; Souleymane Mboup ; Tandakha ND Dieye. "Diagnostic De La Tuberculose Extra Pulmonaire Chez Des Patients Tuberculeux Co-infect S Par Le VIH Au S N Gal: Comparaison De L'IDRT Et Du Quantif Ron-TB Gold ",ICASAconference, Cape Town, 7th – 11th December 2013. 66

POSTERS:

1. Dieye T.N., Delforge M.L., Sow P.S., Gueye-Ndiaye A., Dieye A., Popper S.J., Sarr A.D., Crusiaux A., Van Vooren J.P., Liesnard C., Thiam D., Badiane S., Devleeschouwer M., Kanki P., Mboup S., Diakhate L., Farber C.M. Immunologic and virologic response after tetanus toxoid (TT) booster among HIV-1 and HIV- 2 infected individuals. Abstract, Fifth European on Experimental AIDS Research, Madrid, June 16-19, 2000. 2. Dieye T.N., Vereecken C., Diaw P..A., Ondoa P., Guèye A., Mboup S., Kestens L. Evaluation of anaffordable instrument for absolute CD4 counting in resource-poor settings against two reference clinical flow cytometers.Abstrac t N°1126, Second International AIDS Society Conference, Paris, July 13 - 16, 2003. 3. Camara M, Jennes W, Tavernier A, Diallo A, Dieye T, Mboup S, Kestens L. Cross-reactivity of Gagspecific T cell responses in HIV-1- and HIV-2-infected subjects in Dakar, Senegal. Abstract, AIDS vaccine 2005, Montréal, Québec, Canada - September 6 to 9, 2005. 4. Dieye T.N., Gadji M., Senghor A.B., Ngom-Gueye N. F., Karam F., Abdoulaye O., Camara M., Thiam D., Mboup S.,Diakhaté L. ABO blood group diffculties in HIV-1 and in HIV-2 infected individuals using forward and reverse grouping. Abuja, 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005. Abst N° 397, page 239. 5. Diaw PA, Dieye T, Camara M, Karam F, Toure-Kane NC, Gaye-Diallo A, Diop-Ndiaye H, Mboup S. Décentralisation du traitement ARV au Sénégal " Décentralisation de la numération des lymphocytes T CD4 dans les zones à faible prévalence: Expérience du Sénégal".Abuja, 14th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2005. Abst N° 15 page 100.

6. Diaw PA, Dieye T.N., Karam F, Touré-Kane NC, Mboup S. Le Dynabeads une technique alternative pour la décentralisation de la numération des lymphocytes T CD4 dans les zones de faible prévalence : expérience Sénégal Médecine Sciences, Vol 23, Abst n° 166/40p, pp 105, 2007 7. Ondoa P, Vereecken C, Asahchop, Diallo A, Fransen K, Dieye T.N., Ryder R, Kestens L. Desing and evaluation of heat- denatured p24 antigen assay by flow cytometry as a surrogate marker for the HIV-1 RNA load. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 738 page 172. 8. Diop S, Diakhate M, Seck M, Dieye T, Toure AO, Sall A, Thiam D, Diakhate L. Sécurité transfusionnelle : Place de la selection médicale des donneurs. Dakar, 15th International Conference on HIV / AIDS and Sexually Transmitted Infections in Africa (ICASA) 2008. Abst N° 815 page 182. 9. Dieng AB, Ndiaye BP, Dieye T.N., H Mcshane, Brittain N, S Mboup. A phase I study evaluating the safetyand immunogenicity of a new TB vaccine, MVA 85A, in Healthy volunteers who are infected with HIV, Senegal. Tallin, 2nd TB Vaccine forum, 2010. A Second global forum, Poster 38, page 58. 10. M. Camara, A Padane, T. Ndiaye Dieye, M. Seydi, W. Jennes, A.A. Diallo, M. Fall, P.A. Diaw, P.S. Sow, S. Mboup, L. Kestens.Resistance to HIV-1 infection among HIV-exposed seronegative partners in HIVdiscordant couples is associated with higher frequency of CD8+ T cells expressing CD107a and b molecules.6th IAS Conference in Rome, 17- 20 July 2011. Abstract N° CDA078 - CD-ROM. 11. Camara M, Dieye TN, Seydi M, Sow PS, Mboup S, Kestens L, Jennes W.Lack of association between HSV-2 and HIV-1 infection in a cohort of HIV-1 discordant and concordant couples in Dakar, Senegal. AIDS Vaccine Conference, Bangkok, Thailande, 12-15 September 2011. Abstract N° P21.05, page 229.

12. Dieng AB, Ndiaye BP, Dieye TN, H Mcshane, Brittain N, S Mboup. A phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA 85A, in Healthy volunteers who are infected with HIV,Senegal. 2nd TB Vaccine forum, 2010. A Second global forum, Abst Poster 38, page 58.Tallin September 2010 13. Dieng AB, Ndiaye BP, Dieye TN, Brittain N, S Mboup, H Mcshane, A phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA 85A, in Healthy volunteers who are infected with HIV,Senegal. 16 ième ICASA Abst Poster MOPE070, page 86-87.Addis AbabaDecembre 2011 14. T.N. Dieye1, A Chentouffi2, M. Camara1, S. Sarr1, M.V. Tran2, M. Seydi3, G. Dasgupta2, M. Fall1, G. Daneau4, P.A. Diaw1, L. Kestens4, P.S. Sow3, S. Mboup1, L. Benmohamed2 Low Magnitude and Frequency of HSV-2-Specific Interferon Gamma-Producing CD4+ and CD8+ T cell Responses Detected in HIV-1 Heterosexual Discordant Couples. XIX International AIDS conference (AIDS 2012), Washington CD, 22-27th july, 2012 67

15. Santos N.S.S., Mbow M., Camara M., Niang A., Daneau G., Wade D., Diallo A.A., Ba A., Toupane M., Diakhaté M., Lèye N., Diaw P.A., Mboup S., Kestens L., DieyeT.N. Increased expression of T cell activation markers in HIV/TB co- infected patients in Senegal is not associated with decreased numbers of regulatory T cells. ITM international colloqium, Antwerp, 3-7 decembre 2012 16. Abdoul Aziz DIALLO, Géraldine DANEAU, Aliou NIANG, Josephine Khady BADIANE, Makhtar CAMARA, AbdoulAlmamyHANE,Luc KESTENS, Souleymane MBOUP, Tandakha DIEYE. Evaluation de la précision du “primarygating” sur les lymphocytes T CD4 chez des patientssénégalaistuberculeux coinfectés par le VIH.First International Conference of The African Society of Laboratory Medicine - Cape Town, South Africa, 1st – 7th December 2012. 17. A Padane, M. Camara, T. Ndiaye Dieye, M. Seydi, W. Jennes, A.A. Diallo, M. Fall, P.A. Diaw, P.S. Sow, L. Kestens, S. Mboup. La résistance à l’infection VIH des partenaires séronégatifs chez les couples sérodiscordants serait associée à une forte expression des protéines CD107a et CD107b par les LT CD8+.First International Conference of The African Society of LaboratoryMedicine - Cape Town, South Africa, 1st – 7th December 2012.

18. Djibril Wade,. Ba Saïdou, Diaw Papa Alassane, Daneau Geraldine, Gueye Ndèye Awa, CamaraMakhtar, Mboup Souleymane, Kestens Luc, and Dieye Tandakha Ndiaye "Evaluation Of A New Point Of Care System, The CyFlowMiniPOC For Monitoring Of HIV-infected Patients In Resourcelimited Settings"., ICASA conference, Cape Town, 7th – 11th December 2013.

PUBLICATIONS from 2014: 1. Mbengue MAS, Mboup A, Ly ID, Faye A, Camara FBN, Thiam M, Ndiaye BP, Dieye TN, Mboup S. Vaccination coverage and immunization timeliness among children aged 12-23 months in Senegal: a Kaplan-Meier and Cox regression analysis approach. Pan Afr Med J. 2017 Jun 21;27(Suppl 3):8. 2. Amato T, Sall A, Dièye TN, Gozzetti A, Iacono M, Ambrosio MR, Granai M, Somma S, Diop S, Touré AO, May E, Gattiollat CH, Wiels J, Ahmed Y, Raphael M, Leoncini L, Bellan C, Piccaluga PP. Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. Am J Clin Pathol. 2017 Nov 20;148(6):545-554. 3. Dankwa S, Chaand M, Kanjee U, Jiang RHY, Nobre LV, Goldberg JM, Bei AK, Moechtar MA, Grüring C, Ahouidi AD, Ndiaye D, Dieye TN, Mboup S, Weekes MP, Duraisingh MT. Genetic Evidence for Erythrocyte Receptor Glycophorin B Expression Levels Defining a Dominant Plasmodium falciparum Invasion Pathway into Human Erythrocytes. Infect Immun. 2017 Sep 20;85(10). pii: e00074-17. 4. Mbengue MAS, Sarr M, Faye A, Badiane O, Camara FBN, Mboup S, Dieye TN. Determinants of complete immunization among senegalese children aged 12-23 months: evidence from the demographic and health survey. BMC Public Health. 2017 Jul 6;17(1):630. 5. Faye BF, Sow D, Seck M, Dieng N, Toure SA, Gadji M, Senghor AB, Gueye YB, Sy D, Sall A, Dieye TN, Toure AO, Diop S. Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country. dv Hematol. 2017;2017:3518402. 6. Faye BF, Dieng N, Seck M, Gadji M, Gueye YB, Sy D, Toure SA, Sall A, Toure AO, Dieye TN, Diop S. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting. Ann Hematol. 2016 Oct;95(10):1603-10. . 7. Sall A, Touré AO, Sall FB, Ndour M, Fall S, Sène A, Faye BF, Seck M, Gadji M, Dièye TN, Mathiot C, Reynaud S, Diop S, Raphaël M. Characteristics of chronic lymphocytic leukemia in Senegal. BMC Hematol. 2016 Apr 23;16:10. 8. Erwa NH, Jeddane L, Alao MJ, Esser M, Dieye TN, Chipeta J, Bousfiha AA. A-Project: a Training Program from ASID. J Clin Immunol. 2015 Aug;35(6):517-8. 9. Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov. 2015 Aug;14(8):511-2. 10. BP Ndiaye, F Thienemann, MO, BS Landry, M Camara, S Dièye, TN Dieye, H Esmail, R Goliath, K Huygen, V January, I Ndiaye, T Oni, M Raine, M Romano, I Satti, S Sutton,A Thiam, KA Wilkinson, S Mboup, R J Wilkinson, H McShane. Safety, immunogenicity and efficacy of the candidate tuberculosis vaccine MVA85A in healthy HIV-infected adults: A randomized, placebo-controlled phase 2 trial. Lancet Respiratory Medicine. 2015,

11. D, Diaw PA, Daneau G, Diallo AA, Mboup S, Dieye TN, Kestens L. Laboratory and Field Evaluation of the Partec CyFlow MiniPOC for Absolute and Relative CD4 T-Cell Enumeration. PLoS One. 2015 Feb 17;10(2):e0116663. 12. Fall AO1, Proulle V2, Sall A1, Mbaye A3, Ba PS4, Diao M5, Seck M1, Gadji M1, Gning SB4, Diop S1, Dièye TN1, Faye BF1, Thiam D1, Dreyfus M2. Risk factors for thrombosis in an african population. Clin Med Insights Blood Disord. 2014 Apr 10;7:1-6. 13. Bei AK, Diouf A, Miura K, Larremore DB, Ribacke U, Tullo G, Moss EL, Neafsey DE, Daniels RF, Zeituni AE, Nosamiefan I, Volkman SK, Ahouidi AD, Ndiaye D, Dieye T, Mboup S, Buckee CO, Long CA, Wirth DF. Immune characterization of P falciparum parasites with a shared genetic signature in a region of decreasing transmission. Infect Immun. 2015 Jan;83(1):276-85 14. Meurs L, Mbow M, Boon N, Vereecken K, Amoah AS, Labuda LA, Dièye TN, Mboup S, Yazdanbakhsh M, Polman K. Cytokine Responses to SCHISTOSOMA mansoni and Schistosoma haematobium in Relation to Infection in a Co- endemic Focus in Northern Senegal. PLoS Negl Trop Dis. 2014 Aug 7;8(8):e3080. 15. Mbow M, de Jong SE, Meurs L, Mboup S, Dieye TN, Polman K, Yazdanbakhsh M. Changes in immunological profile as a function of urbanization and life style. Immunology. 2014 ; Dec;143(4):56977. 16. Diallo MS, Mbengue B, Seck A, Ndao AC, Niang MS, Cissoko Y, Thiam A, Diop G, Diallo RN, Diallo M, Ndongo S, Dièye TN, Cissé M, Kane A, Dièye A. [Evolution of autoantibodies profile in systemic lupus erythematosus according to age and clinical manifestations]. Ann Biol Clin (Paris). 2014 MayJun;72(3):351-8. 17. Turner JD, Bourke CD, Meurs L, Mbow M, Dièye TN, Mboup S, Polman K, Mountford AP. Circulating CD14brightCD16+ 'intermediate' monocytes exhibit enhanced parasite pattern recognition in human helminth infection. PLoS Negl Trop Dis. 2014 Apr 24;8(4):e2817. 18. Van den Broeck F, Meurs L, Raeymaekers JA, Boon N, Dieye TN, Volckaert FA, Polman K, Huyse T.Inbreeding within human Schistosoma mansoni: do host-specific factors shape the genetic composition of parasite populations? Heredity (Edinb). 2014 Jul;113(1):32-41.

Espinosa Blay Lluis

Finn Adam Adam Finn was born and brought up in Canterbury, UK on a farm. He studied medical sciences and history of art at Cambridge and medicine and surgery at Oxford, qualifying in 1983. He trained in paediatrics in Sheffield, Bristol and Guy's Hospital, London before undertaking a fellowship in Paediatric Infectious Diseases at the Children's Hospital of Philadelphia, USA under Stan Plotkin. He returned to the UK to spend 4 years as a lecturer at the Institute of Child Health and Great Ormond St. Hospital in London under the late Roland Levinsky where he completed a PhD in immunology. Between 1992 and 2001 he was Senior Lecturer at the University of Sheffield, leaving to become Professor of Paediatrics at the University of Bristol where he is now head of the Section of Infection & Immunity in the School of Clinical Sciences and directs the South West Local Research Network for Medicines for Children. He also leads the paediatric immunology and infectious diseases clinical service for Bristol and the South West region. His main recent research interests continue to relate to elucidation of the nature of naturally acquired mucosal immunity to pneumococcus, meningococcus and other respiratory bacteria and development of tools to assess human immune responses to candidate vaccine antigens. He also leads and supports numerous clinical trials of drugs and medicines in children. Last publications: Gene detection and expression profiling of Neisseria meningitidis using NanoString nCounter platform. Tekletsion YK, Christensen H, Finn A. J Microbiol Methods. 2018 Feb 7;146:100-103.

Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the UK towards participation in clinical trials and routine implementation. McQuaid F, Jones C, Stevens Z, Meddaugh G, O'Sullivan C, Donaldson B, Hughes R, Ford C, Finn A, Faust SN, Gbesemete D, Bedford H, Hughes S, Varghese AS, Heath PT, Snape MD. Acta Obstet Gynecol Scand. 2018 Mar;97(3):330-340

Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. Sadarangani M, Sell T, Iro MA, Snape MD, Voysey M, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Pollard AJ; European MenB Vaccine Study Group. CMAJ. 2017 Oct 16;189(41):E1276-E1285

Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Pollard AJ, Finn A, Curtis N. Arch Dis Child. 2017 Nov;102(11):1077-1081.

Parents' perceptions of influenza and why they accept or decline the nasal vaccine for their child. Moulsdale P, Grant A, Fletcher M, Finn A. Nurs Child Young People. 2017 Apr 11;29(3):28-33.

Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13. Trück J, Thompson A, Morales-Aza B, Clutterbuck EA, Voysey M, Clarke E, Snape MD, Kelly DF, Finn A, Pollard AJ. Vaccine. 2017 May 9;35(20):2701-2708.

Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine? Gessner BD, Knobel DL, Conan A, Finn A. Vaccine. 2017 Feb 1;35(5):716-721.

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Pace D, Khatami A, Attard-Montalto S, Voysey M, Finn A, Faust SN, Heath PT, Borrow R, Snape MD, Pollard AJ. Vaccine. 2016 Dec 7;34(50):6350-6357.

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Vaccine. 2017 Jan 5;35(2):395-402.

Pneumococcal Serotypes Colonise the Nasopharynx in Children at Different Densities. Rodrigues F, Danon L, Morales- Aza B, Sikora P, Thors V, Ferreira M, Gould K, Hinds J, Finn A. PLoS One. 2016 Sep 29;11(9):e0163435. Community paediatric respiratory infection surveillance study protocol: a feasibility, prospective inception cohort study. Anderson EC, Ingle SM, Muir P, Beck C, Finn A, Leeming JP, Cabral C, Kesten JM, Hay AD. BMJ Open. 2016 Aug 31;6(8):e013017

Density Distribution of Pharyngeal Carriage of Meningococcus in Healthy Young Adults: New Approaches to Studying the Epidemiology of Colonization and Vaccine Indirect Effects. Finn A, Morales-Aza B, Sikora P, Giles J, Lethem R, Marlais M, Thors V, Pollard AJ, Faust S, Heath P, Vipond I, Ferreira M, Muir P, Januário L, Rodrigues F. Pediatr Infect Dis J. 2016 Oct;35(10):1080-5.

Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines. Usonis V, Ivaskevicius R, Diez-Domingo J, Esposito S, Falup-Pecurariu OG, Finn A, Rodrigues F, Spoulou V, Syrogiannopoulos GA, Greenberg D; CAP-PRI Working Group. Pneumonia (Nathan). 2016 May 2;8:5.

CNS infection safety signal of RTS,S/AS01 and possible association with rabies vaccine. Gessner BD, Wraith DC, Finn A. Lancet. 2016 Apr 2;387(10026):1376.

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, Dull PM, Kohl I, Barone M, Wang H, Toneatto D, Pollard AJ; European MenB Vaccine Study Group. Pediatr Infect Dis J. 2016 Apr;35(4):e113-23.

The Effects of Live Attenuated Influenza Vaccine on Nasopharyngeal Bacteria in Healthy 2 to 4 Year Olds. A Randomized Controlled Trial. Thors V, Christensen H, Morales-Aza B, Vipond I, Muir P, Finn A. Am J Respir Crit Care Med. 2016 Jun 15;193(12):1401-9.

Jonjic Stipan

Stipan Jonjić, M.D., PhD Curriculum Vitae

PERSONAL DATA

Office Address: Department of Histology and Embryology Center for Proteomics Faculty of Medicine, University of Rijeka B. Branchetta 20 51000 Rijeka, Croatia

Telephone: +385 51 651 170 Cellular: +385 91 1651 206 Fax: +385 51 651 176 web: http://www.medri.hr/~jstipan

EDUCATION AND POSITIONS

1971 – 1976 M.D.,Faculty of Medicine, University of Rijeka 1979 – 1982 Postgraduate Studies, Faculty of Medicine, University of Rijeka 1979 – 1986 Research Assistant, Department of Physiology and Immunology Faculty of Medicine,University of Rijeka 1982 M.Sc., University of Rijeka 1982 - 1983 Research Assistant, Federal Research Center for Virus Diseases – Tübingen, Germany 1985 Ph.D. in Medicine, University of Rijeka 1986 Assistant Professor, Department of Physiology and Immunology Faculty of Medicine, University of Rijeka 1986 Research Assistant, Federal Research Center for Virus Diseases – Tübingen, Germany 1990 Associate Professor, Faculty of Medicine, University of Rijeka 1992 Full Professor, Faculty of Medicine, University of Rijeka 1996 - Professor and Chair, Department of Histology and Embryology, Faculty of Medicine, University of Rijeka 1997 - 2007 Professor and Chair, Department of Biology and Medical genetics Faculty of Medicine, University of Mostar 1999 – 2003 Dean, Faculty of Medicine, University of Rijeka 2006 - Chair, Center for Proteomics Faculty of Medicine, University of Rijeka 2009 - University of Rijeka Board for evaluation of doctoral studies, Chair

AWARDS AND HONOURS

1993 Croatian National Prize for Science "Rudjer Boskovic'' 1994 Günther Weitzel Science Award 1994 (League for the development of molecular biology and biotechnology, Tübingen, Germany) 1995 Medal of the President of the Republic of Croatia 2003 The Annual Award of the Croatian Academy of Sciences and Arts for Scientific Achievements 75

2007 Raine Foundation Visiting Professorship at the University of Western Australia 2009 The Award of the Croatian Academy of Medical Sciences 2012 German National Academy of Science – Leopoldina, member 2013 Lifetime Achievement Award in Science of the Republic of Croatia

EDITORIAL BOARDS

Acta Medica Academica Current Immunology Reviews -Editorial Advisory Board Member European Journal of Immunology (EJI) Frontiers in Microbial Immunity Herpesviridae Microbes and Infections PlosPathogens – guest editor

MEMBERSHIPS

1994 - 2002 The National Scientific Council (Croatia) 2000 - 2003 The National Council for Higher Education (Croatia) 2000 - American Society for Microbiology 2002 - 2006 President of the Croatian Immunological Society 2005 - Society for Natural Immunity 2006 - 2011 EU FP6/ FP7 Programme Committee - Health (Member) 2006 - 2011 President of the National Board for FP7 projects 2010 - Croatian Science Foundation - Board of Directors 2013 - Chairman of the Science Council, University of Rijeka 2014 - Panel member for the ERC Starting grant evaluation panel LS6 – Immunity and Infections

MEETING ORGANIZATION

1. BMBF Summer School "Proteomics Basics”, September 24 – 29 2004, Opatija 2. Croatian Immunological Society Meeting 2005 - Božava, Dugi otok 3. 30th International Herpesvirus Workshop (IHW), July 30 – Aug 5 2005, Turku, Finland 4. Croatian – Israeli Kick-off Meeting on Viral Immunology and Pathogenesis, March 23 2007, Rijeka 5. MC Summer School "NK Defense and Therapy”, Aug 28 – 31 2007 and EPO Course Sep 01 – 05 2007, Božava, Dugi otok 6. Advanced Laboratory Training Course "Viral Subversion of Immune Response”, Howard Hughes Medical Institute, June 08 - 17, 2009, Rijeka 7. 12th Meeting of the Society for Natural Immunity, September 11 - 15, 2010, Cavtat - Dubrovnik 8. Fc protein expression of type I and type II proteins - 1st CAPRI2010 Advanced Laboratory Workshop, May 2 - 8, 2011, Rijeka 9. Advanced production techniques for complex protein biologics - 2st CAPRI2010 Advanced Laboratory Workshop, October 24 - 27, 2011, Rijeka 10. Antibody engineering: from murine hybridoma to therapeutics - 3rd CAPRI2010 Advanced Laboratory Workshop, February 13 - 14, 2012, Rijeka 11. Small Animal Imaging Workshop, TransMedRi, Department of Histology&Embryology, Faculty of Medicine, University of Rijeka, March 15 – 16, 2012, Rijeka 12. Workshop on Congenital Infections, TransMedRi, Department of Histology & Embryology, Faculty of Medicine, University of Rijeka, May 21 - 22, 2012, Rijeka 76

13. I training workshop on commercial strategies: MEDRI meets industry - 1-day training in frame of the IPA SIIF-funded project ''Becoming entrepreneurial:Knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector'' July 15, 2013, Rijeka 14. II training workshop on effective translation of vaccine R&D - 1-day training in frame of the IPA SIIF-funded project ''Becoming entrepreneurial: Knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector'' October 15, 2013, Rijeka 15. III training workshop on partnership strategies in developing diagnostic tools - 1-day training in frame of the IPA SIIF-funded project ''Becoming entrepreneurial: Knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector'' December 6, 2013, Rijeka 16. IV training workshop on ''Pre-clinical testing opportunities'' - 1-day training in frame of the IPA SIIF- funded project ''Becoming entrepreneurial: Knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector'', March 21,2014, Rijeka

RESEARCH INTEREST

Immunology, molecular virology, viral pathogonesis.

Major research achievements in the field of viral immunology and pathogenesis: 1. Discovery of physiological plasticity of T cell response to viral infection – evidence that CD8+ T cells deficient mice eliminate the virus via the compensatory response mediated by CD4+ T cells (J. Virol. 64:5457-5464, 1990) 2. Evidence that CD4 cells and IFN-gamma are necessary for preventing the horizontal transmission of MCMV infection (J. Exp. Med. 169:1199-1212, 198 J. Virol. 66:19771984, 1992) 3. Evidence that antiviral antibodies are not required for the resolution of primary infection and the establishment and maintenance of CMV latency, but play a key role in limiting recurrent herpesvirus infection (J. Exp. Med. 179:1713-1717, 1994) 4. Evidence that CD8+ and CD4+ T cell subsets, IFN-gamma as well as NK cells contribute in a hierarchical and redundant fashion to immunosurveillance of MCMV latency and prevention of recurrent infection (J. Exp. Med. 188:1047-1054, 1998) 5. Evidence for the role in vivo of herpesviral immunoevasins involved in the downmodulation of MHC class I molecules (J. Exp. Med. 190:1285-1295, 1999) 6. First discovery that CMV prevents NK cell activation by down-modulating cellular ligands for the activating NK cell receptor NKG2D and characterization of several other viral inhibitors of cellular NKG2D ligands (Nat. Immunol. 3:529-535, 2002; J. Virol. 79:2920-30, 2005; J. Exp. Med. 201:211- 220, 2005; J. Exp. Med. 203:1843-50, 2006) 7. Establishment of the MCMV model to study CMV infection in the developing CNS (J. Exp. Med. 205:423-35, 2008; J. Virol. 82(24):12172-80, 2008) 8. The newly discovered inhibitory receptor expressed on human NK cells and some subsets of T cells (PNAS USA 106(42):17858-63, 2009) 9. Evidence that MCMV m04 protein is essential for activation of NK cells via Ly49P (J. Exp. Med. 206(3):515-23, 2009) 10. First evidence that ‘missing-self’ dependent NK cell activation plays a role in virus control and characterization of MCMV immunoevasion of this effector mechanism (J. Exp. Med. 207(12):2663- 73, 2010) 11. Evidence that recombinant cytomegalovirus expressing a ligand for the NKG2D receptor has superior vaccine properties (JCI 120:4532-45;2010; PNAS USA, 110:16550-5; 2013)

MANUSCRIPT AND GRANTS REVIEWER

Journals: Antiviral Research, Archives of Virology, Blood, Cell Host & Microbe, Croatian Medical Journal, Expert Review of Vaccines, Infection and Immunity, International Immunology , International Immunopharmacology, Immunity, Nature Immunology, Journal of Experimental Medicine, Journal of Cellular and Molecular Medicine, Journal of General Virology, Journal of Leukocyte Biology, Journal of Virology, Medical Microbiology and Immunology, Methods in Virology, Periodicum Biologorum, PloS Pathogens, Virology, The Journal of Infectuous Diseases

Grants: NIAID Special Emphasis Panel Review The National Science Foundation of the Republic of Croatia, French Research Agency (FRA) - Microbiology, Immunology and Infection panel Innovational Research Incentives Scheme Vidi 2012 Austrian Academy of Sciences ERC Starting grant evaluation

GRANTS

Active grants:

1. "MCMV Infection of the Developing CNS: Neuroinvasion and immune Control” National Institutes of Health (NIH) USA; Grant Number: 1R01NS065845 -01 PI Dr. William Britt (University of Alabama, Birmingham), co-PI Stipan Jonjic, 2010 – 2015, ~ USD 350.000 2. "Congenital CMV and CNS infection mechanisms of protective immunity” National Institutes of Health (NIH) SAD; Grant Number: 1RO1AI089956-01A1; PI William Britt (University of Alabama, Birmingham), co-PI Stipan Jonjic, 2011 - 2016 ~ USD 500.000 3. "Viral Strategies of Immune Evasion (VISTRIE)”, partners: Luka Čičin-Šain, Melanie Brinkmann (Helmholtz Centre for Infection Research, Braunschweig), Martin Messerle (Medical School Hannover), Ulrich Kalinke (TWINCORE Centre for Experimental and Clinical Infection Research, Hannover), Hartmut Hengel, Anne Halenius (University Hospital Düsseldorf), Stipan Jonjic, 2011 - 2016, EUR 4.500.000 4. "Strengthening adaptive immunity via innate immunity: enhancing the CD8 T cell response by using the NKG2D ligand expressed in a herpesvirus vector” - (StAdvInn), EU FP7 ERC-2012- AdG_20120314-Ideas, PI Stipan Jonjić, 2013 - 2018, EUR 1.754.897 5. "Becoming entrepreneurial: knowledge transfer from the University of Rijeka Faculty of Medicine to the biotechnology business sector” Instrument for Pre- accession Assistance – IPA, PI Stipan Jonjic, partner PI Martin Messerle, 2013 - 2015, 440.000 EUR 6. ''Immunosurveillance mechanisms of herpesvirus infection and development of new virus vaccines and vaccine vectors'', University of Rijeka, Uniri projects/516, 2013 – 2014, 167.367,54 kn 7. ''Methods for high-throughput glycoproteomic analysis (HTP-GlycoMet)'', (324400) , FP7 program Marie Curie Actions - Industry-Academia Partnerships and Pathways, coordinator: University of Rijeka, partners: Stipan Jonjić, Faculty of Medicine Rijeka; Genos, Zagreb, Bia Separations, Ajdovščina, Slovenija, Max Planck Society, Magdeburg, Njemačka; 2013 - 2015, EUR 1.818.077,90 8. ''Platform for trans-Academic Cooperation in Innovation (PACINNO)'' IPA Adriatic CBC Strategic project proposals, coordinator: University of Trieste; 7 partners from the Adriatic region (Stipan Jonjic) 2013-2016, EUR 6.272.300/EUR 636.500 9. ''Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines (CERVirVac) '', Ministry of Science, Education and Sports of the Republic of Croatia, coordinator 78

Stipan Jonjic (University of Rijeka Faculty of Medicine), partners: Center for Research and Knowledge Transfer in Biotechnology of the University of Zagreb and The University Hospital for Infectious Diseases Zagreb, 2014 - 2018 Former grants:

1. ''Deletion mutants of cytomegalovirus'' (006204), Ministry of science and technology of the Republic of Croatia, 1996 2. ''Perinatal cytomegalovirus infection'' (006205), Ministry of science and technology of the Republic of Croatia, 1996 3. ''CMV infection and immunosuppression'' (1.08.05.04.06), Ministry of science and 'technology of the Republic of Croatia, 1987-1990 4. ''Surveillance of cytomegalovirus infections'' (3-01-169), Ministry of science and technology of the Republic of Croatia, 1991-1996 5. ''Immunosurveillance of cytomegalovirus latency'', US-Croatian Science Technology Program (project JF 190), 1995-1997 6. ''Regulation of NK-cell receptors by herpes viruses'' (Project 0062004), Ministry of science and technology of the Republic of Croatia, 2002 7. ''Antiviral Antibodies and CNS Infection with CMV – Fogarty International Research Collaboration Award (FIRCA)'', National Institutes of Health, Bethesda (together with Dr. William J. Britt, University of Alabama, Birmingham), co-PI Stipan Jonjic,1999 - 2002 8. ''CNS Maldevelopment and Perinatal Infection'' (1 R01 HD044721-01), National Institutes of Health, Bethesda co-PI Stipan Jonjic (together with Dr. William J. Britt, University of Alabama, Birmingham), 2003 - 2008 9. ''Center for Monoclonal Antibody Production (JEZGRA 17)'' Ministry of science and technology of the Republic of Croatia, PI: S. Jonjic, 2003 – 2007 10. ''Establishment of high-throughput monoclonal antibody production and hybridoma bank'', FP6-2002-INCO-WBC/SSA-3, PI Stipan Jonjic, 2006-2008 11. ''Natural Killer Cell-Mediated Anti-Viral and Anti Tumor Defense and Therapy: Integrated research training in molecular medicine, bioinformatics and issues of biotech patents and SME business'', EU FP6 Marie Curie Research Training Networks Coordinator: E. Hofer, Medical University of Vienna, partner Stipan Jonjic, 2006-2009, EUR 198.628 12. "Conference of the society for natural immunity", National Institutes of Health (NIH) USA, Grant Number: 1R13AI089016-01, co-PI Stipan Jonjić, 2009, USD 7.000 13. "Transcriptomic Approach to Viral Disease Research'', Unity Through Knowledge Fund (UKF) Grant Dr. Joanne Trgovcich (The Ohio State University, Columbus OH, USA) and Dr. Stipan Jonjic (Center for Proteomics – Faculty of Medicine, University of Rijeka), 2007-2010, EUR 106.415 14. "The function of the NK killer receptor NKp46 in CMV and Influenza infection'', Croatia-Israel joint research program, PI Stipan Jonjic, 2009-2011, USD 50.000 15. ''The development of a model for immunotherapy of viral infections by using recombinant proteins which connect the innate and specific immune respons'', The National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia, PI Stipan Jonjic, 2008-2011, EUR 105.000 (NZZ) + EUR 45.000 partner 16. "The Center for Antibody Production Rijeka: Upgrading the Central Research and Service Infrastructure for the South Eastern Region of Europe”, EU FP7REGPOT- 2008- 1, PI Stipan Jonjic, 2009-2012, EUR 619.770 17. "Upgrading the capacities for research in translational medicine at the Faculty of Medicine University of Rijeka (TransMedRi)” - 256686), EU FP7-REGPOT- 20105. S. Jonjic, together with colleagues from the Faculty of Medicine prepared the project proposal. This is an institutional grant

coordinated by the Vice-Dean for Science of the Faculty of Medicine, Bojan Polic. The project aims to strengthen the research potential of the Faculty of Medicine for translational research in biomedicine, particularly in the fields of infectious diseases and cancer. 2010 – 2013; total funding: EUR 1.853.941 18. "Molecular mechanisms of immune evasion by cytomegalovirus”, Ministry of Science, Education and Sports (062-0621261-1263), PI Stipan Jonjić, 2007-2011, EUR 102.740 19. "The role of cystatins in immune response to viruses” Croatia-Slovenia cooperation in science and technology; Ministry of Science, Education and Sports (001.10-1264); co-PI Stipan Jonjic, 2012 - 2013, EUR 2.200 20. "Viral evasion of NK cells”, National Institutes of Health (NIH) USA Grant Number: 1RO1AI083201-01, PI Stipan Jonjic, 2009 - 2013, USD 270.249 21. "New strong CMV–promoter for protein and RNA production” Business Inovation Center of Croatia BICRO, PI Stipan Jonjic, 2012 – 2013, HRK 390.000/350.000

CITATIONS

Web of Knowledge: 4.963 Google Scholar: 6.370 h-index: 37 h-index: 39

PATENTS

Jonjic, S. US Patent Application: VACCINE COMPRISING BETA-HERPESVIRUS. Application number: 20130156808; Filed: November 22, 2012; Published: June 20, 2013 PUBLICATIONS (2015 – 1976)

a) From 2010 publications – source Web of Science

1. Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity. 2018 Feb 20;48(2):396-398. 2. Milbradt J, Sonntag E, Wagner S, Strojan H, Wangen C, Lenac Rovis T, Lisnic B, Jonjic S, Sticht H, Britt WJ, Schlötzer-Schrehardt U, Marschall M. Human Cytomegalovirus Nuclear Capsids Associate with the Core Nuclear Egress Complex and the Viral Protein Kinase pUL97. Viruses. 2018 Jan 13;10(1). pii: E35. 3. Miletic A, Lenartic M, Popovic B, Brizic I, Trsan T, Miklic K, Mandelboim O, Krmpotic A, Jonjic S. NCR1-deficiency diminishes the generation of protective murine cytomegalovirus antibodies by limiting follicular helper T-cell maturation. Eur J Immunol. 2017 Sep;47(9):1443-1456. 4. Tršan T, Vuković K, Filipović P, Brizić AL, Lemmermann NAW, Schober K, Busch DH, Britt WJ, Messerle M, Krmpotić A, Jonjić S. Cytomegalovirus vector expressing RAE-1γ induces enhanced anti-tumor capacity of murine CD8+T cells. Eur J Immunol. 2017 Aug;47(8):1354-1367. 5. Popovic B, Golemac M, Podlech J, Zeleznjak J, Bilic-Zulle L, Lukic ML, Cicin-Sain L, Reddehase MJ, Sparwasser T, Krmpotic A, Jonjic S. IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 2017 Apr 27;13(4):e1006345. 6. Aguilar OA, Berry R, Rahim MMA, Reichel JJ, Popović B, Tanaka M, Fu Z, Balaji GR, Lau TNH, Tu MM, Kirkham CL, Mahmoud AB, Mesci A, Krmpotić A, Allan DSJ, Makrigiannis AP, Jonjić S,

Rossjohn J, Carlyle JR. A Viral Immunoevasin Controls Innate Immunity by Targeting the Prototypical Natural Killer Cell Receptor Family. Cell. 2017 Mar 23;169(1):58-71.e14. 7. Lenac Rovis T, Kucan Brlic P, Kaynan N, Juranic Lisnic V, Brizic I, Jordan S, Tomic A, Kvestak D, Babic M, Tsukerman P, Colonna M, Koszinowski U, Messerle M, Mandelboim O, Krmpotic A, Jonjic S. Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. J Exp Med. 2016 Aug 22;213(9):1835-50. 8. Glasner A, Simic H, Miklić K, Roth Z, Berhani O, Khalaila I, Jonjic S, Mandelboim O. Expression, Function, and Molecular Properties of the Killer Receptor Ncr1-Noé. J Immunol. 2015 Oct 15;195(8):3959-69. Bradford RD, Yoo YG, Golemac M, Pugel EP, Jonjic S, Britt WJ. Murine CMV- induced hearing loss is associated with inner ear inflammation and loss of spiral ganglia neurons. PLoS Pathog. 2015 Apr 13;11(4):e1004774. 9. Eifler M, Uecker R, Weisbach H, Bogdanow B, Richter E, König L, Vetter B, Lenac-Rovis T, Jonjic S, Neitzel H, Hagemeier C, Wiebusch L: PUL21a-Cyclin A2 Interaction is Required to Protect Human Cytomegalovirus-Infected Cells from the Deleterious Consequences of Mitotic Entry. PLoS Pathogens, 13;10(10):e1004514. 2014 10. Pyzik M, Dumaine AA, Charbonneau B, Fodil-Cornu N, Jonjic S, Vidal SM: Viral MHC Class I-like Molecule Allows Evasion of NK Cell Effector Responses In Vivo. Journal of Immunology, 193(12):6061-9, 2014 11. Gabaev I, Elbasani E, Ameres S, Steinbrück L, Stanton R, Döring M, Lenac Rovis T, 12. Kalinke U, Jonjic S, Moosmann A, Messerle M: "Expression of the Human 13. Cytomegalovirus UL11 Glycoprotein in Viral Infection and Evaluation of its Effect on Virus-Specific CD8 T Cells", Journal of Virology, pii: JVI.01691-14, 88(24):14326, 2014 14. Brizic I, Lenac Rovis T, Krmpotic A, Jonjic S: ''MCMV avoidance of recognition and control by NK cells.'', Seminars in Immunopathology, 36(6):641-50, 2014 15. Celis-Gutierrez J, Boyron M, Walzer T, Pandolfi PP, Jonjić S, Olive D, Dalod M, Vivier E, Nunès JA: Dok1 and Dok2 proteins regulate natural killer cell development and function. EMBO Journal, pii: e201387404, 2014 16. Baird NL, Bowlin JL, Yu X, Jonjic S, Haas J, Cohrs RJ, Gilden D: Varicella zoster virus DNA does not accumulate in infected human neurons.Virology, 458-459:1-3, 2014 17. Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, 18. Vivier E, Jonjic S, Oxenius A: Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1. Immunity, 19;40(6):961-73, 2014 19. Slavuljica I, Kvestak D, Huszthy P, Kosmac K, Britt W, Jonjic S: Immunobiology of Congenital Cytomegalovirus Infection of the Central Nervous System - Murine Cytomegalovirus Model. Cellular and Mollecular Immunology, 2014 20. Zarama A, Perez-Carmona N, Farre´ D, Tomic A, Borst EM, Messerle M, Jonjic S, Engel P, Angulo A: Cytomegalovirus m154 hinders CD48 cell-surface expression and promotes viral escape from host natural killer cell control. PLoS Pathogens, 10(3):e1004000 doi:10.1371/journal.ppat.1004000; 2014 21. Trilling M, Khanh Le V, Rashidi-Alavijeh J, Katschinski B, Scheller J, Rose-John S, Androsiac G, Jonjic S, Poli V, Pfeffer K, Hengel H:'Activated' S TAT proteins - a paradoxical consequence of inhibited JAK-STAT signalling in cytomegalovirusinfected cells. Journal of Immunology, 192(1):447-58; 2014 22. Geyer H, Hartung E, Mages HW, Weise C, Beluzic R, Vugrek O, Jonjic S, Kroczek RA, Voigt S: Cytomegalovirus expresses the chemokine homologue vXCL1 capable of attracting XCR1+CD4- dendritic cells. Journal of Virology, 88(1):292-302; 2014 23. Trsan T, Busche A, Abram M, Wensveen FM, Lemmermann NA, Arapovic M, Babic M,Tomic A, Golemac M, Brinkmann MM, Jäger W, Oxenius A, Polic B, Krmpotic A, Messerle M, Jonjic S: Superior induction and maintenance of protective CD8 T cells in mice infected with MCMV vector expressing RAE-1γ. Proceedings of the National Academy of Sciences of the United States of America, 110(41):16550-5; 2013 (IF: 9.737, Q1 in Multidisciplinary sciences)

24. Juranic Lisnic V, Babic Cac M, Lisnic B, Trsan T, Mefferd A, Mukhopadhyay CD, Cook CH, Jonjic S, Trgovcich J: Dual Analysis of the Murine Cytomegalovirus and Host Cell Transcriptomes Reveal New Aspects of the Virus-Host Cell Interface.PLoS Pathogens, 9(9):e1003611. doi: 10.1371/journal.ppat.1003611. 2013 (IF: 8.136, Q1 in Microbiology, Q1 in Parasitology and Q1 in Virology) 25. Wensveen MF, Lenartic M, Jelencic V, Lemmermann AN, ten Brinke A, Jonjic S, Polic B: NKG2D Induces Mcl-1 Expression and Mediates Survival of CD8 Memory T Cell Precursors via Phosphatidylinositol 3-Kinase. J Immunol, 191(3):1307-15; 2013 (IF:5.520, Q1 in Immunology) 26. Jordan S, Ruzsics Z, Mitrovic M, Baranek T, Arapovic J, Krmpotic A, Vivier E, Dalod M, Jonjic S, Döelken L, Koszinowski UH: Natural killer cells are required for extramedullary hematopoiesis following murine cytomegalovirus infection. Cell Host & Microbe, 13, 535-545; 2013 (IF:12.609, Q1 in Microbiology, Parasitology and Virology) 27. Stanietsky N, Lenac T, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S, Mandelboim O: Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. European Journal of Immunology, 43(8):2138-50; 2013 (IF:4.970, Q1 in Immunology) 28. Lenac Rovis T, Bailer SM, Pothineni VR, Ouwendijk WJ, Simic H, Babic M, Miklic K, Malic S, Verweij MC, Baiker A, Gonzalez O, von Brunn A, Zimmer R, Früh K,Verjans GM, Jonjic S, Haas J.:A comprehensive analysis of varicella zoster virus proteins using a new monoclonal antibody collection. Journal of Virology, 87(12):6943-6954; 2013 (IF:5.076, Q1 in Virology) 29. Miletic A, Krmpotic A, Jonjic S: The evolutionary arms race between NK cells and viruses: Who gets the short end of the stick? European Journal of Immunology, 43(4):867-77; 2013 (IF:4.970, Q1 in Immunology) 30. Lankry D, Lenac Rovis T, Jonjic S, Mandelboim O:The interaction between CD300a and Phosphatidylserine inhibits tumor cell killing by NK cell. European Journal of Immunology, doi: 10.1002/eji.201343433; 2013 (IF:4.970, Q1 in Immunology) 31. Kosmac K, Bantug R,Pugel E, Cekinovic Dj, Jonjic S, Britt W: Glucocorticoid Treatment of MCMV Infected Newborn Mice Attenuates CNS Inflammation and Limits Deficits in Cerebellar Development PLoS Pathogens, 9(3): e1003200. 2013 (IF:8.136, Q1 in Microbiology, Parasitology and Virology) 32. Handke W, Luig C, Popovic B, Krmpotic A, Jonjic S, Brune W: Viral inhibition of BAKpromotes murine cytomegalovirus dissemination to salivary glands. Journal of Virology, 87(6):3592-6; 2013 (IF:5.076, citations: 2, Q1 in Virology) 33. Wensveen FM, Klarenbeek PL, van Gisbergen K, Pascutti MF, Derks I, van Schaik B, ten Brinke A, de Vries N, Cekinovic D, Jonjic S, van Lier R,Eldering E: Pro-Apoptotic Protein Noxa Regulates Memory T Cell Population Size and Protects against Lethal Immunopathology. Journal of Immunology, 190(3):1180-91; 2013 (IF:5.520, citations:1, Q1 in Immunology) 34. Borst M, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, Degenhardt I, Kalesse M, Jonjic S, Bauerfeind R, Messerle M: The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. Journal of Virology, 87(3):1720-32; 2012 (IF:5.076, Q1 in Virology) 35. Yu X, Seitz S, Pointon T, Bowlin J, Cohrs R, Jonjic S, Haas J, Wellish M, Gilden D: Varicella Zoster Virus Infection of Highly Pure Terminally Differentiated Human Neurons. Journal of Neurovirology, 19(1):75-81; 2013 (IF:2.850, Q3 in Neurosciences and Q2 in Virology) 36. Mitrovic M, Arapovic J, Traven L, Krmpotic A, Jonjic S: Innate immunity regulates adaptive immune response: lessons learned from studying the interplay between NK and CD8(+) T cells during MCMV infection. Medical Microbiology and Immunology, 201(4):487-95; 2012 (IF:3.545, citations: 1, Q2 in Immunology and Q2 in Microbiology) 37. Rodrıguez-Martin S, Kropp K, Wilhelmi V, Juranic Lisnic V,Yuan Hsieh W, Blanc M, Livingston A, Busche A, Tekotte H, Messerle M, Auer M, Fraser I, Jonjic S, Angulo A, Reddehase M,Ghazal P: Ablation of the Regulatory IE1 Protein of Murine Cytomegalovirus Alters In Vivo Pro-inflammatory

TNFalpha Production during Acute Infection. PLoS Pathogens 8(8):e1002901; 2012 (IF:8.136, citations: 1, Q1 in Microbiology, Q1 in Parasitology and Q1 in Virology) 38. van Gisbergen K, Kragten N, Hertoghs K , WensveenF, Jonjic S, Hamann J, Nolte M,van Lier R: Mouse Hobit is a homolog of the transcriptional repressor Blimp-1 that regulates NKT cell effector differentiation. Nature Immunology, 13(9):864-71; 2012 (IF:26.199, citations:3, Q1 in Immunology) 39. Mandaric S, Walton S, Ruelicke T, Richter K, Girard-Madoux M, Clausen B, Zurunic A, Kamanaka M, Flavell R, Jonjic S, Oxenius A: IL-10 Suppression of NK/DC Crosstalk Leads to Poor Priming of MCMV-Specific CD4 T Cells and Prolonged MCMV Persistence. PLoS Pathogens, 8(8):e1002846; 2012 (IF:8.136, citations: 3, Q1 in Microbiology, Parasitology and Virology) 40. Glasner A, Zurunic A, Meningher T, Lenac Rovis T, Tsukerman P, Bar-On Y, Yamin R, Meyers A, Mandeboim M, Jonjic S, Mandelboim O: Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS ONE, 7(5):e36837; 2012 (IF:3730, citations: 6, Q1 in Multidisciplinary sciences) 41. Poglitsch, M, Weichhart T, Hecking M, Werzowa J, Katholnig K, Antlanger M, Krmpotic A, Jonjic S, Hörl W, Zlabinger G, Puchhammer E, Säemann M: CMV Late Phase-Induced mTOR Activation Is Essential for Efficient Virus Replication in Polarized Human Macrophages. American Journal of Transplantation, 2(6):1458-68; 2012 (IF:6.192, citations: 10, Q1 in Surgery and Transplantation) 42. Mitrovic M, Arapovic J, Jordan S, Fodil-Cornu N, Ebert S, Vidal SM, Krmpotic A, Reddehase MJ, Jonjic S: The NK-cell response to mouse cytomegalovirus infection affects the level and kinetics of the early CD8+ T-cell response. Journal of Virology, 86(4):2165-75; 2012 (IF:5.076, citations: 11, Q1 in Virology) 43. Marcinowski L, Tanguy M, Krmpotic A, Rädle B, Juranic Lisnic V, Tuddenham L, Chane-Woon- Ming B, Ruzsics Z, Erhard F, Benkartek C, Babic M, Zimmer R, Trgovcich J, Koszinowski U, Jonjic S, Pfeffer S, Dölken L: Degradation of cellular miR-27 by a novel, highly abundant viral transcript is important for efficient virus replication in vivo. PLoS Pathogens, 8(2): e1002510; 2012 (IF:8.136, citations: 12, Q1 in Microbiology, Parasitology and Virology) 44. Slavuljica I, Krmpotic A, Jonjic S: Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response. Frontiers in Immunology, 2:85; 2011 45. Kropp KA, Robertson KA, Sing G, Rodriguez-Martin S, Blanc M, Lacaze P, Noor Hassim MF, Khondoker MR, Busche A, Dickinson P, Forster T, Strobl B, Mueller M, 46. Jonjic S, Angulo A, Ghazal P: Reversible inhibition of MCMV replication by IFN{gamma} in primary macrophages involves a primed type I IFN signaling subnetwork for full establishment of an immediate-early antiviral-state. Journal of Virology, 85(19):10286-99; 2011 (IF:5.402 citations: 3, Q1 in Virology) 47. Jordan S, Krause J, Prager A, Mitrovic M, Jonjic S, Koszinowski UH, Adler B: Virus Progeny of MCMV Bacterial Artificial Chromosome pSM3fr Shows Reduced Growth in Salivary Glands Due to a Fixed Mutation of MCK-2. Journal of Virology, 85(19):10346-53; 2011 (IF:5.402 citations: 8, Q1 in Virology) 48. Babic M, Krmpotic A, Jonjic S: All is fair in virus-host interactions: NK cells and cytomegalovirus. Trends in Molecular Medicine, 17(11):1471-4941; 2011 (IF:10.355, citations: 15, Q1 in Biochemistry & Molecular Biology, Q1 in Cell Biology and Q1 in Medicine, Research & Experimental) 49. Pyzik M, Charbonneau B, Gendron-Pontbriand EM, Babic M, Krmpotic A, Jonjic S, Vidal S: Distinct MHC class I-dependent NK cell-activating receptors control cytomegalovirus infection in different mouse strains. Journal of Experimental Medicine, 208(5):1105-17; 2011 (IF:13.853, citations:12, Q1 in Immunology and Q1 in Medicine, Research & Experimental) 50. Jonjic S, Trsan T: Resistance to Mousepox Virus: CD94 on a Special Mission. Immunity, 34(4):458- 60; 2011 (IF:21.637, Q1 in Immunology) 51. Jovanovic I, Radosavljevic G, Mitrovic M, Lisnic Juranic V, McKenzie A, Arsenijevic N, Jonjic S, Lukic M: ST2 Deletion Enhances Innate and Acquired Immunity to Murine

52. Mammary Carcinoma. European Journal of Immunology, 41:7,1902-1912; 2011 (IF:5.103, citations:8, Q1 in Immunology) 53. Radosavljevic G, Jovanovic I, Majstorovic I, Mitrovic M, Lisnic VJ, Arsenijevic N, Jonjic S, Lukic ML: Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clinical and Experimental Metastasis, 28(5):451-62; 2011 (IF:3.524, citations:15, Q2 in Oncology) 43. Colonna M, Jonjic S, Watzl C. Natural Killer cells: fighting viruses and much more. Nature Immunology, 12(2):107–10; 2011 (IF:26.008, Q1 in Immunology) 54. Slavuljica I, Busche A, Babic M, Mitrovic M, Gasparovic I, Cekinovic Dj, Markova Car E, Pernjak Pugel E, Cikovic A, Juranic Lisnic V, Britt WJ, Koszinowski U, Messerle M, Krmpotic A, Jonjic S: Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. Journal of Clinical Investigation, 120(12):4532-45; 2010 (IF:14.152, citations:14, Q1 in Immunology and Q1 in Medicine, Research & Experimental) 55. Babic M, Pyzik M, Zafirova B, Mitrovic M, Butorac V, Lanier LL, Krmpotic A, Vidal SM and Jonjic S: Cytomegalovirus immunoevasin reveals the physiological role of „missing self” recognition in NK cell dependent virus control in vivo. Journal of Experimental Medicine, 207(12):2663-2673; 2010 (IF:14.776, citations:17, Q1 in Immunology and Q1 in Medicine, Research & Experimental) 56. Doelken L, Krmpotic A, Koethe S, Tuddenham L, Tanguy M, Marcinowska L, Ruzsics Z, Elefant N, Altuvia Y, Margalit H, Koszinowski U, Jonjic S, Pfeffer S: Cytomegalovirus microRNAs facilitate persistant virus infection in salivary glands. PloS Pathogens, 14;6(10):e1001150; 2010 (IF:9.076, citations:18, Q1 in Microbiology, O1 in Parasitology and Q1 in Virology) 57. Lankry D, Simic H, Klieger Y, Levi-Schaffer F, Jonjic S, Mandelboim O: Expression and function of CD300 in NK cells. Journal of Immunology, 185(5):2877-86; 2010 (IF:5.745, citations:17, Q1 in Immunology) 58. Steer B, Adler B, Jonjic S, Stewart J, Adler H: A gammaherpesvirus complement regulatory protein promotes initiation of infection by activation of protein kinase Akt/PKB. PLoS ONE, 21;5(7):e11672; 2010 (IF:4.411, citations:2, Q1 in Biology) 59. Champsaur M, Beilke JN, Ogasawara K, Koszinowski UH, Jonjic S, Lanier LL: Intact NKG2D- Independent Function of NK Cells Chronically Stimulated with the NKG2D Ligand Rae-1. Journal of Immunology, 185(1):157-65; 2010 (IF:5.745, citations:12, Q1 in Immunology) 60. Juranic Lisnic V, Krmpotic A, Jonjic S: Modulation of natural killer cell activity byviruses. Current Opinion in Microbiology, 13:1-10; 2010 (IF:7.714, citations:20, Q1 in Microbiology) 61. Jonjic S: Functional plasticity and robustness are essential characteristics of biological systems: lessons learned from KLRG1 deficient mice. European Journal of Immunology, 40(5):1241-3; 2010 (IF:4.942, citations:2, Q1 in Immunology) 62. Zhi L, Mans J, Paskow M, Brown P, Schuck P, Jonjic S, Natarajan K, Margulies D: Direct interaction of the mouse cytomegalovirus m152/gp40 immunoevasin with RAE-1 isoforms. Biochemistry, 49(11):2443-5; 2010 (IF:3.226, citations:12, Q2 in Biochemistry & Molecular biology)

BOOK CHAPTERS

1. Cekinovic D, Juranic Lisnic V, Jonjić S: Rodent models of congenital cytomegalovirus infection. Human Cytomegaloviruses, Methods and Protocols, Methods in Molecular Biology, editor: Andrew Yurochko, ISSN: 1064- 3745, Volume 1119, pp.289-310, Humana Press, Springer, New York, 2014 2. Vidal S, Krmpotic A, Pyzik M, Jonjic S: Innate Immunity to Cytomegalovirus in the Murine Model. Chapter II.9, Cytomegaloviruses From Molecular Pathogenesis to Intervention, editor: Matthias J. Reddehase, ISBN: 978-1-908230-18-8, pp.192-214, Caister Academic Press, Germany, 2013 3. Britt W, Cekinovic D, Jonjic S: Murine Model of Neonatal Cytomegalovirus Infection Chapter II.6, CytomegalovirusesFrom Molecular Pathogenesis to Intervention, editor:Matthias J. Reddehase , ISBN: 978-1-908230-18-8, pp.119-141, Caister Academic Press, Germany, 2013

4. Juranic Lisnic V, Gasparovic I, Krmpotic A, Jonjic S. Virus Interactions with NK Cell Receptors, Natural Killer Cells, editor: J. Zimmer, pp.125-152, Springer-Verlag, Berlin Heidelberg, 2009 5. Cekinovic D, Slavuljica I, Lenac T, Krmpotic A, Polic B, Jonjic S: Innate Immunity to Mouse Cytomegalovirus; in National Institute of Allergy and Infectious Diseases, NIH:Frontiers in Research, editors: Vassil St. Georgiev, Karl A. Western, JJ McGowan, pp. 445-456. The Humana Press Inc., 2008 6. Jonjic S, Krmpotic A, Arapovic J, Koszinowski UH.: Dissection of the Antiviral NK Cell Response by MCMV Mutants; in: Methods in Molecular Biology, vol. 415: InnateImmunity,editors: J. Ewbank and E. Vivier, pp.127-149, The Humana Press Inc., 2008 7. Koszinowski UH, Jonjic S: Microbial Subversion of NK Cell Function; Chapter 2 In: Microbial Subversion of Immunity: Current Topics, editor: Peter Lachmann, pp.17-51, Caister Academic Press, 2006 8. Jonjic S, Bubic I, Krmpotic A: Innate Immunity to Cytomegalovirus; in Cytomegaloviruses: Molecular Biology and Immunology, editor: Matthias J. Reddehase, pp.286-319, Caister Academic Press, 2005 9. Jonjic S: Current Protocols in Immunology. editors: J. Coligan, A. Kruisbeek, D. Marguiles, E. Shevach & W. Strober, 1.11.1 - 1.11.4, John Wiley, New York; 2001 10. Koszinowski UH, Reddehase MJ, Jonjic S: The role of T lymphocyte subsets in the control of cytomegalovirus infection. editors: Thomas BB, Marcel Dekker, pp.429 – 445, Viruses and the Cellular Immune Response Inc, N.Y 1991. 11. Koszinowski UH, Jonjic S, Reddehase MJ: Pathogenesis of virus host interactions in vivo during CMV infection. Progress in Cytomegalovirus Research, editor: Landini MP, pp.277- 292, Elsevier,1991 12. Koszinowski UH, Reddehase MJ, del Val M, Munch K, Messerle M, Volkmer H, Jonjic S: Molecular analysis of the protective immune response to murine cytomegalovirus. Progress in Immunology vol.VII (Proc.of the 7th Int. Con. Immunol., Berlin 1989), pp.946-953., Springer, 1989

INVITED TALKS

1. "NKG2D independent immune function of RAE-1: enhanced CD8 T cell response induced by CMV vector expressing RAE-1 gamma", Deutsches Rheuma Forschungszentrum, January 15 – 17, 2015, Berlin, Germany 2. ''Innate & Adaptive Immunity Interface'', 2nd Waldthausen Cytomegalovirus Symposium, University of Mainz, November 21 – 22, 2014, Waldthausen Castle, Budenheim, Germany 3. ''Differential innate immune resistance of ovarian corpora lutea and follicles to cytomegalovirus infection'', Croatian immunological society annual meeting, HID2014, October 17 – 18, 2014, Krk, Croatia 4. ''Genetically modified and immunologically attenuated herpesviruses as potent vaccine vectors.'', Power of Viral Vectors in Gene Therapy and Basic Science Summer School, Croatian microbiological society, September 17 – 21, 2014, Primošten, Croatia 5. ''CMV vaccine research – coupling the innate and adaptive immunity arms'', 2nd European Seminar in Virology, University of Bologna, June 13 – 15, 2014, Bertinoro, Italy 6. ''Scientific career in adverse economic and social conditions'', 24th European Society of Clinical Microbiology and Infectious Diseases ECCMID2014, May 9 – 12, 2014, Barcelona, Spain 7. ''Lecture of the ERC Advanced Grant holder', National Institute of Chemistry, April 25, 2014, Ljubljana, Slovenia

8. "Enhancing the CD8 T cell response by RAE-1 gamma expressed in a herpesvirus vector – not only NKG2D", Immunology Seminar, Cambridge Institute for Medical Research, February 14, 2014, Cambridge, Velika Britanija 9. "Recognition of murine cytomegalovirus infected cells by activating an inhibitory Ly49 NK cell receptors" Virus & Immunity course, Centre International de Recherche en Infectiologie (CIRI), INSERM, February 13, 2014, Lyon, Francuska 10. ''Expression of NKG2D ligand improves vaccine properties of recombinant cytomegalovirus'' PhD seminar on Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine, November 28, 2013, Vienna, Austria 11. ''Expression of NKG2D ligand RAE-1 gamma by recombinant cytomegalovirus enhances its immunogeneicity and vaccine efficacy'', PhD course on tumor immunology and immunotherapy, Center for Immunity and Infection Lausanne, Ludwig institute for cancer research, November 5, 2013, Lausanne, Swiss 12. ''Genetically modified herpesviruses as vaccine vectors.'', CROCMID-10th Croatian congress of clinical microbiology and 7th Croatian congress on infectious diseases, October 24 - 27, 2013, Rovinj, Croatia 13. ''Superior induction and maintenance of protective CD8 T cells with mouse cytomegalovirus vector expressing NKG2D ligand RAE-1y.'', 2nd Meeting of MiddleEuropean Societies for Immunology and Allergology, October 10 - 13, 2013, Opatija, Croatia 14. ''Curious case of specific recognition of MCMV by NK cells: the role of uORFs and ncRNAs.'', NK2013 - 14th Meeting of the Society for Natural Immunity, September 18 -22, 2013, Heidelberg, Germany 15. ''How can viruses teach us to make better immune response?'', 3rd Congress of Croatian physiological society, September 13 - 15, 2013, Rijeka, Croatia 16. ''Viral regulation of inhibitory and activating Ly49 receptors'', 15th International Congress of Immunology ICI2013, August 22 - 27, 2013, Milano, Italia 17. 'NKG2D -dependent and -independent immune function of RAE-1: superior induction and maintenance of protective CD8 T cells in mice infected with MCMV vector expressing RAE-1'' , Medical Immunology Campus Erlangen, July 1 - 2, 2013, Erlangen, Germany 18. ''MCMV transcript with multiple coding and non-coding functions needed for recognition of infected cells by activating Ly49 NK cell receptors'', 4th CMI Symposium on Immunology: Innate Immunity and NK Cells, June 17 - 19, 2013, Hefei, Anhui Province, China 19. ''Expression of NKG2D ligand by cytomegalovirus enhances virus immunogenicity and vaccine efficacy'', introductory lecture at the Meeting of class II, German National Academy for Science Leopoldina, May 22 - 23, 2013, Halle, Germany 20. "Recognition of murine cytomegalovirus infected cells by activating an inhibitory Ly49 NK cell receptors", International Graduate School in Molecular Medicine Ulm, April 11 – 13, 2013, Ulm, Germany 21. "Differential requirements for activating and inhibitory Ly49 receptors in recognition of MCMV- infected cells", ETH Zürich (Eidgenössische Technische Hochschule Zürich), February 27 - 28, 2013, Zürich, Switzerland 22. "Strengthening adaptive immunity via innate immunity.", Doctoral School of Biomedicine– Department of Molecular Medicine, University of Padova, February 20, 2013, Padova, Italy 23. "Herpesviruses as vectors - what did cytomegaloviruses teach us?", 120th Anniversary of Immunological Society, November 20, 2012, Zagreb, Croatia 24. "NK cells in MCMV infection – from no function to too many functions", CMV Liaison Symposium, Max von Pettenfoker-Institut, November 16 - 18, 2012, Munich, Germany 25. "Highly attenuated MCMV vector expressing NKG2D ligand RAE-1 gamma provides long-lived memory CD8+T cells with outstanding protective capacity.", 14th International CMV/BetaHerpesvirus workshop, October 29 - November 2, 2012, San Francisco, USA

26. "Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 provides long-lived memory CD8 T cells with outstanding protective capacity against Listeria monocytogenes", 5th Croatian Congress of Microbiology with International Participation, September 26 -30, 2012, Primošten, Croatia 27. "Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 gamma provides long lived memory CD8+ T cells with outstanding protective capacity ", TWINCORE-Symposium, September 27 - 28, 2012, Hannover, Germany 28. "Activating and inhibitory LY49 receptors have differential requirements for recognition of MCMV- infected cells", European Congress of Immunology, September 5 - 8, 2012, Glasgow, Scotland 29. "Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 provides long-lived memory CD8 T cells with outstanding protective capacity.", Mikrobiologisch-Infektiologische Seminarreih, June 4 - 5, 2012, Virological Institute, Ulm, Germany "Genetic manipulation of viral genome as a tool to generate more efficient virus vaccine and vaccine vectors.", 3rd Congress of Croatian Geneticists, May 13 - 16, 2012, Krk, Croatia 31. "Enhancing the adaptive immune response by the NKG2D ligand expressed in a herpesvirus vector", 13th meeting of the Society for Natural Immunity, April 20 - 24, 2012, Asilomar, California, USA 32. "Can we improve CD8 response to viral infection - lessons from cytomegalovirus expressing NKG2D ligand.", Washington University, School of Medicine, April 18 - 19, 2012, St.Louis, USA 33. "Vaccines and innate immunity: lessons from cytomegalovirus immunoevasion of NKG2D", Final Symposium of the SFB 490 "Invasion and Persistence of Infectious Organisms”, March 8 – 10, 2012, Mainz, Germany 34. "Regulation of inhibitory and activating LY49 receptors by murine cytomegalovirus", Virus & Immunity course, Centre International de Recherche en Infectiologie (CIRI), INSERM, January 30 - February 10, 2012, Lyon, France 35. "Vaccines and innate immunity: lessons from cytomegalovirus immunoevasion of NKG2D", British Society of Immunology congress, December 5 - 9, 2011, Liverpool, UK 36. "Immunobiology of a recombinant cytomegalovirus expressing the NKG2D ligand – an approach towards live attenuated vaccine and vaccine vector.", Croatian Immunological Society, 2011 Annual Meeting, October 7 - 9, 2011, Rabac, Croatia 37. "Viral interference with activating and inhibitory NK cell receptors.", 3rd South East European Immunology School (SEEIS2011), October 1 - 4, 2011, Arandjelovac, Serbia 38. "How can viruses teach us to make better vaccines and vaccine vectors", 7th ISABS Conference in Forensic, Anthropological and Medical Genetics and Mayo Clinic Lectures in Translational Medicine, June 20 – 24, 2011, Bol, Island of Brač, Croatia 39. "MCMV interference with activating and inhibitory LY49 NK cell receptors", SFB900 seminar, June 16, 2011, Hannover Medical School, Germany 40. "Recent advances in the pathogenesis of CMV infection", 21st ECCMID/27th ICC 2011, May 7- 10, 2011, Milan, Italy 41. "Expression of NKG2D ligand improves vaccine properties of recombinant cytomegalovirus", Natural Killer Cell Symposium, April 18-20, 2011, Mainz, Germany 42. "Vaccine properties of recombinant herpesvirus expressing ligand for NKG2D receptor", Annual Meeting of the Austrian Society for Allergology and Immunology 2010, December 3 - 5, 2010, Wien, Austria 43. "Pathogenesis of CMV infection of the fetal brain", 3rd Congenital Cytomegalovirus Conference, September 23 - 25, 2010, Paris, France 44. "Cytomegalovirus protein m04 abolishes NK cells activation via the "missing-self"

recognition mechanism, "Viral infection" Symposia, 14th International Congress of Immunology (ICI 2010) , August 22 - 27, 2010, Kobe, Japan 45. "Cytomegalovirus immunoevasin reveals the physiological role of "missing-self" recognitionin NK cell dependent virus control in vivo", 35th Annual International Herpesvirus Workshop, July 24 -29, 2010, Salt Lake City, Utah, USA

INTERNATIONAL RESEARCH COLLABORATION

Dr. Ulrich Koszinowski, Max von Pettenkofer-Institute, München; Dr. Barbara Adler, Max von Pettenkofer-Institute, München; Dr. William J. Britt, UAB, Birmingham; Dr. Mathias Müller, Veterinary University of Vienna; Dr. Hartmut Hengel, University clinic Freiburg; Dr. Martin Messerle, Hannover medical school, Hannover; Dr. Wayne M. Yokoyama, Washington University Medical Centre, St. Louis; USA Dr. Dirk Busch, Technical University München; Dr. Alec Redwood, University of Western Australia Dr. Francesco Colucci, The Babraham Institute, Cambridge; UK Dr. Matthias Reddehase, University of Mainz; Dr. Joanne Trgovcich, Ohio State University, Columbus; Dr. Silvia Vidal, McGill University, Canada; Dr. Lars Dölken, University of Cambridge; UK Dr. Luka Čičin Šain, Helmholtz-Zentrum für Infektionsforschung, Braunschweig Dr. Ofer Mandelboim, The Hebrew University of Jerusalem

University of Rijeka • Faculty of Medicine

Braće Branchetta 20/1 • 51000 Rijeka • CROATIA Department of Histology and Embryology

Prof. Dr. Stipan Jonjić, Chair

Phone : + 385 51 651 170• Fax : + 385 51 651 176 e- mail: [email protected]

VAT:HR98164324541

Professor Christine DELPRAT, LIVE consortium coordinator CNRS 5239 FACULTE DE MEDECINE LYON SUD-Secteur 1 165 Chemin du Grand Revoyet : BP12 69921 OULLINS CEDEX

Rijeka, February 3, 2015.

Re: Leading International Vaccinology Education (LIVE project)

Dear Professor Delprat, I was honored to be approached by you, as LIVE consortium coordinator, to serve as invited scholar in this LIVE project, a master of Science and multidisciplinary programme that you are organizing together with 5 European Universities , and am hereby declaring my interest and willingness to partake at the LIVE project as invited scholar. I am working as a full Professor at the Faculty of Medicine, University of Rijeka. I am also a head of the Department of Histology and Embryology and a chair of the Center for proteomics. My main research interest is immunology and pathogenesis of viral infection. More recently, we are developing new vaccine vectors based on attenuated cytomegalovirus expressing NKG2D ligand Rae-1. I firmly believe my expertise in the field can strongly contribute to this educational programme, and I stay at your disposal for further activities.

Sincerely, Stipan Jonjic

Professor and Chair

Kieber-Emmons Thomas UNIVERSITY OF ARKANSAS for MEDICAL SCIENCES (UAMS) Curriculum Vitae

February 08, 2015

Thomas Kieber-Emmons Ph.D.

Home Address: 2420 Riverfront Dr. Apt 911 Little Rock Arkansas

Office Address: Department of Pathology University of Arkansas for Medical Sciences 4301 West Markham St. #824 Little Rock, Arkansas 72205 Education: 1973-1977 B.S. Florida Institute of Technology, Melbourne, FL. (Environmental Engineering Technology)

1977-1985 PhD. State University of New York at Buffalo Roswell Park Division (Biophysics). R. Rein thesis advisor. Intermolecular interaction theory/ Computational structural biology

Postgraduate Training and Fellowship Appointments: 1985-1986. Postdoctoral Associate in Molecular Immunology Department of Molecular Immunology, Roswell Park Memorial Institute. Heinz Kohler Post-Doctoral Mentor: Tumor Immunology /Vaccine Design/Antibody Design

Faculty Appointments:

1986-1987 Lecturer, Department of Microbiology & Immunology, State University of New York at Buffalo 1986-1987 Director, Molecular Modeling Facility, Department of Molecular Immunology, Roswell Park Memorial Institute 1987-1990 Scientist, IDEC Pharmaceuticals Corp., Head, Peptide Design and Biophysics 1990-1994 Assistant Professor, The Wistar Institute, Philadelphia, PA 1990-1994 Director of Biocomputational Facility, The Wistar Institute, Philadelphia PA. 1991-1994 Wistar Institute Assistant Professor of Medicine, University of Pennsylvania, Philadelphia, PA 1994-1997 Adjunct Assistant Professor The Wistar Institute, Philadelphia, PA. 1994-2002 Member - Cancer Center - University of Pennsylvania 1994-1997 Research Assistant Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania. Philadelphia, PA. 1997-2002 Adjunct Associate Professor, The Wistar Institute, Philadelphia, PA 1997-2002 Research Associate Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania. Philadelphia, PA. 2002- Present Professor of Pathology (Tenure) - University of Arkansas for Medical Sciences (UAMS), Little Rock Arkansas 2002-Present Josetta Wilkins Chair in Breast Cancer Research 2002-2008 Director of Breast Cancer Research Development, Winthrop P Rockefeller Cancer Institute 2002-2007 Program Leader in Molecular Signatures and Cancer Therapeutics 2006-2008 Interim Experimental Pathology Division Chief – Department of Pathology 2008-2009 Associate Director for Research Winthrop P. Rockefeller Cancer Institute 90

2010-2014 Deputy Director - Winthrop P. Rockefeller Cancer Institute 2014-Present Associate Director for Prevention Research - Winthrop P. Rockefeller Cancer Institute

Faculty Service (UAMS) Past Member - IT Research Strategic Planning Past Member – UAMS Research Council Past Member – UAMS Patent and Copyright Committee Past Member – COM Research Mentoring subcommittee – Past Member - COM Search Committee for Chair of Internal Medicine Past Member - COM Search Committee for Chair of Pharmacology Past Member - COM Search Committee for Chair of Urology Past Member - COM Search Committee for Chair of Surgery Past Member - COM Search Committee for Chair of Biomedical Informatics Past Member - CTSA Steering Committee - Leader informatics initiative Past Member - Vice Chair –COM Promotion and Tenure rewrite committee Past Chair - UAMS Conflict of Interest Committee Past Member: UAMS Chancellor’s Research Retreat Advisory Board Past Member: Faculty Search Committee – Biomedical Informatics Current Member: Community Advisory Board for UAMS Center Clinical Translational Research Current Member: Cancer Institute Executive Committee

Graduate School Activities (UAMS): Past Member - Bioinformatics Graduate School Steering Committee Past UAMS Bioinformatics Liaison for joint University of Arkansas Little Rock (UALR) and UAMS Bioinformatics Graduate program. Past Chairman - Student Evaluation Committee Bioinformatics Graduate program. Lecturer – Molecular Mechanisms in Immunology – Microbiology Graduate program Editorial Positions: 2007-present Editorial Board DNA and Cell Biology 2004 –2007 Editorial Board, Section Editor Immunobiology, DNA and Cell Biology 1994 -Present Editorial Board Hybridoma 1986 Guest Editor, International Reviews of Immunology 1992-1994 Editorial Board Viral Immunology

Study Section Activities 1992 - 1994 Study Section Member -American Cancer Society - Cell Biology 1995 - 1997 Study Section Member - US Army Breast Cancer Initiative- Molecular Biology 1992 - 1995 Study Section Member - US Army Osteoporosis Program - Cell Biology 1999 - present Reviewer: Human Frontier Science Program 1999 - present Reviewer: The Welcome Trust 2000 - 2003 Study Section Member – NIH SS2 (SBIR) 2003 Ad Hoc Reviewer Vaccines Study Section (01/04) 2004 Reviewer NIH Road Map - P20s for Novel Technology Centers 2005 Ad Hoc DOD Prostate Cancer Program - Immunology 2005 - present Aids Fonds Netherlands 2005 - present Austrian Science Fund 2004 - present Ad Hoc Study section member Onc -L- NIH (SBIR/STTR) 2007 Ad Hoc Study section member NIH TTT 2006-2007 DOD Prostate Cancer IMS panel 2009 Ad Hoc P30 Faculty Recruitment – NIH 2009 Ad Hoc NCI Eureka Program 2009-2010 Ad Hoc NCI Challenge Program 2010-2012 Ad Hoc NCI Clinical Immunology Immunotherapy (CII)

2013 -Present Ad Hoc NCI R21 Tumor Immunology Emphasis Panel

Selected Organizing Roles in Scientific Meetings:

2006-2008 American Society Clinical Oncology (ASCO) Scientific Program Committee - Developmental Therapeutics-Immunotherapy. 2008 American Society Clinical Oncology (ASCO) - Track Leader in Immunotherapy 2008 International Board 6th World Congress on Vaccines and Immunization – Milan Italy 2009 International Board 7th World Congress on Vaccines and Immunization – Berlin Germany 2010 Session Organizer on Cancer Vaccines - International Union Against Cancer – Athens Greece Nov 2010.

Current Grant Support

P20 RR16460-05 L.E. Cornett (PI) 8/23/010 - 4/30/2015; Kieber-Emmons T (15% effort) Role: Bioinformatics Co-director Partnerships for Biomedical Research in Arkansas This statewide project proposes to expand biomedical research capability within the state through support of mentored research projects, biotechnology cores, and a developing multi-campus bioinformatics graduate program.

1 UL1RR029884 Lowery (PI) (10% effort) 07/01/09 – 03/31/14

Role: Biomedical Informatics advisor

This CTSA is to establish a Clinical Translational Research Center (CCTR). The Arkansas Center for Clinical and Translational Research (CCTR) unites all UAMS Colleges and its Graduate School behind the translational research endeavor. The overarching goal is to establish an integrative CCTR that transforms the pace, effectiveness, and quality of translational research at UAMS, resulting in better health for all Arkansans.

3P20RR016460-08S2 Cornett (PI) (10% effort) 09/07/09 – 09/06/10 Role: Director of Program NIH Supplement to Partnerships for Biomedical Research in Arkansas – Development of Service Learning Program for Minority Undergraduates in Arkansas.

Previous Grant Support (Kieber-Emmons, PI) AmFar 1/91-12/93 Peptide vaccine for HIV $120,000 Total Direct ACS 2/92-3/95 Development of antimetastatic inhibitors $315,000 Total Direct USMRDDC 9/94-8/98 Lewis Y as a Target for Breast Cancer $800,000 Total Direct ACS 2/95-3/98 GMCSF-Mimetics $315,000 Total Direct NIH R21A144412 12/98-11/02 Mimotope Conversion of HIV-1 Carbohydrate Antigens

$600,000 Total Direct NIH R01A145133 09/99-02/02 Basis for mimotope conversion of carbohydrate antigens $493,650 Total Direct DOD DAMD17-0101-0366 03/03-06/06 Maximizing immune responses to carbohydrate antigens on Breast Tumors $300,000 Total Direct NIH CA089480-01 03/99-02/06 Mimotope Conversion of Carbohydrate Antigens $658,200 Total Direct 92

NIH AI049092-01 09/02-12/07 Mimotope Conversion of HIV-1 Carbohydrate Antigens $1,125,000 Total Direct DOD Breast Cancer Program Clinical Translational Research Award: Kieber-Emmons, PI- 30% effort- 04/06-010/13 -$2.9M Total Vaccination of High-Risk Breast Cancer Patients with Carbohydrate Mimicking Peptides This project brings to the clinic carbohydrate mimetic peptides for prevention of breast cancer recurrence.

Research Areas of Interest: There are a variety of Tumor Associated Carbohydrate Antigens (TACAs) that have received attention as targets for immunotherapeutics. These include the gangliosides GM2, GD2, GD3 expressed on melanomas, sarcomas and neuroblastomas, the Thomsen-Friedenreich antigen (TF), Tn and sialylated Tn (sTn) blood-group-related antigens that are expressed on mucins in a variety of epithelial cancers, fucosyl-GM1 expressed on small-cell lung cancers and the histo-blood group related Lewis antigens like Lewis Y and Globo H antigens also expressed on a variety of epithelial cancers. TACAs however are T cell independent antigens. As such, they function as poor immunogens. As a means to convert T independent responses to T dependent responses we are pioneering the development of carbohydrate mimetic peptides (CMPs) to bridge anti-tumor humoral and cellular responses to TACA. We have developed peptides that mimic bacterial, viral and tumor associated carbohydrates using a combination of screening random peptide display libraries and molecular modeling (structure assisted vaccine design). In this regard we have shown that it is possible to define CMPs theoretically using computer-based approaches (drug-design approaches) that validate those identified experimentally. CMPs have significant advantages as vaccines. This approach constitutes a novel strategy in developing immunotherapeutic’s to reduce micrometastases and prevention of recurrence. The FDA approved IND14715 for a Phase I safety study of a CMP in metastatic breast cancer, which is now complete. This is a true a bench-to-bedside project being a first in man CMP testing of a computer-designed immunogen. We are initiating a Phase II study in Breast Cancer patients and Phase I studies in Lung cancer and Melanoma with this CMP. The preclinical testing of this CMP vaccine, led by my group, was conducted as part of a restructuring effort to perform FDA approved GLP studies at UAMS in the context of a Cancer Institute shared resource, with this vaccine being the first GLP study conducted at UAMS. In the glycomics area I am interested in how glycan profiles on tumor cells influence organ tropism and how nutrient/gene interactions impact on cancer mortality especially among special populations. My group was the first to define antibodies reactive with glycans expressed on tumor cell surface that can exacerbate disease in breast cancer patients by stimulating tumor cell growth. We have defined this type of antibody response similar to autoantibodies in lupus. This work is leading to the design of a clinical trial at UAMS using Rituxan to reduce the presence of these autoantibodies in breast cancer patients. These studies emphasize the relative contribution of the glycan shield expressed on tumor cells to affect routes of metastases (e.g. lymph node or blood). Like wise, we are demonstrating that demethylating agents such as hydralazine, an anti-hypertensive drug, can modify tumor cell glycan profiles and tumor cell phenotypes. We have shown that tumor cells that colonize the bone express sialylated glycans and generate IL-8 under epigenetic control. We have also shown that Hydralazine modifies the epigenetic profile, changing the glycan profile and shuts off tumor cell production of IL-8. We are planning to use hydralazine in a clinical trial at UAMS as a combination therapy to modify the glycan profile of tumor cells associated with bone metastases in breast patients. Other concepts being developed by my Lab include combination therapies using velcade and CMP vaccine and small molecules targeting lipid rafts and transport proteins.

Leadership Roles: At the Winthrop P. Rockefeller Cancer Institute I provide a voice to programmatic direction and a leadership conduit by which programmatic needs can gain support from available Cancer Center resources. In my capacity as Deputy Director I participated in setting the overall direction and development of the Cancer Center's research programs, emphasizing growth in the important areas of translational and clinical research. I While I have taken on a new leadership role as Associate Director for Prevention research I am still responsible for writing the P30 application as we progress toward NCI designation as a cancer Institute. Consequently, my specific responsibility is to encourage cooperative research involving Basic, Clinical, Translational and Prevention approaches undertaken at the Cancer Center and working to develop funding to meet these needs. We have recently completed a 12-story expansion of our Cancer Center and secured NIH funding to finish off two full research floors providing 48,000 square feet of additional research space afforded to our programs and reserved for recruitment. When recruited to UAMS to further develop breast cancer research efforts, I was provided $2 million to establish research directions within the Breast program. The breast cancer research program has increased in extramural funding by close to $41 million (total)—a 20-fold return in funding on the UAMS investment. In this position I oversaw all of basic science that interfaced with translational activities associated with the breast program, including stimulating interdisciplinary research collaboration, evaluating new research opportunities and working to fully integrate shared facilities into the research and clinical/translational enterprise. In this position a new cultural research tone was set at 93

the heart of the present organization of the Cancer Institute, functioning as the conceptual cornerstone of the Cancer Institute as it is today. In my own research I have worked toward maintaining a balanced portfolio of research between studies on basic mechanisms and studies more focused on the pathogenesis and therapy of cancer. In this way I seek to further the Cancer Institute mission of translating research progress into preventive and therapeutic benefit. At UAMS, this intersection of ideas, with the assistance of other cancer center program leaders, fueled by opportunity to facilitate communication and cooperation between cancer center investigators with clinical and community directed programs, we have developed a bench to curbside culture of thinking about cancer research. This has translated into UAMS being awarded a coveted NIH Clinical Science Translational Award. In this effort I lead the Informatics team to a successful P20 and developed the infrastructure for the Informatics Center that is fundamental to the success of this award. We have further developed this informatics infrastructure to elevate the Cancer Institute into a recognized force in the NCI caBIG initiative. I have further encouraged partnerships to foster community based participatory research within our cancer prevention program. In particular, I have encouraged an integrated disparity program emphasizing a systems biology approach to cancer control, prevention cancer and population sciences. This is a novel approach that involves endocrinologists interested in Obesity and Diabetes research and treatment, and community based participatory research practices in cancer. We are now establishing a new program in metabolic oncogenesis that focuses on how metabolism influences cancer. My leadership and administrative roles have curtailed my research efforts to a large extent the last few years, with most of my funding now coming from infrastructure support grants. Within an emerging cancer center, program development and mentoring is a full time job. I have chosen to concentrate on developing the success of others, using my key skills of effective team leadership and mentorship required to develop strategies to meet the challenges of developing a cancer center. Developing a cancer center is very different than maintaining one. It requires entrepreneurism in program building and integration, but more importantly it requires promoting a culture of team science that recognizes the value of self-development and reflection that will benefit both the research and clinical enterprise to be competitive at the next level.

Bibliography: Citations: Google Scholar: 4937 Research Gate: RG Score: 41.23 h-index: 39

Research Publications, Peer Reviewed from 2010: Todorova VK, Klimberg VS, Hennings L, Kieber-Emmons T, Pashov A. Immunomodulatory effects of radiofrequency ablation in a breast cancer model. Immunol Invest. 2010;39(1):7492.

Monzavi-Karbassi B, Hine RJ, Stanley JS, Ramani VP, Carcel-Trullols J, Whitehead TL, Kelly T, Siegel ER, Artaud C, Shaaf S, Saha R, Jousheghany F, Henry-Tillman R, KieberEmmons T. Fructose as a carbon source induces an aggressive phenotype in MDAMB-468 breast tumor cells. Int J Oncol. 2010 Sep;37:615-22

Pashov A, Monzavi-Karbassi B, Raghava GP, Kieber-Emmons T. Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol. 2010;2010:354068.

Pashov A, Monzavi-Karbassi B, Kieber-Emmons T. Glycan mediated immune responses to tumor cells. Hum Vaccin. 2011 Jan 1;7. [Epub ahead of print]

Hennings, L, Jousheghany F, Pashov, A, Artaud, C, Monzavi-Karbassi B, Kieber-Emmons T, Carbohydrate mimetic peptides induce tumor-associated carbohydrate-reactive antibodies in the absence of pathological autoimmunity. Cancers 2011, 3, 4151-4169.

Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011 Jun 9;13(3):R58.

Kieber-Emmons, T, Monzavi-Karbassi,B, Pashov, A, Saha, S, Murali, R, Kohler, H. The promise of the anti-idiotype concept. Front Oncol. 2012;2:196. doi: 10.3389/fonc.2012.00196. Epub 2012 Dec 19.

Ohtaki, A, Kieber-Emmons,T, Murali, R. Structure-based peptide mimicry of tumor-associated antigens. Monoclon Antib Immunodiagn Immunother. 2013 Feb;32(1):1-5.

Murali R, Kieber-Emmons T. Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens. Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):179-82.

Steplewski Z, Kieber-Emmons T.Hilary Koprowski, MD: A lifetime of work. Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):1-43.

Steplewski Z, Kieber-Emmons T.Hilary Koprowski, MD December 5, 1916-April 11, 2013. Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):153.

Kieber-Emmons T, Saha S, Pashov A, Monzavi-Karbassi B, Murali R. Carbohydrate-mimetic peptides for pan anti-tumor responses. Front Immunol. 2014 Jun 30;5:308.

Saha S, Pashov A, Siegel ER, Murali R, Kieber-Emmons T. Defining the recognition elements of Lewis Y-reactive antibodies. PLoS One. 2014 Aug 12;9(8):e104208.

Greer-Williams, N., Enoch, K. S., Booth, B., Starlard-Davenport, A., Sarto, G. E., & KieberEmmons, T. (2014). Rural African American women and breast cancer: Social determinants of health shape ability to conceptualize health in the Arkansas Delta. Journal of Rural and Community Development, 9(2), 51-66.

Makhoul I, Hutchins L, Emanuel PD, Pennisi A, Siegel E, Jousheghany F, Karbassi-Monzavi B, Kieber-Emmons T. Moving a Carbohydrate Mimetic Peptide into the clinic: Clinical response of a breast cancer patient after mimotope-based immunotherapy. Hum Vaccin Immunother. 2014 Aug 5;11(1).

Herman D, Leakey TI, Behrens A, Yao-Borengasser A, Cooney CA, Jousheghany F, Phanavanh B, Siegel ER, Safar AM, Korourian S, Kieber-Emmons T, Monzavi-Karbassi B. CHST11 gene expression and DNA methylation in breast cancer. Int J Oncol. 2015 Mar;46(3):1243-51.

Kieber-Emmons, T, Pennisi, A., Lane, A., Siegel, E., Cannon, M., Monzavi-Karbassi, B., Makhoul, I., Defining and Managing Expectations for Early Immunotherapy Cancer Trials. Rev Recent Clin Trials. 2015;10(1):47-60. Review.

Yao-Borengasser A, Monzavi-Karbassi B, Hedges RA, Rogers LJ, Kadlubar SA, Kieber-Emmons T. Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells. Oncol Rep. 2015 Jun;33(6):2689-94.

Garimalla S, Kieber-Emmons T, Pashov AD. The Patterns of Coevolution in Clade B HIV Envelope's N-Glycosylation Sites. PLoS One. 2015 Jun 25;10(6):e0128664.

Steplewski Z, Thurin M, Kieber-Emmons T. Antibodies: At The Nexus of Antigens and Cancer Vaccines. J Infect Dis. 2015 Jul 15;212 Suppl 1:S59-66.

Saha S, Murali R, Pashov A, Kieber-Emmons T. The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen. Monoclon Antib Immunodiagn Immunother. 2015 Oct;34(5):295-302.

Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, Fuhrman BJ, Safar AM, Hutchins LF, Kieber-Emmons T. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer Metab. 2016 Apr 6;4:7.

Monzavi-Karbassi B, Siegel ER, Medarametla S, Makhoul I, Kieber-Emmons T. Breast cancer survival disparity between African American and Caucasian women in Arkansas: A race-by-grade analysis. Oncol Lett. 2016 Aug;12(2):1337-1342. Epub 2016 Jun 29. 95

Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer. Breast Cancer (Auckl). 2016 Jul 25;10:103-6.

Monzavi-Karbassi B, Jousheghany F, Kieber-Emmons T. Tumor-associated Glycans and Tregs in Immunogenicity of an Autologous Cell-based Vaccine. Immunol Invest. 2016 Oct 19:1-13. [Epub ahead of print]

Kieber-Emmons T, Monzavi-Karbassi B, Hutchins LF, Pennisi A, Makhoul I. Harnessing benefit from targeting tumor associated carbohydrate antigens. Hum Vaccin Immunother. 2017 Feb;13(2):323-331.

Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck JT, Hutchins LF. Managing Expectations in the Transition to Proof of Concept Studies. Rev Recent Clin Trials. 2017;12(2):111-123. Hutchins LF, Makhoul I, Emanuel PD, Pennisi A, Siegel ER, Jousheghany F, Guo X, Pashov AD, Monzavi-Karbassi B, Kieber-Emmons T. Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic- peptide vaccine in stage IV breast cancer subjects. Oncotarget. 2017 Oct 23;8(58):99161-99178.

Book Chapters

Kieber-Emmons, T. and Rein, R. 1981. Evolving nucleotide binding surfaces. In: Origin of Life (Y. Wolman, ed.). D. Reidel Publ. Co., pp. 415-422.

Rein, R., Shibata, M., and Kieber-Emmons, T. 1982. Computer-aided studies of biomolecular structure and function. In: Frontiers of Chemistry: Plenary and Keynote Lectures Presented at 28th IUPAC Congress (K. Laidler, ed.). Pergamon Press, pp. 179-203.

Rein, R., Shibata, M., Garduno, R., and Kieber-Emmons, T. 1983. Structure of mispairs leading to substitution mutations. In: Structure and Dynamics: Nucleic Acids and Proteins (E. Clementi and R.H. Sarma, eds.). Adenine Press, pp. 269- 288.

Parthasarathy, R., Rajewswaran, M., Kieber-Emmons, T., and Rein, R. 1983. Reciprocal conformational relationships of 2', 5' and 3', 5' polynucleotides: Single-stranded helices of 2', 5' polynucleotides. In: Conformation in Biology: The Festschrift Celebrating the Sixtieth Birthday of G.N. Ramachandram, F.R.S. (R. Srinivasan and R.H. Sarma, eds.). Adeine Press, pp. 267-274.

Köhler, H., Cheng, H-L., Sood, A.K., McNamara-Ward, M., Huang, J-H., Ward, R.E., and Kieber-Emmons, T.. 1987. On the mechanism of internal image vaccines. In: Idiotypes (Proc. Oklahoma Conf. on Idiotype Vaccines). Academic Press, Inc., New York, pp. 179-190.

Kieber-Emmons, T., McNamara-Ward, M., Ward, R.E., and Köhler, H. 1987. Structural considerations in idiotype vaccine design. Monographs in Allergy, 22: 126-133.

Köhler, H. and Kieber-Emmons, T. 1987. New concepts in antibody structure. In: Antibodies (A. Szentivanyi, P.H. Mauer, and B.W. Janick, eds.). Plenum Publishing Corp., pp. 11-17.

Kieber-Emmons, T., Getzof, E., and Köhler, H. 1987. Perspectives on idiotypes and antigenicity. Int. Rev. Immunol. 2: 339- 356.

Köhler, H., Kaveri, S., Kieber-Emmons, T., Morrow, W.J.W., Müller, S., and Raychaudhuri, S., 1989. Overview of idiotypic networks and the nature of molecular mimicry. Meth. Enzymol. 178: 3-35.

Williams, W.V., Kieber-Emmons, T., Weiner, D.B., and Greene, M.I. 1989. Molecular analysis of an autoantibody-receptor interaction. Arthritis Rheum. 32: S136.

Kieber-Emmons, T., Whalley, A., Williams, W.M., Ryskamp, T., Morrow, W.J.W., Krowka, J., Williams, W.V., Schmid, I., Girogi, J.V., Merva, M.J., and Weiner, D.B. 1990. Biological characteristics of an HIV-1

envelope-derived synthetic peptide. In: Vaccines 90 (F. Brown, R.M., Chanock, H.S. Ginsberg, and R.A. Lerner, eds.). Cold Spring Harbor Laboratory Press, pp. 321-326.

Ugen, K.E., Perussia, B., Kamun, M., Merva, M.J., Williams, V.W., Nara, P., Kieber-Emmons, T., and Weiner, D.B. 1991 Inhibition of HIV-1 cellular infection by immunologic reagents. In: Vaccines '91: Modern Approaches to New Vaccines Including Prevention of AIDS (Chanock, R.M., Ginsberg, H.S., Brown, F., and Lerner, R.A., eds.). Cold Spring Harbor Laboratory Press, NY, pp. 115-121.

Kieber-Emmons,T., Ugen, K.E., Merva,M., Whalley, A., Morrow, W.J.W., Williams, W.V., Nara, P.L., and Weiner, D.B. 1991 Engineered peptides that mimic HIV-1 neutralizing envelope structures. In: Vaccines '91: Modern Approaches to New Vaccines Including Prevention of AIDS (Chanock, R.M., Ginsberg, H.S., Brown, F., and Lerner, R.A., eds.). Cold Spring Harbor Laboratory Press, NY, pp. 165-173.

Ugen, K.E., Goodert, J.J., Boyer, J., Refaeli, Y., Frank, I. Williams, W.V., Willoughby, A., Landesman, S., Rubinstein, A., Berzofsky, J., Kieber-Emmons, T., and Weiner, D.B. 1991. Vertical t ransmission of HIV infection: Maternal humoral immune response to gp120 and gp41 peptides. In: Vaccines '92: Modern Approaches to New Vaccines Including Prevention of AIDS (Chanock, R.M., Ginsberg, H.S., Brown, F., and Lerner, R.A., eds.). Cold Spring Harbor Laboratory Press, NY, pp.183-189.

Williams, W.V., Kieber-Emmons, T., Weiner, D.B., and Greene, M.E. 1991. Use of Antibodies as molecular mimics to probe intermolecular interaction landscapes. Molecular evolution of rugged landscapes: Proteins, RNA and the Immune System. In: Studies in the Science of Complexity, Santa Fe Institute Series. pp.52-63.

Kieber-Emmons, T., Williams, V.W., and Greene, M.I. 1991. Anti- receptor antibody structure and peptide design. In: Monoclonal Antibodies: Application in Clincial Oncology (A. Epenetos, ed.). Chapman and Hall Medical, pp. 53-63.

Kieber-Emmons, T. 1992. Rational approaches for peptide design. In: Biologically Active Peptides: Design, Syntheis, and Utilization. (W.V. Williams ans D.B. Weiner eds.) Vol.1, Biomedical Applications of Biotechnology. Technomic, pp. 3-34.

VonFeldt, T.J., Ugen, K.E., Kieber-Emmons, T., and Williams, W.V. 1992. Bioactive peptide design based on antibody structure. In: Biologically Active Peptides: Design, Syntheis, and Utilization. (W.V. Williams and D.B. Weiner eds.) Vol.1, Biomedical Applications of Biotechnology. Technomic, pp. 55-86.

Kieber-Emmons, T. and Weiner, D.B. 1992. Structural perspective of the CD4 antigen. 1992 AIDS Research Reviews, Vol. 2, Ed. W.C. Koff, F. Wong-Staal, R.C. Kennedy, Marcel Dekker, Inc. New York, Basel, Hong Kong, pp. 65-90.

Prammer, K., Wiener, M., Kieber-Emmons T. 1995. Biocomputational approaches to rational protein based drug design. Critical Reviews in Chemistry. Chemical and Structural Approaches to Rational Drug Design. Ed. D.B. Weiner and W.V. Williams. pp. 181-214 . Kieber-Emmons, T., Luo, P., Agadjanyan, M., Hutchins, W., Westerink, M.A.J., Steplewski, Z. 1996 . Peptide mimicry of carbohydrate epitopes. In Vaccines: New Advances in Technologies and Applications. IBC Biomedical Library Series.4.4. 1-4.4.18.

Madaio, M.P., Yanase, K., Foster, M.H., Smith, R.M., Kieber-Emmons, T., Fabbi, M., Puccetti, A., Jarett, L. Nuclear Localization of Autoantibodies: Novel Insights into Protein translocation and Cellular Function. 1997. Annals of the New York Academy of Sciences. 815: 263266.

O,I., Kieber-Emmons T, Otvos L Jr, Blaszczyk-Thurin M. Peptides mimicking sialyl-Lewis A isolated from a random peptide library and peptide array. Ann N Y Acad Sci 1999;886:276-9.

Kieber-Emmons, T., Carbohydrate interactions and HIV-1. In " Human Retroviral Infection: Immunological and Molecular Therapies" Edited by Kenneth Ugen and Herman Friedman. Plenum. 2000 pp.61- 85. 97

Cunto-Amesty, G. and Kieber-Emmons T., Exploiting Molecular Mimicry in Targeting Carbohydrate Antigens. In. Molecular Mimicry, Microbes and Autoimmunity, eds. Madeleine Cunningham and Robert Fujinami. 2000 ASM Press pp. 175-196.

Saha,S., Pashov,A., Karbassi,B., Kieber-Emmons, A.M., Otaki,A., Murali,R., Thomas KieberEmmons, T., Carbohydrate Mimetic Peptide Vaccines. Anticarbohydrate Antibodies - from molecular basis to clinical applications. Ed P. Kosma. Springer-Verlag GmbH. 2012. Patents Published 20030144479 Biologically active compounds and methods of constructing and using the same. 20030017497 Peptide mimotopes of carbohydrate antigens 5,837,460 Methods of identifying biologically active receptor-binding peptides 5,951,983 Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies 09/831,047 Compositions and Methods for Treatment of Cancer 09/485,421 Functional Fragments of HIV-1 VPR Protein and Methods of Using Same

Breast Cancer Research Development

4301 W. Markham, #824 Little Rock, AR 72205-‐‐7199 501-‐‐526-‐‐5930 501-‐‐526-‐‐5934 (fax)

www.uams.edu/cancer

Professor Christine DELPRAT, LIVE consortium coordinator CNRS 5239 FACULTE DE MEDECINE LYON SUD-Secteur 1 165 Chemin du Grand Revoyet : BP12 69921 OULLINS CEDEX

February 08, 2015

Re: International Vaccinology Education (LIVE project)

Dear Professor Delprat,

I am writing to express my enthusiastic support for the LIVE project in Vaccinology that you are organizing together with other European Universities. The multidisciplinary Master of Science program as outlined is very exciting and innovative. This program accomplishes several things. The program provides a vision to foster a multi-disciplinary community to enhance the training of students to address the future needs in the field of vacccinology. The program’s mission in training helps to establish and sustain research partnerships among universities and industry that generates scientific knowledge and discovers the tools/technologies to develop the next generation of vaccines. The nature of the program, therefore, promotes collaboration within the vaccinology research community to establish links with Industry. It provides students a focus for discussion on novel technologies/technology development and an immunology toolbox for targeted approaches in vaccinology by exposing students to experts in the field in different venues. This interaction is expected to have the added benefit of facilitating the sharing of knowledge by coordinating current research activities and the sharing of reagents and resources. This novel approach to training can facilitate new research collaborations and initiate collaborative groups for funding.

I would be honored to participate in the LIVE project as an invited scholar. I am a Full Professor in the Department of Pathology and Associate Director for Prevention Research at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS). My research expertise is in structural biology/immunology, glycobiology, tumor immunology and immune therapy of cancer by antibodies and vaccines. In recognition of my research in Breast Cancer I received an Endowed Chair in 2002. I have lead therapy programs in both Industry and in Academics. At Idec Pharmaceuticals (now Biogen/Idec) I worked on the forerunners of Rituxan. I humanized an anti-CD2 antibody, Siplizumab, an IgG1k class monoclonal antibody that targets CD2 expressing T-and NK-cells and clinically developed by Medimmune for peripheral T cell lymphoma. In the vaccine area we have developed peptides that mimic bacterial, viral and tumor associated carbohydrates using a combination of screening random peptide display libraries and molecular modeling 99

(structure assisted vaccine design). As a means to convert T independent responses to tumor associated carbohydrate antigens (TACA) to T dependent responses we pioneered the development of carbohydrate mimetic peptides (CMPs) to bridge anti-tumor humoral and cellular responses to TACA. In this regard we have shown that it is possible to define CMPs theoretically using computer-based approaches (drug-design approaches) that validate those identified experimentally. This approach constitutes a novel strategy in developing immunotherapeutics to reduce micrometastases and prevention of recurrence. The US FDA approved IND14715 for a Phase I safety study of one of our CMPs in metastatic breast cancer, which is now complete. This is a true a bench-to-bedside project being a first in man CMP testing of a computer-designed Breast Cancer Research Development

4301 W. Markham, #824 Little Rock, AR 72205-‐‐7199 501-‐‐526-‐‐5930 501-‐‐526-‐‐5934 (fax)

www.uams.edu/cancer immunogen. We are now conducting a Phase II study in Breast Cancer patients in the neoadjuvant setting (at UAMS) and Phase I studies in Lung cancer and Melanoma with this CMP.

Most importantly to the importance of outcomes to the training of Masters of Science students in vaccinology is an example from my own Laboratory. Cecile Artraud, the Medicinal Product development project manager at the Institut Pasteur was trained under my direction as a Master’s student in Immunology at UAMS and became study director for the GLP portion in our vaccine development. This training and experience in our program provided her with a great opportunity to find a position in France at a remarkable Institution. I believe that your Live program in Vaccinology will offer opportunities for many talented students to make a difference at Institutions worldwide. Therefore, my expertise in the field is at your disposal.

Sincerely

Thomas Kieber-Emmons PhD Professor of Pathology Josetta Wilkins Chair in Breast Cancer Research Associate Director Prevention Research Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences 4301 West Markham St., #824 Little Rock AR 72205 Phone 501-526-5930 Fax 501-526-5934

Kollmann Tobias Tobias R. Kollmann FACULTY POSITIONS Associate Professor, Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia and BC’s Children’s Hospital, Vancouver, Canada, 2010 – present

Assistant Professor, Division of Infectious and Immunological Diseases, Department of Pediatrics, University of British Columbia and BC’s Children’s Hospital, Vancouver, Canada, 2006 – 2010

Associate Member, Department of Experimental Medicine, and Department of Pathology, University of British Columbia, Canada, 2006 - present

EDUCATION Fellow in Pediatric Infectious Disease, University of Washington, Seattle, WA, 7/01- 8/04

Pediatric Resident at the Children’s Hospital and Regional Medical Center, Seattle, WA, 6/98 – 7/01

M.D., Albert Einstein College of Medicine, Bronx NY, 1998

Ph.D., (Microbiology & Immunology) Albert Einstein College of Medicine, Bronx, NY, 1995

BOARD CERTIFICATION & CURRENT LICENSES Royal College of Physicians & Surgeons of Canada, 2013- present

British Columbia Medical License 2006-present

MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS World Health Organization, Expert Advisory Group on Non-specific Immunological Effects of Vaccination; 2015 - present

Canadian Paediatric Society, 2014 - present

Royal College of Physicians & Surgeons of Canada, 2013 - present

Canadian Coalition for Global Health Research, 2013 - present

Canadian Society for Immunology, 2012 - present

Association of Medical Microbiology and Infectious Disease Canada (AMMI), 2012 - 2014

HONORS AND AWARDS Michael Smith Foundation for Health Research Career Investigator Award, 2012-2020

Canadian Child Health Clinician Scientist Career Development Award, 2007-2011

Burroughs Wellcome Career Award in the Biomedical Sciences, 2005-2010

Pfizer Postdoctoral Fellowship in Infectious Diseases, 2001-2004

Alpha Omega Alpha (National Honor Medical Society), 1998 101

ADMINISTRATIVE LEADERSHIP Director, Global Pediatric Infectious Diseases Training Program (GpID), UBC, 2011-present

Director, Vancouver Immune & Vaccine Analysis Research Centre (VIVArc), 2008- present

Co-Director, Flow Cytometry Facility, CFRI, UBC, 2007-present

Associate Director, MicroResearch (microresearch.ca), 2013 – present

BC Children’s Hospital Drug Dosage & Guidelines Formulary; Member, 2009 - present

PHSA Pharmacy & Therapeutics Quality & Safety Committee, Member 2009 - present

Training & Education Committee, CFRI, UBC, Member 2009 – present

Advisory Board, UBC Neglected Global Disease Initiative; Member 2014 – present

Advisory Board, Scholar of Excellence Program, Child & Family Research Centre, UBC; Member 2014 – present

Director, Pediatric Infectious & Immunological Diseases Fellowship Training Program, UBC, 2010-2012

British Columbia Advisory Committee on Causality Assessment For Pandemic Influenza Vaccine, Member 2009.

Vaccine Vigilance Technical Advisory Committee, Public Health Agency of Canada, Member 2007- 2010

TEACHING EXPERIENCE Course & Curriculum Development: -‘Week-Development Team’, ‘Case Author’ and ‘Case Development Team’ for ‘Principles of Human Biology’ (PRIN401), 1st Year MD/DMD UBC Medical School; 2007 – 2013. - ‘MicroResearch-Applied’. Developed curriculum for academic institutions in East Africa based on the MicroResearch principles (http://microresearch.ca); 2013/2014. - ‘Transplant Related Infections’ and ‘Neonatal Infections’; developed and delivered both of these course series for UBC pediatric- and adult-infectious disease fellows; 2009-2012. UBC Undergraduate & Graduate School Teaching: Principles of Human Biology (PRIN 401), 1st Year MD/DMD (4 lectures/year) on Immunology from 2007 – present; Human Diseases (IDMM) 1st year (1 lecture/year) on Viral Infections from 2011 – present; PRIN 402 Medical 2nd year (1 lectures/year) on Perinatal Infections from 2010 - present; Antibiotics in Pediatric Infectious Disease as part of the Academic Half Day Series for 3rd year MD/DMD students (~every other month since 2006). Molecular Pathogenesis of Malaria (Department of Experimental Medicine, June 2006); Research insights into Malaria (Department of Experimental Medicine, June 2007); Vaccine Response (Department of Experimental Medicine, September 2007); Neonatal Vaccination (CFRI Summer Students, June 2009). UBC Post-Graduate (Medical Resident & Fellow) Teaching: - Residents: Immunopathology of Malaria (August 2006); Neonatal Infections (January 2007); Infections in the Immunocompromised (February 2007); Antibiotic Pharmacokinetics, Resistance Mechanisms (December 2007 and 2008); Congenital Infections (2012). - Adult Infectious Diseases Fellows: Congenital Infections; 1h lecture/year (2009-present). - Neonatology Fellows: Congenital Infections 1h lecture/year (2010 - present); 102

- Pediatric Infectious Diseases Fellows: Transplant Related Infections (2009-2012); Neonatal Infections (2011-2013). - UBC Course in Molecular and Clinical Immunology (Jan. 2013). Invited International Teaching: - MicroResearch Course Co-Director and Facilitator (http://microresearch.ca), Nairobi, Kenya. Yearly two- week course taught in East Africa (2012 - present). - “Development of Immunity in Early Life”. Hot Topics in Infectious Diseases in Children, Oxford University, UK; July 2014.

MENTORING & SUPERVISORY EXPERIENCE Currently supervising: Kathleen Wee (UBC PhD; NSERC & CIHR Scholar) 2009-; Nelly Amenyogbe (UBC PhD) 2012-; Sheka Aloyounie (UBC PhD) 2013-; Duncan MacGillivray (UBC MSc), 2013-; Rym Ben Othman (Postdoctoral Fellow) 2013-; Mathieu Garand (Postdoctoral Fellow) 2013-; Byron Brook (UBC PhD) 2014-. Supervised students who have graduated at UBC under my primary supervision: 4 BSc; 7 MSc; 5 PhD; also mentored 4 post-doctoral fellows. International co-supervised students who have graduated: Sofia Pederson (PharmD U. Gothenburg, Sweden); 2008-2009; Lisa Franzen (PharmD U. Gothenburg, Sweden) 2009-2010; Rozanne Adams (MSc Stellenbosch University; South Africa,) 2009 – 2011; Victor Cagerus (PharmD U. Gothenburg, Sweden) 2012-2013; Oliver Alka (BSc, U. Freiburg, Germany) 20132014. Graduate Thesis Committee Member UBC: Aaron Wyatt 2008 (Hancock lab); Paxton Bach 2008 (Dutz lab); Vicky Cheng, 2007-2014 (Dutz lab); Agatha Jassem, 2009-2013 (Speert Lab); Alicia McMurchy, 2009-2013 (Levings Lab); Marta Wlodarska, 2010-2014 (Finlay lab); Leah Stiemsma 2013- present (Turvey Lab); Ngan Hien Lyle, 2013- present (Hancock lab); Jessica Tuengel, 2014 - present (Gantt lab); Seyhon Cho, 2014 - present (Gantt lab). External Examiner: MSc, Yuexin Li, UBC (Mentor: Dr. Hancock), January 2007; PhD, Dr. Nicholas Wood MD, Sydney, Australia (Mentor: Dr. P. McIntyre), June 2009; MSc, Matthew Gold, UBC (Mentor: Dr. McNagny), November 2010; MSc, Ulrike Lambertz UBC (Mentor: Dr. Reiner), June 2012; MSc, Daljeet Mahal, UBC (Mentor: Dr. Money), April 2013; PhD, Ho Pan Sham, UBC (Mentor: Dr. Bruce Vallance), April 2013; PhD, Olga Pena, UBC (Mentor: Dr. Hancock), June 2013; PhD, Bethany Henrick, McMaster (Mentor: Dr. Rosenthal), August 2013; MSc, C. Toukam, U. of Cape Town, South Africa (Mentor: Dr. Jaspen); March 2014; PhD, Nita Reva Shah, UBC (Mentor: Dr. Fernandez), May 2014; PhD Kristoffer J. Jensen, U. Southern Denmark, Staten Serum Institute (Mentor: Dr. C. Stabell Benn). Graduate Thesis Defense Chair: MSc Defense, Roger Jen UBC (Supervisor Dr. Lavoie), December 2012; PhD comprehensive examination, Xingji Zheng, UBC (Supervisor Dr. AvGay), December 2012.

RESEARCH FUNDING (present & recent past) “Lower GBP1 expression reduces human host defense against Listeria monocytogenes”. CIHR Operating. PI: Dr. Tobias Kollmann. 2013-2017.

“Maternal-Infant Microbiome and Immunity (MIMI) Network”. CIHR Network. PI: Dr. Tobias Kollmann. 2012-2015.

“Development of Listeria based infectious disease vaccines.” Advaxis Inc. PI: Dr. Tobias Kollmann. 2011- 2013.

“Canadian Healthy Infant Longitudinal Determinants”. CIHR Operating. PI: Dr. Malcolm Sears, McMaster. Co- Investigator: Dr. Tobias Kollmann. 2008-2015.

“The Role of Genetic Variation in the Vaccine Response”. Glaxo Smith Kline Inc. PI: Dr. Tobias Kollmann. 2010-2013.

“Vaccine for Asthma and Allergies”. CIHR Catalyst. PI: Dr. Tobias Kollmann. 2010-2011.

103

“Optimization and Validation of a High-throughput Anti-influenza Peptide Immunoassay”. CIHR Catalyst. PI: Dr. Tobias Kollmann. 2010-2011.

“Development of a Neonatal Pertussis Vaccine: One Shot for Life.” Sick Kids Foundation. PI: Dr. Tobias Kollmann. 2007-2009.

“Vaccine’s New Frontier: The Role of Innate Immune Receptor Function in Vaccine Outcome”. CCHCSP Award, PI: Dr. Tobias Kollmann, 2007-2011.

“Ontogeny & Genetic Polymorphisms”. AllerGen National Center for Excellence. PI: Dr. Tobias Kollmann, 2007-2009.

“Vancouver Immune & Vaccine Analysis Research Center (VIVArc)”. CFI Leaders Opportunity Fund. PI: Dr. Tobias Kollmann, 2007-2008.

“Establishment Award”. BC Research Institute for Child and Family Health. PI Dr. Tobias Kollmann, 2005-2007.

“TLRs in Innate Immunity and the Induction of Adaptive Immunity in the Neonate and Infant”. NIH/NIAID AI-50023. PI: Dr. Chris Wilson, University of Washington, Seattle, WA. Co-investigator Dr. Tobias Kollmann, 2005-2010.

“Immune Memory to Listeria in Neonates.” Burroughs Wellcome Fund Career Award. PI: Dr. Tobias Kollmann, 2005- 2010.

ORIGINAL COMMUNICATIONS IN PEER-REVIEWED JOURNALS 1. Cellular immune responses of older adults to four influenza vaccines: Results of a randomized, controlled comparison. Kumar A, McElhaney JE, Walrond L, Cyr TD, Merani S, Kollmann TR, Halperin SA, Scheifele DW. Hum Vaccin Immunother. 2017 Sep 2;13(9):2048-2057. 2. Early-Life Host-Microbiome Interphase: The Key Frontier for Immune Development. Amenyogbe N, Kollmann TR, Ben-Othman R. Front Pediatr. 2017 May 24;5:111. 3. Maternal immunisation: collaborating with mother nature. Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L, Bjornson G, Jones CE, Halperin SA, Edwards KM, Heath P, Openshaw PJ, Scheifele DW, Kollmann TR. Lancet Infect Dis. 2017 Jul;17(7):e197-e208. 4. Protecting the Newborn and Young Infant from Infectious Diseases: Lessons from Immune Ontogeny. Kollmann TR, Kampmann B, Mazmanian SK, Marchant A, Levy O. Immunity. 2017 Mar 21;46(3):350-363. 5. A Prospective Cohort Study of Common Childhood Infections in South African HIV-exposed Uninfected and HIV-unexposed Infants. Slogrove AL, Esser MM, Cotton MF, Speert DP, Kollmann TR, Singer J, Bettinger JA. Pediatr Infect Dis J. 2017 Feb;36(2):e38-e44. 6. Lack of broad functional differences in immunity in fully vaccinated vs. unvaccinated children. Sherrid AM, Ruck CE, Sutherland D, Cai B, Kollmann TR. Pediatr Res. 2017 Apr;81(4):601-608. 7. The Immune System of HIV-Exposed Uninfected Infants. Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. Front Immunol. 2016 Sep 28;7:383. 8. Environment impacts innate immune ontogeny. Garand M, Cai B, Kollmann TR. Innate Immun. 2017 Jan;23(1):3-10 9. Transfer of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected Newborns. Abu-Raya B, Smolen KK, Willems F, Kollmann TR, Marchant A. Front Immunol. 2016 Aug 31;7:338. 10. Linking Susceptibility to Infectious Diseases to Immune System Abnormalities among HIV-Exposed Uninfected Infants. Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Front Immunol. 2016 Aug 19;7:310. 11. Towards Predicting Protective Vaccine Responses in the Very Young. Kollmann TR, Marchant A. Trends Immunol. 2016 Aug;37(8):523-34. 12. Harnessing the beneficial heterologous effects of vaccination. Goodridge HS, Ahmed SS, Curtis N, Kollmann TR, Levy O, Netea MG, Pollard AJ, van Crevel R, Wilson CB. Nat Rev Immunol. 2016 Jun;16(6):392-400.

104

13. Changing oral vaccine to inactivated polio vaccine might increase mortality. Fish EN, Flanagan KL, Furman D, Klein SL, Kollmann TR, Jeppesen DL, Levy O, Marchant A, Namachivayam S, Netea MG, Plebanski M, Rowland-Jones SL, Selin LK, Shann F, Whittle HC. Lancet. 2016 Mar 12;387(10023):1054-1055 14. Attenuated innate immune defenses in very premature neonates during the neonatal period. Marchant EA, Kan B, Sharma AA, van Zanten A, Kollmann TR, Brant R, Lavoie PM. Pediatr Res. 2015 Nov;78(5):492-7. 15. Age-Related Gene Expression Differences in Monocytes from Human Neonates, Young Adults, and Older Adults. Lissner MM, Thomas BJ, Wee K, Tong AJ, Kollmann TR, Smale ST. PLoS One. 2015 Jul 6;10(7):e0132061. 16. Mang’oli P, Theuri J., Kollmann T., MacDonald NE. Ponseti clubfoot management: Experience with the Steenbeek foot abduction brace. Paediatr Child Health.,19(10):513-4; 2014. 17. Moraes TJ, Lefebvre DL, Chooniedass R, Becker AB, Brook JR, Denburg J, HayGlass KT, Hegele RG, Kollmann TR, Macri J, Mandhane PJ, Scott JA, Subbarao P, Takaro TK, Turvey SE, Duncan JD, Sears MR, Befus AD; CHILD Study Investigators. The Canadian Healthy Infant Longitudinal Development Birth Cohort Study: Biological Samples and Biobanking. Paediatr Perinat Epidemiol. 2014 Epub Nov 18. 18. D. M. MacGillivray and T.R. Kollmann. The role of environmental factors in modulating immune responses in early life. Front. Immunol. 5:434. 2014. 19. P. Aaby, T.R. Kollmann, C. Stabell Benn. Non-specific effects of neonatal and infant vaccination – public health, immunological, and conceptual challenges. Nature Immunology 15:895-9; 2014. 20. K.K. Smolen, B. Cai, L. Gelinas, E.S. Fortuno, M. Larsen, D.P. Speert, M. Chamekh, P.J. Cooper, M. Esser, A. Marchant, T.R. Kollmann. Single cell analysis of innate cytokine responses to pattern recognition receptor stimulation in children across four continents. J. Immunol., 193:3003-12; 2014. 21. B.A. Reikie, R.C.M. Adams, A. Leligdowicz, K. Ho, S. Naidoo, C.E. Ruck, S. Pillay, C. de Beer, W. Preiser, M.F. Cotton, D.P. Speert, M. Esser, T.R. Kollmann. Altered innate immune development in HIV-exposed uninfected infants. JAIDS, 66:245-55; 2014. 22. S.Y. Aloyouni, C.-P. Segeritz, A.M. Sherrid, M. J. Gold, D. I. M. Loeffler, M.-R. Blanchet, B. Cai, J. Hirota, K. M. McNagny, T. R. Kollmann. Perinatal immunization with vaccinegrade Listeria monocytogenes provides protection against murine Th2 airway inflammation. Allergy, Asthma & Immunology Research; 6(4):341-9; 2014. 23. T. Bhate, T.R. Kollmann, K. Hadad. A 9-year-old girl with prolonged fever and headache. Paediatrics & Child Health; 19(4):177-8; 2014. 24. G. Reid, N. Nduti, W. Sybesma, R. Kort, T.R. Kollmann, R. Adam, H. Boga, E.M. Brown, A. Einerhand, H. El- Nezami, G.B. Gloor, I.I. Kavere, J. Lindahl, A. Manges, W. Mamo, R. Martin, A. McMillan, J. Obiero, P.A. Ochieng, A. Onyango, S. Rulisa, E. Salminen, S. Salminen, A. Sije, J.R. Swann, W. Van Treuren, D. Waweru and S.J. Kemp. Harnessing microbiome and probiotic research in sub-Saharan Africa: recommendations from an African workshop. Microbiome; 2(1):12; 2014. 25. Shey MS, Nemes E, Whatney W, de Kock M, Africa H, Barnard C, van Rooyen M, Stone L, Riou C, Kollmann T, Hawn TR, Scriba TJ, Hanekom WA. Maturation of Innate Responses to Mycobacteria over the First 9 Months of Life. J. Immunol.; 192(10):4833-43; 2014. 26. Konya T, Koster B, Maughan H, Escobar M, Azad MB, Guttman DS, Sears MR, Becker AB, Brook JR, Takaro TK, Kozyrskyj AL, Scott JA; CHILD Study Investigators. Associations between bacterial communities of house dust and infant gut. Environ Res.; 131:25-30; 2014. 27. Z.Z. Liang, A.M. Sherrid, A. Wallecha, T. R. Kollmann. Listeria monocytogenes - a promising vehicle for neonatal vaccination. Human Vaccines & Immunotherapeutics; Epub. Feb. 2014. 28. W. K. Cheng, K. Wee, T. Kollmann, J. Dutz. Topical CpG adjuvantation of a proteinbased vaccine induces protective immunity to Listeria monocytogenes. Clinical and Vaccine Immunology 21(3): 329-339; 2014. 29. K. Smolen, C. Ruck, E.S. Fortuno III, K. Ho, P. Dimitriu, W. Mohn, D.P. Speert, P.J. Cooper, M. Esser, T. Goetghebuer, A. Marchant, T.R. Kollmann. Pattern recognition receptormediated cytokine response in infants across four continents. Journal of Allergy and Clinical Immunology; 133(3):818-26; 2014. 30. C. Dias, A. McDonald, M. Sincan, R. Rupps, T.C. Markello, R. Salvarinova, R. Santos, K.

105

31. Menghrajani, C. Ahaghotu, D. Sutherland, E.S. Fortuno, T. R. Kollmann, M. Demos, J.M. Friedman, D. Speert, W. Gahl, C.F. Boerkoel. Recurrent subacute post-viral onset of ataxia associated with a PRF1 mutation. Eur J Hum Genet. 21(11):1232-9. 2013. 32. M. Pettengill, S. Robson, M. Tresenriter, J. Millán, A. Usheva, T. Bingham, M. Belderbos, I. Bergelson, S. Burl, B. Kampmann, L. Gelinas, T. Kollmann, L. Bont, O. Levy. Soluble ecto-5′nucleotidase (5′NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine. J. Biol. Chem. 288:27315-26. 2013. 33. Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine; 32(5):624-30; 2013 34. S. Gantt, L. Yao, T. R. Kollmann, C. Casper, J. Zhang, S.G. Self. Implications of agedependent immune responses to enterovirus 71 infection for disease pathogenesis and vaccine design. Journal of the Pediatric Infectious Diseases Society; Epub. June 2013. 35. Al-Najjar, G. Al-Rawahi, L. Hong, T.R. Kollmann. Clostridium difficile Vertebral Osteomyelitis: A Case Report and Review of the Literature. Pediatric Infectious Disease Journal, 31:2481-2. 2013. 36. M. Al-Dabbagh, K. Lapphra, D.W. Scheifele, S.A. Halperin, J.M. Langley, P. Cho, T.R. Kollmann, Y. Li, G. De Serres, E.S. Fortuno 3rd, J.A. Bettinger. Elevated inflammatory mediators in adults with oculo-respiratory syndrome following influenza immunization. Clin Vaccine Immunol. 20:1108-14. 2013. 37. P. Cho, L. Gelinas, N.P. Corbett, S.J. Tebbutt, S.E. Turvey, E.S. Fortuno III, and T.R. Kollmann. Association of common single nucleotide polymorphisms in innate immune genes with differences in TLR-induced cytokine production in neonates. Genes & Immunity; 14:199-211. 2013. 38. O. Levy, S. Goriely, T.R. Kollmann. Immune Response to Vaccine Adjuvants during the First Year of Life. Vaccine, 31:2500-05. 2013. 39. S. Dobson, S. McNeil, M. Dionne, M. Dawar, G. Ogilvie, M. Krajden, C. Sauvageau, D.W. Scheifele, T.R. Kollmann, S.A. Halperin, J.M. Langley, J.A. Bettinger, J. Singer, D. Money, D. Miller, M. Naus, F. Marra, E. Young. Immunogenicity of 2 doses of human papillomavirus vaccine in younger adolescents versus 3 doses in young women. JAMA 309:1793-802; 2013 40. S. Ali, A.F. Hirschfeld, M.L. Mayer, E.S. Fortuno 3rd, N. Corbett, M. Kaplan, S. Wang, J. Schneiderman, C. D. Fjell, J. Yan, L. Akhabir, F. Aminuddin, N. Marr, T. Lacaze- Masmonteil, R.G. Hegele, A. Becker, M. Chan- Yeung, R.E.W. Hancock, T.R. Kollmann, D. Daley, A.J. Sandford, P.M. Lavoie, S.E. Turvey. Functional genetic variation in NFKBIA and susceptibility to childhood asthma, bronchiolitis and bronchopulmonary dysplasia. J. Immunology 190:3949-58, 2013. 41. K.K. Yam, J. Gupta, A. Brewer, D.W. Scheifele, S. Halperin, G. DeSerres, V. Gilca, S. McNeil, V. Gilca, B. Smith, J. Kellner, J. McDonald, L. Sauve, T. Kollmann, N. Bastien, B.J. Ward; Public Health Agency of Canada/Canadian Institute of Health Research, Influenza Research Network (PCIRN) Rapid Trial Study 3 (RT- 03) Investigators. Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine. Clin Vaccine Immunol. 20:459-67. 2013. 42. M. Azad, T. Konya, H. Maughan, D. Guttman, C. Field, R. Chari, M. Sears, A. Becker, J. Scott, R. Allen, D. Befus, M. Brauer, J. Brook, M. Cyr, E. Chen, D. Daley, S. Dell, J. Denburg, S. Elliott, H. Grasemann, K. HayGlass, R. Hegele, L. Holness, M. Kobor, T. Kollmann, C. Laprise, M. Larché, W. Lou, J. Macri, P. Mandhane, G. Miller, R. Moqbel, T. Moraes, P. Paré, C. Ramsey, F. Ratjen, B. Ritchie, A. Sandford, J. Scott, F. Silverman, P. Subbarao, S. Tebbutt, T. Takaro, P. Tang, T. To, S. Turvey, A. Kozyrskyj. Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months. CMAJ 185:385-94, 2013. 43. N. Aghaeepour, G. Finak; FlowCAP Consortium; DREAM Consortium, H. Hoos, T.R. Mosmann, R. Brinkman, R. Gottardo, R.H. Scheuermann. Critical assessment of automated flow cytometry data analysis techniques. Nature Methods 10:228-38, 2013. 44. A.M. Sherrid & T.R. Kollmann. Age-dependent Differences in Systemic and Cellautonomous Immunity to L.monocytogenes. Clinical & Developmental Immunology; 2013:917198. 45. B. A. Reikie, S. Naidoo, C.E. Ruck, A.L. Slogrove, C de Beer, H. la Grange, R.C.M. Adams, K. Ho, K. Smolen, D.P. Speert, M.F. Cotton, W. Preiser, M. Esser & T.R. Kollmann. Antibody responses to vaccination among 106

South African HIV-exposed and unexposed uninfected infants over the first two years of life. Clinical & Vaccine Immunology, 20:33-8; 2013. 46. T.R. Kollmann. Variation between populations in the innate immune response to vaccine adjuvants. Frontiers in Immunology 4:81, 2013. 47. A.L. Slogrove, Reikie B., Naidoo S., de Beer C., Ho K., Cotton M.F., Bettinger J., Speert D.P., Esser M. & T. Kollmann. HIV exposed uninfected infants are at increased risk for severe infections in the first year of life. Journal of Tropical Pediatrics, 58:505-8, 2012. 48. T.R. Kollmann, O. Levy, R.R. Montgomery, S. Goriely. Innate Immune Function and Toll-like Receptors: Distinct Responses in Newborns and the Elderly. Immunity 37:771-83, 2012. 49. K. Smolen, Gelinas L., Franzen L., Dobson S., Dawar M., Ogilvie G., Krajden M., Fortuno E.S. & T. R. Kollmann. Age of recipient vs. number of doses differentially impact human B vs. T cell immune memory responses to HPV vaccination. Vaccine 30:3572-9, 2012. 50. N. Dauby, Goetghebuer T., Kollmann T.R., Levy J., Marchant A. Uninfected, but not unaffected: the impact of chronic maternal infections during pregnancy on fetal immunity and susceptibility to post-natal infections. Lancet Infectious Diseases, 12:330-40; 2012 51. M. Al-Dabbagh, Van den Driessche K., Marais B.J., T. R. Kollmann. Management of Multidrug-resistant Tuberculosis (MDR-TB) in Children. European Infectious Disease 6:35-40, 2012. 52. M.S. Shey, Hughes E.J., de Kock M., Barnard C., Stone L., Kollmann T.R., Hanekom W.A., Scriba T.J. Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. J Immunol Methods 376:79-88, 2012. 53. H. Behzad, A.L.W. Huckriede, L. Haynes, B. Gentleman, K. Coyle, J.C. Wilschut, T.R. Kollmann, Steven G. Reed, J.E. McElhaney. GLA-SE, a synthetic TLR4 agonist, enhances T cell responses to influenza vaccine in older adults. Journal of Infectious Diseases 205:466-73, 2012. 46. N. Tan, S. Turvey, A. Byrne, J. Ludemann, and T.R. Kollmann. Staphylococcus aureus nasal septal abscess complicated by extradural abscess in an infant. J Otolaryngol Head Neck Surg 41:E7-E12, 2012. 54. B. Reikie, R.C.M. Adams, C.E. Ruck, K. Ho, A. Leligdowicz, S. Pillay, S. Naidoo, E.F. Fortuno III, C. de Beer, W. Preiser, M.F. Cotton, D.P. Speert, M. Esser, T.R. Kollmann. Ontogeny of Toll-like receptor mediated cytokine responses of South African infants throughout the first year of life. PLoSONE 7:e44763, 2012. 55. A.M. Hajjar, R.K. Ernst, E.S. Fortuno III, A.S. Brasfield, C.S. Yam, L.A. Newlon, T.R. Kollmann, S.I. Miller, C.B Wilson. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica.. PLOS Pathogen; 8(10):e1002963; 2012 56. M. Al-Dabbagh, K. Lapphra, R. Pattar, K. Inrig, H.S. Schaaf, B.J. Marais, L. Sauve, I. Kitai and T. R. Kollmann. Drug-resistant tuberculosis: pediatric guidelines. Pediatric Infectious Disease Journal 30:501, 2011. 57. M. Murray, J. Cooper, P. Tang, J. Hajek, T.R. Kollman. Clinical Vignette: An eightmonth-old child with cervical adenitis. The Canadian Journal of Infectious Diseases and Medical Microbiology, 23: e53-e54, 2012. 58. R. Holden, A Wilmer, T. Kollman. Primary peritonitis due to Group A Streptococcus in a previously healthy pediatric patient. The Canadian Journal of Infectious Diseases and Medical Microbiology, 23: 1-2, 2012. 59. Langley J.M., Scheifele D.W., Quach C., Vanderkooi O.G., Ward B., McNeil S., Dobson S., Kellner J.D., Kuhn S., Kollman T., MacKinnon-Cameron D., Smith B., Li Y., Scott A. Halperin. Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 30:3389–3394, 2012. 60. J. Spidlen, P. Shooshtari, T.R. Kollmann and R.R. Brinkman. Flow Cytometry Standards. BMC Res Notes 7:4, 2011. 61. D. Blimkie, E.S. Fortuno III, H. Yan, P. Cho, S.E. Turvey, K. Ho, A. Marchant, S. Goriely and T. R. Kollmann. Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation. Journal of Immunological Methods 366:89, 2011. 62. D.C. Shih, K.C. Ho, K.M. Melnick, R.A. Rensink, T.R. Kollmann and E.S. Fortuno III. Facilitating the Analysis of Immunological Data with Visual Analytic Techniques. Journal of Visualized Experiments 2: 47, 2011.

107

63. B. Reikie, K.K. Smolen, D.I.M. Loeffler, D. Blimkie, E.S. Fortuno III, and T.R. Kollmann.. A Single Immunization Near Birth Protects Immediately And For Life. Vaccine. 29: 8390, 2010. 64. P.M. Lavoie, Q. Huang, E. Jolette, M. Whalen, A.M. Nuyt, F. Audibert, D. Speert, T. Lacaze-Masmonteil, H. Soudeyns, and T. R. Kollmann. Profound Lack of IL-12/23p40 in neonates born early in gestation associated with increased risk of sepsis. Journal of Infectious Diseases 202:1754, 2010. 65. N. Corbett, D. Blimkie, K.C. Ho, C. Bing, D. Sutherland, A. Kallos, J. Crabtree, A. ReinWeston, P.M. Lavoie, S. Turvey, N.R. Hawkins, S.G. Self, C.B. Wilson, A.M. Hajjar, E.S. Fortuno III and T.R. Kollmann. Ontogeny of the Innate Response to TLR Stimulation. PlosONE 5:15041, 2010. 66. P. Shooshtari, E.S. Fortuno III, D. Blimkie, M. Yu, A. Gupta, R.R. Brinkman and T.R. Kollmann. Correlation Analysis of Intracellular and Secreted Cytokines via the Generalized Integrated Mean Fluorescent Intensity (GiMFI). Cytometry A. 77:873-80, 2010. 67. D. Blimkie, E.S. Fortuno III, F. Thommai, L. Xu, E. Fernandes, J. Crabtree, A. ReinWeston, K. Jansen, R.R. Brinkman and T.R. Kollmann.. Identification of B cells through negative gating—an example of the MIFlowCyt standard applied. Cytometry A, 77:546-551, 2010.

BOOK CHAPTERS 4. T.R. Kollmann, T. Mailman, R. Bortolussi. Chapter: Listerosis. In Remington & Klein: Infectious Diseases of the Fetus and Newborn Infant, 8th ed.; anticipated date of publication 2015, Philadelphia: Elsevier Saunders. Eds.: Nizet V, Wilson CB, Baker C. 3. T.R. Kollmann, T. Mailman, R. Bortolussi. Listeriosis. In Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 7th ed., 2013, Philadelphia: Elsevier Saunders. Eds.: Feign R., Cherry J., Demmler-Harrison G., Kaplan S. 2. T.R. Kollmann and S. Dobson. Chapter: Congential Syphillis. In Remington & Klein: Infectious Diseases of the Fetus and Newborn Infant, ed. 7 & 8 ed.; 2010 (7th) and anticipated date of publication for 8th ed. 2015, Philadelphia: Elsevier Saunders. Eds.: Nizet V, Wilson CB, Baker C. 1. C.B. Wilson and T.R. Kollmann. Induction of Antigen-Specific Immunity in Human Neonates and Infants. Nestlé Nutr Workshop Ser Pediatr Program, vol 61, pp 183–195, 2007 (“The Window of Opportunity: Pre-Pregnancy to 24 Months of Age”. Eds: Barker DJP, Bergmann R, Pearay PL).

ABSTRACTS/POSTERS PRESENTED 36. Annette Scheid, David J Dowling, Ilana Bergelson, Matthew A Pettengill, Helen Christou, Tobias Kollmann, Ofer Levy. Toll-like receptor (TLR)-7/8 agonist and Bacille Calmette Guerin (BCG) activate robust cytokine induction in preterm cord blood. New England Society of Perinatal Medicine Meeting Newport, Rhode Island, March 2015. 35. Annette Scheid, David J Dowling, Ilana Bergelson, Matthew A Pettengill, Helen Christou, Tobias Kollmann, Ofer Levy. Informing preterm vaccine development: Toll-like receptor (TLR)-7/8 agonist and Bacille Calmette Guerin (BCG) activate robust cytokine induction in preterm cord blood. Pediatric Academic Society, San Diego, April 2015. 34. Marie-Claire Arrieta, Leah T. Stiemsma, Pedro A. Dimitriu, Lisa Thorson, Shannon Russell, Sophie Yurist, Rollin Brandt, Diana L. Lefebvre, Padmaja Subbarao, Piush Mandhane, Allan Becker, Malcolm Sears, Kelly McNagny, Tobias Kollmann, William W. Mohn, the CHILD Study Investigators, Stuart E. Turvey and B. Brett Finlay. Early-infancy microbial and metabolic alterations preceding asthma. Keystone Symposia, Colorado, Gut Microbiota Modulation of Host Physiology: The Search for Mechanism 2015. 33. Nelly Amenyogbe, Christine Lukac, Tobias R Kollmann. Early-life immunization with Bacillus Calmette- Guerin protects newborn mice from polymicrobial sepsis and alters innate immunity. Canadian Immunization Conference, Ottawa; December 2014. 32. Leah T. Stiemsma, Marie-Claire Arrieta, Pedro A. Dimitriu, Lisa Thorson, Sophie Yurist, Rollin Brandt, Diana L. Lefebvre, Padmaja Subbarao, Piush Mandhane, Allan Becker, Malcolm Sears, Tobias Kollmann, Soren Gantt, William W. Mohn, B. Brett Finlay, Stuart E. Turvey. The early life intestinal microbiota and its association with atopic disease. Canadian Society of Allergy and Clinical Immunology, Ottawa, Canada 2014. 31. Subbarao PJ, Anand SS, Becker AB, Befus AD, Brook JR, Hayglass KT, Kollmann TR,

108

Kozyrskyj AL, Lou WYW, Mandhane PJ, Miller GE, Moraes TJ, Sandford AJ, Scott JA, Takaro TK, Turvey SE, Duncan JD, Lefebvre DL, Sears MR and the CHILD Study investigators. Exploring the origins of asthma: early results of the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study. EAACI Congress, Kopenhagen, Denmark 2014. 30. N. MacDonald, R. Bortolussi, T. Kollmann, J. Kabakyenga. Capacity Building for Community Directed Research in East Africa: 5 Year MicroResearch Outcome. Platform Abstract Presentation, Canadian Paediatric Society 91st Annual Conference, Montreal, Canada, 2014. 29. K. Wee, E.S. Fortuno, T.R Kollmann. Molecular Mechanism Responsible for Differences Between Neonatal and Adult Dendritic Cell Responses. Federation of Clinical Immunology Societies (FOCIS), Chicago, IL, USA 2014. 28. MacDonald N, Bortolussi R, Kollmann TR, Kabakyenga J. Capacity Building for Community Directed Research in East Africa (EA): 5 year MicroResearch (MR) Outcomes. Academic Pediatric Society; Vancouver 2014. 27. Subbarao PJ, Anand SS, Becker AB, Befus AD, Brook JR, Hayglass KT, Kollmann TR, Kozyrskyj AL, Lou WYW, Mandhane PJ, Miller GE, Moraes TJ, Sandford AJ, Scott JA, Takaro TK, Turvey SE, Duncan JD, Lefebvre DL, Sears MR and the CHILD Study investigators. Exploring the origins of asthma: development, demographics and early results of the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort study. American Thoracic Society, San Diego 2014. 26. MacDonald N, Bortolussi R, Kollmann TR, Kabakyenga J. Capacity Building for Community Directed Research in East Africa (EA): 5 year MicroResearch (MR) Outcomes. Canadian Pediatric Society; Montreal, 2014. 25. Wee K, Sherrid A, Fortuno III ES, Kollmann TR. Mechanisms Underlying the AgeDependent Susceptibility to Severe Infection with Listeria monocytogenes. Canadian Student Health Research Forum; Manitoba, June 2012. 24. Aloyouni S, Sherrid A, Kollmann TR. Listeria monocytogenes vaccine platform prevents asthma. Young Investigators Forum; Montreal, June 2012. 23. Aloyouni S, Sherrid A, Kollmann TR. Modulation of the neonatal immune system by listeria monocytogenes: Does it exacerbate hypersensitivity pneumonitis later in life? AllerGen 7th Annual research conference; Toronto, February 2012. 22. Al-Dabbagh M, Lapphra K, Scheifele D, Dobson S, Halperin S, Langley J, Skowronski 3, De Serres G, Kollmann TR & Bettinger J. An Investigation of Inflammatory Mediators in Selected Adverse Events following Influenza Immunization in Adults. 5th Vaccine and ISV Annual Global Congress; Seattle, WA, USA; October 2011. 21. Reikie B, Leligdowicz A, Adams R, Speert D, Cotton M, De Beer C, Esser M & Kollmann TR. HIV Exposed Uninfected (HEU) South African Infants Express a Hyperinflammatory Innate Immune Profile. 3rd International Workshop on HIV Pediatrics & 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy; July 2011. 20. Slogrove AL, Williams S, Kollmann TR, Cotton MF, Bettinger JA, Speert DP & Esser MM. HIV exposed uninfected (HEU) infants: evidence of severe infectious morbidity in South Africa. 3rd International Workshop on HIV Pediatrics & 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy; July 2011. 19. Rassekh RS, Ratzlaff M, Al-Dabbagh M, Lloyd C, Damphousse A, Jamieson D, AlRawahi G & T. R. Kollmann. High Incidence of Fungal Infections in Pediatric Oncoclogy Patients in British Columbia. 43rd Congress of the International Society of Paediatric Oncology, Auckland, New Zealand, October 2011. 18. Corbett N, Blimkie D, Crabtree J, Rein-Weston A, Ali S, Turvey SE, Lavoie PM, Wilson CB, Hajjar AM, Fortuno III ES & T.R. Kollmann. Ontogeny of Early Life TLR-Mediated Innate Immune Responses. Keystone Symposia, Seattle, WA, October 2010. 17. Corbett N, Blimkie D, Crabtree J, Rein-Weston A, Ali S, Turvey SE, Lavoie PM, Wilson CB, Hajjar AM, Fortuno III ES & T.R. Kollmann. Age-Specific Changes in Early Life TLRMediated Innate Immune Responses. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, BC, October 2010. 16. David W. Scheifele, Brian Ward, Marc Dionne, Gaston De Serres, Joanne Langley, Scott Halperin, Otto Vanderkooi, James Kellner, Simon Dobson, Laura J. Sauve, T.R. Kollmann, Yan Li, and Barbara Law. Immunogenicity of AS03-Adjuvanted pH1N1 Influenza Vaccine in Young Canadian Children. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, BC, October 2010.

109

15. David W. Scheifele, Brian Ward, Marc Dionne, Gaston De Serres, Joanne Langley, Scott Halperin, Otto Vanderkooi, James Kellner, Simon Dobson, Laura J. Sauve, T.R. Kollmann, Yan Li, and Barbara Law. Safety of An AS03-Adjuvanted pH1N1 Influenza Vaccine Given to Young Canadian Children. 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, BC, October 2010. 14. Corbett N, Blimkie D, Crabtree J, Rein-Weston A, Ali S, Turvey SE, Lavoie PM, Wilson CB, Hajjar AM, Fortuno III ES & T.R. Kollmann. The fetal & early life immune system is not less responsive to TLR stimulation than the adult, but responds differently. NIAID meeting on Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations, Philiadelphia, PA, September 2009. 13. L. Aplin, D. Loeffler, B. Reikie, T.R. Kollmann. Developing a neonatal pertussis vaccine: One shot for life. 5th International Neonatal Immunology and Hematology Conference, Boston, MA 2008. 12. D. Blimkie, B. Reikie, T.R. Kollmann. Human T cell Evaluation by Polychromatic Flow Cytometry. 3rd Annual Assay and Screening Technologies Conference, San Francisco, CA, USA 2008. 11. B. Reikie, K. Smolen, D. Loeffler, D. Blimkie, T. R. Kollmann. Neonatal vaccination: Immunological mechanisms driving immune memory development in neonates. Published in The Canadian Journal of Infectious Diseases and Medical Microbiology 2008 Sept/Oct; 19(5): 342. 10. B. Reikie, K. Smolen, D. Loeffler, D. Blimkie, T.R. Kollmann. Vaccination of Newborns: Greater protection, stronger primary and secondary immune response and a unique memory T cell profile. Federation of Clinical Immunology Societies, Boston, MA, USA 2008; published in Clinical Immunology 2008 June, (S1) 127:S136. 9. K. Jansen, T.R. Kollmann. High-Throughput Flow Cytometric Analysis of Innate Immune Response to TLR stimulation. NIH meeting on Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations, Maryland, September 2007. 8. D. Blimkie, T.R. Kollmann. Vaccine Response Analysis and Multiplex Assays. CIHR, Toronto, May 2007. 7. L. Hajjar, O. Perwitasari, K. Jansen, T.R. Kollmann, C. Wilson. TLR ligands as vaccine adjuvants in non-human primates. RCE Meeting, St. Louis, MS, 2007. 6. P. Lavoie, C. Pho and T.R. Kollmann. TLR Response of premature infants assessed by Flow Cytometry. Presented at the Canadian Child Health Clinician Scientist Program, Vancouver 2006. 5. H. Goldstein, T.R. Kollmann, N.F. Katapodis, C. Raker, A. Kim, S, Yurasov and M. Petoello-Mantovani. Prevention of HIV infection by treatment of thy/liv SCID-hu mice with combination anti-retroviral therapy. Presented at the Keystone Symposium, 1997. 4. S. Yurasov, T.R. Kollmann, C. Raker, A. Kim, and H. Goldstein. SCID-hu mice as an in vivo model for gene therapy of the human hematopoietic and lymphoid system. British J. Hematology, 1996. 93:338. Presented at the meeting of the European Hematology Association, 1996. 3. H. Goldstein, T.R. Kollmann, A. Kim, M. Pettoello-Mantovani, A. Rubinstein, and M.M. Goldstein. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J. Cellular Biochemistry, 1995:21B:206. 2. T. R. Kollmann, M. M. Goldstein, and H. Goldstein. An animal model for studying the effect of SCID and BNX mice implanted with human fetal thymus and liver: A comparison. Presented at The 7th International Workshop on Immune-Deficient Animals, 1991 1. A. Rubinstein, T. A. Calvelli, T. R. Kollmann, D. Elbaum, and H. Goldstein. Effect of Alkylureas on HTLV-IIIB. Journal of Allergy and Clinical Immunology 1990;87:267. Presented at the American Academy of Allergy and Immunology meeting, 1990.

INVITED SPEAKER OR CHAIR AT INTERNATIONAL SCIENTIFIC MEETINGS 39. “Dissecting the immune response to vaccination in the youngest – do we have the tools?” Royal Society of London, London, November 2014 38. “Approach to Comprehensive Immune Assessment in Newborns and Infants in Large Clinical Trials”. Probiotics to Fight Neonatal Sepsis in Africa, Nairobi, Kenya; July 2014. 37. “MicroResearch – A new era”. Hot Topics in Infectious Diseases in Children, Oxford University, UK; July 2014. 36. “Development of Human Immunity: Implications for Health and Disease”. Keynote Speaker, Canadian National Medical Student Research Symposium, Winnipeg, MB, Canada. June 2014. 35. “A Global Perspective on Molecular Cause & Effect”. Keynote Speaker, Pediatric Resident Research Day, University of Dalhousie, Halifax, NS, Canada. April 2014.

110

34. “Interrogating DOHaD – Common Biology, Immunology, Infection, Inflammation and Microbiome”. Developmental Origins of Health and Disease Meeting, Vancouver, BC, Canada. Februrary, 2014. 33. "Innate Immune Development: A Global View". Canadian Society for Immunology, Whistler, BC, Canada. April 2013. 32. “Innate Immune Development”. AAAAI Annual Meeting. San Antonio, TX, USA. Feb. 2013. 31. ‘Human Innate Immune Development: Windows of Vulnerability - Windows of Opportunity’. Federation of Clinical Immunology Societies (FOCIS) CHIN symposium, Vancouver, BC, June 2012. 30. “Innate Immune Ontogeny”. HIV Vaccine Trial Network, Seattle, WA, USA. May 2012. 29. “What’s Hot in Pediatrics”. Association of Medical Microbiology and Infectious Disease (AMMI); Vancouver, BC, Canada; May 2012. 28. “Ontogeny of the Innate Immune System”. Presented & Session Co-chair at “Development of cellular innate immunity”. U. Freiburg, Germany, Dec. 2011. 27. “Host Environment Interactions in the Ontogeny of the Immune System”. Presented at “The Commensal Microbiota: From Homeostasis to Disease”. College de France, Paris, France. May 2011. 26. “Development of the human immune system”. Montreal General Hospital, Montreal, QB, Canada. March 2011. 25. “Neonatal Immunization”. Montreal Children’s Hospital, Montreal, QB, Canada. March 2011. 24. “Immune Ontogeny”. Royal Melbourne Children’s Hospital, Melbourne Australia, December 2010. 23. “Development of innate immune response to TLR stimulation”. NIAID meeting on ‘Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations’. Washington, DC, December 2010. 22. “Adjuvants”. 9th Canadian Immunization Conference. Chair. Quebec City, ON, December 2010. 21. “Neonatal Vaccines – How Early Can We Start?” Presenter. 48th Annual meeting of the Infectious Disease Society of America. Vancouver, BC. 2010. 20. “H1N1 and HPV: Lessons learned”. Presenter. Annual meeting of the Canadian Pediatric Society. Vancouver, BC, 2010. 19. “Adding Immunological Emphasis: A New Era of Adjuvanted Vaccines”. Presenter. 23rd annual meeting of the Canadian Society for Immunology. Niagra Falls, ON. 2010. 18. “Current Understanding of the Infant Innate Immune Response”. Presenter. NIH Workshop: Challenges in Infant Immunity. Bethesda, MD. 2010. 17. “Development of the human innate immune system”. Presenter. International Neonatal & Maternal Immunization Meeting. Antalya, Turkey, 2010. 16. “Profiling cytokine expression and innate immunity”. Presenter and session moderator; NIAID meeting on ‘Immune Function and Biodefense in Children, Elderly, and Immunocompromised Populations’. Philadelphia, PA, 2009. 15. “Innate Immune Assessment in Mucosal Immunology of the Gut”. Bill & Melinda Gates Foundation. Seattle, WA, 2009. 14. “Adjuvants – The Immunologist’s Secret”. 8th Canadian Immunization Conference. Chair. Toronto, ON. 2008. 13. “Ontogeny of the Human Innate Immune System”. Canadian Child Health Clinician Scientist Program. Edmonton, AB. 2008. 12. “Looking in the Future: Enabling Technology, Automation and HTS”. Foundation Merieux: CMI Techniques Standardization for Vaccine Response Evaluation. Co-Chair Session III. Annecy, Les Pensières, France. 2008. 11. “Innate Immune Assessment’. Foundation Merieux: CMI Techniques Standardization for Vaccine Response Evaluation. Annecy, Les Pensières, France. 2008. 10. “Intelligent Vaccine Design”, CAIRE Master Class, Co-Chair, Vancouver, BC 2008; “Intelligent Vaccine Evaluation”, CAIRE Master Class, Co-Chair. Toronto, ON 2009. 9. “Bioinformatics in High-Throughput Immune Phenotyping”. Neonatal Immunology Workshop. Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium 2008. 8. “Ontogeny of the Human Innate Immune System”. University of Cape Town Lecture Series, Cape Town, South Africa. 2008. 7. ‘How we respond to vaccines’. 11th annual Child Health Research Symposium (MOCERT accredited), Alberta Children’s Hospital, Calgary, UB. Feb 2008. 6. ‘Induction of Protective Immunity in Neonates. VIDO, Saskatoon, SK. June 2007. 5. ‘High-Throughput Immune Phenotyping’. “From Gene to Society’ meeting, Allergen NCE, Hamilton, ON. 2007. 4. “Multiparameter Immune Phenotyping’. South African TB Vaccine Initiative, Cape Town, South Africa. 2007.

111

3. “Assessment of Neonatal TLR Response”. NIH meeting on Immune Function and Biodefense in Children, Elderly and Immunocompromised Populations, Maryland 2006; 2007; 2008. 2. “T cell Immunity in Infants and Immune System Overload Hypothesis”. Institute of Medicine (IOM), Immunization Safety Review Committee, 2001, Seattle, WA. 1. “Effect of IL-3, GM-CSF and IL-6 on the engraftment of human fetal bone marrow in scid mice”. The SCID Mouse in Biomedical and Agricultural Research, 1992, Canada.

ORGANIZER OF INTERNATIONAL & NATIONAL MEETINGS 8. Probiotics to Fight Neonatal Sepsis in Africa. Nairobi, Kenya; August 2014. 7. 1st African Microbiome Conference. Nairobi, November 2013 (co-organized with G. Reid). 6. 10th Canadian Immunization Conference. ‘Correlates of Protection’. Session Chair. Vancouver, December 2012. 5. 9th Canadian Immunization Conference. ‘Advances in Adjuvants’. Session Chair & Presenter. Quebec City, December 2010. 4. 8th Canadian Immunization Conference. ‘Adjuvants’. Session Chair. Toronto, December 2008. 3. Bioinformatics Meeting Series: ‘Addressing the High-Throughput Statistical and Analytical Needs of Vaccine Trials and Cohort Studies’. Vancouver, November 2008. 2. Canadian Immunization Research Network (CAIRE); Master Class Series: ‘Intelligent Vaccine Evaluation’, November 2008. 1. Canadian Immunization Research Network (CAIRE); Master Class Series: ‘Intelligent Vaccine Design’, February 2008.

INVITED REVIEWER OR CONSULTANT 1. Bill & Melinda Gates Foundation: Lead investigator for ‘Landscape Analysis of Immunology Research Gaps Related to Maternal Immunization’; February 2015 – present. 2. Editorial Board: Clinical and Vaccine Immunology (2015 – present) 3. Academic Editor: PLoS ONE (2012-present) 4. Guest Editor: Vaccine, March 2012; Clinical & Developmental Immunology, January 2013; Frontiers in Immunology, December 2013. 5. Journal Reviewer: Nature Review Immunology; Nature Protocols; Blood, PLoS ONE, Journal of Immunology, Journal of Infectious Disease, Vaccine, Human Immunology, Journal of Perinatology, Pediatric Infectious Disease Journal, Pediatric Research, Mucosal Immunology, Trends in Immunology, Infection & Immunity; European Journal of Immunology; Gut & Microbe; Clinical & Experimental Allergy; Acta Paediatrica; British Medical Journal, Scientific Reports Nature.

6. UBC & British Columbia: Internal Grant Reviewer: UBC. 2007- present; Internal Tier 2 Canada Research Chair Competition Reviewer, UBC 2012. Michael Smith Foundation for Health Research (MSFHR) Research Trainee – Biomedical Graduate Studentship Evaluation Committee, UBC; 2009; 2014 – present, Advisory Board Member, Neglected Global Disease Initiative (NGDI), UBC.

7. Canada: a) CIHR Respiratory System Grants Committee; 2013 - present (2 sessions/year). b) CIHR Biological and Clinical Aspects of Aging-A (BCA) Peer Review Committee, 2009. c) Alberta Innovates Health Solutions, Peer Review Committee; 2012. d) Association of Medical Microbiology and Infectious Disease Canada (AMMI) Grants and Awards Committee; 2012- present.

8. USA: a) Member, External Advisory Board (EAB), U.S. National Institute of Allergy and Infectious Disease (NIAID), Bioinformatics Integration Support Contract (BISC) program, 2009present. b) Invited Member, NIH Review Panel, Recovery Act Limited Competition: Protection of Human Health by Immunology and Vaccines (U01, U19), May 2010. c) Invited Reviewer, NIAID Human Immunology Project Consortium (HIPC); July 2011. d) Invited Member, Review Panel, Multiproject Grant Applications (U19), NIAID Centers of Excellence in Translational Research, June 2013. e) Invited Member, Review Panel, Multi-project Grant Applications (U19), NIAID Cooperative Centers on Human Immunology; January 2014. 112

9. International: a) Welcome Trust, UK, 2012; b) South Africa’s National Research Foundation, 2009- present; c) Swiss National Science Foundation, 2012; d) Hong-Kong Research Grants Council, 2013; e) The Netherlands Organisation for Health Research and Development, 2014; f) The UK Meningitis Research Foundation (2014) 10. Other: Promotion and tenure dossiers Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center.

CONTACT DETAILS Dr. Tobias R. Kollmann MDPhD CFRI A5-147; 950 W 28th Ave Vancouver, BC, V5Z 4H4; Canada Ph: 604-875-2466 Fax: 604-875-2226 Email: [email protected]

113

Marchant Arnaud CURRICULUM VITAE

Name: Arnaud Marchant

Birth date: 9/11/1965 Citizenship: Belgian

Address: Institute for Medical Immunology Université Libre de Bruxelles Rue Adrienne Bolland, 8 6041 Gosselies, Belgium e-mail: [email protected]

Degrees, education

Medical School: 1983-1990: Université Libre de Bruxelles Clinical Pathology : 1990-1998, Université Libre de Bruxelles PhD, Immunology : 1996, Université Libre de Bruxelles

Current appointment

Senior research associate, National Fund for Scientific Research, Belgium, October 2006.

Previous appointments

Resident in the Department of Immunology, Haematology, Transfusion, Hopital Erasme, Brussels, October 1990 – March 1991. Resident in the Department of Bacteriology, Hopital Erasme, Brussels, April 1991 – September 1991. Resident in the Department of Clinical Chemistry, Hopital Erasme, Brussels, October 1991 – March 1992. Resident in the Department of Immunology, Haematology, Transfusion, Hopital Erasme, Brussels, April 1992 – September 1992. Research assistant for the Belgian National Fund of Scientific Research, October 1992 - January 1996. Research associate, MRC Laboratories, The Gambia, January 1996 – tenured position from March 2000. Seconded to the Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK, January 2001-July 2003. Research associate, National Fund for Scientific Research, Belgium, tenured position from October 2002October 2006. Chief Scientific Officer, ImmuneHealth, Belgium, March 2007-December 2014.

Teaching

Medical immunology, Biomedical Sciences, University Libre de Bruxelles, 2010 - present Chairman of the Higher Degrees Committee, MRC Laboratories, The Gambia, 1998 – 2000

Supervision of PhD students :

- Mr Ousman Jobe : « Effects of tuberculosis on HIV disease progression », Open University, United Kingdom, 2001. - Dr Johan Vekemans : « T lymphocyte responses to BCG vaccination in newborns », Université Libre de Bruxelles, 2001. - Dr Martin Ota : «Immune responses to vaccines in early life», Open University, United Kingdom, 2002.

114

- Ms Joelle Renneson : « Activation of antigen-specific CD8+ T lymphocytes by neonatal dendritic cells », Université Libre de Bruxelles, 2007. - Dr Muriel Stubbe: Differentiation of CD4 T lymphocyte sub-populations following immunisation in humans ». Université Libre de Bruxelles, 2007. - Ms Ariane Huygens: «Cell mediated immune response to CMV infection in utero», Université Libre de Bruxelles, 2013. - Dr Pierre Antoine : «Pathogenesis of mother to child transmission of CMV», Université Libre de Bruxelles, 2014. - Dr Nicolas Twité : « Immune mechanisms controlling cytomegalovirus replication in human epithelial cells », Université Libre de Bruxelles. - Dr Nicolas Dauby: «B lymphocyte response to CMV infection», Université Libre de Bruxelles. - Dr Yasmina Serroukh: “Transcriptional control of cytolytic CD4 T cell functions”, Université Libre de Bruxelles.

National and international courses:

- Université Libre de Bruxelles: Post-Graduate Programme in Pharmaceutical Medicine and Medicines Development Sciences “Pharmed”, 2010/2011/2012/2013. - Université Libre de Bruxelles, Biopark Formation: “L’immunologie pour les non immunologistes”, 2012. - Advanced WHO/TDR Course on Immunology, Vaccinology and Biotechnology Applied to Tuberculosis, 2011. - Pasteur Institute, Paris: Vaccinology Course, 2011/2012/2013/2014/2015. - HKU-Pasteur Research Centre, Hong-Kong : Immunology Course, 2011/2014. - University of Sienna: Master in Vaccinology, 2011/2013. - ESCMID course on Infectious Diseases in pregnant women, fetuses and newborns, Bertinoro, 2010/2013. - College de France, Paris: Cours de Microbiologie et Maladies Infectieuses du Professeur Sansonetti, 2012. - Université Pierre et Marie Curie, Paris: Master in anti-viral immunity, 2012/2013/2014. - Ecole Normale Supérieure de Lyon: Master in Biosciences. Integrative Cell Biology and Immunology: From Homeostasis to Diseases, 2014/2015.

115

Martinez-Picado Javier

116

Moulin Anne-Marie

117

118

119

Papaevangelou Vana Associate Professor in Pediatrics, National and Kapodistrian University of Athens, Athens, Greece

Professor Vana Papaevangelou is a trained paediatrician, with a special interest in paediatric infectious diseases. After completing her paediatric residency and PID fellowship at the NYU Medical Centre, USA, she returned to Athens Greece and has been a full time clinical paediatrician in a tertiary teaching hospital since 1996. During this time she has been caring for general paediatric cases (40%) and children with infectious diseases (60%). Professor Papaevangelou has been actively involved in the education of medical students and paediatric residents while since 2006, she has also been responsible for the paediatric resident curriculum in her department. Over the past 20 years, Professor Papaevangelou has been actively involved in multiple research projects. During recent years, her main interests have involved the epidemiology of vaccinepreventable diseases (hepatitis A and B, varicella, measles) and vertical transmission of infections, such as HBV, HCV and CMV. She is a member of the National Hepatitis Board and the Viral Hepatitis Prevention Board. Professor Papaevangelou has published more than 65 papers in peer-reviewed journals.

120

Pashov Anastas Curriculum Vitae

Anastas D. Pashov, M.D., Ph.D. Laboratory of Experimental Immunotherapy Institute of Microbiology, Bulgarian Academy of Sciences Acad. G. Bonchev St., block 26, 1113 Sofia Phone: (+359-2) 979 6348 (+359) 897944628 Fax: (+359-2) 8700109 [email protected] [email protected] ______

Marital Status – Married, two children.

Education

Ph.D.(immunology), National Center for Infectious and Parasitic Diseases, Sofia, Bulgaria 1990-1995 (information in the databases of NCID, ID Number: 90024909) M.D. magna cum laude, Medical University, Sofia, Bulgaria 1983-1989

Languages Bulgarian - native English – fluent spoken and written French – spoken Russian- spoken

Appointments Senior research fellow 2010-current Stephan Angeloff Institute of Microbiology at The Bulgarian Academy of Sciences, Sofia, Bulgaria Senior research fellow 2000-2006 Institute of Biology and Immunology of Reproduction at The Bulgarian Academy of Sciences, Sofia, Bulgaria Research of scientist 1998-2000 Institute of Biology and Immunology Reproduction, at The Bulgarian Academy of Sciences, Sofia, Bulgaria

Other Positions and Employment CDD at INSERM UMRS 872(Eq.16), Centre de Recherche des Cordeliers 2010/2012/ 2013 Postdoctoral fellow University of Arkansas for Medical Sciences, Little Rock, AR 2003-2009

Visiting scientist 1996-1997 U430 INSERM, Paris, France and 2002

Certification 121

Senior research fellow (second degree) cert. N 20252 / 09/07/2000 Bulgarian Higher 2000 Certifying Commission, Sofia, Bulgaria GLP course, UAMS, Little Rock. AR

2006

Professional Memberships and Activities Bulgarian Immunological Society Bulgarian 1998- Biomath Society 2010-

Educational Activities Scientific adviser of Ph. D. thesis - 2 student 1997-2001, 2010-current Scientific adviser of master’s thesis – 3 students 1999-2001, 2010-2012

2014 A course in Tumor Immunology in the framework of grant №BG051PO001-3.3.06-0059, financed

by the European Social Fund and Operational Program Human Resources Development

A course in Tumor Immunology in the Master’s Program at the Biology Faculty of Sofia University

2014/2015 Projects Physiological role and therapeutic potential of antibodies with induced polyspecificity. Bulgarian 2015-2016 Scientific Research Fund. PI: Tchavdar Vassilev

Design of modified immunoglobulin preparations with additionally induced polyspecificity 2012-2015 for passive immunotherapy of sepsis. IZEBZ0_142967 from the Swiss NSF, PI: Tchavdar

Vassilev

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk (ABIRISK). Consortium in the framework of IMI, participation as collaborator in WP3 on 2012-2017 behalf of INSERM UMRS872

Translational study on the antigen presenting properties of human vs mouse B cell subpopulations. Marie Curie International Reintegration Grants (IRG) Call: FP7-PEOPLE-RG- 2010-2013 2009, PI

Mimotope Conversion of HIV-1 Carbohydrate Antigens. NIH grant CA-089480, PI : Thomas Kieber-Emmons

Comparative characteristics of natural and disease associated anti-HSP90 autoantibodies. grant: 2002-2007 К702 (Bulgarian Ministry of Education, Science and Technology). – PI

Immunomodulatory activity of antibodies binding heat shock proteins found in therapeutic 1997-2000 preparations of immunoglobulins. grant REO-4E007C (East-West Network project, INSERM,

France) . – PI

Immunomodulatory activity of anti-HSP antibodies in therapeutic immunoglobulin. NATO Linkage 1998-1999 Grant No 971245. – PI

1999

Publications from the last 5 years

1. Schneider C, Smith DF, Cummings RD, Boligan KF, Hamilton RG, Bochner BS, Miescher S, Simon H-U, Pashov A, Vassilev T, von Gunten S. 2015. The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Science Translational Medicine 7: 269ra1

122

2. Lecerf M, Scheel T, Pashov AD, Jarossay A, Ohayon D, Planchais C, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. 2015. Prevalence and Gene Characteristics of Antibodies with Cofactorinduced HIV-1 Specificity. J Biol Chem, Jan 6. pii: jbc.M114.618124. [Epub ahead of print] 3. Saha S, Pashov A, Siegel ER, Murali R, Kieber-Emmons T. 2014. Defining the recognition elements of lewis y-reactive antibodies. PLoS One 9: e104208 4. Pashova S, Dobrev K, Pashov A. 2014. Rregulatory Properties of Mouse Transitional 1 B Lymphocytes. Comptes rendus de l'Academie bulgare des Sciences 67: 361-6 5. Pashov AD, Calvez T, Gilardin L, Maillere B, Repesse Y, Oldenburg J, Pavlova A, Kaveri SV, LacroixDesmazes S. 2014. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia 20: 176-84 6. Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT. 2014. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign? J Am Soc Nephrol 25: 2053-65 7. Kieber-Emmons T, Saha S, Pashov A, Monzavi-Karbassi B, Murali R. 2014. Carbohydrate-mimetic peptides for pan anti-tumor responses. Front Immunol 5: 308 8. Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. 2013. Tumor-Associated Glycans and Immune Surveillance. Vaccines 1: 174-203 9. Djoumerska-Alexieva I, Pashova S, Vassilev T, Pashov A. 2013. The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun Rev 12: 653- 6 10. Saha S, Pashov A, Monzavi-Karbassi B, Kieber-Emmons AM, Otaki A, Murali R, Kieber-Emmons T. 2012. Carbohydrate Mimetic Peptide Vaccines. In Anticarbohydrate Antibodies, ed. P Kosma, S Müller-Loennies, pp. 229- 54. Vienna: Springer 11. Kieber-Emmons T, Monzavi-Karbassi B, Pashov A, Saha S, Murali R, Kohler H. 2012. The promise of the anti-idiotype concept. Front Oncol 2: 196 12. Dimitrov JD, Pashov A, Vassilev T. 2012. Antibody Polyspecificity: What Does It Matter? In Naturally Occurring Antibodies (NAbs), ed. HU Lutz, pp. 268. Austin, TX: Springer 13. Pashov A, Monzavi-Karbassi B, Kieber-Emmons T. 2011. Glycan mediated immune responses to tumor cells. Hum Vaccin 7: 156-65 14. Pashov A, Delignat S, Bayry J, Kaveri SV. 2011. Enhancement of the Affinity of Glucocorticoid Receptors as a Mechanism Underlying the Steroid-sparing Effect of Intravenous Immunoglobulin. The Journal of Rheumatology 38: 2275 15. Hennings L, Artaud C, Jousheghany F, Monzavi-Karbassi B, Pashov A, Kieber-Emmons T. 2011. Carbohydrate Mimetic Peptides Augment Carbohydrate-Reactive Immune Responses in the Absence of Immune Pathology. Cancers 3: 4151-69 16. Todorova VK, Klimberg VS, Hennings L, Kieber-Emmons T, Pashov A. 2010. Immunomodulatory effects of radiofrequency ablation in a breast cancer model. Immunol Invest 39: 74-92 17. Pashov A, Monzavi-Karbassi B, Raghava GP, Kieber-Emmons T. 2010. Bridging innate and adaptive antitumor immunity targeting glycans. J Biomed Biotechnol 2010: 354068 18. Dimitrov JD, Planchais C, Kang J, Pashov A, Vassilev TL, Kaveri SV, Lacroix-Desmazes S. 2010. Heterogeneous antigen recognition behavior of induced polyspecific antibodies. Biochemical and Biophysical Research Communications 398: 266-71

123

Plotkin Stanley A.

Dr. Stanley A. Plotkin is Emeritus Professor of the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. He maintained laboratories at both CHOP and Wistar. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer, Pasteur-Mérieux-Connaught (now called Sanofi Pasteur), where for seven years he was Medical and Scientific Director, based at Marnes-la-Coquette, outside Paris. He is consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations as principal of Vaxconsult.

Dr. Plotkin attended New York University, where he received a B.A. degree, and then the State University of New York Medical School in Brooklyn, where he received an M.D. degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service.

He has been chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. Dr. Plotkin received the Bruce Medal in Preventive Medicine of the American College of Physicians, the Distinguished Physician Award of the Pediatric Infectious Diseases Society, the Clinical Virology Award of the Pan American Society for Clinical Virology, the Richard Day Master Teacher in Pediatrics Award of the Alumni Association of New York Downstate Medical College, and the Marshall Award of the European Society for Pediatric Infectious Diseases. In June 1998, he received the French Legion of Honor Medal; in June 2001, the Distinguished Alumnus Award of the Children’s Hospital of Philadelphia, in September 2006 the gold medal from the same hospital; the Sabin Gold Medal in May 2002, in September 2004 the Fleming (Bristol) Award of the Infectious Diseases Society of America, in May 2007 the medal of the Fondation Mérieux, in 2009 the Finland Award of the National Foundation for Infectious Diseases and the Hilleman Award of the American Society for Microbiology, and in 2013 the Career Achievement Award from the Association for Clincal and Translational Medicine, as well as the Caspar Wistar Medal of the Wistar Institute of Biological Research In 2014 he received the Charles Mérieux Award of the National Foundation for Infectious Diseases and the Sheikh Hamdan (Dubai) Award for Medical Sciences. He was elected to the Institute of Medicine of the National Academy of Sciences in 2005, to the French Academy of Medicine in 2007, to the French Academy of Pharmacy in 2013, and to the Thai Pediatric Infectious Diseases Society in 1915. He is a Fellow of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, the American Academy of Pediatrics and the International Society for Vaccines. Dr. Plotkin holds honorary doctoral degrees from the University of Rouen (France) and the Complutense University of Madrid (Spain). Named lectures in his honor have been established at the Pediatric Academic Societies annual meeting, at the International Advanced Vaccinology Course in Annecy, France, and at the DNA Vaccines Society. A professorship in his name was established at the Children’s Hospital of Philadelphia. His bibliography includes over 700 articles and he has edited several books including the standard textbook on vaccines, now in its 6th edition. He developed the rubella vaccine now in standard use throughout the world, is codeveloper of the pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.

125

[email protected]

Emeritus Professor of Pediatrics, University of Pennsylvania Emeritus Professor of Wistar Institute Adjunct Professor of International Health, Johns Hopkins University Vaxconsult LLC.

Office & Home Address : 4650 Wismer Road Work Telephone : (215) 297-9321 Doylestown, PA 18902 Fax : (215) 297-9323 U.S.A. E-mail: [email protected]

Date of Birth: May 12, 1932 Place of Birth New York, New York Marital Status: Married to Susan Lannon Plotkin Children: Michael, Alec Education: 1948-1952 BA New York University 1952-1956 MD S.U.N.Y College of Medicine, Brooklyn

Postgraduate Training and Fellowship Appointments:

1956-1957 Rotating Internship, Cleveland Metropolitan Hospital 1961-1962 Resident in Pediatrics, Children's Hospital of Philadelphia 1962-1963 Resident in Pediatrics, Hospital for Sick Children, London

Government Service:

1957-60 Senior Assistant Surgeon, Epidemic Intelligence Service, USPHS

Specialty Certification:

1965 American Board of Pediatrics 1988 Pediatric Infectious Diseases Society

Licensure: Pennsylvania, License 5289E

Faculty Appointments:

1959-61 Instructor in Pediatrics, University of Pennsylvania, Philadelphia 1960-61 Associate Member, Wistar Institute of Anatomy and Biology, Philadelphia

126

1963-74 Associate Member, Wistar Institute of Anatomy and Biology, Phil 1964-65 Associate in Pediatrics, University of Pennsylvania, Philadelphia 1966-71 Assistant Professor of Pediatrics, University of Pennsylvania, Phil. 1971-74 Associate Professor of Pediatrics, University of Pennsylvania, Phil. 1974-77 Member, Wistar Institute of Anatomy and Biology, Philadelphia 1974-91 Professor of Pediatrics, University of Pennsylvania, Philadelphia 1977-91 Professor, Wistar Institute of Anatomy and Biology, Philadelphia 1981-91 Professor of Microbiology, University of Pennsylvania, Philadelphia 1991- Professor Emeritus of Pediatrics, University of Pennsylvania, Phil. 1991 Professor Emeritus of Virology, Wistar Institute 1998-2010 Advisor, International AIDS Vaccine Initiative 2002- Adjunct Professor of International Health, Johns Hopkins University 2002- Board Member, Pediatric Dengue Vaccine Initiative,

Hospital and Administrative Appointments:

1965-73 Associate Physician, Children's Hospital of Philadelphia 1969-90 Director, Division of Infectious Diseases, Children's Hospital of Philadelphia 1973-91 Senior Physician, Children's Hospital of Philadelphia 1978-90 Chief, Infection Control Department, Children's Hospital of Philadelphia 1984-86 President, Medical Staff, Children's Hospital of Philadelphia Associate Chairman, Department of Pediatrics, Univ. of Pennsylvania

Positions in Industry:

1991-97 Medical and Scientific Director, Pasteur Mérieux Connaught Vaccines, Paris 1997-2009 Executive Advisor to CEO, Sanofi Pasteur

Awards:

James D. Bruce Award for Preventive Medicine, from American College of Physicians, 1987 Distinguished Physician Award, Pediatric Infectious Diseases Society, 1993 Clinical Virology Award, Pan American Group for Rapid Viral Diagnosis, 1995 French Legion of Honor Medal (Chevalier), 1998 Distinguished Alumnus Award of the Children’s Hospital of Philadelphia, 2001 Sabin Foundation Gold Medal, 2002 Fleming (Bristol) Award of the Infectious Diseases Society of America, 2004 Honorary Lifetime Member, Assoc. of Pharmaceutical Physicians and Investigators, 2005 Elected to Institute of Medicine, National Academy of Sciences, 2005 Distinguished Alumnus, University of Pennsylvania, 2006 Marshall Award, European Society of Pediatric Infectious Diseases, 2006 Children’s Hospital of Philadelphia, Gold Metal, 2006 127

Fondation Mérieux Medal, 2007 Richard Day Master Teacher in Pediatrics Award of the Alumni Association of New York Downstate Medical College Elected to French National Academy of Medicine in 2007 Honorary degrees from the University of Pennsylvania, the University of Rouen (France), and the University Complutense of Madrid Maxwell Finland Award, National Foundation Infectious Diseases, 2009 Maurice Hilleman Award in Vaccinology, American Society Microbiology, 2009 Career Award, Association for Clinical and Translational Medicine, 2013 Caspar Wistar Award, Wistar Instititue of Biological Research, 2013

Honors:

Founding President, Pediatric Infectious Diseases Club, 1978-83 Trustee and Founding Father, Pediatric Infectious Diseases Society, 1983- Committee on Infectious Diseases, American Academy of Pediatrics, 1982-1990 Chairman, Committee on Infectious Diseases, American Academy of Pediatrics, 1987-1990 Liaison member of the Advisory Committee on Immunization Practices, 1987-1990 Chairman, Task Force on Pediatrics AIDS, American Academy of Pediatrics, 1988-1992 Microbiology and Infectious Diseases Research Committee, NIH 1983-87 Chairman, Microbiology and Infectious Diseases Research Committee, NIH, 1986-1987 Member, National Vaccine Advisory Committee (Dept. of Health and Human Services), 1988-1989 and 1997 - President, Pan American Group for Rapid Viral Diagnosis, 1983-1986 Who's Who in America, 1978- Who’s Who in the World, 1999- Trustee, Pennsylvania Pro Musica, 1983-1986 Arthur K. Saz Lecturer, Georgetown University, 1986 Haker Lecturer, Milwaukee Children's Hospital, 1987 Hattie Alexander Lecturer, Columbia University Babies Hospital, 1988 Neter Lecturer, Buffalo Children's Hospital, 1989 Krugman Lecturer, New York University Medical Center, 2005 Wanamaker Lecturer, University of Maryland, 2005 President, World Society for Pediatric Infectious Diseases, 2003- Elected Fellow American Association for the Advancement of Science, 2003- Stanley A. Plotkin endowed lectureship at Pediatric Academic Societies, 2004- Stanley A. Plotkin lectureship in International Advanced Vaccinology Course, Annecy, France 2007- Stanley A. Plotkin lectureship in Vaccinology, DNA Vaccine Society, 2010- Stanley A. Plotkin Professorship, Children’s Hospital of Philadelphia, 2010-

Memberships in Professional and Scientific Societies:

128

American Academy of the Advancement of Science Society for Pediatric Research American Society for Microbiology Infectious Diseases Society of America American Epidemiologic Society American Association of Immunologists American Society for Virology Pan American Group for Rapid Viral Diagnosis Pediatric Infectious Disease Society Philadelphia College of Physicians Pennsylvania Medical Society European Society for Clinical Virology (Corresponding Member) European Society for Pediatric Infectious Diseases

Editorial Positions: Past American Journal of Epidemiology Clinical Pediatrics Pediatric Infectious Diseases Proceedings of the Society for Experimental Biology and Medicine Annales de l'Institut Pasteur (Virology) Molecular and Cellular Probes Infectious Agents and Diseases Perspectives in Infectious Diseases Current Vaccine (American Editor) until 1991, Editorial Board 1991- Human Vaccines Clinical Infectious Diseases (Section Editor) Clinical & Vaccine Immunology (Section Editor) Biologicals (Section Editor) J Human Virology Virologie Vacunas

Books Edited Vaccines, 1st Ed. 1988. W.B. Saunders 2nd Ed. 1994 ” ” 3nd Ed. 1999 ” ” 4th Ed.. 2003 Elsevier 5th Ed. 2008 Saunders-Elsevier 6th Ed. 2013, Elsevier 129

Multidisciplinary Approach to Understanding Cytomegalovirus Disease, 1993, Excerpta Medica Vaccinia, Vaccination, Virology 1995, Elsevier The World’s Debt to Pasteur 1985, Wistar Institute Press Strains of Human Viruses 1972, Karger History of Vaccine Development, 2011, Springer

Principal Investigator of Grants : (In 1990, before leaving University of PA) Prevention of CMV Disease, NIH-RO1-HD18957-22 Virology and Infectious Diseases (Training Grant), NIH-5-732-AIO7278-05 Live Attenuated Cytomegalovirus Vaccine, NIH-FO-R-000267-02 Enhancement of HIV Infection by Cytomegalovirus, NIH-RO1-AI25822-02 Role of HIV in AIDS and AIDS Associated Neoplasms, NIH-5-PO1-AI25380-02 AIDS Research Laboratory, Brandywine Valley Hemophilia Foundation Mérieux Cytomegalovirus Project, Mérieux Institute Mérieux Rotavirus Project, Mérieux Institute

Major Teaching and Clinical Responsibilities at the University of Pennsylvania : 1. Infectious Diseases attending 3 months/year (before 1991) 2. General Pediatrics attending, 1 month/year (before 1991) 3. Pediatric infectious diseases (PE365) teacher (before 1991) 4. Lecturer in Mechanisms of Infection course in Microbiology (before 1991) 5. Lecturer in Infectious Diseases (current) 6. Lecturer in Vaccinology (current)

Vaccines Developed: Rubella vaccine, RA27/3 strain: now manufactured and used in the United States and throughout the world. Cytomegalovirus vaccine, Towne strain Type 3 polio vaccine, WM-3 further attenuated strain Varicella vaccine, Webster strain Rabies vaccine, human diploid cell (assisted H. Koprowski and T. Wiktor) Rotavirus vaccine, WC3 bovine-human pentavalent reassortants (with HF Clark and P Offit), Now licensed as RotaTeq.

130

Scheifele David

University of British Columbia Curriculum Vitae for Faculty Members

Date: January 20, 2015 Initial:

FIRST NAME: David MIDDLE NAME(S): W

1. SURNAME: Scheifele 2. DEPARTMENT/SCHOOL: Pediatrics 3. FACULTY: Medicine JOINT APPOINTMENTS:

4. PRESENT RANK: Professor SINCE: Jul 1, 1987 5. POST-SECONDARY EDUCATION (a)

University or Institution Degree Subject Area Dates University of Western Ontario MD Medicine 1969 (b) Title of Dissertation and Name of Supervisor (c) Continuing Education or Training (d) Continuing Medical Education (e) Professional Qualifications

1 Pediatrics, McGill University Medical School 1970-1974 2 Infectious Diseases, Harvard Medical School 1974-1977 3 Certificate of the Royal College of Physicians & Surgeons (Pediatrics) 1976 4 Certified Specialist in Pediatrics, Corporation of Physicians of Quebec 1976 5 Fellow, Infectious Disease Society of America 1987 6 Fellow, Pediatric Infectious Disease Society 1992 7 Fellow, Royal College of Physicians and Surgeons of Canada, 2010

6. EMPLOYMENT RECORD Prior

University, Company or Organization Rank or title Dates University of Nairobi Medical School Lecturer 1972-1993

Medical Research Council Fellow 1974-1977

131

Instructor, Pediatrics 1975-1977

Harvard Medical School (Children's Hospital)

Present University, Company or Organization Rank or title Dates At UBC (since first employment) University of British Columbia Assistant Professor 1977

Division Head 1981-1990 Division of Infectious Diseases, Dept.of Pediatrics, UBC

University of British Columbia Associate Professor 1982

University of British Columbia Professor 1987

Vaccine Evaluation Center Director 1989-present

BC Research Institute for Child & Family Health Associate Director 1996-1998

UBC, Department of Pediatrics Assistant Head 1997-1998

1997-2005

University of British Columbia Sauder Family Chair in Pediatric Infectious Diseases

University of British Columbia Courtesy Member, UBC, Centre for 2001 -present Disease Control

CIHR/Wyeth Chair in Clinical Vaccine 2005-2010 Research c) Date of granting tenure at UBC: 1982

7. TEACHING (a) Areas of special interest and accomplishments As the first member of the Pediatric Infectious Diseases (PID) division at BC Children’s Hospital (1977), I had the opportunity to introduce this subspecialty to the larger pediatric community and to trainees, teaching by example. My signature was the “informative consultation report” that explained my reasoning in reaching a likely diagnosis and for selecting particular tests and medications. I established the Royal College approved PID training program at BCCH (1985), which has thrived to the present. I have particularly enjoyed teaching these clinical trainees, helping them to understand the disease mechanisms that shape the clinical presentation of infectious diseases. My abiding interest in PID has been 132

understanding disease mechanisms and demonstrating to trainees how such understanding helps to make sense of disease states and aids recollection of presenting symptoms and signs on subsequent encounters. I enjoy teaching at the bedside and use a Socratic approach whenever feasible to help learners focus on key issues and develop insight into case management. I have been honored to receive a number of teaching awards and especially value those from trainees and the Faculty of Medicine. Equally satisfying has been observing the success of graduates from our PID training program, who have taken up academic positions around the globe, including Oxford, Melbourne, Singapore, Jeddah and Kuwait City. I have been very open to providing continuing medical education lectures relating to pediatric infections and immunization. I have been frequently invited to lecture at conferences hosted by the Canadian Paediatric Society, receiving good evaluations from attendees. I received the CPS Ross award for distinguished contributions to the Society and to child health. I have been a speaker at almost every Canadian Immunization Conference since that biannual event started in 1988 and was honored to deliver the Distinguished Lecture in 2010. I have delivered a number of other prestigious lectures including the Royal College Lecture at a CPS Annual Conference, the John Waters Memorial Lecture at the Canadian Immunization Conference and the Grant Gall lecture at the University of Calgary (2 occasions).

I have been a regular lecturer to 3rd Year medical students during their pediatric rotation (describing common infections in children) and to their OSCE exam at rotation-end. I have repeatedly contributed to the academic lecture series of the Pediatric residents and to numerous Advances, Grand Rounds and OSCEs. Within CFRI I have aided with formal teaching of summer students and highschool students interested in science careers. I have been a regular contributor to the weekly academic rounds of the PID division, both as presenter and questioner. I have particularly enjoyed the opportunity to mentor research trainees in vaccinology (S Wootton, M Dawar, K Lapphra, M Al-Dabbagh, M Pinto) and junior faculty in PID (J Bettinger, TKollmann in the Canadian Clinician Scientist Training program).

My one regret as an educator was that being in a clinical department limited my opportunities to supervise graduate students although latterly I have enjoyed participating in the advisory committees of several MSc and PhD students.

(b) Courses Taught at UBC:

Scheduled Class Hours Year Session Course Number Hours Size Taught Lecture Tutorials Labs Other

(c) Graduate Students supervised at UBC: Student Name Program Type Year Principal Supervisor Co-Supervisors Start Finish S. Champagne Subspecialty 1981 1983 D. Scheifele Resident J.C. Forbes Subspecialty 1983 1985 D. Scheifele Resident R. Pennie Subspecialty 1985 1986 D. Scheifele Resident E. Wilson Subspecialty 1986 1987 D. Scheifele Resident A. McKevitt Post-doctoral 1987 1989 D. Scheifele A. Al-Mazrou Subspecialty 1989 1991 D. Scheifele Resident J. Finlay Subspecialty 1990 1992 D. Scheifele Resident M. Jones Subspecialty 1991 1993 D. Speert D. Scheifele Resident M. Watson Subspecialty 1992 1994 D. Speert D. Scheifele Resident G. Liu Subspecialty 1994 1995 S. Dobson D. Scheifele Resident H. Hui Subspecialty 1995 1996 S. Dobson D. Scheifele Resident T. Tam Subspecialty 1995 1997 D. Scheifele S. Dobson 133

Resident D. Greenberg Subspecialty 1997 1999 D. Speert D. Scheifele Resident J. Balfour Subspecialty 1998 1999 S. Dobson D. Scheifele Resident E. Hussein Subspecialty 1999 2001 S. Dobson D. Scheifele Resident A. Pollard Subspecialty 1999 2001 S. Dobson D. Scheifele Resident R. Ulloa-Gutierrez Post-doctoral 2003 2005 D. Scheifele S. Dobson Fellow J. Bettinger Post-doctoral 2003 2005 D. Scheifele Fellow S. Wootton Post-doctoral 2005 2006 D. Scheifele Fellow M. Dawar Field Epidemiology 2006 2008 D. Scheifele S. Wootton trainee L. Sauvé Post-doctoral 2008 D. Scheifele Fellow K. Lapphra Post-doctoral 2010 2012 D. Scheifele J. Bettinger Fellow M. Al-Dabbagh Post-doctoral 2010 2011 D. Scheifele J. Bettinger Fellow

M. Pinto Post-doctoral 2014 2016 D. Scheifele Fellow

Graduate Students at UBC, continued K Smolen PhD program 2011 2014 T. Kollmann D Scheifele, adv. cttee K Wee MSc program 2012 2014 T. Kollmann D Scheifele, adv. cttee

(d) Continuing Education Activities from 2010 106 CAIRE Masters Class on Optimizing Vaccine Surveillance and Investigation, Ottawa, April 2010. Co-chair, planning committee. Ontario Agency for Health Protection First Annual Vaccine Symposium, Toronto (April 2010) 107 CAIRE Masters Class on Improving Adult Immunization, Ottawa, October 2010. Co-chair, planning committee 108 Distinguished Lecturer, 9th Canadian Immunization Conference, Quebec City, December, 2010 109 Royal College Lecture, Canadian Paediatric Society 88th Annual Conference, Quebec City, June 2011. Invited lecturer 110 CPS Immunization competency course, Banff, December 2011 111 Western Canadian Immunization forum, Vancouver, December, 2011 112 Fraser Health Authority Immunization Update, Langley, March, 2012 113 National Immunization Conference, Darwin, Australia, June, 2012. Keynote speaker 114 CAIRE Symposium on Vaccine Education (co-chair), Ottawa, January, 2012 115 CAIRE Workshop on Recommended but Unfunded Vaccines, Ottawa, November, 2012 (co-chair) 116 Invited lecturer, 10th Canadian Immunization Conference, Vancouver, December, 2012 117 Invited speaker, Canadian Immunization Research Workshop, Ottawa, March, 2013 118 Canadian Immunization Competencies course, invited faculty. Toronto, April, 2013 119 Invited speaker, PHAC/CIHR Influenza Research Network Annual Meeting, Toronto, May, 2013 120 Invited speaker, Western Immunization Conference, Edmonton, March, 2014

(e) Visiting Lecturer (indicate university/organization and dates)

1 Department of Pediatrics, Memorial University, 1983 2 Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, 1986 3 Eli Lilly Lecturer, The Hospital for Sick Children, Toronto, 1986 134

4 Department of Pediatrics, University of Western Ontario, London, 1988 5 Department of Pediatrics, University of Calgary, 1989 6 Department of Pediatrics, St. Justine's Childrens Hospital, Montreal, 1990 7 Laval University Health Center, Quebec City, 1990 8 Department of Pediatrics, New Children's Hospital, Sydney, Australia, August 1996 9 Princess Margaret Children's Hospital and Research Institute, Perth, Australia, 1997 10 Montreal Children’s Hospital, April 2001 11 Grand Rounds, Children's Hospital of Eastern Ontario, Ottawa, February 13, 2002 12 Grand Rounds, Children's Hospital of Western Ontario, London, November 13, 2002 13 Grand Rounds in Pediatrics, McMaster Health Sciences Centre, November 14, 2002 14 Montreal Children’s Hospital 100th Anniversary (Infectious Diseases conference), June 16, 2004 15 Public Health Grand Rounds (vaccine safety), Edmonton, October 19, 2004 16 Grand Rounds (vaccine safety), Alberta Children’s Hospital, Calgary, April 20, 2005 17 Keynote speaker, Pediatric Research Annual Celebration, Stollery Children’s, Edmonton, November, 2007 18 Grant Gall lecturer, Alberta Children’s Hospital, Calgary, March 2008

(f) Other 1 Opening Ceremonies, New Childrens' Hospital, Sydney. 1996 2 UBC Management training seminar (course taken) - Strategic planning. May 1996 3 UBC TAG seminar - time management. January 1999 4 UBC Leadership training seminar (course taken) - Leading high performance work teams. March 1999 5 UBC Faculty of Medicine research retreat. May 1999 6 UBC Commerce Executive Programs - Effective Alliances. January 2001 7 Co-chair/presenter, National Workshop on Influenza Research Priorities, Ottawa, May 31/Sept 1, 2005 8 Co-chair, organizing committee, National Immunization Conference, Winnipeg, December 2-6, 2006 9 Invited participant, CIHR Workshop for Pandemic Influenza Team grant applicants, February 2007 10 Organizing committee, co-chair, CAIRE Master Class on Intelligent Vaccine Design, September 2007; Intelligent Vaccine Evaluation, February 2008; Intelligent Program Evaluation, September 2009; Optimal Vaccine Safety Surveillance, April 2010 11 Co-chair, organizing committee, National Immunization Conference, Ottawa, December, 2014

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES (a) Areas of special interest and accomplishments The first decade of my research career was focused on the growing rate of antibiotic resistance in H. influenzae b isolates and on the pathogenesis of neonatal necrotizing enterocolitis (NEC). I was the first to describe spontaneous endotoxinemia in premature infants and among the first to recognize disordered early gut colonization as a contributor to NEC. I identified that toxigenic coagulase negative staphylococci had the potential to cause mucosal injury when present in the bowel in large numbers. In the subsequent decades of my career I have focused on vaccine evaluation, vaccine safety and immunization programs, interests stimulated during my term as chair of Canada’s National Advisory Committee on Immunization. To address the paucity of vaccine trials capacity in Canada, I established the Vaccine Evaluation Center in 1989 as the country’s first academic vaccine center. This was designed from the outset as a research cooperative, with several investigators sharing one field and data team. This proved to be an excellent “business model” affording long term stability to the Center, such that several of the original employees are still with me in 2014, as the most experienced vaccine specialists in the country. The VEC’s organizational model was copied by several other teams across Canada, with whom we collaborated as an informal trials network. The Center grew in 2006 thanks to Research Unit funding from the M Smith Foundation, the first infrastructure funding to be received. The Center benefited again in 2009 from funds obtained from CFI that provided new space, equipment and a research clinic. To date, the VEC has completed over 250 studies spanning the gamut of immunization research and remains one of the largest vaccine centers in Canada and internationally. In 1992, while serving as chair of the CPS Infectious Diseases and Immunization Committee, I served as founding co-PI of the Immunization Monitoring Program, Active (IMPACT), an active surveillance project linking pediatric centers across Canada to monitor vaccine safety and vaccine-preventable infections. The network has had continuous funding from the Public Health Agency of Canada as it nicely augments other federal surveillance activities. I served as co-PI until 2009 and continue to serve as Data Center chief as that function is housed at the VEC. The IMPACT network has been the source of scores of publications relating to vaccine safety, baseline disease burdens and the effectiveness of new vaccine 135

programs. Personally, it was a great pleasure to firstauthor a series of IMPACT reports demonstrating the near disappearance of invasive H. influenzae b infections, having earlier participated in all 12 of the pre-licensure vaccine trials conducted in Canada. In 2000, I led the formation of the Canadian Association for Immunization Research and Evaluation (CAIRE), a unique organization with about 150 members that I continue to chair. CAIRE has provided a means for productive dialogue between researchers and sponsors of vaccine research in industry and government. It provided the framework for the successful bid to form the PHAC/CIHR Influenza Research Network (PCIRN) in 2009. As leader of the Rapid Trials subgroup of 11 trials centers, I coordinated 4 concurrent vaccine trials during the H1N1 pandemic, along with 2 ultra-rapid trials in 2010 and a comparison of 3 vaccines for seniors in 2011. In 2014, PCIRN was replaced by the Canadian Immunization Research Network (CIRN) in which I continue to have a leadership role as CAIRE liaison and an active trialist. CIRN has a broader mandate than influenza vaccine research but shares the same emphasis on translational research addressing public health priorities. I led the first trial to be funded by CIRN, examining the need for a booster dose in BC children given hepatitis B vaccine as infants.

(b)+(c) Research or equivalent grants/contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)) Grant from 2010

Granting Principal Agency Subject COMP $ Per Year Year Investigator Co -Investigator(s) BC Ministry Evaluation of a 2-dose 1,200,000 2007- Dr. Simon D. Scheifele of Health HPV vaccination schedule 2010 Dobson Planning for girls 912 years old PHAC Enhanced surveillance of 89,436 2008 Dr. David W. influenza vaccine among Scheifele adults GlaxoSmithK 704,774 2008- Dr. David W. M. Dawar line 2012 Scheifele

Immunogenicity and safety study of GSK Biologicals Infanrix hexa vaccine in healthy infants Influenza vaccine dose- response in infants and 2008- Dr. Danuta PHAC toddlers 110,209 2009 Skowronski D. Scheifele Sanofi Immune responses in adults 269,100 20082009 Dr. David W. Pasteur to revaccination with Adacel Scheifele 10 years after a previous dose Center for Understanding and 8,066,542 20082011 Dr. David D. Scheifele Preventing Infections in Children Speert

Canada Foundation for Innovation PHAC/CPS Immunization Monitoring 268,145 2008- Dr. David W. J. Bettinger Program, Active (IMPACT) 2009 Scheifele

136

NEAR Research Symposium 30,000 2008 Dr. David W. Meena Dawar Scheifele

Michael Smith Foundation for Health Research Canadian Evaluation of meningococcal C 699,663 2009- Dr. Julie D. Scheifele Institutes of conjugate vaccine programs in 2014 Bettinger Health Canada Research

PHAC/CIHR Influenza Research 13,800,000 2009- Dr. Scott D. Scheifele Canadian Network 2012 Halperin Institutes of Health Research

BC Centre Assessing influenza 42,043 2009 Dr. David for Disease immunization coverage in Scheifele Control children aged 6-23 months of age

74,000 D. Scheifele Partners in prevention: 2009- Dr. Meena BC Centre supporting primary care 2010 Dawar for Disease physicians to deliver Control immunizations PHAC/CPS Immunization Monitoring 219,651 20092010 Dr. David J. Bettinger Program, Active (IMPACT) Scheifele L. Sauve

CIHR 424,763 20092010 Dr. David Scheifele PHAC/CIHR Influenza Research Network Trials of H1N1 Pandemic Influenza Vaccine (4) S. Dobson J. Bettinger S. Halperin Assessment of pertussis antibody 19,750 2009- Dr. David responses in aboriginal children 2010 Scheifele receiving hexavalent vaccine First Nations and Inuit Health, Health Canada M. Dawar CIHR PCIRN Network of Rapid Trials 506,249 2010- Dr. David S. Dobson (2) of Re-exposure to H1N1 2011 Scheifele J. Langley Vaccine S. Halperin

137

GSK Evaluation of a heptavalent 158,365 2010- Dr. David S. Dobson combination vaccine in infants 2011 Scheifele

CIHR 113,397 2011- Dr. David 2012 Scheifele J. McElhaney T. Kollmann PCIRN Network Randomized Comparison of 3 Influenza Vaccines in Canadian Seniors CIHR 176,510 2011- 2013 Enhancing influenza Dr. J Dutz D Scheifele, immunization in the elderly with J McElhaney topical TLR agonists

Influenza Research Network 3,500,000 2012- Dr. S A D. Scheifele PHAC/ CIHR renewal 2015 Halperin Public Health Immunization Monitoring 446,223 2012 Dr. SsA D Scheifele Agency of Program, Active 433,253 2013 Halperin, Canada/ Dr. CPS W Vaudry

Canadian Population-based 29,300 2012 Dr. J A D Scheifele Pediatric surveillance of invasive Bettinger Society meningococcal infections

Pfizer/PCIRN Capacity building for vaccine 21,250 2012- Dr. D studies in adults 2013 Scheifele SA Halperin

Canadian CF 42,546 Foundation Evaluation of LAIV Influenza 2013- Dr. David M. Chilvers Vaccine in CF Children 2014 Scheifele C. Quach

CIHR/PHAC Canadian Immunization 2,200,000 2014- Dr. S Research Network (CIRN) 2017 Halperin

D Scheifele, J Bettinger, S Dobson

138

323,177 2014- Dr. D M Dawar, M Naus, CIRN Assessment of the need for 2015 Scheifele M Krajden, M Pinto booster doses of Hepatitis B vaccine following infant vaccination

68,000 2014- Dr. David BC Ministry Assessment of the need for 2015 Scheifele M. Naus booster doses of Hepatitis M. Dawar B vaccine following infant M. Krajden vaccination

PHAC IMPACT surveillance network 351,553 2014- Dr. David J. Bettinger 2015 Scheifele CIHR PCIRN Readiness Plan for a 50,000 2014- Dr. David J. Langley Future Pandemic Trial 2015 Scheifele S. Halperin

PHSA Demonstration project: Family 25,000 2014 Dr. D M Naus, S Dobson Influenza Vaccination clinic Scheifele Salary Support Award

Granting Subject COMP $ Per Year Principal Co- Agency Year Investigator Investigator(s) Canadian Investigator Establishment C 1978-81 D Scheifele Life

nsurance Companies UBC Sauder Family Chair Career Advancement C 1997-04 D Schfeiele

CIHR/Wyeth Chair in Vaccine Research C 2004-9 D Scheifele J Bettinger Meningitis Vaccinology Fellowship Foundation (S Wootton) C 25.000 2005-7 D Scheifele J Bettinger

Research Fellowship PCIRN (K Lapphra) C 45,000 2009-11 D Scheifele Meningitis Vaccinology Fellowship Foundation (M Pinto) C 25,000 2014-6 D Scheifele

CIRN Fellowship (M Pinto) C 45,000 2014-6 D Scheifele

(d) Invited Presentations 1 North Pacific Pediatric Society annual meeting. 1979/83/85/86/91/95 2 Canadian Pediatric Society Annual Meeting (Heinz seminar). 1982, 1983, 1985, 1983 3 American Academy of Pediatrics Annual Meeting. 1982/83/84/85/87/1990 4 Canadian Infectious Diseases Society Annual Meeting. 1987, 1999 5 Second International Symposium on Neonatal Necrotizing Enterocolitis, Columbus, Ohio. 1989 6 Interscience Conference on Antimicrobioal Agents & Chemotherapy, Houston TX. 1989 7 Second National Immunization Conference, Toronto. 1992 8 4th Mediterranean Congress of Chemotherapy, Athens. 1992 139

9 Child Health 2000, Vancouver. 1992 10 International Hepatitis Congress, Tokyo. 1993 11 NIH Conference on Combination Vaccines, Bethesda. 1993 12 Advisory Committee on Immunization, BC Ministry of Health. March,1994 13 Advisory Committee on Immunization, Alberta Health. April,1994 14 National Immunization Conference (2 research papers), Quebec City. October 1994 15 Adolescent immunization, Child Health 2000. 1995 16 Clinical Trials: Pediatric Investigators Network for Infection in Children, Annual Meeting. 1995 17 Pediatric Investigators Network for Infections in Children, Annual Meeting, San Francisco. 1995 18 Hepatitis A vaccine. International Congress of Chemotherapy Montreal. July 1995 19 Immunization Update: New Children’s Hospital Opening Celebration, Sydney. 1996 20 Immunization Update: Canadian Infection Control Practitioners Association Annual Meeting. 1996 21 Canadian Hospital Infection Control Association Annual Meeting, Vancouver. 1996 22 Conference on acellular pertussis vaccines, Barcelona, Spain. 1996 23 National Immunization Conference (3 presentations), Toronto. December 1996 24 North Pacific Pediatric Society Annual meeting, Vancouver. March 1997 25 Consensus Conference on Control of Antimicrobial Resistance, Montreal. May 1997 26 Symposium on “Hepatitis B virus – the quest for global control and eradication” Toronto. September 1997 27 Canadian Infectious Diseases Society Annual Meeting, Toronto. October 1997 28 Keynote speaker, 4th Annual Child Health Research Symposium, Alberta Children’s Hospital, Calgary. April 1998 29 National Immunization Conference, (3 lectures) Calgary. December 1998 30 Pneumococcal Immunization Conference, Jacksonville FLA. January 1999 31 Hepatitis A Immunization Conference, (Speaker and Chair) Toronto. September 1999 32 Canadian Infectious Diseases Society Annual Meeting, Edmonton. October 1999 33 2nd World Congress on Pediatric Infectious Diseases, Manila. November 1999 34 International Society of Medical Technologists, Vancouver. June 2000 35 Symposium on Pneumococcal Infections, Toronto, co-chair, presenter. September 2000 36 NIH conference on acellular pertussis vaccine. November 2000 37 4th Canadian National Immunization Conference, Halifax. December 2000 38 Symposium on pneumococcal infections, Halifax. December 2000 39 Keynote speaker, Canadian Infectious Diseases Society Annual Meeting. April 2001 40 Annual Meeting Canadian Paediatric Society, Vancouver. June 2001 41 Symposium on Pneumococcal Infections, Vancouver, chair, presenter. June 2001 42 National Immunization Strategy – Research Workshop (presenter, chair). February 23, 2002 43 National Immunization Strategy – Vaccine Safety Workshop. March 25, 2002 44 Grant Gall Lecturer, University of Calgary. April 5, 2002 45 Maternal and Child Health Research Network Workshop, Montreal. October 7-8, 2002 46 Inaugural Pat Melton Memorial Lecture, BC Pediatric Society. November 8, 2002 47 CAIRE Vaccinology course (presenter, organizing committee), Victoria, BC. November 30, 2002 48 BC Research Institute for Children’s & Women’s Health “Mini Medical School”. April 23, 2003 49 CPS/CAIRE Vaccinology Course #2, for resident physicians, Montreal. November 15, 2003 50 First Kuwait Symposium on Pediatric Infectious Diseases, Kuwait City, March 4-7, 2006 (3 lectures). 51 North Pacific Pediatric Society scientific conference, Vancouver, 19 March 2006 52 Canadian Paediatric Society Annual Meeting, Montreal, June 19-23, 2007, symposia on “Control of Meningococcal Infections” and “Human Papillomavirus Infections in Adolescents” 53 CIHR-funded Workshop on Feasibility of an Ontario Vaccine Research Network, Toronto. Keynote speaker. 19 November, 2007. 54 Grand Rounds and Research Day. Keynote speaker. Department of Pediatrics, University of Alberta, Edmonton. 21-22 November, 2007. 55 CAIRE Residents’ Vaccinology course, plenary speaker, Montreal. November 30/December 1, 2007. 56 Grant Gall lectureship, University of Calgary/Alberta Children’s Hospital, March 2008 57 John Waters Memorial Lecture, Canadian Immunization Conference, Toronto, December 2008 58 Infectious Disease Society of American 48th Annual Meeting, Vancouver, October 21, 2010. 59 Distinguished Lecture Award, 9th Canadian Immunization Conference, Quebec City, December, 2010 60 13th National Immunization Conference, Darwin, Australia, June 2012 (2 plenary lectures). 61 10th Canadian Immunization Conference, Vancouver, December 3-5, 2012 “Improved influenza vaccines for children” 62 Western Canada Immunization Forum, Edmonton. March 5-6, 2014. 140

I Other Presentations (f) Other (g) Conference Participation (Organizer, Keynote Speaker, etc.) 1 National Immunization Conference, Quebec City (4 presentations) October 1994 2 Child Health 2000, Vancouver (session organizer, chair) June 1995 3 International Congress on Chemotherapy (organizing committee) July 1995 4 Third National Immunization Conference, Toronto (session organizer, chair) December 1996 5 Consensus Conference on Pneumococcal Vaccination, Ottawa, February 1998 6 Vaccine Research Conference, (abstract presenter/attendee) Maryland, March 1999 7 Canadian Pediatric Society Annual Meeting, (Abstract presenter/attendee) Winnipeg, June 1999 8 Conference on Hepatisis A control in Canada, Toronto (organizing committee, chair) September 1999 9 Infectious Diseases Society of America Annual Meeting, (Abstract presenter/attendee) Philadelphia, November 1999 10 Vaccine Research Conference, Washington, DC (abstract presentation) May 2000 11 Canadian Pediatric Society annual meeting, Ottawa (abstract presentation) June 2000 12 International Society on Pediatric Surveillance programs, Ottawa (presenter) June 2000 13 Interscience Conference on Antimicrobial Agents & Chemotherapy, Toronto, September 2000 14 NIH Conference on Acellular Pertussis Vaccines. Bethesda, (invited presenter) November 2000 15 Consensus Conference on Vaccine Safety, Health Canada, Montreal, (invited presenter) November 2000 16 Canadian National Immunization Conference, Halifax, (session organizer, chair, presenter x3) December 2000 17 Vaccine Research Conference, Arlington, VA, (Abstract presenter x2) May 2001 18 Canadian Paediatric Society Annual Meeting, (Invited speaker, poster presenter x2) June 2001 19 5th Canadian National Immunization Conference, Victoria, BC (planning committee, session chair, presenter) December 1-3, 2002 20 UBC Department of Pediatrics 50th Anniversary Conference, Vancouver, May 10, 2003 21 Child Health 2003 International Conference, Vancouver, (planner, lecturer) May 13, 2003 22 Current issues in Immunization Symposium at CPS Annual Meeting, Calgary, (chair and presenter) June 20, 2003 23 Canadian Paediatric Society Annual Meeting (presenter), Vancouver, 2004 24 6th Canadian Immunization Conference (planning committee, presenter), December, 2004, Montreal 25 Canadian Paediatric Society Annual Meeting (presenter), Montreal, 2005 26 Canadian Paediatric Society Annual Meeting (presenter), St. John’s 2006 27 Canadian Public Health Association Annual Meeting (presenter), Vancouver, 2006 28 7th Canadian Immunization Conference (planning committee, presenter), Winnipeg, December, 2006 29 Canadian Paediatric Society Annual Meeting (presenter), Montreal, 2007 30 Centennial Celebration Ste Justine’s Children’s Hospital (presenter), Montreal, 2007 31 Annual Research Celebration, University of Alberta Faculty of Medicine (keynote speaker), Edmonton, 2007 32 Canadian Immunization conference, Scientific Co-chair, Planning committee, Ottawa, 2014

10. PROFESSIONAL SERVICE CONTRIBUTIONS

10a Areas of special interest and accomplishments As one of the first Pediatric Infectious Diseases (PID) specialists in Canada, I was privileged to have numerous leadership opportunities unique to a new discipline. I was the first PID specialist to chair the Infectious Diseases and Immunization committee of the Canadian Paediatric Society that during my tenure substantially increased publication of helpful guidance statements for pediatricians. It was this committee that was challenged by Health Canada to devise a means to improve surveillance of vaccine safety. I led the development of the active surveillance network involving pediatric hospitals across Canada known as IMPACT, serving as the co-PI for the next two decades of successful operation. The network has published scores of papers and been copied by several other countries. I was the first infection specialist to chair the National Advisory Committee on Immunization, my predecessors being microbiologists. As chair I was able to influence the editorial style of the Canadian Immunization Guide, making it more useful for practitioners. A key policy change during my term was the adoption of a 2-dose measles immunization schedule, a controversial move at the time but one that proved successful in reducing measles outbreaks in Canada. Serving on NACI made me acutely aware of the lack of capacity in Canada for evaluating new vaccines and immunization programs, at a time when many new vaccines were soon to become available. In response, I established the Vaccine Evaluation Center (VEC) at UBC/BCCH as the nation’s first academic vaccine studies facility. This model was copied in 141

other centers, enabling the establishment of an informal vaccine trials network. In 2000, I led the establishment of the Canadian Association for Immunization Research and Evaluation (CAIRE) to formalize the network and broaden participation in vaccine research. The Association’s office is housed within the VEC and in 2014 includes about 150 members from across the spectrum of vaccine sciences. The existence of CAIRE made possible the successful application for the PHAC/CIHR Influenza Research Network that proved invaluable during the 2009 pandemic. As CAIRE director I have been able to lobby for greater funding of vaccine evaluation research, an indirect result of which was the recently funded Canadian Immunization Research Network (a successor to PCIRN). CAIRE has also led a number of innovative workshops such as a series of Master Classes to keep leaders in the vaccine field abreast of developments in vaccine science. Other workshops defined research agendas for new vaccines such as HPV and group B meningococcal vaccines. CAIRE is a formal partner in hosting the biannual Canadian Immunization Conference, responsible for the scientific components of the program. As CAIRE director I have been on the planning committee for most conferences since 2000 and am Scientific co-chair for the 2014 conference. As a founding member of the PID subspecialty in Canada, I have been honored to receive a number of accolades. I was the first PID specialist to hold a University chair, to receive the CPS Ross award and to be appointed to the Order of Canada.

10.1 SERVICE TO THE UNIVERSITY (a) Memberships on committees, including offices held and dates A. University 1 Coordinator, Pediatric Refresher Course for general practitioners 1978-1982 2 Dept. of Pediatrics Residency Training committee member 1978-1979; 1984-1988 Chair 3 Coordinator, Pediatric Grand Rounds 1979-1981 4 UBC Research Coordinating committee 1981-1986 5 Director, Residency Training Program in Pediatric Infectious Diseases 1982-1990 6 Department of Pediatrics Appointments and Promotions committee 1987-1996 7 Department of Pediatrics Fellows’ Training committee 1988-1991 8 UBC Vice-President’s Task Force on Biohazards Management 1989 9 Dean’s Search Committee for Head of Pediatrics 1990-1991 10 UBC Post – graduate Awards committee 1990-1994 11 Review Committee Chair, Division of Neurology, Dept. of Pediatrics 1996 12 Executive Advisory Committee (ad hoc member), Department of Pediatrics 1996-1997 13 Review committee, Division of Neonatology, Department of Pediatrics 1997 14 Co-chair, Task Force on Building an Academic Culture, Dept. of Pediatrics 1997 15 Reunion Conference planning committee, Department of Pediatrics 1997 16 Member, Review Committee, Division of Biochemical Diseases 1999 17 Department of Pediatrics, Faculty Appointments and Promotions Committee 2001-2012 (chair 2006-2012), Past chair (2013) 18 Nominating committee, Faculty of Medicine, 2005-2008 (chair, 2008)

B. Hospital

19 BCCH Infection Control Committee 1977-1987 20 BCCH Pharmacy Committee, chair 1985-1988; 1990-1998 21 BCCH Research Advisory committee 1986-1993 22 BCCH Research Advisory committee (Vice-chair) 1989-1993 23 BCCH Research Advisory committee (Chair, Investigatorship subcommittee) 1989-1993 24 BCCH Drug Utilization Management Advisory committee 1994-1995 25 In-Hospital Research Review Committee, BCCH 1996 26 BCCH Telethon Fund grants program review committee 1997 27 Chair, Task Force on Membership, BC Research Institute for Child & Family Health 1997 28 Member, Research and Education Advisory Council, Children’s and Women’s Hospital 1997-1998 29 Member, Search Committe, Division of Pediatric Oncology, BCCH 1997-1998 30 Pharmacy and Therapeutic Committee, C&W Hospital1999-2007 31 BC Research Institute clinical support unit steering committee 2000-2004 32 BC Research Institute working group on Investigator remuneration 2001-2002 33 BC Research Institute for Children’s & Women’s Health, Clinical Research Council Member 2002-2006 34 Telethon grants committee, chair 2005-2006, member 2007 142

35 Child & Family Research Institute, member, Centre for Infectious and Inflammatory Diseases and Centre for Clinical Research 2007- present 36 CFRI/CFI Centre for Understanding and Preventing Infections in Children (CUPIC), member, steering committee, 2007- present

(b) Other service, including dates

1 Examiner in Infectious Diseases, Royal College of Physicians and Surgeons 1985 – 1987 2 Chair, Data Safety and Monitoring committee, for “Study of the Efficacy of Pertussis Immune Globulin, Intravenous”. Funded by NIH. S. Halperin PI. 1997-1999 3 Mentor (Tobias Kollmann) Canadian Child Health Clinician Investigator Awards Program 2008-2010

11. SERVICE TO THE COMMUNITY (a) Memberships on scholarly societies, including offices held and dates 1 American Society for Microbiology 2 Infectious Diseases Society of America Fellow 3 Pediatric Infectious Diseases Society Fellow 4 American Academy of Pediatrics member, Infectious Diseases committee. 1981-1986 5 Canadian Pediatric Society (Member, Infectious Diseases Committee 1981-1997) 6 Canadian Infectious Diseases Society (Member, Publications committee. 1997-2001)

(c) Memberships on scholarly committees, including offices held and dates 7 Grant Review Committee (clinical), BC Health Care Research Foundation. 1979-1981 8 Infectious Diseases and Immunization committee, Canadian Pediatric Society (Chair). 1981-1988 9 National Advisory Committee on Immunization, Member. 1981-1991 10 Grant Review Committee (microbiology), Medical Research Council of Canada. 1983 11 Infectious Diseases and Immunization committee, Canadian Pediatric Society, Consultant. 1989-1997 12 Committee to Advise on Tropical Medicine and Travel, Health Canada. 1993-1995 13 Advisory Committee on Immunization Practices, US Public Health Service. 1993-1997 14 National Advisory Committee on Immunization, Chair. 1993-1997 15 BC Immunization Advisory Committee, Ministry of Health (Chair). 1999-2001 16 Canadian Association for Immunization Research and Evaluation. Chair 2000-present Chair, Research Sponsors’ Advisory Board 2002-present Organizing committee, Annual Vaccinology Course for Trainees, 2002-2007 Organizing committee, Masters Classes in advanced vaccinology, 2008-9 Principal applicant, CIHR/PHAC Pandemic Vaccines Team grant, 2008 (not funded) 17 Liaison Member, National Advisory Committee on Immunization. 2001-2009 18 Chair, BC Immunization Forum, BC Centre for Disease Control. 2003-2004 19 Grant review committee (clinical trials), Canadian Institutes of Health Research. 2006-2011 20 Member, Pandemic Vaccines Working Group, Public Health Agency of Canada, 2006-2010

(d) Memberships on other committees, including offices held and dates 21 Medical Lobby for Appropriate Marketing of Drugs in Third World Countries. 1986-1997

I Editorships (list journal and dates) 22 Pediatric Infectious Diseases Journal (editorial board). 1987-1991 23 Infectious Diseases in Children (editorial board). 1989-1999 24 Lead editor, Canadian Immunization Guide, 5th edition. 1998 25 Vaccines: children and practice (editorial board). 1998-2006 26 Paediatrics and Child Health (editorial board). 1999-present. Associate editor, 2004- present 27 Editorial Board, J. Pediatric Infectious Disease Society 2012-14

(f) Reviewer (journal, agency, etc. including dates) 143

28 Canadian Medical Association Journal. 1982-present 29 Pediatric Infectious Diseases Journal. 1987-present (several per year) 30 American Journal of Diseases of Children. 1989-1995 31 Journal of Pediatrics. 1990-1998, 2007 32 Vaccine. 1990-present (several per year, currently member of Panel of 100 select reviewers) 33 Canadian Infectious Disease Journal. 1990-present 34 Journal of Infectious Disease. 1992-present 35 Canadian Journal of Child & Adolescent Health. 1997-1998 36 King Faisal International Prize in Medicine, reviewer for 1998 Prize 37 Clinical Infectious Diseases. 1998-present 38 Paediatrics & Child Health. 1999-present (several per year) 39 Reviewer for WHO Position Paper on Haemophilus influenzae type b conjugate vaccines (September, 2006). Published in WHO Wkly Epi Record 2006; 81:445-52. 40 Reviewed and updated WHO Monograph on Diphtheria Vaccine (with J. Ochnio), 2007-8

(h) Consultant (indicate organization and dates) 41 External Reviewer, Bureau of Biologics, Health Canada. 1989-1990 42 Member, Health Minister’s Task Force on compensation for vaccine-related injuries. 1987 43 Member, LCDC Task Force on vaccine adverse reaction surveillance in Canada. 1989-1990 44 Measles vaccination consensus conference, Ottawa. 1992 45 Lederle Canada vaccine advisory committee. 1992-2002 46 Influenza vaccination consensus conference, Ottawa (Chair). 1993 47 National Consensus Conference on diphtheria, tetanus, polio, Hib and hepatitis B vaccination, Ottawa. 1994 48 National Consensus Conference on control of antimicrobial resistance, Montreal. 1997 49 Contributing author, Provincial Medical Officer’s Special Report on Child Health. 1998 50 National Consensus Conference on Pneumococcal Vaccination, Ottawa. 1998 51 Contributing Author, Provincial Medical Officer’s Speical Report on Immunization. 1999 52 BC Centre for Disease Control Task Force on Varicella Immunization. 1999 53 National Consensus Conference on Vaccine Safety. 2000 54 Canadian Law Society, Review of Biomedical Ethics. 2000 55 National Immunization Strategy Workshop on vaccine research (chair, presenter). 2002 56 National Immunization Strategy Workshop on vaccine safety surveillance. 2002 57 National Immunization Strategy Workshop on Influenza Research Priorities (co-chair) 2005 58 National Immunization Strategy Workshop on HPV disease prevention, 2006 59 Pan-provincial Vaccine Development Network (PREVENT, NCE Commercialization Program), Board of Directors. 2007-2012 60 Workshop on Tdap vaccine use in adults, 2012 Toronto 61 CIHR/NRC/PHAC workshop on enhancing vaccine development in Canada, Ottawa, 2012 62 National Immunization Strategy review of potential research components, 2012 63 National working group on Meningococcal vaccines, 2012 64 External Advisor, National Network on Immunization of Special Populations, Sydney, Australia, 2011-13 65 Ontario Auditor General’s report on Immunization in Ontario, 2014

(i) Other service to the community 1 Grant reviews in 2002: CIHR-3 2 Peer evaluations for promotion, University of Toronto, Dalhousie University, McGill University. 1994 3 Grant reviews for MRC, NHRDP, HSC Foundation, Alberta Heritage Foundation. 1994-1995 4 Peer evaluations for promotion 1995: Dalhousie University 5 Peer evaluations for promotion 1996: McMaster University 6 Grant reviews in 1996: NHRDP, HSC Foundation 7 Frequent media interviews in support of childhood vaccination including: Immunization segment, Spilled Milk series, CBC-TV, December 14, 1996 (1.5 hours of interviews, taping in preparation.) 8 Peer evaluations for promotion, University of Ottawa. 1997 9 Grant reviews in 1997: MRC 2 10 MRC (1), Alberta Heritage Foundation, Hospital for Sick Children Foundation. 1998 11 Grant reviews in 1999: Alberta Heritage Foundation (2) 12 Peer evaluation for promotion, University of Manitoba. 2000 144

13 Peer evaluation for promotion, Dalhousie University, 2006 14 Peer evaluation for promotion, University of Toronto, McGill University, 2007 15 Peer evaluation for promotion, University of Toronto, Hong Kong University, Dalhousie University, Ottawa University, 2012 16 Peer evaluations (2) for nominees for Order of Canada, 2014 17 Instructor, Canadian Power and Sail Squadron, White Rock squadron, 2014-

12. AWARDS AND DISTINCTIONS (a) Awards for Teaching (indicate name of award, awarding organizations, date) 1 Teacher of the Year award, Pediatric Resident Staff, BCCH (1979-80) 2 Best Teaching Division, Pediatric Resident Staff, BCCH 1982-1983, 1985-1986, 2002-2003 3 Killam Excellence in Teaching Award, UBC (1992)

(b) Awards for Scholarship (indicate name of award, awarding organizations, date) 4 Medical Research Council Fellowship 1974-1977 5 Canadian Life Insurance Companies Association Research Scholarship 1978-1981 6 Outstanding Achievement by an Investigator Award, BCCH Foundation (1988) 7 Career Investigator award, BCCH Foundation (1989-1997) 8 Sauder Family Chair in Pediatric Infectious Diseases (1997-2004) 9 CIHR/Wyeth Chair in Clinical Vaccine Research (2004- 2009) 10 Distinguished Lecture in Canadian Immunization (recognizing outstanding career achievement in the field of immunization in Canada) (2010) 11 Royal College Lecturer, Canadian Paediatric Society 88th Annual Conference, Quebec City, June 2011

(c) Awards for Service (indicate name of award, awarding organizations, date) 12 Distinguished Service award, Scouts Canada (1989) 13 Canadian Paediatric Society’s Alan Ross Award for Distinguished Career Achievement, June 2007 14 Clinical Infectious Diseases Award for Outstanding Peer Review (2010) 15 Appointed Officer of the Order of Canada, December, 2012 16 The Queen Elizabeth II Diamond Jubilee Medal, 2012, for service to Canada 17 Merck Patients First Award, for contributions to childhood immunization, 2013

(d) Other Awards 18 Election to Alpha Omega Alpha, London, Ontario (1967) 19 Prize in Pharmacology (1967) 20 AKK Gold Medal, Poulenc Award and Gold Medal, Scholarship in Medicine (1969) 21 Nominee for “Transformational Canadians” recognition, Globe & Mail 14 September 2010. Nominated by Child & Family Research Institute, Vancouver

13. OTHER RELEVANT INFORMATION (Maximum One Page) Training courses attended:

UBC Executive programs – Strategic planning (May 1996) UBC Executive programs – Leading High Performance teams (March 1999) UBC Executive programs – Effective alliances (January 2001) UBC TAG courses – Power Point 1 and 2 (November 2002) UBC TAG courses – Effective time management (October 2004)

University of British Columbia Publications Record FIRST NAME: David 1. SURNAME: Scheifele MIDDLE NAME(S): W

01. Refereed Publications from 2010 145

(a) Journals 1 Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, Law B, Tyrrell G, for Members of the Canadian Immunization Monitoring Program, Active (IMPACT). The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 2010; 28:2130-36. 2 Bettinger JA, Sauvé LJ, Scheifele DW, Moore D, Vaudry W, Tran D, Halperin SA, Pelletier L. Pandemic influenza in Canadian children: A summary of hospitalized pediatric cases. Vaccine 2010; 28(18):3180-4. (Among 10 most cited papers in Vaccine in 2010, with 43 citations). 3 Sauvé LJ, Bettinger J, Scheifele D, Halperin S, Vaudry W, Law B and members of the Canadian Immunization Monitoring Program, Active (IMPACT). Postvaccination thrombocytopenia in Canada. Pediatr Infect Dis J 2010; 29(6):559-61. 4 Scheifele D, Halperin S, Skowronski D, Kellner J, Ward B, Gemmill I, De Serres G. Regrettable lack of definition of the “well tolerated” vaccine. Vaccine 2010; 28:3755-6. 5 Scheifele DW, De Serres G, Gilca V, Duval B, Milner R, Ho M, Ochnio JJ. A nationwide survey of past hepatitis A infections among Canadian adults. Vaccine 2010; 28:5174-5178. 6 Grunau RE, Tu MT, Whitfield MF, Oberlander TF, Weinberg J, Yu W, Thiessen P, Gosse G, Scheifele D. Cortisol, behavior, and heart rate reactivity to immunization pain at 4 months corrected age in infants born very preterm. Clin J Pain 2010 Jul 20. 7 Le Saux N, Bettinger JA, Halperin SA, Vaudry W, Scheifele DW for Members of IMPACT. Substantial morbidity for hospitalized children with community-acquired rotavirus infections – 2005-2007 IMPACT surveillance in Canadian hospitals. Pediatr Infect Dis J 2010; 29:879-82. 8 Lapphra K, Huh L, Scheifele D. Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination. Pediatr Infect Dis J 2011; 30:84-6. 9 Al-Rawahi G, Dobson SR, Scheifele DW, Rassekh R, Murphy JJ. Severe genital ulceration in an acute EpskinBarr virus infection. Pediatr Infect Dis J 2011; 30:176-178. 10 Bettinger JA, Wills K, Le Saux N, Scheifele DW, Halperin SA, Wendy V for Members of the Canadian Immunization Monitoring Program, Active (IMPACT). Heterogeneity of rotavirus testing and admitting practices for gastroenteritis among 12 tertiary care pediatric hospitals: implications for surveillance. Can J Infect Dis Med Microbiol 2011; 22(1):15-18. 11 Le Saux N, Bettinger J, Halperin S, Vaudry V, Scheifele D, for members of the Canadian Immunization Monitoring Program, Active (IMPACT). Hospital acquired rotavirus infections: burden in Canadian padeiatric hospitals. J Inf Prevention 2011; 12(4): 159-162. 12 Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, Dobson S, Li Y, Law B, Halperin SA for the Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Rapid Trials Investigators. Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children. Pediatr Infect Dis J 2011; 30(5):402-7. 13 Scheifele DW, Naus M, Crowcroft N, Dobson S, Halperin SA, Bjornson G. Optimizing Canadian Public Immunization Programs: A Prescription for Action. Can J Public Health 2011; 102(3):193-95. 14 Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabiduc S, Petric M. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011; 128:e276-289. 15 Rubinstein E, Predy G, Sauvé L, Hammond GW, Aoki F, Sikora C, Li Y, Law B, Halperin S, Scheifele D. The responses of Aboriginal Canadians to adjuvanted pandemic (H1N1) 2009 influenza vaccine. CMAJ 2011; 183(13): E1033-7. 16 Lapphra K, Scheifele D. Can children with minor illnesses be safely immunized? Pediatr Child Health 2011; 16:463. 17 Scheifele DW, Marty K, LaJeunesse C, Fan SY, Bjornson G, Langley J and Halperin S. Strategies for successful rapid trials of influenza vaccine. Clinical Trials 2011, 8(6):699-704. 18 Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012; 31:72-77. 19 Coleman BL, Kuster SP, Gubbay J, Scheifele D, Li Y, Low D, Crowcroft N, Mazzuli T, Shi L, Halperin SA, Law B, McGeer A. Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. Eur J Clin Microbiol Infect Dis 2012; 31:591-7. 20 Halperin SA, Scheifele DW, De Serres G, Noya F, Meekison W, Zickler P, Larivée L, Langley JM, McNeir SA, Dobson S, Jordanov E, Thakur M, Decker MD, Johnson DR. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine 10 years after a previous dose. Vaccine 2012; 30(5):974-82. 146

21 Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeill S, Dobson S, Kellner JD, Kuhn S, Kollmann T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012; 30(23):3389-94. 22 Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Vanderkooi OG, Schryvers A, De Serres G, Alcantara J. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis. Vaccine 2012; 30:4023-27. 23 Coyle D, Coyle K, Bettinger JA, Halperin SA, Vaudry V, Scheifele DW, Le Saux N. Cost-effectiveness of infant vaccination for rotavirus in Canada. Can J Infect Dis Med Microbiol 2012; 23:71-77. 24 Scheifele DW, Ward BJ, Dionne M, Vanderkooi Og, Loeb M, Coleman BL, Li Y, and PHAC/CIHR Influenza Research Network. Compatibility of AS03-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial. Vaccine 2012; 30:4728-32. 25 Tan B, Bettinger J, McConnell A, Scheifele D, Halperin S, Vaudry W, and Law B, for Members of the Canadian Immunization Monitoring Program, Active (IMPACT). The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT Centers, Canada, 2000-2008. PIDJ 2012; 31(9):956-63. 26 Tran D, Varudy W, Moore DL, Bettinger JA, Halperin SA, Scheifele DW, Aziz S; for the IMPACT investigators. Comparison of children hospitalized with seasonal versus pandemic influenza A, 2004-2009. Pediatrics 2012; 130(3):397-406. 27 Skowronski DM, Janjua NZ, De Serres G, Purych D, Gilca V, Scheifele DW, Dionne M, Sabaiduc S, Gardy JL, Li G, Bastien N, Petric M, Boivin G, Li Y. Cross-reactive and vaccine-induced antibody to an emerging swineorigin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 1852-61. 28 Cooper C, Klein M, Walmsley S, Hasse D, MacKinnon-Cameron D, Marty K, Li Y, Smith B, Halperin S, Law B, Scheifele D, PHAC CIHR Influenza Research Network. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials 2012; 13(1):23-32. 29 Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R for Members of the Canadian Immunization Monitoring Program, Active (IMPACT). The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013; 32(1):e20-e25. 30 Yam KK, Gupta J, Brewer A, Scheifele DW, Halperin S, Ward BJ, PHAC/CIHR Influenza Research Network (PCIRN) Rapid Trial Study #3 Investigators. Unusual patterns of IgG avidity in some young children following two doses of adjuvanted pandemic H1N1(2009) influenza vaccine. Clin Vaccine Immunol 2013; 20(4):459-67. 31 Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women. A Randomized Clinical Trial. JAMA 2013; 309(17):1793-1802. 32 Bettinger JA, Deeks SL, Halperin SA, Tsang R and Scheifele DW. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 2013; 12(5):505-517. 33 Al-Dabbagh M., Lapphra K, Scheifele DW, Halperin SA, Langley JM, Cho P, Kollmann TR, Li Y, De Serres G, Fortuno ES 3rd, Bettinger, JA. Elevated inflammatory mediators in adults with oculorespiratory syndrome following influenza immunization: a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network Study. Clin & Vaccine Immunol 2013; 20(8):1108-1114. 34 Scheifele DW, McNeil SA, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Hatchette T, Li Y, Montomoli E, Schneeberg A, Bettinger JA, Halperin SA, and PHAC/CIHR Influenza Research Network. Safety, immunogenicity, and tolerability of three influenza vaccines in older adults. Results of a randomized, controlled comparison. Hum Vaccines & Immunotherapeutics 2013; 9(11):2460-2473. 35 Top KA, Constantinescu CM, LaFleche J, Bettinger JA, Scheifele DW, Vaudry W, Halperin SA, Law BJ. Applicability of the Brighton Collaboration case definition for seizure after immunization in active and passive surveillance in Canada. Vaccine 2013; 31(48):5700-5705. 36 Sadarangani M, Bettinger JA, Scheifele DW. How best to describe the risk of meningococcal B infection? Pediatr Child Health 2013; 18:543-4. 37 Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, Halperin SA; PHAC/CIHR Influenza Research Network. Safety and immunogenicity of 2010–2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. Hum Vaccin Immunother. 2013 Jan; 9(1):136-43. 38 Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Le Saux N. Response to the changing epidemiology of meningococcal disease in North America 1945-2010. Hum Vaccin Immunother. 2013 Jun; 9(6):1323-4.

147

39 Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R, for the members of the Canadian Immunization Monitoring Program, Active (IMPACT). Diversity of Canadian meningococcal serogroup B isolates and estimated coverage of an investigational meningococcal serogroup B vaccine (4CmenB). Vaccine 2014; 32(1):124-130. 40 Scheifele DW, Ward BJ, Halperin SA, McNeil SA, Crowcroft NS, Bjornson G. Approved but non-funded vaccines: Accessing individual protection. Vaccine 2014; 32(7):766-770. 41 Omura J, Buxton J, Kaczorowski J, Catterson J, Li J, Derban A, Hasselback P, Machin S, Linekin M, Morgana T, O’Briain B, Scheifele D, Dawar M. Immunization delivery in British Columbia – Perspectives of primary care physicians. Can Fam Physician 2014; 60(March):e187-e193. 42 Scheifele DW, Halperin SA, Bettinger JA. Childhood immunization rates in Canada are too low: UNICEF. Paediatr Child Health 2014; 19(5):237-8. 43 Yam KK, Gipson E, Klein M, Walmsley S, Haase D, Halperin S, Scheifele D, Ward BJ, Cooper C. High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol 2014; 34:655-662. 44 Schneeberg A, Bettinger JA, McNeil S, Ward BJ, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Scheifele DW, Halperin SA. Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health 2014; 14:442. 45 Burton C, Vaudry W, Moore D, Bettinger JA, Tran D, Halperin SA, Scheifele DW for the IMPACT Investigators. Burden of seasonal influenza in children with neurodevelopmental conditions. Pediatr Infect Dis J 2014; 33:710714. 46 Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA, for the investigators of the Canadian Immunization Monitoring Program, ACTive (IMPACT). The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis 2014; 59(9):1208-15. 47 Thollot F, Scheifele D, Pankow-Culot H, Cheuvart B, Leyssen M, Ulianov L, Miller JM. A randomized study to evaluate the immunogenicity and safety of a heptavalent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, haemophilus influenzae b, and meningococcal serogroup C combination vaccine administered to infants at 2, 4, and 12 months of age. Pediatr Infect Dis J 2014; 33(12):1246-54. 48 Pinto M, Scheifele D. Discussing the need for an adolescent hepatitis B vaccine booster in infant accines. Paediatr Child Health 2014;19(8):404. 49 Bettinger JA, Halperin SA, Vaudry W, Law BJ, Scheifele DW, on behalf of the Canadian IMPACT members. The Canadian Immunization Monitoring Program, ACTive (IMPACT): Active surveillance for vaccine adverse events and vaccine-preventable diseases. CCDR 2014;40 S-3. 50 Sadarangani M, Scheifele DW, Halperin SA, Vaudry W, Le Saux N, Tsang R, Bettinger JA. Outcomes of invasive meningococcal disease in adults and children in Canada between 2002 and 2011: a prospective cohort study. Clin Infect Dis 2015; doi:10.1093/cid/civ028.

(b) Conference Proceedings from 2010 1 Skowronski DM, Hottes TS, Petric M, Lafleche J, Law B, Scheifele D, McGeer A, Janjua NZ, Chan T, DeSerres G, Ward BJ, Bastien N, Li Y. Product-related differences in cross-reactive non-neutralizing antibody to pandemic H1N1 induced by 2008-2009 triavlent influenza vaccines in Canada. 13th Annual Conference on Vaccine Research, April 26-28, 2010, Bethesda MD. Abstract S11. 2 Balakrishnan S, Sauvé LJ, Vaudry W, Scheifele D, Halperin S, Law B. Could HSP be an adverse event following immunization? A report from the Canadian Pediatric Society Immunization Monitoring Program, Active (IMPACT). Canadian Paediatric Society 87th Annual Conference, June 22-26, 2010, Vancouver, B.C. Paediatr Child Health 2010; 15:Suppl A p35A (Abstract 84). 3 Bettinger J, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Bortolussi R, Tsang R. Update on the incidence of meningococcal invasive infections in Canada, IMPACT 2002-2009. 17th International Pathogenic Neisseria Conference, Banff AB, September 11-16, 2010 Abstract P036. 4 Scheifele DW, Ward B, Dionne M, Langley JM, Vanderkooi O, Dobson S, Halperin SA, Law B. Immunogenicity of an AS03-adjuvanted pH1N1 influenza vaccine in young Canadian children. Infectious Disease Society of America 48th Annual Meeting, Vancouver, October 21-24, 2010 (Poster 1354). 5 Scheifele DW, Ward B, Dionne M, Langley JM, Vankerdooi O, Dobson S, Halperin SA, Law B. Safety of an AS03-adjuvanted pH1N1 influenza vaccine in young Canadian children. Infectious Disease Society of America 48th Annual Meeting, Vancouver, October 21-24, 2010 (Poster 1363).

148

6 Bettinger JA, Scheifele DW, Kellner JA, Vaudry W, Halperin SA for Members of IMPACT. Emergence of pneumococcal serotype 19A in Canadian children: 2000-2009. Infectious Disease Society of America 48th Annual Meeting, Vancouver, October 21-24, 2010 (Poster 1374). 7 Sauvé L, Bettinger JA, Scheifele DW, Vaudry W, Halperin SA, Law B for Members of IMPACT. Reported adverse events following adjuvanted pandemic influenza vaccine. Infectious Disease Society of America 48th Annual Meeting, Vancouver, October 21-24, 2010 (Poster 1362). 8 Bettinger JA, Scheifele DW, Kellner JD, Vaudry W, Halperin SA, Law B, Tyrrell G. Emergence of pneumococcal serotype 19A in Canadian children: IMPACT 2000-2009. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract O-07. Can J Infect Dis Med Microbiol 2010; 21:178. 9 Bettinger JA, Le Saux N, Scheifele DW, Vaudry W, Halperin SA, Bortolussi R, Tsang R. The epidemiology of serogroup B meningococcal infections in Canada: IMPACT 2002-2009. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract O-10. Can J Infect Dis Med Microbiol 2010; 21:179. 10 Sauvé LJ, Bettinger JA, Vaudry W, Moore D, Scheifele DW, Halperin SA, Law B. IMPACT network active surveillance for adverse events following adjuvanted pandemic influenza vaccine in Canadian children. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract O-14. Can J Infect Dis Med Microbiol 2010; 21:180. 11 Rubinstein E, Scheifele DW, Hammond G, Aoki F, Predy G, Sikora C, Sauvé L, Li Y, Law B, Halperin SA, Smith B. PCIRN study of immunogenicity of monovalent adjuvanted H1N1 vaccine in aboriginal adults. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract O-15. Can J Infect Dis Med Microbiol 2010; 21:180. 12 Scheifele DW, Ward B, Dionne M, De Serres G, Langley J, Halperin SA, Vanderkooi O, Kellner J, Dobson S, Sauvé L, Li Y, Law B. One dose or two? Results of a PCIRN study of dosing requirements of toddlers given adjuvanted H1N1 influenza vaccine during the 2009 pandemic. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract O-16. Can J Infect Dis Med Microbiol 2010; 21:181. 13 Shuel M, Tan B, Scheifele D, Law B, Vaudry W, Halperin S, Grimsrud K, Bortolussi R, Pless R, Tsang R. Update on IMPACT surveillance of Haemophilus influenza isolates in Canada. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract P056. Can J Infect Dis Med Microbiol 2010; 21:199. 14 Coleman BL, Gubbay J, Scheifele DW, Li Y, Low D, Mazzuli T, Shi L, Green K, Halperin S, Law B, McGeer A. Immunogenicity of a reduced dose of ArepanrixTM H1N1 vaccine in healthy adults. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract P115. Can J Infect Dis Med Microbiol 2010; 21:218. 15 Cooper C, Haase D, Walmsley S, Klein M, Scheifele DW, Halperin S, Li Y, Law B, Smith B. PCIRN randomized trial to compare the immunogenicity of adjuvanted pandemic H1N1 2009 vaccine with or without a second “booster” dose in HIV-infected adults. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract P116. Can J Infect Dis Med Microbiol 2010; 21:218. 16 Scheifele DW, Dionne M, De Serres G, Loeb M, McGeer A, Vanderkooi O, Kellner J, Dobson S, Sauvé L, Li Y, Law B, Halperin SA. PCIRN study of adults given monovalent adjuvanted H1N1 vaccine with concurrent or delayed trivalent seasonal influenza vaccination. 9th Canadian Immunization Conference, Quebec City, December 5-8, 2010. Abstract P141. Can J Infect Dis Med Microbiol 2010; 21:226. 17 Cooper C, Walmsley S, Klein M, Hasse D, Scheifele D. Immediate and long-term immunogenicity and efficacy of adjuvanted pandemic H1N1 2009 vaccine (Arepanrix) with or without booster: A randomized trial in HIV infectd adults. Canadian Association for HIV Research 20th Annual Conference, Toronto, April, 2011. Oral presentation. Can J Infect Dis Med Microbiol 2011; SupplB, p35B (Abstract O089). 18 Scheifele DW, Dionne M, Ward B, Cooper C, Vanderkooi O, Dobson S, De Serres G, Li Y, Law B, Halperin SA. Safety and immunogenicity of re-vaccination with H1N1-containing 2010-2011 seasonal influenza vaccine after priming with 2009 adjuvanted pandemic vaccine. 14th Annual Vaccine Research Conference, Baltimore MD, May 16-18, 2011. Abstract S18. 19 Langley JM, Scheifele D, Quach C, Vanderkooi O, Dobson S, Ward B, Kellner J, Kuhn S, Kollmann T, McNeil S, Smith B, MacKinnon-Cameron D, Halperin S. Rapid pre-season trial of the safety of 2010-2011 H1N12009containing trivalent inactivated influenza vaccine in young children 12 to 59 months of age who received AS03adjuvanted pandemic vaccine: a PHAC/CIHR (PCIRN) Influenza Research Network Study.14th Annual Vaccine Research Conference, Baltimore MD, May 16-18, 2011. Abstract S17. 20 Skowronski DM, Hottes TS, Chong M, De Serres G, Scheifele DW, Ward BJ, Halperin SA, Janjua NZ, Chan T, Sabaiduc S, Petric M. Randomized controlled trial of dose-response to influenza vaccine in children 6-23 months of age.14th Annual Vaccine Research Conference, Baltimore MD. May 16-18, 2011. Abstract S19. 21 Bettinger JA, Scheifele DW, Kellner J, Halperin SA, Vaudry W, Shane A, Tyrrell G for IMPACT Members. Pneumococcal vaccine failures and missed opportunities: IMPACT 2005-2010. Canadian Paediatric Society 88th Annual Conference, June 15-18, 2011, Quebec City. Paediatrics & Child Health 2011; Suppl A: 13A.

149

22 Bettinger JA, Scheifele DW, Halperin SA, Le Saux N, Vaudry W, Findlow J, Medini D, Tsang R. Estimated coverage of meningococcal B isolates by a meningococcal serogroup B vaccine. Proceedings of the 5th Vaccine & ISV Annual Global Congress, October 2-4, 2011, Seattle. Poster P1.2.4. 23 Bettinger JA, Scheifele DW, Halperin SA, Kellner JD, Schryvers A, De Serres G. Evaluation of meningococcal C conjugate vaccine programs in Canadian children: interim analysis. ibid Poster P.1.2.7. 24 Yam KK, Scheifele DW, Ward BJ. The immunobiology of oil-in-water adjuvants for influenza vaccines. ibid Poster P2.18. 25 Al-Dabbagh MA, Lapphra K, Scheifele DW, Dobson S, Halperin SA, Bettinger JA, Skowronski D, De Serres G. An investigation of inflammatory mediators in selected adverse events following influenza immunization in adults. ibid Poster P2.30. 26 Sauve L, Bettinger J, Scheifele D, Kalil J, Vaudry W, Halperin S, Le Saux N, Law B, for the members of the Immunization Monitoring Program Active (IMPACT). Immunization Monitoring Program Active Surveillance for Intussusception in Canada. Poster presentation at the 7th World Congress for Pediatric Infectious Diseases, November 16-19, 2011, Melbourne, Australia. 27 Schneeberg A, Bettinger JA, McNeil S, Ward B, Dionne M, Cooper C, Coleman B, Loeb M, Rubinstein E, McElhaney J, Scheifele DW, Halperin SA. Knowledge, attitudes and beliefs of older adults about pneumococcal immunization. 10th Canadian Immunization Conference, Vancouver, BC, December 3-5, 2012 (Abstract O-03). 28 Scheifele DW, McNeil S, Dionne M, Ward B, Cooper C, Loeb M, Coleman B, McGeer A, Rubinstein E, McElhaney J, Li Y, Hatchette T, Halperin S. Randomized, controlled comparison of 3 seasonal influenza vaccines in Canadian seniors: immunogenicity data from a PCIRN trial. ibid (Abstract O-09). 29 Ricketson L, Wood M, Vanderkooi O, Scheifele D, Church D, MacDonald J, Martin I, Kellner JD. Serotypespecific trends in pneumococcal nasopharyngeal colonization before and after PCV7 and PCV13 vaccine programs in Calgary, Canada. ibid (Abstract P.007). 30 Sadarangani M, Halperin SA, Vaudry W, Le Saux N, Tsang R, Scheifele DW, Bettinger JA. Outcomes of invasive meningococcal disease in Canadian children and adults between 2002 and 2010. ibid (Abstract P.008). 31 Bettinger JA, Scheifele DW, Halperin SA, Le Saux N, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R. Estimated coverage of Canadian meningococcal serogroup B isolates by an investigational meningococcal serogroup B vaccine (4C MenB). ibid (Abstract P.009). 32 Conradi N, Ricketson L, Vanderkooi O, MacDonald J, Church D, Scheifele DW, Kellner JD. Changes in the nature and severity of invasive pneumococcal disease in children before and after the 7-valent pneumococcal protein-polysaccharide conjugate vaccine program in Calgary, Canada. ibid (Abstract P.044). 33 Ricketson L, Vanderkooi O, Church D, MacDonald J, Scheifele DW, Kellner JD. Epidemiology of invasive pneumococcal disease (IPD) in Calgary, Alberta, before and after PCV7 and PCV13 vaccine introduction. ibid (Abstract P.051). 34 Scheifele DW, McNeil S, Dionne M, Ward B, Cooper C, Loeb M, Coleman B, McGeer A, Rubinstein E, McElhaney J, Li Y, Hatchette T, Halperin S. Randomized, controlled comparison of 3 seasonal influenza vaccines in Canadian seniors: safety observations from a PCIRN trial. ibid (Abstract P.052). 35 Cosgrove A, LaJeunesse C, Bettinger J, Fan SY, Kwon L, LaJeunesse K, Scheifele D. Evaluation of communication and social media preferences in recruitment and retention of research participants. ibid (Abstract P.057). 36 Sadarangani M, Halperin SA, Vaudry W, Le Saux N, Tsang R, Scheifele DW, Bettinger JA. A decade of serogroup C Neisseria meningitides surveillance in Canada. ibid (Abstract P.156). 37 Schneeberg A, Bettinger JA, Scheifele DW. Acceptability of the seasonal influenza vaccine among older adults given intradermal, intramuscular or adjuvanted intramuscular vaccines in a Canadian trial. ibid (Abstract P.158). 38 Scheifele DW, Ferguson M, Predy G, Dawar M, Assundani D, Kuriyakase S, Van der Meeren O, Han HH. Immunogenicity of safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib vaccine in Canadian Aboriginal and non-Aboriginal infants. ID Week Philadelphia PA. October 8-12, 2014. 39 Scheifele D, Ward B, Halperin S, Crowcroft N, McNeil S, Bjornson G. Drawing attention to recommended but unfunded vaccines in Canada. Oral abstract. Canadian Immunization Conference 2014, Ottawa, ON. December 2-4, 2014. 40 Bettinger J, Scheifele D, Kellner J, Vanderkooi O, Schryvers A, Alcantara J.Evaluation of meningococcal C conjugate vaccine programs in Canadian children. Oral abstract. ibid. 41 Le Saux N, Halperin S, Vaudry W, Scheifele D, Bettinger J. Decreases in hospitalizations: effect of rotavirus vaccine programs. Oral abstract. ibid.

02. Non Refereed Publications from 2000

150

(a) Journals 1 Bjornson G, Scheifele D, Binder F, Talling D. Population-based incidence rate of invasive pneumococcal infection in children: Vancouver, 1994-1998. Can Commun Dis Rep 2000; 26: 149-152. 2 Scheifele DW. Tools of the immunization trade: vials, needles and syringes. Vaccine: Children and Practice 2000; 3: 39-40. 3 Scheifele D, Halperin S, Vaudry W et al. Historic low Haemophilus influenzae type b case tally - Canada, 2000. Can Commun Dis Rep 2001; 27: 149-150. 4 Scheifele D. The burden of pneumococcal infections in children. Pediatr Child Health 2001; 6 (Suppl B): 5B8B. 5 Scheifele DW, Kellner J, Tapiero B, de Wals P. Colloquium: Emerging trends in S. pneumoniae and childhood ilness. Medical Post. January 9, 2001. 6 Scheifele D, Blustein N. Clinical focus: pneumoncoccal infection in children. Medical Post August 21, 2001; 37(28). 7 National Advisory Committee on Immunization (including D. Scheifele as contributing author). Supplementary statement for the 2002-2003 influenza season: update on oculo-respiratory syndrome in association with influenza vaccination. Can Commun Dis Rep 2002; 28: ACS-6, 1-8. 8 Scheifele DW. For coughs, colds and SARS, wear a mask (editorial). Paediatr Child Hlth 2003; 8:601. 9 Scheifele D, Law B, Vaudry W, Halperin S, Kellner J, King A, Dawar M and Members of the CPS/Health Canada Immunization Monitoring Program, Active (IMPACT). Invasive pneumococcal infections among Canadian Aboriginal children. Can Commun Dis Rep 2003; 29:37-42. 10 Scheifele DW. Immunization practice: selecting the injection site. Vaccines: Children and Practice 2003; 6:357. 11 Gustafson R, Scheifele DW. Upshots: practical questions and answers about childhood immunization. Paediatr Child Health 2004; 9 (pages ?). 12 Scheifele D, Tam T, Bjornson G et al. Addressing a public health priority: first Canadian research agenda on influenza prevention, control and management. Can Commun Dis Rep 2006; 32:266-70. 13 McGeer A, McElhaney J, Scheifele D, Slayter K, Weiss K. Colloquium on Best Practices: Emerging trends in the prevention and management of seasonal influenza. Medical Post October 14, 2010.

(b) Conference Proceedings from 2000 1 Montreal Children’s Hospital Centennial Conference in Infectious Diseases, Montreal, June 16, 2004. Canadian Paediatric Society 81st Annual Conference, Montreal, June 18, 2004.

(c) Other 1 Scheifele DW. Immunization: a call to action (editorial). BC's Children 3:3 (1979) 2 Scheifele DW. Bacterial meningitis. Medicine, North America 1:843-55 (1981) 3 Scheifele D. A parent's guide to colds and flu in children. Canadian Pediatric Society (1991)

03. Books (a) Authored 1 Scheifele D, member and co-author of National Advisory Committee on Immunization. Guide to Immunization for Canadians (second edition) (1984) 2 Scheifele DW (contributing author). Canadian Immunization Guide (third edition). Health & Welfare, Canada (1989) 3 National Advisory Committee on Immunization (D. Scheifele, member and contributor). Canadian Immunization Guide. 4th edition. 1993. 4 Your Child's Best Shot - a parent's guide to vaccination. Canadian Paediatric Society, 1997. (D. Scheifele served as contributor and editor).

(b) Edited 1 National Advisory Committee on Immunization (D. Scheifele, chair and senior editor). Canadian Immunization Guide, 5th edition, 1998.

(c) Chapters from 2000 1 Scheifele DW. Pediatric Immunizations. In: Problems in Pediatric Drug Therapy, 4th edition, Pagliaro LA and Pagliaro AM editors, American Pharmaceutical Association, Washington, DC, p433-458 (2004) 2 Scheifele DW. "Childhood Vaccines" in Neonatal & Pediatric Pharmacology, 3rd edition, SJ Yaffe & JV Aranda editors, Lippincott Williams & Wilkins, p795-809 (2005)

151

3 Fera EV, Mauratua P, Scheifele DW, Ogra PL. “Childhood Vaccines” in Neonatal and Pediatric Pharmacology – Therapeutic Principles in Practice. Yaffe SJ, Aranda JV eds. Lippincott Williams & Wilkins 2010 p850-885.

4 Scheifele DW. Childhood immunization and brain health. Topic ed. In: Tremblay RE, Boivin E, Peters RDeV, eds. Encyclopeida on Early Childhood Development [online]. Montreal, Quebec: Centre of Excellence for Early Childhood Developmetn and Strategic Knowledge Cluster on Early Child Development; 2013:1-10 (April 2013) 5 Scheifele DW. “What else could it be?” When neurologic disorders follow immunization. Topic ed In: Tremblay RE, Boivin M, Peters RDeV, eds. Encyclopedia on Early Childhood Development [online]. Montreal Quebec: Centre of Excellence for Early Childood Development and Strategic Knowledge Cluster on Early Child Development; 2013:1-5 (April 2013).

06. Artistic Works, Performances, Designs Videos 1 "Immunizing Your Baby" (educational video for parents) contributor, narrator. 1995.

152

Seib Kate Research Leader, Institute for Glycomics, Griffith University, Queensland, Australia

Kate Seib got her phD in microbiology in 2004 from the University of Queensland, Brisbane, Australia. She worked at Novartis Vaccines, where she was part of the team working on the serogroup B meningococcal vaccine (Bexsero™). Currently, she is the group leader at the Institute for Glycomics and an Associate Editor for the journals Scientific Reports, and BMC Microbiology. Dr Seib’s research focuses on understanding how certain bacteria cause disease in humans, with the aim to identify vaccine and drug targets. Current Work

Dr Seib’s research focuses on understanding how certain bacteria cause disease in humans, with the aim to identify vaccine and drug targets. She currently works on several pathogenic bacteria, including Neisseria gonorrhoeae (causes the sexually transmitted infection gonorrhea, which can lead to infertility), Neisseria meningitidis (causes sepsis, meningitis), and Moraxella catarrhalis (causes middle ear infections, exacerbations of chronic obstructive pulmonary disease),

Publications shown from 2010:

45 (Journal Articles (Refereed Article): 40, Book Chapter: 4, Non Refereed: 1)

1. Phasevarions of Bacterial Pathogens: Methylomics Sheds New Light on Old Enemies. Atack JM, Tan A, Bakaletz LO, Jennings MP, Seib KL. Trends Microbiol. 2018 Feb 13. pii: S0966-842X(18)30020-9. 2. The glycointeractome of serogroup B Neisseria meningitidis strain MC58. Mubaiwa TD, Hartley-Tassell LE, Semchenko EA, Jen FE, Srikhanta YN, Day CJ, Jennings MP, SeibKL. Sci Rep. 2017 Jul 18;7(1):5693. 3. Gonorrhoea vaccines: a step in the right direction. Seib KL. Lancet. 2017 Sep 30;390(10102):1567-1569. 4. Complete Genome Sequence of Moraxella catarrhalis Strain CCRI-195ME, Isolated from the Middle Ear. Tan A, Blakeway LV, Bakaletz LO, Boitano M, Clark TA, Korlach J, Jennings MP, Peak IR, Seib KL. Genome Announc. 2017 May 25;5(21). pii: e00384-17. 5. Semchenko, E., & Seib, K. (2016). Intractable problems require novel solutions: it’s time to get serious about developing a gonorrhoea vaccine. Sexually Transmitted Infections, 1–2. 6. Edwards, J. L., Jennings, M., Apicella, M. A., & Seib, K. (2016). Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Critical Reviews in Microbiology, 42(6), 928–941. 7. Seib, K., & Jennings, M. (2016). Epigenetics of Infectious Diseases. In Medical Epigenetics (pp. 443– 458). 8. Tan, A., Hill, D. M. C., Harrison, O. B., Srikhanta, Y., Jennings, M., Maiden, M. C. J., & Seib, K. (2016). Distribution of the type III DNA methyltransferases modA, modB and modD among Neisseria meningitidis genotypes: implications for gene regulation and virulence. Scientific Reports, 6, 21015–1–21015–11. 9. Vacca, I., Tordello, E. D., Gasperini, G., Pezzicoli, A., Fede, M. D., Paccani, S. R., … Delany, I. (2016). Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells. PLoS One, 11(10), e0162878–1–e0162878–17.

153

10. Craig, A. P., Gray, R. T., Edwards, J. L., Apicella, M. A., Jennings, M., Wilson, D. P., & Seib, K. (2015). The potential impact of vaccination on the prevalence of gonorrhea. Vaccine, 33(36), 4520–4525. 11. Seib, K., Jen, F., Tan, A., Scott, A., Kumar, R., Power, P., … Jennings, M. (2015). Specificity of the ModA11, ModA12 and ModD1 epigenetic regulator N6-adenine DNA methyltransferases of Neisseria meningitidis. Nucleic Acids Research, 43(8), 4150–4162. 12. Seib, K., Scarselli, M., Comanducci, M., Toneatto, D., & Masignani, V. (2015). Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. Expert Review of Vaccines, 14(6), 841–859. 13. Blakeway, L., Power, P., Jen, F., Worboys, S., Boitiano, M., Clark, T. A., … Seib, K. (2014). ModM DNA methyltransferase methylome analysis reveals a potential role for Moraxella catarrhalis phasevarions in otitis media. The FASEB Journal, 28(12), 5197–5207. 14. Jen, F., Seib, K., & Jennings, M. (2014). Phasevarions Mediate Epigenetic Regulation of Antimicrobial Susceptibility in Neisseria meningitidis. Antimicrobial agents and Chemotherapy, 58(7), 4219–4221. 15. Nesta, B., Valeri, M., Spagnuolo, A., Rosini, R., Mora, M., Donato, P., … Serino, L. (2014). SslE elicits functional antibodies that impair in vitro mucinase activity and in vivo colonization by both intestinal and extraintestinal Escherichia coli strains. PLoS Pathogens, 10(5), e1004124–1–e1004124–12. 16. Delany, I., Rappuoli, R., & Seib, K. (2013). Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harbor perspectives in medicine, 3(5), a012476–1–a012476–17. 17. Delany, I., & Seib, K. (2012). Oxidative and Nitrosative Stress Responses in Pathogenic Neisseria. In Stress Response in Microbiology (pp. 41–90). United Kingdom: Caister Academic Press. 18. Moriel, D. G., Rosini, R., Seib, K., Serino, L., Pizza, M., & Rappuoli, R. (2012). Escherichia coli: Great Diversity around a Common Core. mBio, 3(3), e00118–12–1–e00118–12–3. 19. Seib, K., Zhao, X., & Rappuoli, R. (2012). Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clinical Microbiology and Infection, 18, 109–116. 20. Serino, L., Seib, K., & Pizza, M. (2012). Design of new vaccines in the genomic and post-genomic era. In Innovation in Vaccinology: From Design, Through to Delivery and Testing (pp. 3–15). Germany: Springer. 21. Veggi, D., Gentile, M. A., Cantini, F., Surdo, P., Nardi-Dei, V., Seib, K., … Scarselli, M. (2012). The Factor H Binding Protein of Neisseria meningitidis Interacts with Xenosiderophores in Vitro. Biochemistry, 51(46), 9384–9393. 22. Budroni, S., Siena, E., Hotopp, J. C. D., Seib, K., Serruto, D., Nofroni, C., … Medini, D. (2011). Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. National Academy of Sciences. Proceedings (PNAS), 108(11), 4494–4499. 23. Echenique-Rivera, H., Muzzi, A., Tordello, E. D., Seib, K., Francois, P., Rappuoli, R., … Serruto, D. (2011). Transcriptome Analysis of Neisseria meningitidis in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival. PLoS Pathogens, 7(5), e1002027–1–e1002027–18. 24. Seib, K., Brunelli, B., Brogioni, B., Palumbo, E., Bambini, S., Muzzi, A., … Pizza, M. (2011). Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies. Infection and Immunity, 79(2), 970–981. 25. Seib, K., Pigozzi, E., Muzzi, A., Gawthorne, J., Delany, I., Jennings, M., & Rappuoli, R. (2011). A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44. FASEB Journal, 25(10), 3622–3633. 26. Seib, K., & Rappuoli, R. (2010). Difficulty in Developing a Neisserial Vaccine. In Neisseria: Molecular Mechanisms of Pathogenesis (pp. 195–226). United Kingdom: Caister Academic Press. 27. Seib, K., Oriente, F., Adu-Bobie, J., Montanari, P., Ferlicca, F., Giuliani, M. M., … Delany, I. (2010). Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine, 28(12), 2416–2427.

28. Serruto, D., Spadafina, T., Ciucchi, L., Lewis, L. A., Ram, S., Tontini, M., … Aricò, B. (2010). Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. National Academy of Sciences. Proceedings (PNAS), 107(8), 3770–3775. 29. Wu, H.-J., Seib, K., Srikhanta, Y., Edwards, J., Kidd, S. P., Maguire, T. L., … Jennings, M. (2010). Manganese regulation of virulence factors and oxidative stress resistance in Neisseria gonorrhoeae. Journal of Proteomics, 73(5), 899–916.

Tsai Theodore Fang

CURRICULUM VITAE

NAME: Theodore Fang Tsai

PLACE OF BIRTH: Nanking, China

CITIZENSHIP: United States, Naturalized 1957

MARITAL STATUS: Married: Sherry M. Woodruff, 1976 Pediatric Nurse Practitioner Children’s Hospital, Boston

Children: Tobias J. Tsai MD Acting Chief, Pediatric Physiatry North Carolina Health

Elizabeth M. Tsai JD MA Crown attorney, Ontario

CURRENT POSITION: Head, Policy and Scientific Affairs Takeda Vaccines 40 Landsdowne Street Cambridge, MA 02139 [email protected]

EDUCATION AND TRAINING:

1967-74 Laboratory Assistant in Virology, Collaborative and Field Research Branch, National Institutes of Neurological Diseases and Blindness

1969 Antioch College, B.A., Chemistry

1973 Walter Reed Army Institute of Research, Graduate Course in Tropical Medicine

1974 University of Pennsylvania, M.D.

155

1974-76 Internship and Residency (PL I, II, and III) 1978-79 Harriet Lane Home Service, Johns Hopkins Hospital

1976-78 Epidemic Intelligence Service Officer, Special Pathogens Branch, Bacterial Diseases Division, Centers for Disease Control 1979-80 Pediatrician, Columbia Medical Plan, Columbia, Maryland

1980-82 Epidemiology Training Program, Office of the Director, National Institutes of Health

1981-82 Johns Hopkins University School of Hygiene and Public Health, M.P.H. 1992-93 Fellow, Clinical Microbiology, Clinical Center, National Institutes of Health

CURRENT AND PREVIOUS POSITIONS

1981-83 Medical Officer, Special Pathogens Branch, Division of Viral Diseases, Centers for Disease Control, Atlanta, Georgia

1983-87 Medical Officer, Immunochemistry Branch, Division of Vector-Borne Viral Diseases, Centers for Disease Control Ft. Collins, Colorado

1988-89 Acting Chief, Lyme Disease Program Division of Vector-Borne Infectious Centers for Disease Control Ft. Collins, Colorado

1989-92 Chief, Arboviral Diseases Branch Division of Vector-Borne Infectious Diseases Centers for Disease Control Ft. Collins, Colorado

1993-99 Assistant Director for Medical Science, Division of Vector-Borne Infectious Diseases, Center for Infectious Diseases, Centers for Disease Control, Fort Collins, Colorado

1999-2000 Director, Vaccines Research and Development Wyeth-Lederle Vaccines Pearl River, New York

2000-2004 Senior Director, Vaccines Global Medical Affairs Wyeth Pharmaceuticals Radnor, PA

2005-2006 Senior Director, Global Medical Affairs Intercontinental Medical Affairs (Asia-Pacific region) Wyeth Pharmaceuticals Collegeville, PA 19426

2006-2007 Head, Medical Affairs, N. America Novartis Vaccines Philadelphia, PA 19102

2008- 2014 Chief Medical Officer, Americas Novartis Vaccines Cambridge, MA 02139

Head, Global Medical Affairs

Head, Global Scientific Affairs

OTHER PROFESSIONAL RESPONSIBILITIES:

2012-present Vaccine (Journal)– among top reviewers for the journal 2012-present Industry representative, VRBPAC 2010-11 Industry representative, alternate VRBPAC 2011 Decade of Vaccines, consultant 2011 Clinical expert, WHO Japanese encephalitis guidelines for live attenuated Japanese Encephalitis vaccines. 2004 Medical affairs representative, Wyeth Access (social responsibility) Committee Wyeth ad hoc Pneumo ADIP committee 2002 Medical Affairs liason, medical expert Wyeth Transmissible Spongiform Encephalopathy Working Group 2001-2003 Wyeth Representative, IFPMA, Influenza Vaccine Supply Task Force 1998-2000 Member, Armed Forces Epidemiology Board 1998-99 Member, CDC IRB 1998-99 Member CDC, Blood safety working group 1997-99 Member CDC, Emerging Infections Program (EIP) steering committee 1997-99 Member CDC, Unexplained deaths project 1996-99 Chair CDC, Tickborne diseases working group 1996-99 Member CDC, EIP Prevention working group 1998 Consultant CDC, Division of Quarantine consultants group 1997-98 Member CDC, Antimicrobial resistance working group 1997-98 Co-Chair, World Health Organization, Flavivirus Steering Committee 1997-98 Member, World Health Organization, Epidemiology and Field Research Steering Committee 1997 Vice Chair, USPHS Asian-Pacific American Officers Committee 1993-94 CLIA Coordinator, DVBID 1983-99 Faculty Affiliate, Depts. of Microbiology and Environmental Health, Colorado State University 1987-92 Commissioned Corps representative, DVBID 1984-87 EEO Representative, DVBID

MEDICAL LICENSE: Maryland State License Colorado State License

BOARD CERTIFICATION: American Academy of Pediatrics, 1979 National Board of Medical Examiners, 1975 157

LANGUAGES Mother tongue: Chinese, fluency – poor, spoken until age 7 years Other languages: English – fluency –like mother tongue, spoken since age 2 years French, Spanish – some reading comprehension

HONORS and AWARDS: 1974 Alpha Omega Alpha, University of Pennsylvania Chapter 1975 Bristol-Myers Pediatric house staff award, Johns Hopkins Hospital 1977 Coauthor, Alexander Langmuir Prize, CDC, (for exemplary manuscript and investigation) 1978 Centers for Disease Control - Unit Commendation - Special Pathogens Branch (for work on Legionnaire's Disease)

1987 U.S. Public Health Service - Outstanding Service Medal 1989 U.S. Public Health Service - Commendation Medal 1989 Fellow, Infectious Disease Society of America 1989 Fellow, Society for Pediatric Research 1990 U.S. Public Health Service - Outstanding Service Medal 1993 U.S. Public Health Service - Unit Commendation Medal 1993 American Society for Microbiology - Fellow of American Academy of Microbiology 1995 U. S. Public Health Service - Outstanding Unit Citation 1996 CDC - Group Honor Award - Nicaraguan Epidemic Investigation Group 1996 DHHS - Secretary’s’ Award for Distinguished Service - Member, plague emergency response team 1998 DHHS Secretary’s’ Award for Distinguished Service, Unexplained Deaths and Serious Illnesses Surveillance Team

1999 CDC Honor Award, International Travel Working Group 2005 Wyeth, Exceptional Performance Award 2005 Wyeth President’s, Achieving Excellence Award

OTHER AFFILIATIONS: Member Brighton Collaborations – viscerotropic disease case definition; local adverse events case definition Consultant, PATH – Japanese encephalitis project Consultant, W.H.O., Viral Diseases, multiple projects Consultant, PAHO, Viral Diseases, yellow fever and other Consultant, Rockefeller Foundation, Viral Diseases, multiple projects Consultant, International Development Research Centre, childhood vaccines Consultant, FDA advisory committee, Japanese encephalitis vaccine Consultant, NRC, Board on Science and Technology for International Development Consultant, Armed Forces Epidemiology Board Consultant, Task Force for Child Survival Consultant, USAID, Epidemic Investigation, vaccine policy Contributor, American Academy of Pediatrics, Redbook Advisor, The Medical Letter Member, Pediatric Infectious Disease Society Consultant, IOM National Vaccine Plan Consultant, Decade of Vaccines VRBPAC – industry representative, alternate, 2009-2013

TEACHING RESPONSIBILITIES

Affiliate Faculty Member, Colorado State University

Departments of Microbiology and Environmental Health, 1983-1992 Visiting Professor of Epidemiology, Shanghai Medical University, 1987-1989.

COMMUNITY VOLUNTEER WORK

Volunteer physician, Larimer County Health Department Volunteer physician, Children’s’ Clinic (nonprofit clinic for indigent) Member at large, City of Fort Collins, Commission on Disabilities

PUBLICATIONS FROM 2007:

1. Lanciotti R, Tsai TF. Arboviruses. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Landry M eds. Manual of Clinical Microbiology 9th ed. Am Society for Microbiology, Washington DC. 2007. 2. Tsai TF, Xu ZY. Vaccines and vaccination in Asia. In: Orenstein W, Offit P, Plotkin S eds. Vaccines 5th ed. WB Saunders Phila, PA. 2008; 1525-40. 3. Burchard G, Caumes E, Connor BA, Freedman DO, Jelinek J, Jong JC, von Sonnenburg F, Steffen R, Tsai TF, Wilder-Smith A, Zuckerman J. Expert opinion on Japanese encephalitis vaccination of travelers. J Travel Med; 16:204-16. 2009. 4. Tsai TF. Alphaviruses. Eastern equine encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2300-3 5. Tsai TF. Alphaviruses. Western equine encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2304-9. 6. Tsai TF. Venezuelan equine encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2310-13 7. Tsai TF. Other alphaviral infections. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2323-24 8. Tsai TF St Louis encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2325-30. 9. Tsai TF. Japanese encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2356-63. 10. Aebi C and Tsai TF. Tickborne encephalitis. In Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 236775. 11. Tsai TF Other flaviviral infections. In. Feigin RD, Cherry JD, Demmler-Harrison G, Kaplan SL. Eds. Textbook of Pediatric Infectious Diseases. 6th ed. Saunders. 2009 Phila, PA. 2375-79. 12. Lanciotti R and Tsai TF. Arboviruses. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW eds. Manual of Clinical Microbiology 10th ed. Am Society for Microbiology, Washington DC. 2011. pp1488- 1503. 13. Schmitt HJ, Tsai TF, Broker M. Zur sicherheit von influenza-impfstoffen, deren herstellungsprozess auf Zelllinien beruht. Dtsch Med Wochenschr 2009; 134: 2471-2. 14. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A. .Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis. 2009; 200(6):841-8 15. Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy-A retrospective analysis. Vaccine. 2010; Dec 5 16. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, Tsai TF. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine. 2010; 28(3):840-8. 17. Minor PD, Engelhardt OG, Wood JM, Robertson JS, Blayer S, Colegate T, Fabry L, Heldens JG, Kino Y, Kistner O, Kompier R, Makizumi K, Medema J, Mimori S, Ryan D, Schwartz R, Smith JS, Sugawara K, Trusheim H, Tsai TF, Krause R. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine. 2009;27:2907-13. 18. O’Hagan D, Tsai T, Reed S. Emulsion based adjuvants for improved influenza vaccines. In Rappuoli R, DelGiudicce G Eds. Influenza vaccines for the future. 2nd ed. Birkhauser-Verlag (in press) 159

19. Gershman MD, Staples JE , Bentsi-Enchill D, Breugelmans JG, Brito GS, Bastos Camacho LA, Cottin P, Domingo Carrasco C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, de Menezes Martins A, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella Ak, Wilson ME, Kohl Ka. Viscerotropic Disease: Case definition and guidelines for collection, analysis and presentation of immunization safety data. (submitted). 20. Campbell,GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai, TF, Tsu VD, Ginsburg AS. Estimated Global Incidence of Japanese Encephalitis: a systematic review. 2011;89(10):766-74, 774A-774E 21. Tsai TF Arboviruses of Medical Importance. In Jong EC, Stevens DL eds. Netter’s Infectious Diseases. Elsevier. Phila, PA. 2011. 419-424 22. Tsai TF, Pedotti P, Hilbert A, Lindert K, Hohenboken M, Borkowski A, Groth N, da Silva LJ, Kyaw MH. Regional and age-specific patterns of pandemic H1N1 influenza virus seroprevalence inferred from vaccine clinical trials, August-October 2009. Euro Surveill. 2010;15(30) pii: 19624. 23. Wanich N, Bencharitiwong R, Tsai T, Nowak-Wegrzyn A. In vitro assessment of the allergenicity of a novel influenza vaccine produced in dog kidney cells in individuals with dog allergy. Ann Allergy Asthma Immunol. 2010;104(5):426- 33. 24. O’Hagan D, delGiudice G, Tsai TF, Rappuoli R. MF59 Adjuvant: The best insurance against influenza strain diversity. Expert Rev Vaccines. 2011;10(4):447-62. 25. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, Jaeger R, Baehner F, Borkowski A, Tsai TF, Clemens R. Efficacy of MF59-adjuvanted versus non-adjuvanted seasonal influenza vaccine or non-influenza vaccine comparators in children, 6-<72 months of age. NEJM 2011 ;365(15):1406-16. 26. Vesikari T, Tsai TF. Influenza vaccine in young children. N Engl J Med 2012; 366:383-384. 27. Tsai TF. Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo®). Korean J Pediatr Infect Dis 2012; 19. 89-110. 28. Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, Ferguson J, Clemens R Explorations of clinical trials and pharmacovigilance databases of MF59(®)-adjuvanted influenza vaccines for associated cases of narcolepsy..Scand J Infect Dis. 2011;43(9):702-6. 29. Tsai TF, Lim PL, von Sonnenburg F, Clemens R. The potential utility of adjuvanted seasonal influenza vaccine for travelers. J Travel Med. 2011;18(4):231-2. 30. Tsai TF. MF59® adjuvanted seasonal and pandemic influenza vaccines. J Pharmaceutical Soc Japan 2011;131(12):1733-41. 31. Black SB, Vesikari T, Knuf M, Wutzler P, Nicolay U, Tsai TF, Clemens RL, Rappuoli R. Hemagglutination Inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011 Dec;30(12):1081-5. 32. Dormitzer P, Tsai TF, delGiudice G. New technologies for influenza vaccines. Hum Vaccin Immunother. 2012;8(1):45-58. 33. Bencharitiwong R, Leonard S, Tsai TF, Nowak-Węgrzyn A. In vitro assessment of the allergenicity of novel MF59- adjuvanted pandemic H1N1 influenza vaccine produced in dog kidney cells. Hum Vacc Immunotherapeut. 2012;8:1- 3 34. Gershman MD, Staples JE, Bentsi-Enchill AD, Breugelmans JG, Brito GS, Bastos Camacho LA, Cottin P, Domingo C, Durbin A, Gascon J, Guenaneche F, Hayes EB, Jelenik Z, Khromava A, Martins RD, Wilson MM, Massy N, Nasidi A, Niedrig M, Sherwat A, Tsai T, Vilella A, Wilson ME, Kohl KS; The Brighton Collaboration Viscerotropic Disease Working Group. Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012 Jul 13;30(33):5038-5058. 35. Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, Gibbs NA, Hennig R, Jovancevic M, Netterlid E, O'Connor T, Oleske JM, Varricchio F, Tsai TF, Seifert H, Schuind AE; The Brighton Immunization Site Pain Working Group. Immunization site pain: Case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012 Jun 22;30(30):4558-4577. 36. Tsai TF, Bock H Xu ZY. Vaccines and vaccination in Asia. In: Orenstein W, Offit P, Plotkin S eds. Vaccines 6th ed. WB Saunders Phila, PA. 2013 37. Tsai TF. Japanese Encephalitis. In Feigin RD, Cherry JD, Demler-Harrison G, Kaplan SL eds. Textbook of Pediatric Infectious Diseases, 7th ed. Elsevier 2013.

38. Tsai TF. Other Alphaviruses. In Feigin RD, Cherry JD, Demler-Harrison G, Kaplan SL eds. Textbook of Pediatric Infectious Diseases, 7th ed. Elsevier 2013. 39. Tsai TF. Orbiviruses, Coltiviruses, Seadornaviruses. In Feigin RD, Cherry JD, Demler-Harrison G, Kaplan SL eds. Textbook of Pediatric Infectious Diseases, 7th ed. Elsevier 2013. 40. Tsai TF. Other Flaviviruses. In Feigin RD, Cherry JD, Demler-Harrison G, Kaplan SL eds. Textbook of Pediatric Infectious Diseases, 7th ed. Elsevier 2013. 41. Tsai TF. Tickborne encephalitis. In Feigin RD, Cherry JD, Demler-Harrison G, Kaplan SL eds. Textbook of Pediatric Infectious Diseases, 7th ed. Elsevier 2013. 42. Tsai TF Fluad – MF59-adjuvanted influenza vaccine in older adults. Infect Chemotherapy 2013; 45: 159-74.

43. Tsai TF, DelGiudice G, Crucitti A, Weill J, Narasimhan V. Is the adjuvant solely to blame? Brit Med J 2013; April 17: 346. 44. Bischoff AL, Folsgaard NV, Carlson CG, Stockholm J, Pedersen L, Holmberg M, Bisgaard A, Birch S, Tsai TF, Bisgaard H. Altered response to A/H1N1pnd 09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS 2013; April 18; 8(4). 45. Donis RO; Influenza Cell Culture Working Group et al. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing. Vaccine 2014; 32(48):6583-90.

MMWR ARTICLES (AUTHOR OR CONTRIBUTOR):

1. Respiratory infection - Pennsylvania; 25:244, 1976. 2. Update on respiratory illness - Pennsylvania; 25:251, 1976. 3. Follow-up on respiratory disease - Pennsylvania; 25:259, 1976. 4. Follow-up on respiratory disease - Pennsylvania; 25:267, 1976. 5. Follow-up on respiratory disease - Pennsylvania; 25:270, 1976. 6. Follow-up on respiratory disease - Pennsylvania; 25:308, 1976. 7. Melioidosis - Pennsylvania; 25:419-420, 1977. 8. Follow-up on respiratory disease - Philadelphia; 26:9-11, 1977. 9. Follow-up on respiratory disease - Philadelphia; 26:43-44, 1977. 10. Yersinia enterocolitica outbreak - New York; 26:53-54, 1977. 11. Follow-up on respiratory disease - Pennsylvania; 26:93, 1977. 12. Follow-up on Legionnaires' disease; 26:111-112, 1977. 13. Group A streptococcal wound infections in an abattoir - Vermont; 26:121, 1977. 14. Follow-up on Legionnaires' disease - Pennsylvania; 26:152, 1977. 15. Legionnaires' disease - Pennsylvania; 26:162-167, 1977. 16. Legionnaires' disease - United States; 26:224, 1977. 17. Legionnaires' disease - Ohio; 26:300, 1977. 18. Follow-up on Legionnaires' disease - Ohio; 26:308, 1977. 19. Outbreak of scarlet fever - California; 26:311-312, 1977. 20. Legionnaires' disease - Pennsylvania; 26:319-320, 1977. 21. Legionnaires' disease - Tennessee, Vermont; 26:336, 1977. 22. Legionnaires' disease - Scotland, Spain, United States; 26:344, 1977. 23. Follow-up on Legionnaires' disease - Tennessee, Vermont; 26:368, 1977. 24. Sporadic cases of Legionnaires' disease - United States; 26:369, 1977. 25. Follow-up on sporadic Legionnaires' disease - United States; 26:408, 1977. 26. Follow-up on Legionnaires' disease - United States; 26:443, 1977. 27. Zinga virus: a strain of Rift Valley Fever virus; 32:90-92, 1983. 28. Arboviral encephalitis - United States; 32:441-442, 1983. 29. Arboviral encephalitis - United States; 32:557-560, 1983. 30. Human arboviral encephalitis - United States; 33:339-342, 1984. 31. St. Louis encephalitis - California; 33:649-651, 1984. 32. Arboviral infections of the central nervous system - United States, 1984; 34:283-294, 1985. 33. Arboviral infections of the central nervous system - United States, 1985; 35:341-350, 1986. 34. St. Louis encephalitis - Baytown and Houston, Texas; 35:693-695, 1986.

161

35. Arboviral infections of the central nervous system - United States, 1986; 36:450-456, 1987. 36. Western equine encephalitis - United States and Canada, 1987; 36:655-659. 37. LaCrosse encephalitis in West Virginia, 1988; 37:798-82. 38. Arboviral infections of the central nervous system - United States - 1987; 37:506-515, 1988. 39. Yellow fever virus activity - Trinidad & Tobago; 38:57-59, 1989. 40. Update: Aedes albopictus infestation - United States, Mexico. 38:440-446, 1989. 41. Eastern equine encephalitis - United States - 1989. 38:619-626, 1989. 42. Lyme disease - United States - 1987 and 1988. 38:668-672, 1989. 43. Seizures temporally associated with use of DEET insect repellent - New York and Connecticut. 38:678-680, 1989. 44. U.S. Department of Health and Human Services. Yellow fever vaccine - recommendations of the immunization practices advisory committee (ACIP). MMWR 1990; 39 RR-6:1-6. 45. Arboviral infections of the central nervous system, United States, 1989. 39:407-412 1990. 46. Arboviral Surveillance - United States, 1990. 39:593-598, 1990. 47. Update - Arboviral Surveillance - Florida, 1990. 39:650-651, 1990. 48. Update - St. Louis Encephalitis - Florida and Texas, 1990. 39:756-759, 1990. 49. Eastern equine encephalitis - Florida, Eastern United States, 1991. 40:533-535, 1991. 50. U.S. Department of Health and Human Services: Inactivated Japanese encephalitis vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1993; 42RR-1:1-15. 51. St. Louis encephalitis outbreak - Arkansas, 1991. 40:605-607, 1991. 52. Human plague - India 1994. 43:689-691, 1994. 53. Update - Human plague, India. 43:722-723, 1994. 54. Dengue fever among US military personnel - Haiti, September-November, 1994. 43:845-8. 1994. 55. Venezuelan equine encephalitis - Colombia, 1995. 44:721-4. 1995. 56. Update: Venezuelan equine encephalitis - Colombia, 1995. 44:775-7. 1995 57. Outbreak of acute febrile illness and pulmonary hemorrhage - Nicaragua, 1995. 44:841-3. 1995. 58. Dengue fever at the U.S.-Mexico border, 1995-1996. 45:841-844. 1996.

Van Der Pol Leo

Biography Dr. Leo van der Pol is principal scientist at Intravacc, the Institute for Translational Vaccinology, responsible for the development of processes for both bacterial and viral vaccines. From 2005 to 2013 he was Head of Process Develoment at the NVI (Netherlands Vaccine Institute) and RIVM-Vaccinology. Before this he was senior scientist and manager R&D at the pioneer Contract Manufacturing Company Bio-Intermediair that later evolved to DSM Biologics, involved in process development, scale-up, process validation, and trouble shooting. Though monoclonal antibodies were a model product in this 18 years CMO experience, process development was also performed for enzymes, hormones, blood factors, immuno-modulants and vaccines with different expression systems such as hybridoma, myeloma, CHO, BHK, insect-cell/ baculovirus, adherent animal and human cells. Leo van der Pol holds a PhD in Bioprocestechnology from the Wageningen University & Reseach Centre (WUR). Recent research focuses on vaccine development according to current ICH guidelines (QbD and PAT) and the development of new platform-technology for vaccines.

Fields of expertise at Intravacc Polio Expertise Center that contribute to the eradication of polio worldwide. We use our proven platform technologies to swiftly develop an affordable, high quality polio vaccine in accordance with EMA and WHO requirements. Bacterial and Viral vaccines from discovery up to phase I/II clinical trials. We developed advanced technologies and use these, as well as established technologies, such as Outer Membrane Vesicles (OMV), conjugation and regulatory approved Vero cells. Innovative Concepts, Formulation and Delivery to ensure state of the art expertise and knowledge, we offer innovative research and have several development programs on vaccine delivery and formulation. Specialist of Quality Assurance to develop or improve vaccine technology.

163